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Abstract 
This thesis describes the development of novel methodology for the synthesis of diverse 
heterocycles with physicochemical properties desirable in early stage drug development. The 
methodology developed in this thesis aims to allow the systematic variation of molecular 
scaffold from readily available building blocks by using strategies utilising the chemoselective 
pairing of ambiphilic/ bifunctional building blocks. 
Chapter 1 evaluates the requirement for lead-like compounds in early stages of drug 
development as well as summarising methods for the generation of diverse libraries of 
compounds. Chapter 2 describes the approaches taken towards the development of a modular 
approach to ketopiperazines, piperazines and related ring systems through the pairing of either 
amino acid or cyclic sulfamidate building blocks with amino alcohol derived building blocks. Key 
to this methodology was a ‘hydroxy-activation’ approach to induce cyclisation to generate 
heterocyclic scaffolds. Chapter 3 describes the synthesis of tetrahydropyrazine and related 
heterocycles through the pairing of cyclic sulfamidate and propargyl amine derived building 
blocks. Key to this approach was the transition metal‒mediated cyclisation of unsaturated 
acyclic substrates to give unsaturated heterocycles. Furthermore, unsaturated heterocycles 
were used as substrates for further complexity‒generating reactions to give saturated 
heterocycles. The potential ability of the methods described in both Chapter 2 and Chapter 3 to 
deliver lead-like heterocycles was illustrated by the in silico generation of virtual libraries of 
compounds from readily available materials and assessed according to calculated 
physicochemical properties. 
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Chapter 1: Introduction 
The drug discovery process, and thus the pharmaceutical industry, remains hugely 
dependent upon the ability of synthetic organic chemistry to create new biologically active 
molecules. The evolution of synthetic chemistry over the past decades has facilitated the 
synthesis of molecules which were once considered to be an insurmountable challenge.1 
As such, it would be fair to expect that the advance in synthetic abilities would be 
mirrored by advancements in the productivity of the pharmaceutical industry. However, 
the number of new drugs reaching market has seen a dramatic decrease in the past five 
years.2 Furthermore, it is estimated that 93-96% of potential clinical candidates fail to 
progress to market.2 As such there is a huge demand for increasing the likelihood that a 
clinical candidate will progress to a marketable medicine during the drug discovery 
process. 
 
1.1 Overview of the Drug Discovery Process 
The process for the discovery of new biologically active molecules which aid in the 
treatment of clinical conditions (drugs) is interdisciplinary in nature. A summary of the 
key phases of the drug discovery process, highlighting the role of organic synthesis, is 
schematically shown in Figure 1.3 Chemical starting points in drug discovery are often 
found by screening compounds from small molecule libraries.4 Compounds identified from 
initial screening approaches are commonly known as ‘hit’ compounds, which may be 
defined as compounds which have activity in both compound screening assays and more 
focussed assays.3 The chemical libraries utilised in screening campaigns contain 
compounds from wide variety of sources, such as previous discovery campaigns, natural 
products, commercial libraries, etc.5  
With initial hits identified from screening, a ‘lead optimisation’ process aims to improve 
the desirable characteristics of the hit compound to improve its drug-like profile.6 This 
optimisation process is achieved by the synthesis of many analogues, typically to build up 
structure-activity relationships (SAR), to allow for a quantitative optimisation process.7 
Typically the methods used to generate the large numbers of analogues required, on 
limited time scales, are chemistries which have been proven to be robust and predictable. 
From the arrays of analogues, a single candidate molecule is eventually selected to be 
carried forward to the trial stages as a clinical candidate. The requirement for large, often 
multi-Kg, quantities of the clinical candidate molecule requires an optimised and robust 
synthetic route with the scope to deliver such quantities of product. 
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Figure 1: The typical key phases of drug discovery. The requirements of the synthetic chemist 
(boxes) and typical numbers of compounds (rounded boxes) at each stages are shown. 
An example of a classical discovery approach leading to the development of a blockbuster 
drug is illustrated by the Pfizer discovery of Sildenafil (Viagra) (Scheme 1).8 It was 
proposed that selective inhibition of phosphodiesterases (PDE) would be an attractive 
target for the Pfizer discovery group. It was suggested that a potent inhibitor of type 5 PDE 
would have therapeutic utility in the treatment of hypertension and angina. Prior to the 
Pfizer studies, Zaprinast (1), an anti-allergy agent, had been developed as a type-5 PDE 
inhibitor although it was only weakly active and a poorly selective compound. However, 
this compact, low molecular weight compound was taken as a start point (hit compound) 
for the development of novel type 5 PDE inhibitors. A wide range of 2-alkoxyphenyl-
substituted heterocyclic systems were explored, leading to the identification of 2, an active 
(IC50 330 nM) PDE 5 inhibitor. Further scope for increasing both potency and selectivity 
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was explored by focussed structure‒activity relationships (SAR) around the heterocyclic 
core (sites for intensive SAR activity shown as coloured balls in Scheme 1, 3). A key 
observation in these SAR studies was the requirement for co-planarity between the phenyl 
and heterocyclic systems, which was maintained by hydrogen bonding between the 
pyrimidinone NH and the 2-substituent on the phenyl group. In silico modelling 
approaches suggested that substituents positioned at the 5-position of the phenyl group 
would occupy the position normally occupied by phosphate residues of cGMP and as such, 
an array of bulky groups were screened. This optimisation led to the incorporation of the 
morpholine sulfonamide motif and subsequently the discovery of Sildenafil, 4, a highly 
potent (IC50 3.0 nM) and selective type-5 PDE inhibitor which remains as one of the top 50 
highest selling drugs (sales of $1.93 billion in 2008).9 
 
Scheme 1: Summary of the development approach taken by Pfizer leading to the discovery of 
Sildenafil. 
 1.1.1 Identifying Hit and Lead Compounds 
One of the most common approaches to the identification of hit compounds is that arising 
from high throughput screening (HTS).4 Typically, large collections of compounds are 
screened against a biological target to identify small molecule ligands which are known as 
hit compounds. Thanks to huge advances in screening technology, HTS campaigns can 
  
12 
 
screen around 100 000 compounds per day, with total compound library sizes running 
into millions of compounds.10 However, the question remains that although large numbers 
of compounds can be screened, are millions of compounds representative of drug‒
relevant chemical space? 
Chemical space is the collection of all possible molecules.11,12 The chemical space 
determined by  molecules of molecular weight below 500 Da is populated by at least 1060 
possible organic molecules. The combined efforts of synthetic chemistry over the last 
century has resulted in the production of over 60 million compounds (as collected by 
Chemical Abstracts Service),13 a number that pales into insignificance when compared to 
chemical space relevant to drug discovery. 
 
1.1.2 Screening Efficiency 
It has been estimated that the addition of one extra heavy atom to an organic molecule 
leads to an increase in the number of potential structures by a factor of 10.1 As such there 
are approximately 107 more molecules with a molecular weight of ≈400 than those with a 
molecular weight of ≈300. It thereby follows that a screening set of lower molecular 
weight compounds would cover a relatively greater proportion of chemical space, 
increasing the probability of identifying hit molecules.14 This concept is easily illustrated 
by the comparison of carboxylic acid containing compounds held in GSK libraries with an 
estimation of the potential number of carboxylic acid‒containing compounds (Chart 1).10 
 
Chart 1: Number of carboxylic acid‒containing chemical entities plotted against molecular weight. 
The blue arrow shows increasing divergence between number of real compounds and exponential 
model above molecular weight~300. Plot adapted from Hann and Oprea.10 
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All carboxylic acid-containing compounds held in the GSK compound library were plotted 
against molecular weight (Chart 1, red triangles), as were the cumulative number of 
compounds (black squares). Also added was an exponential line as a model for the 
estimate of the total number of carboxylic acid‒containing compounds as a function of 
molecular weight (black circles). The precise numbers are unknown but there may be 1010 
carboxylic acid containing compounds with a molecular weight of less than 450 Da.10 
Comparing all three trends it is clear to see that at low molecular weights (MW < 225) 
both estimated and cumulative libraries have similar populations. However at increasing 
molecular weights (i.e. MW>225) there is an increasing disparity between observed 
library and estimated library population which dramatically diverges at MW~300 (blue 
arrow). This demonstrates that small compound libraries are much more representative 
of total possible compounds at low molecular weights and therefore screening of low 
molecular weight compounds is inherently more efficient and also, perhaps, more 
representative of chemical space as a whole. 
The concept of screening low molecular weight entities has been pushed further in the 
area of fragment-based drug design.15 This approach uses structure-guided rational design 
and sensitive biophysical techniques to identify and optimise small-molecules with 
molecular weight in the regions of 100-250 Da. With low molecular weight ligands as 
starting points further rational design approaches are employed to ‘build up’ the small 
molecule to increase binding affinity. 
 
1.1.3 General Characteristics of Drugs and Lead-Like Compounds 
There is a strong correlation between the molecular properties of clinical candidates and 
the likelihood of their successful progression through the development process to yield a 
marketed drug. 16,17,18,19 The link between physicochemical properties and drug-like 
characteristics has been known for some time. For example, Lipinski’s description of orally 
available drug molecules suggests parameters that within which compounds are generally 
thought of as ‘occupying drug-like chemical space’.20 The Lipinski ‘rule-of-five’ (RO5) was 
devised by the analysis of physicochemical properties of over 2000 drugs and drug 
candidates in clinical trials. Analysis of these physicochemical properties revealed that a 
compound is more likely to be both membrane penetrable and readily adsorbed (key 
factors in oral bioavailability) if the properties match the preferred values outlined in 
Table 1. 
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Drug-Likeness Guide Preferred Values 
Molecular weight MR ≤ 500 Da. 
Lipophilicity logP ≤5 
No. H–Bond donors ≤5 
No. H–Bond acceptors ≤10 
 
Table 1: Summary of Lipinski’s description of orally available drug-like molecules. 
Although these drug-like parameters are useful as general guidelines, the Lipinski RO5 is 
often taken out of context and there is no guarantee that a compound will be a successful 
drug if it passes the Lipinski criteria;21 indeed Lipinski states that not all criteria need to 
be met for good penetration and adsorption.20 Conversely, there are numerous 
compounds used in clinical environments which are not RO5‒compliant. Typical examples 
include those which do not require oral dosing or target specific tissues within the body 
which have specialised membranes preventing free diffusion (such as central nervous 
system (CNS) drugs which have to cross the blood-brain barrier and antibacterials which 
have to cross bacterial membranes). 
 
1.1.4 Evolution of Physicochemical Properties during Drug Discovery 
One of the main challenges of drug discovery is to optimise both binding affinity and target 
selectivity whilst maintaining drug-like character (as defined by Lipinski’s RO5). The 
comparison of the properties of marketed and late stage development compounds with 
the lead compounds from which they have evolved leads to clear trends indicating the 
increase of numerous properties,22,23 including both molecular weight and logP.24  The 
observed trend for the increase of these key properties may be rationalised by considering 
that the lead-to-drug development process requires optimisation of target-substrate 
binding which may, in some cases, exploit additional lipophilic interactions. Several 
analyses of these trends suggest that the progression from lead to drug compounds results 
in, typically, an increase of molecular weight of 100-200 Da and an increase of logP by 0.5-
4 log units.18,19 
 
1.1.5 Summary of Desirable Characteristics for Lead Compounds 
Given the limits of drug-like chemical space, and the trend for the increase in value of key 
physicochemical properties in the process of lead-to-drug development, it is essential to 
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control the molecular properties of lead compounds. The concept of Lead-oriented 
Synthesis (LOS)1 has been recently introduced to highlight specific challenges related to 
the generation of lead-like compounds. This concept has highlighted physicochemical 
properties which would be desirable in compounds which may form good starting points 
for lead optimisation. Preferred values for these properties are summarised in Table 2.  
Molecular Property Preferred Values 
Molecular Weight MR~ 200-350a 
Lipophilicity -1< clogP <3 
Aromatic rings nAr ≤ 3 
Shape Favour high 3D b 
Sub-structures 
No chemically reactive, 
electrophilic or redox-
active groups 
 
Table 2: Preferred values proposed for lead-like small molecules. a Equivalent to ~ 14-26 heavy 
atoms. b Fraction of sp3 centres (Fsp3) may be used to assess three dimensional shape. 
Analysis of commercially available screening libraries against the parameters outlined 
above show that the vast majority of compounds (>99%) do not have lead-like properties.1 
Similarly, analysis of compounds reported in recent synthetic methodology literature 
showed that >98% do not lie within these lead-like parameters.1 As such, the requirement 
for methodology which can generate diverse compounds with properties which lie within 
the parameters of lead-like chemical space may be of great significance to those involved 
in the early stages of drug development.  
 
1.2 Existing Methods for Generation of Diverse Compound Libraries 
Libraries of highly diverse small molecules are essential for enabling efficient screening of 
chemical space. Diversity-oriented synthesis (DOS) is an innovative field of chemistry 
which has evolved to address this demand for diverse small molecules.25 Numerous 
approaches have been developed to generate substitutional or appendage diversity 
around a common molecular skeleton.26 Furthermore, more challenging approaches which 
generate diverse molecular scaffolds have been developed. Approaches which allow the 
variation of molecular skeleton allow the generation of libraries which cover greater areas 
of chemical space and are thus deemed more powerful approaches to diverse libraries. 
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These approaches have been categorised into three conceptually different approaches; 
branching pathways, folding pathways and oligomer‒based approaches (Figure 2). 
 
Figure 2: Summary of common approaches utilised in diversity-oriented synthesis campaigns.  
Panel A- Appendage approaches generate one molecular skeleton (bold lines) but allows the 
introduction of diverse substituents (coloured shapes) although skeletal diversity approaches allow 
the generation of different molecular skeletons. Panel B- Skeletal diversity may be generated by 
using differing reagents from a common starting material (branching pathways), common 
conditions from differing starting materials (folding pathways) or coupling of common building 
blocks in different sequences followed by cyclisation (oligomer‒based approaches). 
 
1.2.1 Diverse Skeleton Generation through Branching Pathways 
The branching approach to skeletal diversity involves sequences of divergent reactions 
which convert common reactants into a variety of distinct molecular skeletons. In order to 
facilitate this type of approach the initial reagents need to exhibit the versatility to 
undergo multiple transformations. An excellent example of the branching approach to 
skeletal diversity has been described by Schreiber and co-workers.27 A four component 
Petasis reaction was used to generate common reagents (such as 5) which contain 
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multiple sites for potential synthetic modification (Scheme 2). Alternative cyclisation 
reactions were then used to transform 5 into a variety of molecules containing different 
scaffolds: Pd‒mediated cyclisation (⟶ 6a); Hoveyda–Grubbs mediated ene-yne 
metathesis (⟶ 6b); ruthenium‒mediated cycloheptadiene formation (⟶ 6c); gold‒
catalysed acetal formation (⟶ 6d); base‒induced lactonisation (⟶ 6e) and α,β-
unsaturated ketone formation under Pauson–Khand conditions (⟶ 6f). Some of these 
reaction conditions were used in a second round of diversity generation branching from 
6e to generate four further molecular scaffolds (7b-e). Furthermore, dienes (such as 6b) 
were utilised as substrates for Diels–Alder reactions to give heterocycles such as 7a. The 
key to this approach was the versatility of the initial branching reagent (such as 5) to act 
as substrates for chemo- and diastereo-selective cyclisations to generate diverse 
skeletons. Numerous alternative branching pathways have been developed which have 
allowed the generation of diverse libraries of compounds containing a variety of bioactive 
molecules.  
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Scheme 2: Branching approach to generate diverse molecular skeletons from a common 
intermediate by Schreiber et al. Reagents and conditions; A: 10 mol% Pd(PPh3)2(OAc)2, benzene, 80 
°C. B: 10 mol% Hoveyda–Grubbs 2nd gen. cat., CH2Cl2, Δ. C: 10 mol% CpRu(MeCN)3PF6, acetone, rt. 
D: 10 mol% NaAuCl4, MeOH, rt. E: NaH, PhMe, rt. F: Co2(CO)8, Et3NO, NH4Cl, benzene, rt. G: 4-Methyl-
1,2,4-triazoline-3,5-dione, CH2Cl2, rt. 
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1.2.2 Diverse Skeleton Generation through Folding Pathways 
Complementary to branching approaches, folding pathways utilise a common set of 
reagents to induce formation of a variety of scaffolds from alternative substrates. An 
approach to alkaloid-like analogues using a folding approach was developed by Oguri and 
Schreiber (Scheme 3).28 
 
Scheme 3: Folding approach to alkaloid-like skeletons by Oguri and Schreiber. Panel A- General 
mode of reactivity exploited in this folding approach. Panel B- Folding approach utilised to generate 
alkaloid-like polycycles. Reagents and Conditions: Rh(O2CC7H15)4, benzene, 50 °C. 
The folding approach outlined above (Scheme 3) utilised the ruthenium‒catalysed 
cyclisation-cycloadditon cascade developed by Padwa and co-workers.29 The treatment of 
diazo‒containing precursors with catalytic amounts of a Rh(II) catalyst induced selective 
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cyclisation-cycloaddition cascades to give a series of diverse alkaloid like skeletons. Key to 
this approach was the ability to generate different carbonyl ylides by the variation of the 
position at which both the σ,β-unsaturated diazo motif and the indole was positioned.  
 
1.2.3 Diverse Skeleton Generation through Oligomer-Based Approaches 
Oligomeric pathways utilise elements of both branching and folding pathways and can be 
an exceptionally powerful tool for the generation of diverse molecular skeletons.  
Approaches developed within the Nelson group have exploited oligomeric pathways 
which have resulted in the generation of libraries with unprecedented levels of skeletal 
diversity.30 Their approaches utilised a common modular strategy which allowed the 
construction of cyclisation precursors through the coupling of unsaturated building blocks 
with either permanent or temporary tethers using a build/couple/pair strategy30e (Scheme 
4). This modular pairing approach required employment of only limited types of reaction: 
sulfonamide formation under Fukuyama–Mitsunobu conditions (to install permanent 
tethers), mixed silaketal formation and ester formation (to install temporary tethers). 
Subsequent skeletal reprogramming of these cyclisation-precursors, using cascade 
metathesis, generated different molecular skeletons dependent upon the position of 
unsaturation (alkene or alkyne) in the parent molecule. Finally, removal of temporary 
tethers and purification tags revealed a library of diverse compounds, based on over 80 
different molecular scaffolds.  
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Scheme 4: Oligomeric pathway developed by Nelson and co-workers which generated a library of 
compounds with unprecedented levels of molecular scaffold diversity. 
This modular, oligomeric approach to generate diverse libraries was extended to 
incorporate further complexity generating reactions.31 The selective incorporation of 
unsaturated groups at certain sites of the cyclisation precursor allows for the formation of 
1,3 diene motifs to be generated in the cyclic products. These diene motifs were exploited 
as substrates for [4+2] cycloadditions in both an intra- and inter-molecular fashion to 
create more complex molecular skeletons (Scheme 5). Intermolecular cycloaddition was 
achieved by treating the diene 27 with a hetero-dienophile to give the imide 30. 
Intramolecular cycloaddition was achieved by appending dienophiles on the free hydroxy 
groups of the diol 26 to give an intermediate which underwent intramolecular cyclisation, 
under microwave irradiation, to give the ester 29. An alternative approach was to 
generate the dienophile during the metathesis cascade. As such, the cyclisation substrate 
25 was designed which gave the triene 28 after cyclisation under cascade metathesis 
conditions. Heating the triene 28 in p-xylene resulted in the intramolecular cycloaddition 
to give the lactam 31. 
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Scheme 5: Combining cascade metathesis with intra- and inter-molecular Diels–Alder reactions to 
generate compounds with diverse molecular skeletons. aRequired cleavage of temporary silyl 
linkers post-metathesis cascade. Reagents and conditions: A- mono-Methyl fumarate, DCC, DMAP, 
THF. B- MeCN, MW irradiation. C- 4-Phenyl-[1,2,4]-triazole-3,5-dione, CH2Cl2. D-p-Xylene, reflux. 
 
1.2.4 Analysis of DOS Libraries 
In order to assess the ability of DOS approaches to deliver compounds with properties 
desirable for drug discovery programmes, a selection of over 6500 molecules from 
different DOS campaigns were analysed.32 Analysis of key criteria (molecular weight and 
LogP as described in section 1.1.5) allowed an assessment of the ability of DOS 
approaches to deliver compounds which may be described as lead-like. As such, each 
compound was given a numerical identifier which was plotted against both molecular 
weight (Chart 2) and ALogP (Chart 3).33,34 Similarly, both molecular weight and ALogP for 
each individual compound was analysed as shown in Chart 4.  
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Chart 2: Molecular weight analysis of compounds generated in DOS campaigns. Dashed red lines 
show molecular weight limits for lead-like compounds. 
 
 
 
 
Chart 3: ALogP analysis of compounds generated in DOS campaigns. Dashed red lines show AlogP 
limits for lead-like compounds. 
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Chart 4: ALogP Vs MR analysis of compounds generated in DOS campaigns. Dashed red lines show 
limits of lead‒like chemical space. 
Molecular weight analysis of the DOS compound library (shown in Chart 2) shows a wide 
variance (Min MR= 93.1, Max MR= 1187.1). However, only 11% of the compounds analysed 
would be described as lead-like as their molecular weights lay within the boundaries 
defining the perimeters of lead-like chemical space (red dashed lines on Chart 2). 
Similarly, analysis of ALogP (Chart 3) shows a wide variation (Min ALogP= −3.0, Max 
ALogP= 18.6) but with a low compound population which lie within lead-like parameters 
(30%). Furthermore, the population of compounds which would be deemed lead-like on 
the basis of both molecular weight and AlogP (Chart 4) is only 4% (!). This analysis clearly 
shows that although DOS approaches are able to generate libraries of diverse compounds 
with wide variation of both molecular weight and ALogP, the compounds typically do not 
have the physicochemical properties which would be desirable for the early stages of drug 
development. 
 
1.3 Strategies for the Synthesis of Diverse Lead-Like Compounds 
A significant challenge for synthetic chemists is to develop synthetic methodologies that 
allow the variation of molecular lead-like skeletons. The origin of this challenge may be 
due to the need to employ low molecular weight, highly hydrophilic, molecules in order to 
maintain the required pharmacokinetic properties of the desired products. Many reactions 
are systematically less successful with polar building blocks, a phenomenon which results 
in the logP distribution of successful products being higher than that of the proposed 
library, known as Array logP Drift.1 However, numerous approaches have recently 
emerged that allow (or have the potential to) the systematic variation of molecular 
skeleton whilst remaining within lead-like space. 
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Particularly valuable approaches to allowing systematic variation of molecular skeletons 
utilise methods whereby multiple bonds are formed to each of the new building blocks or 
the employment of multiple building blocks. Herein, examples of approaches which allow 
(or may allow) the generation of varied molecular skeletons whilst remaining within lead-
like space are discussed. 
 
1.3.1 Classification of Strategies  
Approaches to generating compounds with varied molecular skeletons by the pairing of 
multiple building blocks bearing multiple reactive sites are very common. However, there 
are conceptual differences between different approaches utilising two building blocks 
which have been classified by a conceptual framework.35 Examples of these concepts are 
represented in Figure 3.  
 
Figure 3: Different concepts in the pairing of two building blocks. In this scheme different building 
blocks (represented by colours) are chemoselectively paired (represented by shapes) to give cyclic 
products. 
The classification of these reactions are defined by the number of new bonds formed to 
each building block in the conversion to products, with new bonds between functional 
groups within building blocks being counted only once. As such building blocks which 
form one new bond are classified as uni building blocks, building blocks which make two 
new bonds are bi, etc. Overall, the process for molecular scaffold generation is classified by 
a compound naming of the building block functionality, such as (bi/bi) or (bi/uni) (Figure 
3, Panel A and B respectively).  
1.3.2 Scaffold Generation Using bi/uni Approaches 
Aminoarylation approaches utilising a bi/uni strategy have been widely used to generate a 
wide range of (poly) heterocyclic scaffolds (Scheme 6). The aminoarylation approach 
developed by Wolfe and co-workers exploited the palladium catalysed cyclisation of 
unsaturated amines (Scheme 6, Panel A) such as 32 with an external aryl halide to 
generate heterocycles, such as 34.36 This approach yielded 2,6-disubstituted piperazines 
containing varied functional groups which may be used as handles for further chemistries 
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(Scheme 6, Panel B). Under related conditions, the synthesis of substituted morpholines 
was achieved which allowed the authors to generate 3,5- and 3,6-disubstituted systems as 
well as polycyclic systems (Scheme 6, Panel C).37,38 
 
Scheme 6- Aminoarylation approach to substituted heterocycles developed by Wolfe and co-
workers. Panel A- Representative example of synthetic approach to piperazines by the synthesis of 
34. Panel B-   Examples of 2,6-substituted piperazines synthesised from this work. Panel C- 
Illustrative examples of substituted morpholine scaffolds generated by Wolfe and co-workers. 
During efforts towards bicyclic pyrrolidines, the Wolfe group developed an approach 
which remarkably allowed regioselective aminoarylation of unsaturated amine substrates 
(Scheme 7).39 The selective approach to substituted pyrrolidine scaffolds was dependent 
upon the phosphine ligand with a variety of aryl groups giving reproducible 
regioselectivities.  The authors propose that the ligands control relative rates of reductive 
amination or migration steps, leading to regioisomeric products under alternative 
conditions. 
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Scheme 7- Regioselective aminoarylation approaches to the synthesis of polycyclic pyrrole 
scaffolds. a ligand= 2-diphenylphosphino-2’-(N,N-dimethylamino)biphenyl. 
 
1.3.3 Scaffold Generation Using bi/bi Approaches 
Pairing of bifunctional building blocks can be a particularly powerful approach to the 
synthesis of lead like compounds with diverse molecular scaffolds, especially if building 
blocks can be systematically varied. The pairing of some bifunctional building blocks has 
been dubbed ambiphile pairing due to the nucleophilic and electrophilic nature. An 
example of an ambiphilic approach to generate sultam scaffolds was developed by Hanson 
and co-workers (Scheme 8).40 
 
Scheme 8- Synthesis of sultam scaffolds using an ambiphile pairing approach. 
Treatment of the α,β-unsaturated sulfonamide 41 with the epoxide 42 led to the 
formation of the sultam 43. Although the ambiphilic nature of the sulfonamide 41 is clear 
from the functionality in the reagent, the ambiphilic nature of the epoxide is only revealed 
once it has been opened to an acyclic intermediate as shown in Scheme 8. The ambiphilic 
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nature of the α,β-unsaturated sulfonamide 41, and substituted analogues thereof, has been 
utilised in further campaigns to generate a variety of different molecular scaffolds as 
illustrated in Figure 4.41,42 
 
Figure 4-Diverse molecular scaffolds generated by exploiting the ambiphilic nature of analogues of 
the sulfonamide 41. 
An alternative approach to the synthesis of medium ring heterocycles using an ambiphilic 
pairing pathway was developed by Buchwald and co-workers.43 Their approach to 
medium ring nitrogen heterocycles was based on a tandem copper-catalysed C—N bond 
formation–ring-expansion cascade (Scheme 9).  
 
Scheme 9- The Buchwald approach to the synthesis medium ring aza-cycles by way of a cross 
coupling–ring-expansion cascade. Panel A- Representative procedure for the synthesis of medium 
ring heterocycles. Panel B- Examples of alternative ring systems generated using this approach. 
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Treatment of β-lactam 40 and the aryl bromide 41 with 5 mol% CuI and 10 mol% N,N’-
dimethylethylenediamine at 110 °C led to the formation of the lactam 52 in an 83% yield. 
This approach is thought to proceed via an N-arylation followed by an intramolecular acyl 
transfer to give the observed product. Analogously, the heterocycles 53a, 53b and 53c 
(Scheme 9, Panel B) were also generated. This approach clearly shows that the systematic 
variation of building blocks (in this case the aryl halides and β-lactams) in combination 
with a common reaction sequence can rapidly generate diverse molecular scaffolds to give 
novel heterocyclic ring systems. 
A general approach to spirocyclic scaffolds was developed by Gallagher and co-workers by 
exploiting the ambiphilic nature of cyclic sulfamidate building blocks (Scheme 10).44 The 
approach relied upon the reactive nature of the cyclic sulfamidate 55. The cyclic 
sulfamidate 55 was opened with an enolate derived from treating ketopiperadine 54 with 
LiHMDS and Boc2O to give carbamate 56. Hydrogenolysis of the Cbz group, followed by 
base mediated lactamisation and concomitant desilylation, gave 57 at which point 
diastereoisomers could be separated. Final borane‒mediated reduction gave the 
spirocycle 58. This approach proved itself to be highly flexible, enabling the synthesis of 
various spirocyclic motifs, including benzo-fused ring systems, shown in Panel B. 
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Scheme 10: The approach developed by Gallagher and co-workers for the synthesis of compounds 
with diverse spirocyclic scaffolds. Panel A- Synthesis of piperadine 58 exploiting the ambiphilic 
nature of cyclic sulfamidate 55. Panel B- Examples of diverse spirocyclic molecules generated from 
this campaign. 
 
1.3.4 Multicomponent Approaches to Lead-Like Scaffolds 
The ability of approaches to generate small molecule scaffolds is greatly enabled by the 
combination of more than two building blocks.  Such multicomponent approaches may 
allow the variation and systematic combination of all components resulting in rapid access 
to diverse small molecules. A multicomponent approach to pyrrolidinones was developed 
by Dixon et al. employing a nitro-Mannich/lactamisation cascade (Scheme 11).45  
Treatment of the ester 60 with the imine formed from the condensation isobutyraldehyde 
and butylamine led to the isolation of the pyrrolidone 61 in 93% as an 82:18 mixture of 
diastereoisomers. (Panel A). This approach showed wide building block tolerance allowing 
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variation in both amine, aldehyde and ester components allowing the synthesis of highly 
substituted scaffolds with moderate to high levels of diasterocontrol (Panel B).46  
 
Scheme 11: Dixon’s multicomponent approach to the synthesis of pyrrolidones. 
 An alternative stereoselective multicomponent approach to similar pyrrolidones was 
developed using a conjugate addition/nitro-Mannich/Lactamisation strategy (Scheme 
12).47 In this approach an asymmetric conjugate addition of dialkyl zinc reagents into 
nitro-olefins such as 63 gave an intermediate nitronate species (64) which, upon addition 
of an imine and warming to room temperature, underwent a nitro-Mannich addition.  
Subsequent lactamisation gave the N-protected heterocyclic scaffolds, such as 66, with 
high levels of enantio- and diastereo-selectivity.  
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Scheme 12: Enantioselective multicomponent approach to the synthesis of pyrrolidones. 
An approach to the synthesis of morpholinone scaffolds was developed by Kim who made 
use of a variation of an Ugi multicomponent reaction (Scheme 13).48 An Ugi five-centre 
three-component reaction between aldehydes, amino acids and isonitriles led to the 
generation of diverse heterocyclic products based upon the identity of each of the three 
components. Condensation of the amine and aldehyde components led to iminium 
formation (⟶ 69) which was trapped by the addition of the isonitrile to generate a 
nitrilium species. Subsequent intramolecular nitrilium trapping, with the carboxylic acid, 
led to a cyclic intermediate (⟶70). Intramolecular rearrangement, by virtue of an 
appended nucleophile, led to the formation of the morpholinone 71. Systematic variation 
of amino acid building blocks, such as acyclic (⟶72) or homologated cyclic amino acids 
(⟶73), allowed variation of molecular scaffold. The generation of final heterocyclic 
scaffolds is dependent upon the nature of the tethered nucleophile; the alcohol motif from 
glycoaldehyde leads to morpholinone scaffolds. Variation of the tethered nucleophile to 
incorporate alternative nucleophiles, such as amines, using a similar multicomponent 
approach has led to the synthesis of various nitrogen based heterocycles (Panel B, 74 and 
75).49 An obvious deficiency of this approach is the poor diastereoselectivity observed 
during the synthesis of the morpholinone 71. 
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Scheme 13: Multicomponent approach to morpholinone utilising an Ugi five-centre three-
component approach. Panel A- Overview of the Ugi‒based approach taken to the synthesis of 
heterocycles exemplified by the synthesis of 71. Panel B- Examples of scaffolds generated by this 
approach (72 and 73) and through a similar multicomponent reaction approach (74 and 75). 
 
 
 
 
 
  
34 
 
1.4 Project Outline 
This project is focused on the development of methodology for the facile generation of 
heterocyclic compounds, with desirable physicochemical properties for drug discovery, 
from readily available building blocks.  
In order to generate diverse heterocycles from a limited number of building blocks a 
modular strategy, based upon selective coupling of bifunctional molecules, was devised 
and is summarised in Scheme 14.  
Scheme 14: Summary of approaches taken to the generation of heterocycles with lead-like 
properties. Panel A- proposed strategy for the systematic pairing of bifunctional molecules may 
allow the generation of a variety of lead-like heterocyclic scaffolds. Panel B- Examples of building 
blocks used in these approaches and the heterocycles which may be generated. 
The proposed strategy is based on a modular coupling approach in which bifunctional 
building blocks (those containing two electrophilic sites, two nucleophilic sites, or one 
nucleophilic and one electrophilic site) would be chemoselectively coupled to give 
cyclisation precursors (Scheme 14, Panel A). The cyclisation precursors would then be 
chemoselectively cyclised to give heterocyclic scaffolds. The selection of both the building 
blocks and methods for coupling may allow the synthesis of diverse heterocyclic scaffolds 
which, after decoration with various capping groups, may lead to heterocycles with lead-
like physicochemical properties.  
The development of approaches to allow the generation of diverse heterocycles will focus 
on three readily available classes of building blocks: amino-acids, amino-alkynes and 
amino alcohols (Scheme 14, Panel B). The methodology developed within these studies 
aims to allow the systematic combination of these classes of building blocks in both formal 
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hetero-coupling approaches (i.e. ⟶76 and ⟶77) or a formal homo-coupling approach 
(⟶78). The key to these approaches is the ability to generate different ring sizes of 
heterocycle as well as the ability to selectively introduce substitution onto the carbon 
framework of the ring system. Furthermore, the ability to introduce orthogonally 
cleavable functional groups may allow further diversity generating reactions, giving more 
complex molecular skeletons. The development of these methods for the synthesis of 
heterocycles with lead-like physicochemical properties will be described in the following 
Chapters. 
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Chapter 2: Development of a Modular Approach to Piperazines, Diazepines 
and Related Ring Systems 
This Chapter describes the development of approaches to the synthesis of diverse 
heterocyclic scaffolds. The approaches involve the pairing of bifunctional building blocks, 
with the reaction of an activated alcohol as the key step in heterocycle formation. A key 
challenge was to control the chemoselective condensation of the required ambiphilic 
building blocks. This Chapter focusses on the development, and subsequent 
exemplification, of methods for the ambiphilic pairing of amino acids with amino alcohols 
(Figure 5, Panel A) and cyclic sulfamidates with amino alcohols (Figure 5, Panel B) 
 
Figure 5: Overview of approaches for the formation of heterocycles described in this Chapter. 
Bonds shown in bold are those made during the proposed heterocycle formation. Panel A- The 
bifunctional paring of amino acids and amino alcohols to give ketopiperazines and related ring 
systems. Panel B- The bifunctional pairing of cyclic sulfamidates and amino alcohols to give 
piperazines and related heterocycles. 
 
2.1 Overview of Amino Acid – Amino Alcohol Pairing 
This Section outlines the development of an approach to the synthesis of ketopiperazines 
and related heterocycles. An overview of the proposed approach is given in Figure 6. The 
approach would involve the condensation of an amino acid derivative with an amino 
alcohol building block to give a heterocyclic ring. 
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Figure 6: Proposed approach to the synthesis of ketopiperazines and related ring systems. Panel A- 
Proposed general approach for the formation of ketopiperazines through the condensation of 
amino acid and amino alcohol derived building blocks. This approach would exploit sequential 
amide formation and intramolecular cyclisation to generate new heterocycles (new bonds formed 
are highlighted by broad bonds). Panel B- Examples of diverse ketopiperazine derived heterocycles 
which might be synthesised using this approach. 
Initially, a pair of readily available building blocks ‒ an amino acid derivative and an 
amino alcohol derivative ‒ would be coupled by amide formation. Subsequently, it was 
proposed to form a new heterocyclic ring system, either using hydrogen-borrowing 
chemistry or a Mitsunobu reaction. The development of methods for these individual steps 
are outlined in Sections 2.1.1.2 and 2.1.1.3 respectively. Ideally, the methods developed to 
generate ketopiperazine‒derived heterocycles would be performed using as few labour 
intensive purification steps as possible. As such, synthetic approaches have also taken into 
account the potential impurities for each coupling step. The scope and limitations of this 
approach were investigated by the synthesis (Section 2.1.2) and subsequent coupling of 
varied amino acid and amino alcohol building blocks (Section 2.1.2.3). The potential 
power of this approach was illustrated by the in silico generation of a diverse 
ketopiperazine based library from commercial amino alcohols and amino acids, guided by 
the results of the scope and limitation studies (Section 2.1.3). 
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2.1.1 Reaction Development 
This Section outlines the development of methodology for the efficient condensation of 
model amino acids and amino alcohols (Section 2.1.1.1) and subsequent intramolecular 
cyclisation to give ketopiperazine ring systems (Section 2.1.1.2 and 2.1.1.3). 
2.1.1.1 Synthesis of Building Blocks for the Investigation of the Approach 
In order to study the initial development of the method discussed in section 2.1 a small 
selection of commercially available amino acid and amino alcohol building blocks was 
required; these building blocks are shown in Figure 7.  
 
Figure 7: Amino acid and amino alcohol building blocks required for the development of 
methodology. a Commercially available. 
 The synthesis of non-commercially available amino acid derived building blocks is 
outlined in Scheme 15. The sulfonamides 79 and 80 were synthesised from the amino acid 
85 and amino ester 86 respectively by treatment with 2-nitrobenzenesulfonyl chloride. 50 
The amino ester 81 was obtained from the hydrochloride salt 87 by means of a two-step 
reductive amination sequence. 51 
 
Scheme 15: Synthesis of valine-derived building blocks 
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The required amino alcohol building blocks were procured from commercial sources. 
However, the amino alcohol 84 was not readily available and was subsequently 
synthesised.52 The amino alcohol 84 was synthesised from the amine 82 using a two-step 
reductive amination procedure as shown in Scheme 16.  
 
Scheme 16: Synthesis of 8 from 7 by reductive amination 
 
2.1.1.2 Methods for Amide Formation 
With a small selection of amino acid and amino alcohol derived building blocks in hand, 
the first step of the proposed bifunctional pairing approach was studied. The synthesis of 
cyclisation substrates through the amide coupling of amino alcohol building blocks and 
either amino acid- or amino ester- building blocks was studied and is outlined in Table 3. 
 
Entry 
Amino Acid 
Derivative 
Amino Alcohol Conditions Product 
Yield 
(%) 
1 
 
 
A 
 
88 
88 
2 
 
 
A 
 
89 
91 
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3 
 
 
A 
 
90 
75 
4 
 
 
B 
 
91 
72 
5 
 
 
C 
 
92 
56 
6 
 
 
A 
 
93 
78 
7 
 
 
C 
 
94 
18 
8 
 
 
D 
 
94 
No 
reactiona 
9 
 
 
E 
 
94 
38 
10 
 
 
F 
 
94 
No 
reactiona 
11 
 
 
G 
 
94 
70* 
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Table 3: Investigation into the condensation of amino acid and amino alcohol derivatives.  *Yield 
calculated by integration of the 500 MHz 1H NMR- comparison of product to coupling agent by-
product. a No product observed by TLC or LCMS analysis of crude reaction mixtures. Conditions: A: 
TBD (30 mol%), 70°C; B: 30 mol% TBD, NEt3 , MeOH, 70°C; C: 30 mol% TBD, PhMe, 70°C; D: DCC; E: 
Acid, SOCl2, DCM, then Amino alcohol, Na2CO3, DCM; F: PPh3Cl2, CHCl3; G: Acid, Ghosez’s reagent, 
DCM then Amino alcohol, K2CO3, 
TBD-catalysed amide formation from methyl esters (Table 3, entries 1-7) generally 
proceeded in high yield.53 However, reactions between the amino esters 86 and 80 and the 
amino alcohol 84 (entries 5 and 7) were slow to progress, giving poor yields of expected 
product, and required dilution of the viscous reaction mixtures to allow the reaction to 
proceed. The condensation of the acid 79 with the amine 84 under a variety of conditions 
(entries 8-11) gave mixed results. The best results were achieved using Ghosez’s reagent, 
to generate an acid chloride intermediate, (entry 11) which was significantly higher 
yielding than the TDB mediated method (entry 7).54  As such, it was decided Ghosez’s 
reagent would be exploited in an operationally simple approach to give model amides, 
with orthogonally cleavable nitrogen protecting groups, in good yields.  
 
2.1.1.3 Heterocycle Formation under Hydrogen Borrowing Conditions 
Hydrogen-borrowing approaches allow redox-neutral alkylation of nucleophiles through a 
reductive alkylation manifold.55 The alkylation of amines with alcohols is proposed to 
proceed through a reductive amination process as illustrated in Scheme 3. 
 
Scheme 17: Proposed55,56 catalytic manifold for hydrogen borrowing alkylation of aniline with 
benzyl alcohol. 
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In order to investigate hydrogen borrowing as a route to intramolecular cyclisation 
towards heterocycles the commercially available [Ir(Cp*)Cl2]2 complex was used to 
investigate substrate compatibility. A selection of amines were treated with an alcohol 
under conditions which have been demonstrated to induce hydrogen borrowing alkylation 
as outlined in Table 4.56   
Entry Amine Alcohol Product 
Yield 
(%) 
1 
  
 
96 
75 
2 
 
 
— 0 
3 
 
 
— 0 
4 
 
 
— 0 
 
Table 4: Attempted amine alkylation under hydrogen borrowing conditions. Conditions- amine, 
alcohol, [Cp*IrCl2]2 (3 mol%), K2CO3 (5 mol%), PhMe, 110°C, sealed tube. 
Gratifyingly, repeating literature conditions (Table 4, entry 1) led to the aniline 96 in a 
yield comparable to that reported.56 However, variation of either amine or alcohol source 
led to a complete loss in reactivity in the intermolecular alkylation (entries 2-4).  
It was hypothesised that an intramolecular hydrogen borrowing approach may allow an 
approach towards heterocycle formation. With amides 88 and 89 in hand, the 
intramolecular cyclisation under iridium catalysed conditions were studied as shown in 
Scheme 18. Attempts to induce intramolecular cyclisation using the [Ir(Cp*)Cl2]2  system 
reported by Fujita failed to give any desired material with significant quantities of starting 
material remaining even after extended reaction times (>48 h). A potential hypothesis for 
the failure of this approach is that the amide substrate may form a stable chelate with the 
iridium thus preventing any free catalyst from performing the desired transformation 
(Figure 8). Due to this clear substrate incompatibility with iridium catalysed hydrogen 
borrowing methodology this route was abandoned.   
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Scheme 18: Attempted iridium mediated intramolecular hydrogen borrowing to form keto-
piperazines 97 and 98. 
 
Figure 8: Hypothesises substrate‒catalyst coordination modes preventing catalysis. 
Due to this clear substrate incompatibility with iridium catalysed hydrogen borrowing 
methodology this route was abandoned.   
 
2.1.1.4 Heterocycle Formation under Mitsunobu Conditions 
An alternative method for the in situ electrophilic hydroxyl group activation to give 
heterocycles is the Mitsunobu reaction.47 Accordingly, the amide was treated with 
diethylazodicarboxylate (DEAD) and PPh3 in cold (0°C) THF. This approach for 
intramolecular cyclisation was explored as outlined below (Table 5).  
 
Entry R R’ Yield (%)* Product 
1 H H No reaction 99 
2 H Ns No reaction 100 
3 Me H 55 101 
4 PMB H 73 102 
5 PMB o-Ns 90 103 
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Table 5: Cyclisation of keto-piperazine precursors under Mitsunobu conditions.* Isolated yields of 
purified product. Conditions; Amide (1.0 eq.), DEAD (1.4 eq.), PPh3 (1.4 eq.), THF (0.05 M), rt. 
Exposing amino alcohols 90 and 93 (which are secondary amides) to DEAD and 
triphenylphosphine in THF failed to give any identifiable cyclic material (Table 5, entries 1 
and 2). However, compounds containing tertiary amides (91, 92 and 94) gave the cyclised 
products in good yields (entries 3, 4 and 5). 500 MHz 1H NMR analysis of tertiary amides 
(entries 3, 4 and 5) shows the presence of two rotameric species, arising from slow 
rotation of the amide bond. It is proposed that a low population of the reactive 
conformation of the secondary amides, due to a preferred Z conformation minimising 
steric interactions, may be preventing the intramolecular cyclisation as outlined in Figure 
9. 
 
Figure 9: Reactive and unreactive conformations of reactive intermediates. Conformations place 
nitrogen nucleophile in close proximity to the C-O σ* orbital allowing cyclisation to proceed. 
However, unreactive conformations place reactive groups remotely, preventing reaction 
progression. 
 Optimal cyclisation was achieved with sulfonamide 94 (Table 5, Entry 5), presumably due 
to the increased acidity of the amine N-H (pKa approx. 10),58 and subsequently the 
nitrobenzensulfonyl (Ns)59 group was employed in further building blocks. 
 
2.1.1.5 Ketopiperazine Deprotection 
As incorporation of the nosyl group led to optimal yields of ketopiperazine 102 (Table 3, 
Entry 5) it was deemed necessary to study the removal of the sulfonamide group in order 
to facilitate future scaffold elaboration. The cleavage of both 2- and 4- isomers of the nosyl 
group has been demonstrated with a variety of nucleophilic reagents (usually thiols). The 
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compatibility of this deprotection approach with ketopiperazines was investigated as 
shown in Scheme 19. Treatment of the sulfonamide 103 with thiophenol and K2CO3 in 
DMF led to the clean isolation of 76 after isolation of the free base by ion exchange resin. 
 
Scheme 19: Nosyl group cleavage under nucleophilic conditions 
 
2.1.1.6 Development of a ‘One-Pot’ Procedure 
With a reliable method for the step-wise synthesis of ketopiperazine 76 from amino 
alcohol 84 and amino acid 79 in hand, efforts were focussed on the telescoping of the 
process. In order to develop a minimally labour-intensive approach, avoiding laborious 
purification steps such as column chromatography, a telescoped route for the synthesis of 
ketopiperazine 76 from amino acid 79 was investigated. The approach taken to the 
telescoping of the ketopiperazine formation process is outlined in Scheme 20. 
 
Scheme 20: Telescoped route to the formation of ketopiperazine 76 using SCX as the only 
purification step. Compounds in square brackets were used as crude mixtures. 
The treatment of the acid 79 with Ghosez’s reagent, followed by amino alcohol 84 and 
K2CO3 in dichloromethane presumably gave the amide 94 as a crude reaction mixture after 
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aqueous work up. The crude mixture of 94 was then treated with diethylazodicarboxylate 
(DEAD) and triphenylphosphine which induced heterocycle formation. Finaly, cleavage of 
the 2-nitrophenylsulfonamide (o-Ns) group with thiophenol and K2CO3 in DMF, followed 
by purification with strong cation exchange resin (SCX), gave the ketopiperazine 102 in 
22% yield over 3 synthetic steps. In comparison, the step-wise synthesis of the 
ketopiperazine 76 proceeded in an overall yield of 50%, requiring the purification of 
intermediates 94 and 102 by column chromatography.  The lower yields presumably 
stems from unreacted starting materials or by-products reacting with required 
intermediates to give unwanted material. However, although the yields are diminished, 
this process demonstrated the viability of the ambiphile-pairing approach with minimal 
labour-intensive purification.   
 
2.1.2 Scope and Limitation Studies 
The scope and the limitations of this amino acid- amino alcohol pairing approach was 
investigated by the systematic variation of amino alcohol and amino acid building blocks 
bearing varied substitution on the carbon chains. The proposed building blocks were 
selected to include substitution on the amino alcohol chains (both α and β to OH), cyclic 
substituents (towards the incorporation of fused ring systems) and extended chain 
variants (1,2- and 1,3- amino alcohols towards variation of heterocycle size). The building 
blocks required for these scope and limitation studies are outlined in Figure 10. 
 
Figure 10: Proposed building blocks for scope and limitation studies. 
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2.1.2.1 Synthesis of Amino Alcohol Building Blocks 
The amino alcohol building blocks identified in Section 2.1.2 were synthesised from 
commercially available amino alcohols. In each case the primary amine was reductively 
aminated by treatment with anisaldehyde and an appropriate reducing agent (Table 6).60 
Entry Primary amine Conditionsa Product Yield (%)b 
1 
 
A  
105 
89 
2 
 
A  
106 
80 
3 
 
A  
107 
64 
4  B 
 
108 
80 
5 
 
A  
84 
82 
 
Table 6: Synthesis of N-PMB amino alcohols by reductive amination. aConditions; A- amino alcohol 
(1.0 eq.), anisaldehyde (1.2 eq.), 4 Å mol. sieves, MeOH (1 M), 50 °C then NaBH4 (2.0 eq.), 0 °C to rt; 
B- anisaldehyde (1.0 eq.), amino alcohol (2.0 eq.), Na(CN)BH3 (1.0 eq.) MeOH (0.1 M), rt. b Isolated 
yields. 
A similar approach was employed to prepare the amino alcohols 111 and 115. In these 
cases, the parent amino alcohol was synthesised and subsequently alkylated, without 
isolation, to give the required secondary amine. The synthese of the amino alcohols 111 
and 115 are outlined in Scheme 21. 61, 62 
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Scheme 21: Multistep synthesis of the amino alcohols 111 and 115. 
Reduction of amino acid 109 with LiAlH4 gave the intermediate amino alcohol 110 which 
was used as a crude mixture for the reductive alkylation with anisaldehyde to give amino 
alcohol 111 in 45% over two steps. The synthesis of amino alcohol 115 was achieved by 
the treatment of the epoxide 112 with LiCN to give the nitrile 113 which was reduced 
with LiAlH4 to give the amino alcohol114 as a crude product; which was then alkylated 
under reductive conditions to give the amino alcohol 115 in 77% yield over 3 steps. 
 
2.1.2.2 Synthesis of Amino Acid Building Blocks 
The sulfonamides identified in section 2.1.2 were synthesised from commercially available 
amino acids. Treatment of the commercially available amino acids with 2-
nitrobenzenesulfonyl chloride under biphasic conditions gave the required sulfonamides 
79 and 116 (Table 7, entries 1 and 2). The preparation of the hindered amino acid 117 
required the temporary protection of the acid group, giving 117 in 35% yield (entry 3). 
Entry Amino Acid Conditionsa Product Yield (%)b 
1 
 
A 
 
79 
98 
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2 
 
A  
116 
46 
3 
 
A 
B 
C 
 
117 
No isolated material 
No isolated material 
35 
 
Table 7: Synthesis of sulfonamides from amino acids. a Conditions; A- Amino acid (1.0 eq.), NsCl (1.3 
eq.), THF/H2O (1:3.5, 0.8 M); B- Amino acid (1.0 eq.), NsCl (1.5 eq.), NaHCO3 (2.0 eq.), DMF/ H2O 
(1:1, 0.2 M); C- Amino acid (1.0 eq.), N, O- Bistrimethylsilylacetamide (2.0 eq.), CH2Cl2 (0.2 M), then 
NsCl (1.1 eq.), then NaHCO3 (5% w/w, 0.2M). b Isolated yields. 
 
2.1.2.3 Scope and Limitation Studies- Building Block Pairing 
With the required building blocks in hand investigations into the systematic coupling of 
building blocks were carried out using the general procedure shown in Scheme 8. In each 
case, the acid building block was treated with Ghosez’s reagent in dichloromethane, 
followed by addition of the appropriate amino alcohol and K2CO3 to give the amide 
intermediate which was not isolated.  Amide intermediates were treated with DEAD and 
triphenylphosphine to give a crude heterocycle; subsequent exposure to thiophenol and 
K2CO3 gave the final deprotected heterocycle after purification with ion exchange resin. 
The results of this systematic building block coupling are shown in Table 8. 
 
Scheme 22: General one pot approach to the formation of ketopiperazine like compounds by amino 
acid/ amino alcohol pairing illustrated by the synthesis of 76. 
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Entry Acid Amino alcohol Product Yield (%)a 
1 
 
  
102 
22 
2 
 
 
 
118 
12 
3 
 
 
 
119 
9 
4 
 
  
120 
5 
5 
 
  
121 
18 
6 
 
 
 
122 
42 
7 
   
123 
- 
8 
 
 
 
124 
- 
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9 
 
  
125 
15 
Table 8: Synthesis of ketopiperazine based ring systems for the determination of scope and 
limitations in the amino acid - amino alcohol pairing approach. a Isolated yields of compound over 3 
step procedure outlined in Scheme 22. 
2.1.3 Summary Amino Acid ‒ Amino Alcohol Pairing 
Overall, these scope and limitation studies gave ketopiperazine and ketopiperazine 
derived heterocycles in generally disappointing yields, as outlined in Table 8. However, it 
is clear that heterocycle size can be readily altered by the variation of either amino alcohol 
(entry 2) or amino acid (entry 3) when comparing with model ketopiperazine 76 (entry 
1). Alkyl substituents are tolerated in the amino alcohol building blocks; either α- or β- to 
the hydroxy group (entries 4, 5 and 6) allowing substitution to be incorporated directly 
onto the heterocycle carbon framework. More complex substitution in amino alcohol 
building blocks are not well tolerated (entries 7 and 8) which may be due to steric factors 
affecting the amide formation step. However, spirocyclic substitution is well tolerated in 
the amino acid building blocks (entry 9). The achieved yields in this approach were often 
low and this may be indicative of significant undesired by-products. However, this 
approach clearly demonstrates the concept of bifunctional building block coupling 
through amino acid and amino alcohol pairing, thus acting as a ‘proof of principle’. 
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2.2 Overview of Cyclic Sulfamidate – Hydroxy Sulfonamide Pairing 
This Section describes the development of an approach for the synthesis of piperazines 
and related heterocycles. This approach involved the coupling of cyclic sulfamidate and 
amino alcohol building blocks, followed by an intramolecular cyclisation (Figure 11). It 
was envisaged that variation of either, or both, building blocks would facilitate access to 
heterocycles of varied size and substitution patterns (Figure 11, Panel B). 
 
Figure 11: Panel A- General approach for the formation of piperazines through the fusion of amino 
alcohol building blocks. This approach would exploit sequential C-N bond forming steps 
(highlighted with bold bonds) to generate new heterocycles. Panel B- Examples of diverse 
piperazine-like heterocycles which might be synthesised using this approach. 
Initially, pairs of readily available amino alcohol and cyclic sulfamidate building blocks 
would be chemoselectively paired using sequential C-N bond forming steps: cyclic 
sulfamidate opening and cyclisation using either hydrogen borrowing or Mitsunobu 
methods (Section 2.2.1). The scope and limitations of this approach were investigated by 
systematically varying the combination of amino alcohol and cyclic sulfamidate building 
blocks and studying the subsequent pairing reactions (Section 2.2.2). The potential power 
of this approach was further illustrated by the in silico enumeration of likely accessible 
diverse lead-like heterocycles from readily or commercially available building blocks 
(Section 2.2.3) and exemplified by the synthesis of a small library of diverse heterocycles 
(Section 2.2.4). 
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2.2.1 Reaction development 
To investigate the feasibility of the proposed amino alcohol pairing approach a model 
system was devised. This model system was based on the pairing of the ethanolamine-
derived cyclic sulfamidate 130 and the hydroxy sulfonamide 131 to give the piperazine 
78 (Figure 12). 
 
Figure 12: Proposed model piperazine synthesis through formal dimerisation of ethanolamine. 
In order to control selectivity (i.e. hetero-pairing of building blocks over homo-pairing) in 
the approach proposed above, consideration needs to be focussed on controlling the 
reactivity of functional groups in each reaction step. Cyclic sulfamidates behave as latent 
ambiphiles, i.e.  their nucleophilic character is only revealed upon successful opening and 
subsequent sulfamic acid hydrolysis (Figure 13). 
 
Figure 13: General reactivity of cyclic sulfamidates allowing the selective unmasking of latent 
nucleophiles under protic conditions. 
 
2.2.1.1 Synthesis of Building Blocks for the Investigation of the Approach 
Ethanolamine-derived building blocks 84 and 131 were synthesised by employing 
literature methods (Scheme 23). Reductive amination of the amine 82 with anisaldehyde 
gave the amino alcohol 84 which was subsequently converted into the cyclic sulfamidate 
130 using the two-step cyclisation/ oxidation procedure developed by the Gallagher 
group.64 
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Scheme 23: Synthesis of cyclic sulfamidate 130 from the amino alcohol 82. 
The sulfonamide 131 was synthesised by the treatment of ethanolamine 82 with 2-
nitrobenzensulfonyl chloride under Schotten—Baumann conditions (Scheme 24). 
 
Scheme 24: Synthesis of the sulfonamide 131 from the amino alcohol 82. 
2.2.1.2 Ring Opening of Cyclic Sulfamidates with Hydroxy Sulfonamides. 
With both the cyclic sulfamidate 130 and the hydroxy sulfonamide 131 in hand the 
intermolecular pairing was investigated (Scheme 25). Treatment of the sulfonamide 131 
with sodium hydride in DMF followed by the addition of the cyclic sulfamidate 130 led to 
the isolation of the amine 132 after proteolytic work up.65 In this case, facile purification 
by strong cation exchange (SCX) resin gave the expected material as pure product. This 
method of purification was deemed particularly powerful in this pairing step as only 
successful pairing of the building blocks 130 and 131 reveal the basic amine present in 
132, allowing for purification by SCX (no trace of 84 was observed through a potential 
acid mediated decomposition of cyclic sulfamidate 130). Although the sulfonamide 131 
could be seen as nucleophilic at both N and O termini; the only observed product was the 
amine 132 with no polymerisation or O-alkylation observed. This selectivity is believed to 
be due to the differences in pKa between the sulfonamide NH and alcohol OH (pKa approx. 
10 and 15 respectively58) allowing selective deprotonation of the sulfonamide and 
facilitating N-alkylation. 
 
Scheme 25: Nucleophilic opening of cyclic sulfamidate 130 with sulfonamide 131 under basic 
conditions. 
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2.2.1.3 Heterocycle Formation under Hydrogen Borrowing Conditions 
Having identified a facile method for the formation of the amine 132, the subsequent 
intramolecular cyclisation was studied using hydrogen borrowing methodology (Scheme 
26). In a replication of literature method, the diol 133 was reacted with p-
methoxybenzylamine by treatment with 5 mol% [Cp*IrCl2]2 which led to the formation of 
the morpholine 134.66 Presumably, this method proceeds via an amino alcohol 
intermediate, such as 135.  Attempts to induce intramolecular cyclisation of 132 using 5 
mol% [Cp*IrCl2]2 resulted in recovered starting materials or traces of debenzylated 
starting material. This contrasting reactivity may stem from the potential for metal-
substrate chelation resulting in the inactivation of the catalyst as previously discussed 
(Section 2.1.1.3). 
 
Scheme 26: Attempted piperazine formation through intramolecular hydrogen borrowing 
approach from amino alcohols. 
2.2.1.4 Heterocycle Formation under Mitsunobu Conditions 
With the failure of hydrogen borrowing, attention was turned to an alternative method of 
activation of the hydroxyl group. The amine 132 was treated with diethylazodicarboxylate 
(DEAD) and triphenylphosphine: the piperazine 78 was obtained in a 93% yield after 
isolation with ion exchange resin (Scheme 27).  
 
Scheme 27: Cyclisation of the amino alcohol 132 to the piperazine 78 under Mitsunobu conditions. 
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2.2.1.5 Summary of Cyclic Sulfamidate – Hydroxy Sulfonamide Paring Method 
The combination of both anionic opening of cyclic sulfamidates with sulfonamides and 
cyclisation of the resulting acyclic intermediate, under Mitsunobu conditions, was thus 
validated as a process for the fusion of amino alcohol derived ambiphilic building blocks. 
Furthermore, the use of strong cation exchange resins as a facile purification method was 
also validated (Scheme 28). 
 
 
Scheme 28: Validated approach for the synthesis of piperazines by ambiphilic paring of amino 
alcohols. 
 
2.2.2 Scope and Limitation Studies 
In order to determine the scope for the formation of heterocycles (Scheme 5), a small 
selection of substrates was chosen. The factors which were studied were: 
1. Ring Size- Potential for variation of the size of the heterocyclic ring system. 
2. Substitutional Diversity- Potential to vary the pattern of substituents on carbon 
atoms in the heterocycle. 
3. Matched and Mismatched effects- The potential to prepare either 
diastereoisomeric series of heterocycles with substitutions on the carbon atoms in 
the heterocycle.  
4.  
2.2.2.1 Synthesis of Cyclic Sulfamidate Building Blocks 
The synthesis of a small array of cyclic sulfamidates was performed in order to determine 
scope and limitations of the approach. The required cyclic sulfamidate building blocks 
were synthesised from commercially-available amino alcohols (Table 9). 
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Entry Amino alcohol 
Secondary amine 
(Yield, %) 
Yield 
(%) 
Cyclic 
sulfamidate 
(Yield, %) 
Yield 
(%) 
1 
 
 
84 
82  
130 
89 
2  
 
108 
 
90 
 
144 
83 
3 
 
 
107 
98 
 
145 
95 
4 
 
 
140 
93 
 
146 
88 
5  
 
 
141 
80 
 
147 
89 
 
Table 9: Synthesis of cyclic sulfamidates. Reagents and conditions; 1. Anisaldehyde (1.2 eq,), MeOH 
(1.0 M) 4Å mol. sieves., 50 °C then NaBH4 (2.0 eq.), 0 °C to rt. 2. SOCl2 (1.1 eq.), imidazole (4 eq,), 
NEt3 (2.2 eq.), CH2Cl2 (0.1 M), −60 °C to rt., 4. Cyclic sulfamidite (1.0 eq.), NaIO4 (1.1 eq.), RuCl3⋅3H20 
(0.1 mol.%), MeCN (0.13 M), H2O (0.13 M) 0 °C to rt. 
The synthesis of cyclic sulfamidates from commercially available amino alcohols was 
performed using a two-step reductive amination procedure with anisaldehyde, giving 
amines 84, 107, 108, 140 and 141 in good yields (Table 9). Subsequent two-step cyclic 
sulfamidate formation was undertaken by treatment of the amino alcohol with thionyl 
chloride, to give the corresponding cyclic sulfamidite, followed by oxidation using NaIO4 
and catalytic amounts of RuCl3 to the target materials 130, 144‒147. In all cases, this 
approach proceeded in uniformly high yields for both reductive amination and subsequent 
cyclic sulfamidate formation steps. 
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2.2.2.2 Synthesis of Hydroxy Sulfonamide Building Blocks 
The synthesis of required sulfonamides from commercially-available amino alcohols was 
performed by treatment with 2-nitrobenzenesulfonyl chloride under Schotten—Bauman 
conditions (Table 10). In all cases, sulfonamide formation proceeded well, giving the 
target sulfonamides in >80% yield. 
Entry Amino Alcohol Sulfonamide Yield (%) 
1 
 
 
131 
84 
2  
 
151 
98 
3 
 
 
152 
94 
4 
 
 
153 
95 
5 
 
 
154 
88 
 
Table 10: Synthesis of hydroxysulfonamides. Reagents and conditions; Amino alcohol (1.05 eq.) 
2-nitrobenzenesulfonyl chloride (1.0 eq.), Na2CO3 (1.05 eq.), CH2Cl2‒H2O (1:1, 0.8 M) 
 
2.2.2.3 Scope and Limitation Studies- Building Block Pairing 
Combinations of the amino alcohol and cyclic sulfamidate building blocks were 
systematically investigated. In each case the hydroxy sulfonamide building block was 
treated with NaH in DMF, followed by the addition of a cyclic sulfamidate building block. 
Upon completion of the reaction (as determined by TLC and LCMS analysis), the reaction 
mixture was treated with HCl to cleave residual sulfamic acid intermediates allowing the 
basic nature of the amine to be revealed. Purification of crude reaction mixtures by 
treatment with strong cation exchange resin gave cyclisation substrates (Table 11). 
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Entry 
Cyclic 
sulfamidate 
Hydroxy 
Sulfonamide 
Amino alcohol 
Yield 
(%) 
1  
130 
131 
 
 
132 
74 
2 130 154 
 
156 
72 
3 
 
144 
131  
157 
49 
4 144 151 
 158 
60 
5 
 
145 
154 
 
159 
0a 
6 145 153 
 
160 
68 
7 145 152 
 
161 
71 
8 
 
146 
154 
 
162 
0 a 
9 146 153 
 
163 
78 
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Table 11: Nucleophilic opening of cyclic sulfamidates. Reagents and conditions; sulfonamide (1.1 
eq.), sulfamidate (1.0 eq.), NaH (1.1 eq.), DMF (1.0 M) then HCl (5.0 M, 1 mL). a Consumption of 
cyclic sulfamidate was not observed even after extended reaction times or reaction at 
elevated temperature (80°C). 
Generally, nucleophilic opening of cyclic sulfamidates proceeded smoothly, tolerating 
variation in sulfamidate ring size and carbon centred substitution in both sulfamidate and 
sulfonamide building blocks. The combination of enantiomerically-pure building blocks 
resulted in similar yields of diasteroisomeric products (Table 11, entries 6 and 7, 9 and 10, 
13 and 14) which suggest that any matched/ mismatched effects have no detrimental 
outcome on the product yield.67 One readily identifiable limitation is the combination of 
sulfonamides bearing substitution α- to the sulfonamide nitrogen with substituted 
sulfamidates (entries 5, 8 and 12) which did not react (even at elevated temperatures). 
The sulfonamide 147 has been shown to be a competent electrophile under these reaction 
conditions (entry 2) as have substituted cyclic sulfamidates (entries 6, 9 and 13). As such, 
10 146 152 
 
164 
74 
11 
 
147 
131  
165 
75 
12 147 154 
 
166 
0 a 
13 147 153  
167 
87 
14 147 152  
168 
86 
15 147 151  
169 
78 
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it is believed that the origin of the lack of reactivity arises from steric factors between 
substituents on both cyclic sulfamidates and sulfonamides (Figure 14). 
 
Figure 14: Orientation of the nucleophile to maximise overlap with the carbon – oxygen σ*orbital 
(blue) may result in alkyl substituents being proximal to each other ((B) and (C), red arrows) which 
may hinder reactivity resulting in a lack of observable product when compared to situation (A) with 
minimal steric interactions (green arrows). 
With the acyclic amino alcohols in hand, the ring-closures under Mitsunobu conditions 
were studied using conditions identified in section 2.2.1.2. The acyclic amino alcohols 
were treated with DEAD and triphenylphosphine in THF, followed by purification by 
treatment with strong cation exchange resin to give the heterocyclic products (Table 12). 
Entry Amino alcohol Heterocycle Yield (%) 
1 132  
78 
94 
2 137  
170 
80 
3 165  
171 
96 
4 156  
172 
95 
  
62 
 
5 160 
 
173 
48 
6 163 
 
174 
48 
7 167 
 
175 
46 
8 161 
 
176 
41 
9 152 
 
177 
55 
10 168 
 
178 
57 
11 158  
179 
95 
12 169 
 
180 
56 
 
Table 12: Intramolecular cyclisations under Mitsunobu conditions. Reagents and conditions; 
Amino‒alcohol (1.00 eq.), DEAD (1.4 eq.), PPh3 (1.4 eq.), THF (0.05M), 0 °C to rt. 
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Cyclisation under Mitsunobu conditions proceeded well in all examples. These conditions 
allow the variation of ring sizes in good to excellent yields (Table 12). For example, this 
approach enabled the synthesis of unsubstituted 6- (entry 1), 7- (entry 2), and 8- (entry 
11) membered rings. This methodology is tolerant of having single carbon- based 
substitutions on either the parent cyclic sulfamidate or amino alcohol building block 
(entries 3 and 4). Piperazines containing multiple carbon-based substitutions on the 
heterocycle skeleton are produced in a slightly diminished yield when compared to no 
substitutions (entries 5 to 10 compared to 1). However, the synthesis of all stereoisomers 
of 160 (entries 5, 6, 8 and 9) show that there are no significant matched or mismatched 
effects on the observed product yield, demonstrating the stereospecific nature of this 
process. Also the synthesis of diastereoisomers 175 and 178 (entries 7 and 10) again 
reinforce the lack of any significant matched/ mismatched effects.67 
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2.2.3 Diverse Piperazine Based Lead-Like Library 
In order to illustrate the potential power of the synthetic approach in the generation of 
diverse molecules, with properties desired in lead like compounds, an in silico library of 
piperazine and piperazine-like compounds was enumerated.33 A schematic outline of this 
in silico approach is shown in Figure 15.  
 
Figure 15: A schematic outline to the in silico approach employed to illustrate the potential power 
of the amino alcohol and cyclic sulfamidate coupling approach to diverse heterocycles. Panel A- An 
overview of the in silico protocol utilised in this approach. Text in hashed boxes represents 
‘synthetic’ transformations and text given in blue represents virtual libraries of compounds used/ 
generated in this approach. Panel B- An example of structures used in the in silico approach by 
demonstrating the synthesis of piperazine B61 from ethanolamine B1. 
The in silico approach used amino alcohols and amino acids from commercial sources 
(Figure 15, A1), which were appropriately modified to include required functionalities 
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(i.e. N-Ns and N-PMB groups respectively) and protect any appended functionality, which 
would otherwise be incompatible with the proposed synthetic chemistry, to give virtual 
libraries of hydroxy sulfonamides (A2) and N-PMB cyclic sulfamidates (A3). These two 
virtual libraries were then systematically coupled to give a library of acyclic amines (A4). 
Cyclisation generated an array of diverse heterocycles (A5). Furthermore, as the 
enumerated heterocycles contain orthogonally cleavable protecting groups (N-PMB and N-
Ns) and as such further diversity is introduced by means of capping the nitrogen atoms 
with commercially available reagents to give series of diverse ‘capped’ heterocycles 
(A6).58,68 This in silico approach is exemplified by the synthesis of piperazine B61 (Scheme 
15, Panel B) from amino alcohol B1. Further diversity may be introduced by a systematic 
capping strategy whereby heterocycles might contain no capping groups (⟶B61), one 
capping group on either heteroatom (⟶B62), from a selective capping approach, or two of 
the same capping groups (⟶B63) from a global capping approach. 
The selections of amino alcohols from commercial sources were made by considering their 
compatibility with the reaction conditions and reactivity insights gleaned from scope and 
limitation studies. Furthermore, amino alcohols and capping groups were selected in such 
a way that the final in silico library may be biased toward the enumeration of compounds 
which might possess the physicochemical properties desirable in libraries of lead-like 
compounds (i.e. mol. weight < 350, -1<logP<3, etc.).  
As such, a library of 10 cyclic sulfamidates and 10 hydroxy sulfonamides was selected and 
subjected to the in silico enumeration. This gave 14256 diverse piperazines and related 
ring systems which were analysed by considering their adherence to lead-like parameters 
(i.e. molecular weight between 200 and 350 and logP between -1 and 3). The variation of 
AlogP and molecular weight for the virtual library is shown in Chart 5.  
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Chart 5: Prediction of molecular weight and logP of the in silico generated piperazine and 
piperazine-like library. Red dashed lines represent the limits of lead-like chemical space whereas 
the solid red lines outline the limits of drug-like (Lipinski) chemical space. Building blocks used in 
this in silico approach are given in appendix A. 
The systematic in silico pairing of a selection of 10 amino-alcohol building blocks and 12 
capping groups (Appendix A) allowed the generation of a virtual library consisting of 
14256 compounds. Of these compounds 99 were uncapped, core heterocycles, 2177 
contained one capping group at either of the nitrogen centres within the ring skeleton and 
11978 contained two capping groups. The uncapped compounds have average molecular 
weight (225.5 Da) and logP (0.05) within the limits of lead like chemical space. However, 
less than half (42%) the compound library lies within of the limits of lead-like chemical 
space due to having molecular weight and logP lower than the minimum values. This 
suggests that these uncapped cores are more fragment-like than lead-like.  
The capped compounds have average calculated properties within lead like space (average 
molecular weight 321.0, average logP 0.22) however now over 62% of compounds lie 
within lead-like chemical space. This suggests that a library based on the selected building 
blocks bearing one capping group would have a high population of compounds which 
would be considered lead-like. Compounds bearing two capping groups tend to have 
properties outside of chemical space with only 13% of the compound population lying 
within lead-like chemical space. However, a significant proportion of compounds bearing 
two capping groups have properties within the boundaries of Lipinski chemical space 
suggesting that these compounds may be more suited to drug-like chemical space. Overall, 
0
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this in silico generated library contains a high proportion of compounds which would be 
deemed to be lead-like as they lie within the previously outlined parameters of lead-like 
chemical space. As such, it is believed that this computational approach has illustrated the 
potential power of the cyclic sulfamidate-amino alcohol pairing methodology for the 
generation of diverse, lead-like, compounds.  
2.2.4 Exemplification of Methodology 
In order to demonstrate the ability of the methodology developed in Section 2.2.1 to 
generate diverse lead like heterocycles a small number of commercially available amino 
alcohol building blocks were procured and subsequently used to synthesise a library of 
diverse heterocycles, as prepared by Dr Paul MacLellan.69 Examples of heterocycles 
synthesised through this approach are shown in Figure 16. Exemplification of this 
methodology clearly demonstrates the ability to vary ring size, heterocycle skeleton 
substitution and nitrogen substitution. Furthermore, it is also clear that handles for 
further chemistries may be incorporated into building blocks, such as aryl halides or 
amides. 
 
Figure 16- Diverse heterocyclic compounds generated using the cyclic sulfamidate-amino alcohol 
pairing methodology.69 
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2.2.5 Summary of Cyclic Sulfamidate – Hydroxy Sulfonamide Pairing 
This Chapter described the approaches taken towards the development of methods for the 
synthesis of piperazine and piperazine-like heterocycles by the pairing of cyclic 
sulfamidates and amino alcohols. The approach has developed methodology for the 
chemoselective opening of cyclic sulfamidates with amino alcohol derivatives and has 
allowed the systematic introduction of ring substituents and the variation of heterocycle 
size, allowing the synthesis of 6-, 7- and 8-membered systems. Furthermore, efficient 
methods were devised for the cyclisation of un-activated nitrogen nucleophiles to 
generate heterocycles under Mitsunobu conditions. A method for the facile purification of 
products from both building block pairing and cyclisation steps was developed which 
proved to be extremely valuable. The potential power of this approach has been illustrated 
by the generation of a virtual library of piperazine and piperazine-like compounds of 
which high proportions of compounds are deemed to have lead-like properties. 
Furthermore, the power of this approach has been demonstrated with the synthesis of a 
small library of diverse heterocycles, as prepared by Dr Paul MacLellan. 
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Chapter 3: Development of a Catalytic Approach to Piperazines and Related 
Ring Systems 
This Chapter describes the development of an approach for the synthesis of diverse 
heterocyclic scaffolds utilising a transition metal–mediated process. The approach 
involved the pairing of bifunctional building blocks, followed by catalytic activation of an 
alkyne as the key step in heterocycle formation. The Chapter focusses on the development 
and subsequent exemplification of this approach (Figure 17). 
 
Figure 17: Overview of the approach described in this Chapter. The pairing of cyclic sulfamidates 
and propargyl sulfonamides to give unsaturated heterocyclic ring systems which were then utilised 
as substrates for further complexity–generating transformations. 
3.1 Overview of Cyclic Sulfaidate-Proprgyl Sulfonamide Pairing  
This Section outlines the development of an approach to the synthesis of unsaturated 
piperazine heterocycles. An overview of the proposed approach is shown in Figure 18. The 
approach would involve the coupling of a cyclic sulfamidate and an alkyne to give the 
cyclisation substrate. This reaction would then be followed by cyclisation, mediated by a 
transition metal, to give unsaturated heterocycles which may be utilised in further 
complexity generating reactions (Figure 18). 
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Figure 18: Proposed approach to the synthesis of saturated piperazine and piperazine related ring 
systems (new bonds formed are highlighted by broad bonds). Panel A- Proposed general approach 
to the formation of piperazine ring systems through the coupling of cyclic sulfamidate and 
propargyl sulfonamide building blocks. This approach would utilise sequential nucleophilic 
sulfamidate opening and catalysed cyclisation. Finally, unsaturated heterocycles would be used as 
substrates for further diversity generating reactions. Panel B- Examples of heterocyclic systems 
which might be synthesised using this approach. 
Initially, pairs of readily-available cyclic sulfamidate and alkyne building blocks would be 
chemoselectively coupled using sequential C-N bond forming steps: the opening of the 
cyclic sulfamidate, followed by the cyclisation under catalytic conditions (Section 3.1.1). 
The scope and limitations of this approach were investigated by the systematic variation 
of the cyclic sulfamidate and alkyne building blocks and studying the subsequent 
cyclisation reactions (Section 3.1.2). Increasing the diversity of groups appended to the 
heterocyclic skeleton might be achieved by utilising the unsaturation generated in the 
intramolecular cyclisation (Section 3.1.3). The power of this approach was illustrated by 
the in silico enumeration of diverse lead-like heterocycles from readily available building 
blocks (Section 3.1.4).   
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3.1.1 Reaction Development 
This Section outlines the development of methodology for the efficient coupling of cyclic 
sulfamidate and alkyne building blocks (Section 3.1.1.1) and the subsequent development 
of methods for the intramolecular cyclisation (Section 3.1.1.3). 
3.1.1.1 Design and Synthesis of Building blocks 
To investigate the feasibility of the proposed approach, a number of cyclic sulfamidate and 
alkyne building blocks were required (Figure 19). The building blocks selected were 
designed to probe the scope and limitations of both the nucleophilic opening of cyclic 
sulfamidates and the subsequent transition metal–mediated intramolecular cyclisation. 
The cyclic sulfamidate building blocks were selected to investigate if the nature of the 
nitrogen substituent played a significant role in the intramolecular cyclisation to give 
heterocycles. The nucleophile in the alkyne building blocks (X = OH or NHNs) was varied 
to allow investigation of the potential to prepare both morpholine- or piperazine-like 
heterocycles. 
 
Figure 19: Varied cyclic sulfamidate and alkyne building blocks required for initial reaction 
development. 
The proposed cyclic sulfamidate building blocks were synthesised from commercially 
available amino alcohols. The N-protected amino alcohols were transformed into the 
required cyclic sulfamidates using a two-step procedure as shown below (Table 13). 
Treatment of amino alcohol derived compounds with thionyl chloride under basic 
conditions at −60 °C gave the crude cyclic sulfamidite intermediates; ruthenium-catalysed 
oxidation of the cyclic sulfamidites, with NaIO4 then gave the required cyclic sulfamidates 
in good yield.  
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Entry Amino Alcohol Cyclic Sulfamidate Yield (%) 
1 
 
 
195 
 
198 
66 
2 
 
 
196 
 
199 
87 
3 
 
 
197 
 
200 
86 
 
Table 13: Synthesis of cyclic sulfamidates required for initial reaction development. 
The required alkyne building blocks were either commercially available (i.e. propargyl 
alcohol 201) or synthesised from propargyl alcohol using a two-step method. The 
required propargyl sulfonamides o-202 and p-202 were synthesised from propargyl 
alcohol by treatment with the o-203 or p-203, DEAD and PPh3 in THF followed by 
deprotection with TFA in CH2Cl2, respectively (Scheme 29).  
 
Scheme 29: Synthesis of the propargyl sulfonamides o-202 and p-202. 
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3.1.1.2 Cyclic Sulfamidate and Alkyne Building Block Coupling 
With the cyclic sulfamidate and alkyne building blocks in hand (Section 3.1.1.1), the 
pairing of building blocks was studied. The pairing of cyclic sulfamidates with sulfonamide 
nucleophiles under basic conditions has previously been developed (Section 2.2.1.2) and 
thus these conditions were employed. Pairing of cyclic sulfamidate and alkyne building 
blocks is summarised in Table 14.  
 
Entry Alkyne 
Cyclic 
Sulfamidate 
Product Yield (%) 
1 
 
 
201 
 
198 
 
204 
77 
2 
 
 
201 
 
200 
 
205 
77 
3 
 
 
201 
 
199 
 
206 
73 
4 
 
 
202 
 
198 
 
207 
27 
5 
 
 
202 
 
200 
 
208 
>98 
6 
 
 
202 
 
199 
 
209 
95 
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Table 14: Ring opening of cyclic sulfamidates with propargyl nucleophiles. 
The treatment of either alcohol 201 or sulfonamide 202 with NaH followed by the 
appropriate cyclic sulfamidate proceeded smoothly. This approach is tolerant of a range of 
sulfamidate N-protecting groups (Table 14, entries 1, 2 and 3) and either O- or N-
nucleophiles (compare entries 2 and 5). This pairing approach gave a range of substrates 
to allow the investigation into the cyclisation to yield heterocycles. 
3.1.1.3 Development of Catalytic Methodology for Cyclisation 
Alkyne activation with a variety of transition metals, such as copper,70 gold,71, 74, 75 silver 
72and palladium,73 is well known. However, cyclisations of heteroatom-substituted alkyne 
substrates to give heterocycles have only recently been reported. Of particular interest 
were the reports from Hammond et al. which describes the tandem intramolecular 
cyclisation followed by iminium trapping (Scheme 30). 76 
 
Scheme 30: Reports by Hammond et al. into the tandem cyclisation/ trapping of alkyne-containing 
substrates.76,78 
In order to validate the catalytic system developed by Hammond et al. as a key step for 
heterocycle formation a model reaction was performed (Scheme 31).The commercially 
available alcohol 214 was transformed into the amine 210 using a Mitsunobu reaction 
with BnNHNs, 77 221, followed by de-sulfonylation with PhSH and DBU in acetonitrile. The 
amine 210, a known substrate compatible with the copper cyclisation methodology,78 was 
then exposed to the reported reaction conditions to give the pyrrolidine 215. Although the 
yield of 215 was diminished compared to literature reports, the result validates the use of 
a copper‒based catalytic system. 
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Scheme 31: Confirmation of experimental procedure by the synthesis of 215 by catalytic 
intramolecular cyclisation. 
It was demonstrated that numerous substrates can undergo cyclisation to give 
heterocycles containing one heteroatom. However there is only one example of cyclisation 
to give a morpholine scaffold.78 These reports clearly demonstrate the requirement for 
different catalytic systems dependent upon the substitution of the nucleophilic nitrogen: a 
more π acidic metal (Au in the reported examples) is required for examples with 
delocalised lone pairs (such as N-carbamates).  As such, a variety of conditions were 
selected, based upon the reports by Hammond et al.,76, 78 and a selection of cyclisation 
substrates (synthesised in Section 3.1.1.2) were exposed to these conditions, the results of 
which are summarised in Table 15.  
 
Entry Substrate Conditions 
Anticipated 
Product 
1 
 
204 
A 
 
216 
2 
 
207 
A 
 
217 
3 
 
208 
B 
 
218 
  
76 
 
4 
 
204 
C 
 
219 
5 
 
207 
C 
 
220 
 
Table 15: Summary of cyclisation conditions investigated. Conditions- A: TMSCN, CuBr (5 mol.%), 
dioxane, 100°C, 0.5h, microwave irradiation., B: TMSCN, IPr-AuCl (5 mol.%) AgOTf (5 mol.%), H2O, 
Dioxane, 100°C, 0.5h, microwave irradiation C: Phenylacetylene, CuBr (5 mol.%), dioxane, 100°C, 
0.5h, microwave irradiation. 
The use of CuBr with either TMSCN or phenylacetylene has been shown to induce 
cyclisation of N-benzyl substrates. The replacement of Cu(I) with an Au(I) source has been 
shown to induce cyclisation of N-carbamate substrates.77 However, exposing selected 
substrates from Section 3.1.1.2 to the cyclisation conditions above led, in all cases, to no 
identifiable product. In all cases, significant amounts of starting materials were observed 
by both LCMS and 1H NMR analysis of crude reaction mixtures. These disappointing 
results clearly show substrate incompatibility, however the origin of the lack of reactivity 
is unknown. 
The reports by Hammond et al. describe the tandem intramolecular cyclisation/ trapping 
as a dual addition to the alkyne and propose a mechanism outlined in Scheme 32.  
 
Scheme 32: Proposed mechanism for the intramolecular amino alkyne cyclisation to give 
substituted pyrrolidines. 
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The proposed mechanism for formation of substituted pyrrolidines begins with a metal‒
mediated amine addition to the alkyne to give the proposed exocyclic enamine which is 
trapped with cyanide, presumably via tautomerisation to the iminium species. It was 
hypothesised that if the hydroamination product was stabilised in such a way that the 
olefin could be retained and isolated the overall ‘dual addition’ could be performed in a 
two-step process (Figure 20). The N-carbamate was selected as the tautomerisation to an 
N-acyl iminium species (Figure 20, panel B) may bias the formation of an unsaturated 
species. 
 
Figure 20: Proposed rationale for the potential stabilisation of unsaturated intermediates by the 
delocalisation of amine lone pair. 
It has been suggested that copper is a poor catalyst for inducing hydroamination with 
carbamate nucleophiles. 78 As such, the substrates synthesised in Section 3.1.1.2 were 
subjected to gold‒mediated conditions which have been demonstrated to be competent in 
inducing carbamate addition to alkynes. These results are summarised in Table 16. 
 
Entry Substrate Product Yield (%) 
1 
 
208 
 
77 
97% 
  
78 
 
2 
 
209 
 
222 
98% 
3 
 
204 
 
223 
‒a 
4 
 
207 
 
224 
‒a 
5 
 
205 
 
225 
‒b 
6 
 
206 
 
226 
‒b 
 
Table 16: Intramolecular cyclisation of alkynes under gold mediated hydroamination conditions. 
Conditions: Au(PPh3)Cl (5 mol%), AgSbF6 (5 mol%), dioxane, 100°C, 10 min, microwave. a A 
complex material was obtained as determined by 500 MHz 1H NMR and LCMS analysis of reaction 
mixtures. b Significant amounts of starting materials remained as determined by 500 MHz 1H NMR 
and LCMS analysis of reaction mixtures. 
Pleasingly, subjecting the cyclisation substrates 208 and 209 to catalytic amounts of both 
Au(PPh3)Cl and AgSbF6 (both 5 mol%) in dioxane at 100 °C under microwave irradiation, 
gave the tetrahydropyrazines 77 and 222 (Table 16, entries 1 and 2) in near-quantitative 
yields, supporting the stabilisation hypothesis discussed previously (Figure 20). N-Benzyl 
substrates (entries 3 and 4) gave complex mixtures of materials with no identifiable 
product by LCMS or NMR. Interestingly, etheric substrates 205 and 206 (entries 5 and 6) 
returned only starting materials, demonstrating the importance of a sulfonamide β- to the 
alkyne. 
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3.1.1.4 Investigations into Gold Catalysed Conditions 
The use of  of AuI and AgI complexes in combination in catalytic transformations is well 
known.79 Typically AgI complexes with weakly coordinating anions (such as SbF6-, OTf- and 
NTf2-) are used to generate cationic AuI complexes in situ by undergoing ligand exchange 
(Scheme 33). 
 
Scheme 33: Typical use of Ag complexes with weakly coordinating ligands to generate cationic gold 
phosphine complexes. 
However, there is an on-going debate as to whether silver plays an active role in 
catalysis.79 In order to investigate the role of each component in the cyclising conditions 
identified in Section 3.1.1.3, systematic variation of reaction conditions was undertaken 
(Table 17). 
 
Entry 
Variation from standard 
conditions 
Product Yield (%) 
1 None 
 
77 
98 
 
2 
 
No Au(PPh3)Cl starting material only c — 
 
3 
 
1 mol% Au(IPr)Cla  
in place of Au(PPh3)Cl 
1 mol% AgSbF6  
77 
97 
  
80 
 
 
4 
 
No AgSbF6 starting material only c 
 
— 
 
5 
 
No Au or Ag complexes starting material only c 
 
— 
 
6 
 
MsOH (10 mol%) 
No Au(PPh3)Cl or AgSbF6 
starting material only c 
 
— 
7 Thermal heating (100 °C, 3h) 
 
77 
95 
8 
CH2Cl2, rt 
16h 
 
77 
83 (15b) 
 
Table 17: Systematic investigation into reaction conditions.a IPr= 1,3-Bis(2,6-diisopropylphenyl)-
1,3-dihydro-2H-imidazol-2-ylidene. bAlso isolated was the ketone 227. Analysis of crude reaction 
mixtures showed a 5.5:1 mixture of 77 to 227.  c Starting material observed by 500 MHz 1H NMR 
spectroscopic analysis of crude reaction mixtures. 
When comparing the variations in reaction conditions to those previously established 
(Table 17, entry 1) it is clear to see that removing the gold source, the silver source or 
both gold and silver (entries 2, 4 and 5 respectively), results in a complete lack of reaction. 
In each case, analysis of crude reaction mixtures by 500MHz 1H NMR spectroscopy 
revealed only starting materials to be present. This is clear evidence that both gold and 
silver complexes are required for the generation of an active catalytic species. The 
cyclisation appears to be tolerant to variation of the source of gold (entry 3) with the NHC-
gold complex readily catalysing the cyclisation even at lower catalyst loadings.85 Replacing 
metal catalysts with methanesulfonic acid (entry 6) failed to give any observable product, 
suggesting the cyclisation is not due to trace amounts of strong acid. The mode of heating 
also appears to be well tolerated, with the reaction proceeding well with conventional oil 
bath heating (entry 7) or even at room temperature in DCM (entry 8) although here the 
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reaction time was significantly increased. A by-product isolated from the room 
temperature reaction (entry 8) was the ketone 227. This by-product may have arisen due 
to moisture entering the reaction vessel over the extended period required for completion. 
Ideally the reactivity of the alkyne 208 would be studied in a silver free system, possibly 
by the use of Au(PPh3)SbF6,79 or a suitable alternative, in the absence of any silver 
sources.80 
3.1.1.5 Insights into the Mechanism of Tetrahydropyrazine Formation 
The observation of the formation of the ketone 227 in dichloromethane at room 
temperature prompted investigation into plausible mechanisms for formation of 
tetrahydropyrazine 77. Electrophilic activation of alkynes, and subsequent reactions with 
nucleophilic species (such as alcohols,81, 82, 85 amines83 and alkenes84), with gold complexes 
is well known. From these literature reports two mechanisms which may account for the 
formation of tetrahydropyrazine 77 from the carbamate 208, and the potential formation 
of the ketone 227, may be proposed (Figure 21). 
 
Figure 21: Two possible mechanisms for the formation of 77 from 208 by either metalation or 
hydration pathways. 
A possible mechanism follows a metalation pathway, via a formal 6-exo-dig cyclisation 
(⟶231). Subsequent protodeauration (⟶232) and tautomerisation to the observed 
product (⟶77) would account for the direct formation of tetrahydropyrazine 77. An 
alternative approach may be a hydrative pathway, following a regioselective alkyne 
hydration (⟶233) and subsequent protodeauration-tautomerisation (⟶227) would 
account for the observation of the ketone 227 as observed in Table 17.  Finally, 
intramolecular enamine formation by dehydration would give the observed 
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tetrahydropyrazine 77. In order to investigate these suggested mechanisms a small study 
was initiated. These studies aim to probe the feasibility of the hydrative route shown in 
Figure 21 by investigating the formation, and subsequent reactivity, of the ketone 227.  
With ketone 227 synthesised and isolated (Table 17) the ability for dehydration to 
tetrahydropyrazine 77 was studied (Scheme 34). The dehydration of the ketone 227 to 
the tetrahydropyrazine 77 was studied by 500 MHz 1H NMR analysis of a solution of 
ketone 227 in DCM-d2, with and without catalysts, as a function of time.  It was observed 
that the ketone 227 did not undergo dehydration to tetrahydropyrazine 77 without the 
addition of catalyst, even after extended period (>2 weeks). However, re-subjecting the 
ketone 227 to reaction conditions in DCM-d2 showed a rapid conversion to 
tetrahydropyrazine 77; 77 was observed in < 10 min from addition of Au(PPh3)Cl and 
AgSbF6 to 227 in CH2Cl2-d2, progressing to approximately 5.5:1 of 77:227 in 16h (Scheme 
34). However, re-exposing tetrahydropyrazine 77 to Au(PPh3)Cl and AgSbF6 in CH2Cl2-d2, 
and subsequently monitoring the mixture by 1H NMR spectroscopy failed to identify even 
trace formation of ketone 227. 
 
Scheme 34: Investigation into the dehydration of the ketone 227 to give tetrahydropyrazine 77.  
*500 MHz NMR analysis of 1H signals in CH2Cl2-d2. 
The results shown in Scheme 34 clearly suggest that ketone 227 is competent at forming 
tetrahydropyrazine 77 under the reaction conditions given in Table 17. However, omitting 
the metal species from the reaction prevents formation of 77. This may be due to either 
gold or silver complexes acting as Lewis acids, facilitating the dehydration of ketone 227 
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to 77. However, the lack of observed hydration of the tetrahydropyrazine 77, to reform 
the ketone 227, suggests that the tetrahydropyrazine 77 is the thermodynamic product of 
the reaction (with ketone 227 being the kinetic product). 
An alternative approach to investigating the feasibility of a hydrative pathway in the 
formation of tetrahydropyrazine 77 was based on the hydration of carbamate 208. 
Methods for the hydration of simple alkynes to give ketones have been developed using 
gold catalyst bearing N-heterocyclic carbene (NHC) ligands.85 Carbamate 208 was 
subjected to these conditions that are known to induce alkyne hydration (Scheme 35). 
 
Scheme 35: Reactivity of alkyne 208 under hydration conditions. 
Subjecting carbamate 208 to 1 mol% Au(IPr)Cl and 1 mol% AgSbF6 in a 2:1 mixture of 
dioxane and water at 120 °C gave the tetrahydropyrazine 77. This result again suggests 
that although ketone 227 is being formed through alkyne hydration, the 
tetrahydropyrazine 77 is the thermodynamic product. 
Overall, it is clear that the ketone 227 is indeed a competent intermediate on the route to 
the formation of the tetrahydropyrazine 77 from the carbamate 208 as summarised 
below (Figure 22).  However, these studies have not focussed on perturbing the 
hydroamination approach proposed in Figure 21 and thus parallel productive reaction 
pathways cannot be ruled out.  
 
Figure 22: Summary of findings from mechanistic investigations. 
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3.1.2 Scope and Limitation Studies 
To allow a study into both the scope and limitations of the process, a systematic 
investigation into building block tolerance was undertaken. This study involved the 
synthesis (Section 3.1.2.1 and 3.1.2.2), and subsequent pairing (Section 3.1.2.3), of 
substituted building blocks. The proposed building blocks required for this study are 
outlined in Figure 23. 
 
Figure 23: Proposed building blocks required for scope and limitation studies. 
The propargyl sulfonamide building blocks were selected to allow investigation of the 
effect of substituents both α- to nitrogen (236) and on the terminus of the alkyne (235). In 
addition, the sulfonamide 237 would allow the effect of chain length to be studied. The 
cyclic sulfamidate building blocks incorporate both N-Boc and N-Cbz protecting groups, 
both of which have been shown to be competent for cyclisation (Section 3.1.1.3). The 
unsubstituted cyclic sulfamidates were selected to investigate the effect of chain length 
(199, 200 and 238). The substituted cyclic sulfamidates would be derived from 
commercially-available enantiomerically pure β-amino alcohols and as such are all based 
on 5-membered ring systems. Substituents on the cyclic sulfamidates were selected to 
represent a variety substituents and substitution patterns. Building blocks containing 
common protecting groups (242, 243 and 244) were included to investigate compatibility 
of chemically‒sensitive groups.   
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3.1.2.1 Synthesis of Sulfonamide Building Blocks 
The required propargyl sulfonamide building blocks outlined in Section 3.1.2 were 
synthesised from commercially-available materials. Sulfonamides 235, 236 and 237 were 
synthesised from the commercially available alcohols using a two-step approach as 
outlined below (Table 18). The commercially-available alcohols were treated with 
NsNHBoc, DEAD and PPh3 in THF, followed by the removal of the Boc group with TFA in 
DCM to give the required sulfonamides. This approach allowed the synthesis of required 
building blocks on a multi-gram scale.  
 
Entry Alcohol Product Yield (%) 
1 
 
 
o-236 
81 
1 
 
 
p-236 
83 
2 
  
o-235 
82 
2 
  
p-235 
98 
3 
 
 
o-237 
84 
 
Table 18: Synthesis of sulfonamide building blocks. 
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3.1.2.2 Synthesis of Cyclic Sulfamidate Building Blocks 
The required cyclic sulfamidates were synthesised, where possible, from the 
enantiomerically pure amino alcohol (Table 19). The commercially-available amino 
alcohols were transformed into either the N-Boc or N-Cbz carbamates by treatment with 
either Boc2O (entries 1 and 2), or Cbz-Cl (entries 3 and 4). Finally, the carbamates were 
transformed into the cyclic sulfamidates by treatment with SOCl2 to give a crude cyclic 
sulfamidite and ruthenium-mediated oxidation to give the corresponding cyclic 
sulfamidates. 
 
Entry Amino alcohol 
Conditions, 
Yield (%) 
Carbamate Cyclic Sulfamidate Yield (%) 
1 
 
A, 97  
245 
 
249 
82 
2 
 
A, 92  
246  
250 
96 
3 
 
B, 93 
 
247 
 
251 
93 
4 
 
B, 95 
 
248 
 
252 
89 
  
Table 19: Synthesis of N-carbamate cyclic sulfamidates from commercially available amino 
alcohols. Conditions- A: Amino alcohol (1.0 eq.), Boc2O (1.05 eq.), CH2Cl2 (0.3 M). B: Amino alcohol 
(1.0 eq.), CbzCl (1.05 eq.), NaHCO3 (2.0 eq.) THF‒H2O (1:1, 0.15 M), 0 °C to rt. 
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Efforts were then focused on the synthesis of non-commercially available building blocks. 
The synthesis of the cyclic sulfamidates 242 and 243 was achieved from the commercially 
available diol 253 (Scheme 36).86 
 
Scheme 36: Synthesis of cyclic sulfamidates 242 and 244 from commercially amino alcohol 253. 
Synthesis of the carbamate 254 was achieved using a two-step protection procedure. N-
protection was achieved by treatment of 253 with Boc2O which was followed by treatment 
with TBSCl in CH2Cl2, to install the TBS group on the primary alcohol, to give 254. 
Analogously, the carbamate 256 was synthesised by the installation of the Cbz group, by 
treatment with benzylchloroformate, followed by TBS protection with TBSCl in CH2Cl2. 
The carbamates 254 and 256 were transformed into the cyclic sulfamidates 242 and 244 
respectively, by treatment with SOCl2 in CH2Cl2 to give crude cyclic sulfamidites, followed 
by subsequent ruthenium‒mediated oxidation.  
The cyclic sulfamidate 243 was synthesised from commercially available serinol following 
literature precedent87 (Scheme 37). Thus, serinol was treated with Boc2O in CH2Cl2 to give 
the diol 259. Enzymatic desymmetrisation of the diol 259 with Porcine pancreatic lipase 
(PPL) in vinyl acetate gave the acetate 260 in >96% ee (as determined by 500 MHz 1H 
NMR spectroscopic analysis of the corresponding Mosher’s esters 260).88 Finally, the 
carbamate 259 was converted into cyclic sulfamidate 243 by treatment with SOCl2 in 
CH2Cl2 followed by ruthenium‒mediated oxidation. 
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Scheme 37: Synthesis of cyclic sulfamidate 243 from serinol. a The enantiomeric excess of the 
acetate 259 was determined by 500 MHz 1H NMR spectroscopic analysis of the Mosher’s ester 260 
 
3.1.2.3 Pairing of Cyclic Sulfamidate and Propargyl Sulfonamide Building 
Blocks 
The cyclic sulfamidate and propargyl sulfonamide building blocks were paired using the 
conditions identified in Section 3.1.1.2. The cyclisation precursors were synthesised by 
the treatment of a propargyl sulfonamide building block with NaH in DMF followed by the 
addition of a cyclic sulfamidate building block. The combinations of building blocks 
investigated is summarised in Table 20 
 
 
Entry 
Cyclic 
sulfamidate 
Propargyl 
sulfonamide 
Carbamate 
Yield 
(%) 
1 
 
200 
 
o-202  
208 
>98 
  
89 
 
2 
 
200 
 
o-235 
 
261 
>98 
3 
 
200 
 
o-236 
 
262 
88 
4 
 
199 
 
o-202  
209 
95 
5 
 
199 
 
p-235  
263 
91 
6 
 
199 
 
p-236 
 
264 
90 
7 
 
199 
 
o-237 
 
 
265 
88 
8 
 
238 
 
o-202  
266 
86 
9 
 
238 
 
o-235 
 
267 
83 
  
90 
 
10 
 
240 
 
o-202  
268 
72 
11 
 
239 
 
p-202  
269 
70 
12 
 
241 
 
o-202  
270 
94 
13 
 
242 
 
p-202  
271 
68 
14 
 
242 
 
p-202  
272 
74a 
15 
 
244 
 
p-202  
273 
67a 
16 
 
243 
 
p-202  
274 
89 
 
Table 20: Nucleophilic opening of cyclic sulfamidates with propargyl sulfonamide building blocks. 
Reagents and conditions- Propargyl sulfonamide (1.1 eq.), NaH (60% in oil, 1.1 eq.), DMF (0.2M), 
then cyclic sulfamidate (1.0 eq.), then HCl (5 eq., 5M aq. soln.). aProtolytic quench performed with 
citric acid (2 eq., 1M. aq. soln.). 
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Generally, the nucleophilic opening of cyclic sulfamidates proceeded smoothly, showing a 
wide tolerance in variation in sulfamidate ring size and appended substitution on both 
building blocks (Table 20). The N-Boc and N-Cbz cyclic sulfamidates tended to give very 
similar yields of the acyclic carbamate products (e.g. compare entry 1 and entry 4). 
Substitution was well tolerated in propargyl sulfonamide derived building blocks. Both 
non-terminal alkynes (entries 2, 5 and 9) and sulfonamides bearing substitution α- to 
nitrogen (entries 3 and 6) were shown to be competent nucleophiles under these 
conditions. Cyclic sulfamidates containing ring substitution were treated with the 
sulfonamide 202 and in all cases gave good yields of the expected products (entries 10 to 
16).  
It was found that the silyl ether contained in cyclic sulfamidate 242 could either be 
removed (entry 13) or retained (entry 14) depending upon the protiolytic quench used 
upon the completion of ring opening.89 Pleasingly, the acetate group contained in cyclic 
sulfamidate 243 (entry 16) was also retained during the ring opening reactions. 
With the acyclic carbamates in hand (Table 20), heterocycle formation under gold-
catalysed conditions was studied. Initially, the acyclic carbamates derived from propargyl 
sulfonamide 202 and various 5-membered cyclic sulfamidates were investigated. The 
cyclisation reactions attempted are summarised in Table 21. 
Entry Carbamate Heterocycle Yield 
 
1  
208 
 
77 
98 
2 
 
209 
 
222 
98 
3 
 
268 
 
275 
90 
  
92 
 
4 
 
269 
 
276 
96 
5 
 
270 
 
277 
96 
6 
 
271 
 
278 
And 
 
 
279 
 
 
36a 
 
 
 
 
 
 
48 
7 
 
271 
 
279 
81b 
8 
 
272 
 
280 
79 
9 
 
273 
 
281 
85 
10 
 
274 
 
282 
92 
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Table 21: Intramolecular cyclisation of acyclic carbamates to give tetrahydropyrazines. Reagents 
and conditions; A: Au(PPh3)Cl (5 mol%), AgSbF6 (5 mol%), 1,4-dioxane, 100 °C. a Structure 
confirmed by desilylation of 280, see Scheme 42, Section 3.1.3.  b Cyclisation performed at room 
temperature in CDCl3. Observed as the sole product by 500MHz 1H NMR spectroscopy with 
complete consumption of starting material. 
Treatment of the cyclisation substrates (Table 21, entries 1‒10) with 5 mol% Au(PPh3)Cl 
and 5 mol% AgSbF6 in 1,4-dioxane at 100 °C led to the formation of heterocycles in good 
yield. This cyclisation methodology is clearly compatible with substitution either α- or β- 
to the carbamate nitrogen (entries 4 and 5 respectively). Both silyl ether (entries 8 and 9) 
and acetate (entry 10) protecting groups are well tolerated, enabling synthesis of the 
heterocycles 280, 281 and 282. Cyclisation of the alcohol 271 gave an approximately 1:1 
mixture of 278 and 279 under these conditions. The structure of 278 was determined via 
an alternative synthesis of 278 by desilylation of 280 (Section 3.1.3, Scheme 42). 
However, modification of the reaction conditions (room temperature, CDCl3) resulted in 
the formation of 279 as the sole product with complete consumption of the carbamate 
271 suggesting that dihydrooxazine 279 is the kinetic product of the two possible 
heterocyclic compounds 278 and 279.  
In order to determine the scope of the cyclisation methodology, the gold-mediated 
cyclisation was applied to the remaining carbamates from Table 20. It was found that 
heterocycle formation was incompatible with these substrates (Table 22). 
Entry Carbamate Conditions Product Yield (%) 
1 
 
261 
A 
 
 
B 
 
—a 
 
 
285 
 
 
 
 
68 
 
2 
 
262 
A 
 
B 
 
— a 
 
— a 
 
 
  
94 
 
3 
 
263 
A 
 
 
B 
 
— a 
 
 
286 
 
 
 
85 
 
4 
 
264 
A 
 
 
B 
 
— a 
 
 
287 
 
 
 
 
46 
 
5 
 
265 
A 
 
B 
 
— a 
 
— a 
 
 
6 
 
266 
A 
 
B 
 
— a 
 
— a 
 
 
7 
 
267 
A 
 
 
 
B 
 
 
— a 
 
 
 
288 
 
 
 
 
61 
 
 
 
Table 22: Attempted cyclisation under gold-catalysed conditions. Reagents and conditions; A: 
Au(PPh3)Cl (5 mol%), AgSbF6 (5 mol%), 1,4-dioxane, 100°C. B: Au(IPr)Cl (1 mol%), AgSbF6 (1 
mol%), 1,4-dioxane/ H2O (2:1), 120°C, sealed tube. a Complex mixtures returned by analysis of 
crude reaction mixtures by LCMS and 500 MHz 1H NMR spectroscopy. 
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Attempted cyclisation of the acyclic carbamates (Table 22) using 5 mol% Au(PPh3)Cl and 
5 mol% AgSbF6 in 1,4-dioxane at 100 °C (Conditions A) failed to give any detectable 
heterocyclic products with complex reaction mixtures, containing starting material, 
returned. However, employing 1 mol% Au(IPr)Cl and 1 mol% AgSbF6 in  2:1 1,4-dioxane–
water at 120 °C (conditions B which were identified in Section 3.1.1.5)85 resulted, in some 
cases, in the hydration of the alkyne to a ketone. Hydration of carbamates with 
substitution on the propargylic position (entries 2 and 4) appears to be dependent upon 
the nature of the carbamate group (N-Boc or N-Cbz respectively). Attempted hydration of 
262 resulted in consumption of starting materials but resulted in complex mixture of 
unidentifiable materials. Conversely, hydration of the benzyl carbamate 264 gave the 
ketone 287 in a good yield. These differing results may be due to the differing steric 
requirements of the carbamate groups to adopt conformations required for reaction 
progression. Elongation of the chain length between sulfonamide and alkyne (entry 5) also 
appears to have a detrimental effect on the outcome of the reaction with significant 
starting material remaining after elongated reaction times. Similarly, elongation of the 
chain length between sulfonamide and carbamate groups (entry 6) failed to give any 
identifiable materials.  It is clear that non-terminal alkynes readily undergo regioselective 
hydration (entries 1 and 3). The hydration of non-terminal alkynes also tolerates 
elongated chain lengths between sulfonamide and carbamate groups (entry 7) giving 
ketone 288 in a good yield.  
 
3.1.2.3.1 Regioselectivity of Alkyne Hydration 
The hydration of alkynes using the Au(IPr)Cl/ AgSbF6 system, as employed in Section 
3.1.2.3, has previously been shown to mediate the regioselective hydration of  terminal 
alkynes and, to a lesser extent, some unsymmetrical alkynes (Scheme 38).85  
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Scheme 38: Selected alkyne hydration results as reported by Nolan et al. a Au catalyst loading at 
100 ppm with Ag in excess. b Au catalyst loading at 1000 ppm. 
The hydration of terminal alkynes reported by Nolan et al. (Scheme 38)85 showed double 
hydration of the diyne 290 to diketone 291 without observation of any aldehydes. This 
result suggests a substrate bias for ketone formation over aldehyde formation which is in 
agreement with the previously observed ketone formation of terminal alkynes (ketone 
227). Hydration of non-terminal alkynes, such as 292, led to a mixture of regioisomeric 
products 293a and 293b showing that hydration at either position of the parent alkyne is 
feasible under these conditions. Presumably, the product bias towards the benzylic ketone 
293a arises from the formation of a lower energy conjugated product. However, 
successful hydration of substrates shown in Table 22 led, in all cases, to a single 
regioisomer (>98:<2 by 500MHz 1H NMR spectroscopic analysis of crude reaction 
mixtures)  of the ketone product being observed. The regioselective hydration may stem 
from coordination of the sulfonamide group to the Au(I) catalyst, biasing a regioselective γ-
hydration via a 6-membered intermediate (Scheme 39).90 
Scheme 39: Proposed chelation model to explain the observed regioselective hydration of non-
terminal alkynes such as 261 and 263. 
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3.1.3 Reactivity of Products from Gold Mediated Transformations 
It was envisaged that both the heterocyclic and hydrated products from the gold mediated 
transformations (Section 3.1.2) could act as substrates for further complexity-generating 
reactions. This Section outlines the approaches undertaken in order to investigate the 
reactivity of both the hydrated and heterocyclic products.  
It was hypothesised that both cyclic and hydrated products from Section 3.1.2 could 
undergo an iminium formation process which may allow further substitution to 
introduced on the heterocyclic scaffold (Scheme 40). 
 
Scheme 40: Proposed general approach to the introduction of substitution onto heterocyclic 
scaffolds from both cyclic and acyclic substrates. 
The envisaged approach towards saturated heterocycles (Scheme 40) would be initiated 
by iminium ion formation (such as 295), trapping with an appropriate nucleophile, 
leading to saturated heterocyclic systems 296. It was hypothesised a N-Boc group may be 
removed under appropriate conditions, giving an iminium species which may allow 
isolation as a salt 295. The removal of excess acid would then allow the use of acid-
sensitive nucleophilic reagents, such as isonitriles. It was hypothesised that the more 
electrophilic N-acyl iminium 297 would not be isolatable and therefore more acid stable 
nucleophiles, such as silanes, would be required. Furthermore, it was hypothesised that 
the ene-diamine motif contained within tetrahydropyrazine compounds may be able to 
participate in cycloaddition reactions allowing the formation of polycyclic ring systems. 
Investigations undertaken to study the reactivity of the tetrahydropyrazine 77 are 
summarised in Table 23. 
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Entry Conditions Expected product 
Yield 
(%) 
1 
Et3SiH, TFA, CH2Cl2, 
0 °C to rt 
 
300 
 
76 
 
2 
TFA, CH2Cl2, then 
benzylisonitrile, 
EtOH, 0 °C to rt  
301 
70 
3 
Allyl silane, TFA, 
CH2Cl2, 0 °C to rt 
 
302 
— 1 
4 
TFA, CH2Cl2, then 
4-methoxyphenyl 
boronic acid, DCE, rt  
303 
— 1 
5 
4-Methoxyaniline, 
benzaldehyde, 
Sc(OTf3), PhMe, 
reflux  
304 
— 2 
6 
 
PhMe, reflux 
 
305 
— 2 
 
Table 23: Screening or reactivity of 77 under varied of conditions. 1 Only removal of Boc group was 
observed by LCMS analysis of reaction mixtures. 2 Significant amounts of starting material 
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remained even after extended reaction times (up to 7 days) at elevated temperatures with no trace 
of expected products by LCMS. 
The reactions of the tetrahydropyrazine 77 were met with mixed success.  Exposure to 
TFA and triethylsilane in CH2Cl2 (Table 23, entry 1) led to the formation of piperazine 300. 
Alternatively, subjecting the tetrahydropyrazine 77 to TFA in CH2Cl2, followed by 
treatment with benzylisonitrile, in ethanol, gave the piperazine 301 (entry 2). However, 
alternative approaches for the introduction of complexity were met with disappointment. 
Surprisingly, attempted addition of allyl silane, under conditions analogous to silane‒
mediated reduction (entry 3), failed to give any of the expected product with only N‒Boc 
removal products observable by LCMS. Similarly, the attempted addition of electron rich 
aryl boronic acid (entry 4) failed to give detectable products; this result is perhaps not 
surprising as this reaction is formally a Petasis reaction, which typically require the 
presence of a proximal hydroxy group.91 Two attempts to induce [4+2] cycloadditions 
were investigated (entries 6 and 7) although both approaches failed to give detectable 
products with significant quantities of the tetrahydropyrazine 77 remaining even after 
extended reaction times. 
An alternative approach to investigate the reactivity of unsaturated heterocycles was an 
intramolecular complexity‒generating reaction.  This approach was based upon the 
generation of a tethered electrophile, which may allow an intramolecular Mannich 
reaction to give oxa- and aza-bispidines (Scheme 41). An analogous approach towards 
oxygen‒containing bridged heterocycles utilising an intramolecular Mannich approach 
has been reported.92 
 
Scheme 41: Proposed approach to polycyclic scaffolds via an intramolecular Mannich cyclisation. 
In order to investigate the proposed intramolecular Mannich cyclisation, the synthesis of a 
series of building blocks was undertaken (Scheme 42). The tetrahydropyrazines 280 and 
281 were deprotected using aqueous HF in DCM‒MeCN to give the alcohols 310 and 312. 
The alcohols 310 and 312 were transformed into the amines 311 and 314 respectively by 
the treatment with DPPA, DEAD and PPh3 in THF to give the corresponding azides, 
followed by reduction by treatment with PPh3 and water in THF.   
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Scheme 42: Synthesis of amines and alcohols for the investigations into intramolecular Mannich 
cyclisation. 
With both the alcohols 310 and 312 and amines 311 and 314 in hand, the subsequent 
intramolecular cyclisations were studied. Cyclisation conditions were based upon both 
Lewis and Brønsted acid-mediated processes with benzylic aldehydes (Table 24).92 
 
 
Entry Substrate Conditions Outcome 
1 310 
4-methoxybenzaldehyde, 
BF3⋅OEt2, CH2Cl2 
—a 
2 310 
4-methoxybenzaldehyde, 
Et3SiH, BF3⋅OEt2, CH2Cl2 
— a 
3 310 
4-methoxybenzaldehyde 
dimethylacetal, PTSA or 
PPTS, MeOD-d4 
— b, c 
4 311 
4-methoxybenzaldehyde, 
PTSA, MeOH 
— b 
5 314 
4-methoxybenzaldehyde, 
PTSA, 4Å mol. sieves, MeOH 
— b, c, d 
6 314 
4-bromobenzaldehyde, 
PTSA, MeOH 
— b 
7 314 
4-methoxybenzaldehyde, 
BF3⋅OEt2, CH2Cl2 
— b 
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8 314 
4-methoxybenzaldehyde, 
Et3SiH, BF3⋅OEt2, CH2Cl2 
— b 
9 314 
4-methoxybenzaldehyde 
dimethylacetal, Et3SiH, 
BF3⋅OEt2, CH2Cl2 
— b 
 
Table 24: Attempted intramolecular Mannich approach toward polycyclic scaffolds. a Complex 
mixture of products by analysis by LCMS and 500 MHz 1H NMR.  b Significant amounts of starting 
material remained, even after extended durations (up to 7 days), as determined by LCMS and 500 
MHz 1H NMR analysis of crude reaction mixtures. c Reactions performed at 65°C. d Imine pre-formed 
by condensation of aldehyde and amine over molecular sieves, as confirmed by 500 MHz 1H NMR, 
prior to addition of PTSA and heating. 
A variety of alcohol and amine substrates (Table 24), Lewis and Brønsted acids, aldehydes, 
additives and solvents were screened in order to identify conditions for an intramolecular 
Mannich type cyclisation. In each case, one substrate was treated with one aldehyde (or 
acetal) and one acid, whose selection was driven by the successful employment in 
literature reports.92 In all cases the approaches summarised in Table 24 failed to give 
detectable products with either significant amounts of starting substrate remaining or 
complex mixtures being returned. 
Throughout this section a variety of reaction conditions have been screened in order to 
probe potential inter- and intra-molecular complexity generating reactions towards 
saturated heterocycles. It is clear that both reduction and formal Ugi reactions (Table 23, 
entries 1 and 2 respectively) were possible with the substrates derived from gold‒
mediated cyclisation of alkyne substrates. 
 
3.1.3.1 Reactivity of Unsaturated Heterocycles and Ketones under Reductive 
Conditions 
With conditions for the reduction of the tetrahydropyrazine 77 in hand, the scope and 
limitations of this approach to deliver saturated heterocycles were investigated. This 
approach employed both unsaturated heterocycles and ketones generated from gold‒
mediated cyclisation/ hydration of alkynes (Table 25). 
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Entry Substrate Product 
Yield, % 
(dr)a 
1 
 
77 
 
300 
76 
2 
 
222 
 
314 
72 
 
3 
 
275 
 
315 
68 
(88:12) 
4 
 
282 
 
316 
76 
(60:40) 
5 
 
276 
 
317 
71 
(89:11) 
6 
 
280 
—c  
8 
 
287 
 
318 
82b 
7 
 
285 
—d  
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9 
 
288 
—d  
 
Table 25: Reduction of cyclic and acyclic substrates to give saturated heterocycles. Reagents and 
conditions: Substrate (1.0 eq.), TFA (10.0 eq.), Et3SiH (6.0 eq.), CH2Cl2 (0.05 M), 0 °C to rt. a Major 
diastereoisomer shown. b Isolated as a single isomer as determined by 500 MHz 1H NMR 
spectroscopy. C Complex mixtures of products were observed by analysis of crude reaction mixtures 
by LCMS and 500 MHz 1H NMR spectroscopy. d No product formation observed with carbamate 
removal products observed by LCMS analysis of reaction mixtures. 
Treatment of the tetrahydropyrazines 77, 222, 275, 282 and 276 with Et3SiH and TFA in 
CH2Cl2 led to good isolated yields of piperazines (Table 25, entries 1‒5). Modest 
diastereoselectivity (60:40 to 89:11) was observed when substrates already containing 
substitution on the heterocycle ring (entries 3‒5). Subjecting the ketone 287 to Et3SiH and 
TFA in CH2Cl2 led to the formation of the piperazine 318 with retention of the Cbz group. 
However, ketones 285 and 288 (entries 7 and 9 respectively), leading toward 7‒ and 8‒
membered heterocyclic systems, failed to give any detectable products with only N‒
deprotected material observed by LCMS analysis of reaction mixtures.  
3.1.3.1.1 Determination of the Stereochemical Outcome of Reduction 
Reactions 
The determination of the stereochemical outcome of the products shown in Table 25 was 
performed using 1H NMR spectroscopy and investigating key nOe interactions. The 
determination of the configurations of the structures of 317 and 315 are summarised in 
Figure 24. 
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Figure 24: Key coupling constants and observed nOe used in the structural determination of 317 
and 315. Panel A- Key coupling constants and observed nOe used in the structural determination of 
317. Panel B- Coupling constants and nOe used in the structural determination of 315. 
Analysis of the 500 MHz 1H NMR spectrum of the piperazine 317 (Figure 24, Panel A) 
showed Hf coupling to Hd with a coupling constant of 10.6 Hz, indicative of an axial–axial 
orientation. The coupling between Hc and Ha was observed 10.4 Hz, again indicative of an 
axial–axial orientation. Furthermore, a strong nOe was observed between Hd and Ha 
suggesting that these protons are positioned axially leading the structure to be assigned as 
the 2,6-syn product. Similarly, analysis of the 1H NMR of 315 (Panel B) showed Hx coupling 
to Hz with a coupling constant of 2.2 Hz, indicative of equatorial–equatorial coupling. A 
strong nOe was observed between the methyl group and Hw leading the structure of 315 
to be assigned as the 2,6-anti product. In both cases the key nOes observed for the major 
diastereoisomers were not observed for the minor diastereoisomers.  
 
3.1.3.1.2 Rationalisation of Stereochemical Outcome of Reduction Reactions 
As shown in Section 3.1.3.1.1 the stereochemical outcome of the reduction reactions 
appear to be dependent upon the N‒protecting group. Reduction of the N-Boc substrates 
276 and 282 resulted in 2,6-syn products as the major diastereoisomer, presumably via a 
transition state which proceeds by an axial approach of silane to the iminium with ring 
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substitution placed in a pseudo-equatorial position (Scheme 43, panel A).93 Conversely, 
reduction of the N-Cbz substrate 275 resulted in the 2,6-anti substitution. This outcome 
may be rationalised by the potential for minimisation of 1,3-strain between N-Cbz and C-6 
benzyl group by the placement of the benzyl group in an pseudo-axial position which 
allows axial silane addition to give the major diastereoisomer observed (Scheme 43, panel 
B). 
 
Scheme 43: Rationalisation of stereochemical outcome for the reduction of substituted piperazines. 
Panel A- Reduction of N-Boc substrate 276, via postulated iminium species, gives 2,6-syn product as 
major diastereoisomer. Panel B- Reduction of N-Cbz substrate 275, via hypothesised N-acyl 
iminium species, to give the 2,6-anti substitution as the major diastereoisomer. 
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Z.1.3.2 Reactivity of Unsaturated Heterocycles and Ketones under Ugi‒Type 
Conditions 
With conditions identified for the formal Ugi94, 95 reaction with iminium derived from the 
tetrahydropyrazine 77, the scope and limitations of this approach to saturated 
heterocycles were studied. This study employed both the heterocycles and the acyclic 
ketones generated from the gold mediated cyclisation/ hydration studies and are 
summarised in Table 26.  
 
Entry Substrate Product 
Yield, 
% 
1 
 
77 
 
301 
70e 
2 
 
276 
 
320 
 
321 
28d,f 
 
 
 
 
59d,f 
 
3 
 
282 
 
322 
 
65d,f 
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4 
 
280 
—a  
5 
 
285 
 
323 
71e 
6 
 
288 
—c  
7 
 
287 
—b  
 
Table 26: Formal Ugi approach to give saturated heterocycles.. a Complex mixtures of products 
observed by analysis of crude reaction mixtures by LCMS and 500 MHz 1H NMR spectroscopy. b No 
iminium formation was observed by LCMS or 500 MHz 1H NMR spectroscopy. c No isonitrile 
addition observed by LCMS analysis of crude reaction mixtures. d Single diastereoisomers observed 
by 500 MHz 1H NMR analysis. e Obtained with benzylisonitirle. f Obtained with 4-(2-
isocyanoethyl)morpholine. 
Treatment of N-Boc heterocycles 77, 276 and 282 (Table 26, entries 1‒3) with TFA in 
CH2Cl2 followed by treatment of the crude iminum salt with either benzylisonitrile (entry 
1) or 2-morpholinoethyl isocyanide (entries 2 and 3) led to the formation of piperazines 
301, 322, 320 and 321 (which was presumably formed from the decomposition of 320) 
in >98:<2 diastereoselectivity. However, the tetrahydropyrazine 280 failed to give any 
detectable product with complex mixtures of products, including desilylated starting 
material, observed. Exposing the ketone 285 to these conditions (entry 5) led to the 
isolation of the amide 323 in a good yield showing that it is possible to form 7-membered 
heterocycles using this approach. However, attempts to generate the 8 membered 
analogue (entry 6) failed to give any detectable product. Similarly, the N-Cbz substrate 
(entry 7) failed to give any observable product. 
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3.1.3.2.1 Determination of the Stereochemical Outcome of Ugi‒Type 
Reactions 
The determination of the stereochemical configuration of the products shown in Table 26 
was performed using both 1H NMR spectroscopy and investigating key nOe interactions in 
a similar fashion to that described in Section 3.1.3.1.1. The determination of the 
structures of 320 and 321 is summarised in Figure 25. 
 
 
Figure 25: Key coupling constants and observed nOe used in the structural determination of 320 
and 321. Panel A- Key coupling constants and observed nOe used in the structural determination of 
320. Panel B- Coupling constants and lack of nOe used in the structural determination of 321. 
The configuration of 320 was determined by using key coupling constants and observed 
nOe (Figure 25, Panel A). Ha is observed as an apparent doublet with a coupling constant 
of 4.9 Hz, indicative of an axial–equatorial coupling. This could originate from either 
coupling between Ha and Hb in the conformation shown or if Ha was axially orientated. A 
strong nOe between the C-2 methyl group and the C-6 phenyl group is observed 
suggesting that these substituents are both axially orientated. These observations thus 
lead to the conclusion that the piperazine 320 is 2,6-syn substituted with both the methyl 
and phenyl groups occupying axial positions. The piperazine 321 showed similar 2J 
coupling constants to that of the piperazine 320. However, no nOe was observed between 
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the C-2 methyl group and either the C-6 phenyl group or Hw. This suggests the again 2,6-
syn substitution but with both the amide and Hw axially oriented. 
 
3.1.3.2.2 Rationalisation of Stereochemical Outcome of Ugi Reactions 
The stereoselectivity of the Ugi reaction is often thought to be determined by the 
irreversible Mumm rearrangement.95 However, there are selected reports that suggest 
that the stereoselectivity may arise, in some cases, from the isonitrile addition to an 
iminium species.96 In order to rationalise the outcome of the Ugi reactions found in these 
studies both Mumm rearrangement and isonitrile addition were considered (Scheme 44).     
 
Scheme 44: Rationalisation of observed diastereoselctivity for ‘Ugi’ reaction of tetrahydropyrazine 
276. Panel A- Proposed diastereoisomeric pathways of isonitrile addition to iminum species. Panel 
B- Proposed plausible intermediates in the Mumm rearrangement pathway. 
Initial formation of iminium an species formed, by protolytic carbamate cleavage from 
276, is postulated to place the phenyl substituent in a pseudo-equatorial position which 
allows reversible isonitrile addition via an axial approach (Scheme 44, ⟶326).93 
Alternatively, the phenyl group may adopt an axial orientation which would generate 
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diastereoisomer 327. In order to rationalise the diastereoselectivity of the Mumm 
rearrangement the hypothesised intermediates 328 and 329 were considered. It was 
hypothesised that during the Mumm rearrangement the breaking five-membered ring 
becomes flattened in order to accommodate the formation of numerous sp2 centres. This 
flattening creates bowl shaped intermediates and as such the methyl groups, in both cases, 
were placed on the outside face of the bowl in order to minimise transannular 
interactions. Intermediate 328 shows destabilising 1,3-transannular interactions between 
the phenyl and methyl groups if placed in an axial orientation. Alternatively, placing the 
phenyl group in an equatorial orientation (329) increases the 1,3-strain between the 
phenyl group and the forming trifluoromethyl amide. Although it is not abundantly clear 
which of these intermediates is favourable, it is believed that 328 is favoured as this leads 
to the observed product. 
 
3.2.4 Diverse Heterocyclic Lead-Like Library Design 
In order to illustrate the potential power of the synthetic cyclic sulfamidate-propargyl 
sulfonamide pairing approach in the generation of diverse molecules, with properties 
desired in lead like compounds, an in silico library of piperazine and piperazine-like 
compounds was enumerated.33 A schematic outline of this in silico approach is shown in 
Figure 26. This in silico library generation utilised commercially available amino alcohol 
and alkyne building blocks (Panel A, A1), which were appropriately modified to 
incorporate appropriate protecting groups to prevent unwanted reactivity. These building 
blocks were then transformed into either cyclic sulfamidates (A3) or propargyl 
sulfonamides (A2). Pairs of functionalised building blocks were then systematically 
coupled to give a library of acyclic intermediates (A4). The acyclic intermediates, 
dependent upon their structure, were either cyclised to give unsaturated heterocycles 
(B5) or hydrated to give acyclic ketones. Subsequent reductions and/or Ugi reactions gave 
an array of heterocycles (A7) containing a variety of protecting groups on the nitrogen 
centres contained within the cyclic scaffold. Subsequent selective functionalization and/or 
deprotection at the nitrogen centres gave a library of capped diverse heterocycles (A8). 
The computational approach outlined in Panel A is exemplified by the synthesis of 
piperazines B8 (Panel B) from ethanolamine and propargyl alcohol (B1). 
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Figure 26: An outline of the in silico approach employed to illustrate the potential power of the 
cyclic sulfamidate-propargyl sulfonamide pairing approach to diverse heterocycles. Panel A- An 
overview of the in silico protocol utilised in this approach. Text in hashed boxes represents 
‘synthetic’ transformations and text given in blue represents virtual libraries of compounds used/ 
generated in this approach. Panel B- An example of structures used in the in silico approach by 
demonstrating the synthesis of piperazines B8 from commercially available building blocks B1. 
The selections of amino alcohols from commercial sources were made by considering their 
compatibility with the reaction conditions and reactivity insights gleaned from scope and 
limitation studies (Section 3.1.2). Furthermore, building blocks and capping groups were 
selected in such a way that the final in silico library may be biased toward the enumeration 
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of compounds which might possess the physicochemical properties desirable in libraries 
of lead-like compounds (i.e. mol. weight <350, -1<logP<3, etc.). The variation of AlogP and 
molecular weight for the virtual library are shown in Chart 6 
.
 
Chart 6: Prediction of molecular weight and logP of the in silico generated library using the cyclic 
sulfamidate-propargyl sulfonamide pairing methodology. Red dashed lines represent the limits of 
lead-like chemical space whereas the solid red lines outline the limits of drug-like (Lipinski) 
chemical space. Building blocks used in this in silico approach are given in appendix A. 
The systematic in silico pairing of a selection of 10 cyclic sulfamidates, 7 propargyl 
sulfonamides and 12 capping groups (Appendix A) allowed the generation of a virtual 
library of 11869 compounds. Of these 11869 compounds, 69 were uncapped, core 
heterocycles, 1678 contained one capping group at either of the nitrogen centres within 
the ring skeleton, 10079 contained two capping groups and 43 compounds contained the 
Ugi motif. The uncapped compounds have average molecular weight (232.1 Da) and logP 
(0.29) within the limits of lead like chemical space with 72 % of the population lying 
within this space. The capped compounds have average calculated molecular weight of 
381.2, lying just outside lead-like space. However, this is believed to be due to the 
presence of a relatively small number of significantly heavier compounds (56 of 1678 
compounds have molecular weight >350) rather than a general trend of the library. The 
average logP of the virtual library of capped compounds is -0.8 therefore lying within the 
parameters of lead like chemical space. Overall, 94% of the heterocycles generated bearing 
a single capping group would be described as lead-like when considering both molecular 
weight and logP. Compounds bearing two capping groups tend to have properties outside 
0
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of lead-like chemical space with only 15% of the compound population lying within lead-
like chemical space generally by the virtue of having molecular weight greater than 350 
Da. However, 85% of compounds bearing two capping groups have properties within the 
boundaries of Lipinski chemical space suggesting that these compounds may be more 
suited to drug-like chemical space.  
Overall, this in silico generated library contains a high proportion of compounds which 
would be deemed to be lead-like as they lie within the previously outlined parameters of 
lead-like chemical space. As such, it is believed that this computational approach has 
illustrated the potential power of the cyclic sulfamidate-amino alcohol pairing 
methodology for the generation of diverse, lead-like, compounds.  
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3.1.5 Summary of Cyclic sulfamidate – Propargyl Sulfonamide Pairing 
This Chapter has described an approach to the development of methods for the generation 
of diverse heterocycles from cyclic sulfamidate and propargyl sulfonamide building blocks. 
This approach has resulted in the development of methodology for the electrophilic 
activation of alkynes to give either tetrahydropyrazines or unsaturated ketones dependent 
upon the substrate. Regioselective hydration of non-terminal alkynes was observed to 
occur which is believed to be directed by the proximal sulfonamide group. The utility of 
both tetrahydropyrazines and acyclic ketones to generate saturated heterocycles has been 
demonstrated by the development of both reduction and Ugi methods which allow the 
formation of both 6- and 7-membered heterocycles. The potential power of this approach 
has been illustrated by the in silico generation of a library of heterocyclic compounds of 
which a large proportion lie within lead like space. Examples of the diverse heterocycles 
synthesised within this Chapter are summarised below (Figure 26).   
 
Figure 27: Examples of some of the diverse heterocyclic structures synthesised in this Chapter. 
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Chapter 4: Conclusions and Outlook 
In summary, this thesis reports studies into the development of methodologies for the 
robust and convenient synthesis of lead-like scaffolds. The three methods which have been 
described in this thesis have allowed for the synthesis of a small selection of diverse 
molecular scaffolds. Some examples of the differing heterocyclic compounds synthesised 
in each section are shown (Figure 28). 
 
Figure 28: Examples of some of the diverse heterocyclic scaffolds generated within this thesis. 
These studies have resulted in the development of three approaches to the synthesis of 
nitrogen containing heterocycles; highlights and limitations of these approaches are 
summarised below: 
The chemoselective pairing of amino acid and amino alcohol derived building blocks 
(Section 2.1) has allowed the systematic synthesis of ketopiperazine and ketopiperazine-
like heterocycles. Initial focus on a catalytic approach to heterocycle formation, using a 
hydrogen borrowing approach, failed to be productive. However, the Mitsunobu‒based 
methodology developed in this study led to a non-labour intensive ‘one pot’ approach 
allowing the systematic variation of heterocycle size and substitution pattern on the 
carbon centres of the heterocyclic scaffold. 
Pairing of amino alcohol derivatives was facilitated through the use of cyclic sulfamidate 
building blocks, allowing the chemoselective coupling of amino alcohol derived building 
blocks to give piperazine derived heterocycles (Section 2.2). This approach again was non-
compatible with a catalytic approach to cyclisation and the reactivity of building block 
pairing was limited by substrate substitution. However, the methodology developed in this 
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approach allowed the stereoselective synthesis of piperazine and piperazine-like 
compounds bearing substitution on the carbon centres of the ring system. The potential 
power of this approach to deliver diverse, lead-like, heterocycles was illustrated by an in 
silico generated virtual library of heterocycles, a high proportion of which were deemed to 
be lead-like in accordance with the properties suggested by Churcher et al.1  
The approach developed towards a catalytic route to heterocycle formation again 
exploited the reactivity of cyclic sulfamidates to give unsaturated cyclisation precursors 
containing an alkyne motif (Section 3.1). Methods for cyclisation under gold catalysed 
conditions were developed, to generate tetrahydropyrazine scaffolds. This approach was 
somewhat limited by the nature of the substrate, with substituted alkyne substrates not 
undergoing cyclisation. However, this issue was partially circumvented by the application 
of catalytic alkyne hydration to give ketone substrates. Both tetrahydropyrazines and 
ketones generated from the catalytic cyclisation/ hydration approaches were 
demonstrated to be suitable substrates for further complexity generation, through either 
reductive or Ugi-type pathways, generating saturated heterocyclic systems. Furthermore, 
illustrating the potential power of this approach by the generation of a virtual lead-like 
library, using in silico methods, resulted in a high proportion of the virtual library lying 
within lead-like chemical space.  
 
Further to the exemplification of methodologies by the synthesis of diverse, lead-like 
compounds, future work will focus on the following areas: 
 The development of catalytic methodology for the hydrogen borrowing approach 
to the formation of heterocycles, potentially using ruthenium based catalytic 
systems.55 
 Investigation into newly developed gold catalysts for a milder, lower temperature 
approach to both tetrahydropyrazine formation and alkyne hydration.84  
 Further studies into the origin of regioselective hydration of alkynes through 
potential directing groups at propargylic positions. 
 Development of a catalyst‒directed asymmetric approach to the reduction or Ugi-
type reaction of tetrahydropyrazines. 
It is hoped that the methods developed within this thesis will allow the synthesis of 
diverse libraries of heterocycle containing compounds with properties desirable in early 
stage drug development. As such, it is believed that these methods will be beneficial to the 
pharmaceutical industry.     
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Chapter 5 Experimental 
5.1 General Experimental 
All non-aqueous reactions were performed under an atmosphere of nitrogen unless 
otherwise stated. Water sensitive reactions were performed in oven dried glassware, 
cooled under nitrogen before use, or flame dried, and cooled, under vacuum if stated. 
Solvents were removed in vacuo using a Büchi rotary evaporator and a Vacuubrand 
PC2001 Vario diaphragm pump. Tetrahydrofuran, dichloromethane, toluene, ethanol and 
acetonitrile were dried and purified by means of a Pure Solv MD solvent purification 
system (Innovative Technology Inc.). Anhydrous N,N-dimethylformamide and 1,4-dioxane 
was obtained in Oxford sure/seal™ bottles from Sigma–Aldrich. All other solvents used 
were of chromatography or analytical grade. Ether refers to diethyl ether and petrol refers 
to petroleum spirit (b.p. 40-60 °C). Commercially available starting materials were 
obtained from Sigma–Aldrich, Fluka, Lancaster or Alfa Aesar. 
Thin layer chromatography was carried out on aluminium backed silica (Merck silica gel 
60 F254) plates supplied by Merck. Visualisation of the plates was achieved using an 
ultraviolet lamp (λmax = 254 nm), phosphomolybdic acid, KMnO4 or anisaldehyde.  Flash 
chromatography was carried out using silica gel 60 (35-70 μm particles). 
All optical rotations were carried out on a Schmidt & Haensch H532 instrument with a 
path length of 1 dm; concentrations are g/100 mL, the optical rotations are given in 10-1 
deg cm2 g-1 and units are omitted for clarity. Infrared spectra were recorded on a Perkin-
Elmer One FT-IR spectrometer. 
Proton and carbon NMR data were collected on an Advance 500, Bruker DPX500 and 
DPX300 spectrometer. All shifts were recorded against and internal standard of 
tetramethylsilane. Solvents (CDCl3, DMSO-d6 and MeOD-d4) used for NMR experiments 
were obtained from Sigma-Aldrich. Splitting patterns in this report have been recorded in 
an abbreviated manner; app. (apparent), s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet). NMR data was recorded in the following format; ppm (number of protons, 
splitting pattern, coupling constant (Hz), proton ID). Signal assignments were made with 
the aid of COSY, DEPT 90 and 135, HMQC and HMBC. 
Low resolution mass spectra data were recorded on an Aligent 1200 series LC system 
comprising a Bruker HCT Ultra ion trap mass spectrometer, a high vacuum degasser, a 
binary pump, a high performance autosampler, an autosampler thermostat, a 
thermostated column compartment and a diode array detector. The system used two 
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solvent systems; MeCN/H2O + 0.1% formic acid with a Phenomenex Luna C18 50 × 2 mm 5 
micron column or MeCN/H2O with a Phenomenex Luna C18 50 × 2 mm 5 micron column. 
Nominal and high resolution mass spectrometry, using electrospray ionisation, was 
recorded by Mrs Tanya Marinko-Covell on a Micromass LCT-KA11 or a Bruker Daltronics 
micrOTOF spectrometer. 
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5.2 General Procedures 
A. Reductive Amination 
4-Methoxybenzaldehyde (1.2 eq.) was added to a suspension of amine (1.0 eq.) and 
molecular sieves (4Å) in methanol (1.0 M) and stirred at 50 °C until consumption of amine 
was complete (as indicated by TLC). The reaction mixture was filtered, cooled to 0 °C, 
NaBH4 (2.0 eq.) added, and the reaction mixture warmed to rt and stirred until completion 
was observed. The reaction mixture was acidified (HCl, 5 M aq., to pH<2) concentrated to 
half volume in vacuo , extracted with EtOAc, and the aqueous phase basified (K2CO3, sat. 
aq. soln., to pH>12), extracted with EtOAc, and the resulting organic phase washed with 
brine, dried (MgSO4) and concentrated in vacuo to give the crude product. 
B. TBD catalysed ester aminolysis 
1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD, 0.3 eq.) was added to a stirred mixture of ester 
(1.0 eq.) and amine (1.2 eq.) in toluene (to 0.3 M) and heated at 75 °C until completion was 
indicated by TLC. The reaction mixture was concentrated in vacuo to give the crude 
product. 
C. Cyclisation under Mitsunobu conditions 
Diethylazodicarboxylate (1.3 eq.) was added dropwise to a solution of the alcohol (1.00 
eq.) and PPh3 (1.4 eq.) in THF (0.05 M) at 0 °C, the resulting solution was warmed to room 
temperature and stirred until completion was indicated by TLC (typically 16 h). The 
resulting reaction mixture was concentrated in vacuo to give the crude product.  
D. ‘One pot’ ketopiperazine synthesis 
•Ghosez’s reagent (1-chloro-N,N-2-trimethyl-1-propenylamine, 1.0 eq.) was added to the 
desired acid (1.0 eq.) in CH2Cl2 (to 0.1 M) and the resulting suspension was stirred at rt for 
1 h. Amine (1.2 eq.) and K2CO3 (5.0 eq.) were added and stirred until completion was 
indicated by TLC (typically 20 h). The reaction mixture was concentrated in vacuo , diluted 
with water, acidified (2 M HCl to pH<2) extracted with EtOAc, the combined organic 
phases washed with K2CO3 (sat. aq. soln.), dried (MgSO4) and concentrated in vacuo to give 
the crude amide which was carried forward without purification. 
•Diethylazodicarboxylate (1.4 eq.) was added to a solution of crude sulfonamide (1.0 eq.) 
and triphenylphosphine (1.4 eq.) in THF (to 0.05 M) and stirred at rt until completion was 
indicated by TLC (typically 4 h). The reaction mixture was concentrated in vacuo to give 
the crude sulfonamide which was carried forward without purification.  
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•Thiophenol (1.2 eq.) was added to a suspension of crude sulfonamide (1.0 eq.) and K2CO3 
(3.0 eq.) in DMF (0.05 M) and stirred at rt until completion was indicated by TLC (typically 
5 h). The reaction mixture was concentrated in vacuo , diluted with EtOAc, extracted with 
HCl (2 M aq. to pH<2), basified with K2CO3 (sat. aq. soln., to pH>11), extracted with EtOAc, 
dried (MgSO4) and concentrated in vacuo to give the crude product.  
E. Hydroxy sulfonamide formation 
2-Nitrobenzenesulfonyl chloride (1.0 eq.) was added to a vigorously stirred solution of 
amino alcohol (1.05 eq.), Na2CO3 (1.05 eq.) in CH2Cl2/ H2O (1:1 mixture, 0.8 M solution) 
and the resulting mixture stirred at rt until completion was indicated by TLC (typically 24 
h). The reaction mixture was acidified (HCl, 5 M aq., to pH<2), extracted with CH2Cl2, 
organic phase washed with brine, dried (MgSO4) and concentrated in vacuo to give the 
crude product.  
F. Cyclic sulfamidate formation  
Amino alcohol derivative (1.0 eq.) in CH2Cl2 (0.4 M) was added dropwise to a stirred 
solution of SOCl2 (1.1 eq.), NEt3 (2.2 eq.) and imidazole (4 eq.) in CH2Cl2 (0.1 M) at −60 °C 
(CO2 and CHCl3) and the resulting solution was stirred at −60 °C until completion was 
indicated by TLC (typically < 3 h). The reaction mixture was warmed to room 
temperature, quenched by addition of water, the phases separated and the organic phase 
washed with brine, dried (MgSO4) and concentrated in vacuo to give the crude cyclic 
sulfamidite. The crude cyclic sulfamidite was dissolved in MeCN (0.13 M), cooled to 0 °C 
(ice water bath), NaIO4 (1.1 eq) RuCl3⋅3H2O (0.1 mol%) and water (0.16 M) were added 
sequentially and the resulting solution was stirred until completion was indicated by TLC. 
The cold reaction mixture was diluted with water (equal volume to that used in reaction), 
warmed to room temperature, extracted with Et2O, washed with brine, dried (MgSO4) and 
concentrated in vacuo to give the crude product.  
G. Opening of cyclic sulfamidates with sulfonamides 
NaH (60 % dispersion in oil, 1.1 eq.) was added to a solution of the sulfonamide (1.1 eq.) in 
DMF (0.2 M) and stirred for ten minutes, at which point the cyclic sulfamidate (1.0 eq.) 
was added and the resulting solution was stirred at room temperature (unless otherwise 
stated) until completion was indicated by TLC (typically 24 h). The reaction mixture was 
acidified (5 M HCl aq., 6 eq.), stirred for 1 h, basified (K2CO3 sat. aq. soln., to pH>12), 
extracted with EtOAc, washed with brine, dried (MgSO4) and concentrated in vacuo to give 
the crude product.  
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H. Cbz Protection of amino alcohols 
Benzylchloroformate (1.05 eq,) was added drowpise to a suspension of amino alcohol (1.0 
eq.) and NaHCO3 (2.0 eq.) in THF‒H2O (1:1, 0.15 M) at 0 °C and the resulting solution 
warmed to rt and stirred for 1 h. The reaction mixture was acidified with HCl (1 M aq., to 
pH<2), extracted with EtOAc, organics washed with brine, dried (MgSO4) and concentrated 
in vacuo to give a crude product. 
I. Boc Protection of amino alcohols 
Di-tert-butyl dicarbonate (1.05 eq.) was slowly added to a solution of amino alcohol (1.0 
eq.) in CH2Cl2 (0.3 M) at 0 °C and the resulting solution was warmed to rt and stirred until 
completion was indicated by TLC. The reaction mixture was diluted with H2O acidified 
with HCl (1M aq, to pH<2), exctracted with CH2Cl2, organics washed with brine, dried 
(MgSO4) and concentrated in vacuo to give a crude product. 
J. Propargyl sulfonamide formation 
Diethyl azodicarboxylate (1.3 eq.) was added to a solution of alcohol (1.0 eq.), sulfonamide 
203 (1.1 eq.) and PPh3 (1.3 eq.) in THF (to 0.1 M) at 0 °C, the resulting solution warmed to 
rt and stirred until completion was observed by TLC and the reaction mixture was 
concentrated in vacuo to give  the crude product. Filtration through a silica gel plug, 
eluting with Petrol‒EtOAc, followed by concentration in vacuo gave the intermediate 
sulfonamide. TFA (10.0 eq.) was added to a solution of intermediate sulfonamide (1.0 eq.) 
in CH2Cl2 (0.1 M) at rt and stirred until completion was observed by TLC. The reaction 
mixture was quenched by addition of K2CO3 (sat. aq. soln., to pH>11), extracted with 
CH2Cl2, combined organic phases washed with brine, dried (MgSO4) and concentrated in 
vacco to give the expected sulfonamide. 
K. Gold mediated cyclisation 
Au(PPh3)Cl (5 mol%), AgSbF6 (5 mol%) and cyclisation substrate (1.0 eq.) were combined 
in 1,4-dioxane (0.2 M) and stirred at 100 °C until completion was observed by TLC. The 
reaction mixture was cooled to rt and concentrated in vacuo to give the crude product.  
L. Gold mediated alkyne hydration 
Au(IPr)Cl (1 mol%), AgSbF6 (1 mol%) and hydration substrate (1.0 eq.) were combined in 
1,4-dioxane (0.5 M), H2O (0.8 M) added, and the resulting solution heated at 120 °C in a 
sealed tube until completion was observed by TLC. The reaction mixture was cooled to rt 
and concentrated in vacuo to give the crude product.  
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M. Triethylsilane mediated reduction  
Triethylsilane (6.0 eq.) was added to a solution of substrate (1.0 eq.) and TFA (10 eq.) in 
CH2Cl2 (0.05 M) at 0 °C and slowly allowed to warm to rt until completion was observed by 
TLC. The reaction mixture was quenched with K2CO3 (sat. aq. soln., to pH>11), extracted 
with CH2Cl2, the combined organics washed with brine, dried (MgSO4), and concentrated in 
vacuo to give the crude product. 
N. Ugi Reaction  
TFA (4 eq.) was added to a solution of substrate (1.0 eq.) in CH2Cl2 (0.1 M) at rt and stirred 
until completion was observed by TLC. The crude reaction mixture was concentrated in 
vacuo to give an intermediate TFA salt. Isonitrile (2.0 eq,) was added to a solution of the 
intermediate TFA salt (1.0 eq.) in EtOH (0.05 M) at 0 °C and stirred at rt until completion 
observed by TLC. The reaction mixture was concentrated in vacuo to give the crude 
product. 
Purification by strong ion exchange (SCX) resin 
Strong cation exchange resin (SCX, 5.0 g pre-packed cartridge, Supelco) was conditioned 
by washing with MeOH (>20 mL). The crude amine (<1 mmol) in MeOH (<5 mL) was 
added and non-basic compounds were eluted with MeOH. Basic compounds were eluted 
with NH3 in MeOH (sat. soln.) and concentrated in vacuo to give the product. Resin was 
reconditioned by treatment with TfOH (1 M in MeOH, 20 mL) followed by washing with 
MeOH (10 mL).  
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5.3 Experimental Procedures 
2-(4-Methoxybenzylamino)ethanol, 8497 
 
By general procedure A, 2-aminoethanol (4.10 g, 67.0 mmol) gave alcohol 84 (10.0 g, 55.3 
mmol, 82%) as a light brown oil which required no further purification; Rf 0.32 (50:8:1 
CH2Cl2‒EtOH‒NH4OH); δH (500 MHz; CDCl3) 7.25 (2H, d, J 8.7, Ar 2-H and Ar 6-H), 6.88 
(2H, d, J 8.7, Ar 3-H and Ar 5-H), 3.8 (3H, s, OMe), 3.75 (2H, s, CH2Ar), 3.65 (2H, t, J 5.2, 1-
H), 2.79 (2H, t, J 5.1, 2-H), 2.24 (2H, s (broad), NH and OH); δC (75 MHz; CDCl3) 159.1 (Ar 4-
C), 132.6 (Ar 1-C), 129.7 (Ar 2-C and Ar 6-C), 114.2 (Ar 3-C and Ar 5-C), 61.3 (1-C), 55.7 
(OMe), 53.3 (CH2Ar), 50.8 (2-C); νmax/cm-1 (film) 3307, 1612, 1514, 1248; m/z (ESI) 182.1 
(100%, MH+); HRMS found MH+, 182.1176. C10H15NO2 requires MH, 182.1176.  
3-(4-Methoxybenzylamino)propan-1-ol, 10897 
 
Na(CN)BH3 (420 mg, 6.7 mmol) was added to a stirred solution of 3-aminopropanol (1.01 
mL, 13.0 mmol) and 4-methoxybenzaldehyde (0.81 mL, 6.7 mmol) in methanol (50 mL) 
and stirred at rt for 16 h. Reaction was quenched by addition of HCl (5 M, to pH<2), 
concentrated in vacuo , taken up in water (20 mL) basified with K2CO3 (sat. aq. soln., to 
pH>11), extracted with CH2Cl2 (3 × 25 mL), dried (MgSO4) and concentrated to give a 
crude product. Purification by column chromatography, eluting with 50:8:1 CH2Cl2‒EtOH‒
NH4OH, gave the amine 108 (1.04 g, 5.30 mmol, 80%) as a light brown oil; Rf 0.22 (50:8:1 
CH2Cl2‒EtOH‒NH4OH); δH (500 MHz; CDCl3) 7.21 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.86 
(2H, d, J 8.6, Ar 3-H and Ar 5-H), 3.80 (5H, m, CH2OH and OMe), 3.72 (2H, s, CH2Ar), 3.05 
(2H, s (broad), NH and OH), 2.88 (2H, t, J 5.7, CH2NH), 1.71 (2H, pent, J 5.6, CH2); δC (75 
MHz; CDCl3) 159.2 (Ar 4-C), 132.1 (Ar 1-C), 129.8 (Ar 2-C and Ar 6-C), 114.3 (Ar 3-C and Ar 
5-C), 64.9 (CH2OH), 55.7 (OMe), 53.8 (CH2NH), 49.8 (CH2Ar), 31.1 (CH2); νmax /cm-1 (film) 
3295, 1613, 1514, 1248; m/z (ESI) 196.1 (100%, MH+); HRMS found MH+, 196.1340. 
C11H17NO2 requires MH, 196.1332. 
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(R)-2-(4-Methoxybenzylamino)propan-1-ol, 10560 
 
By general procedure A, followed by purification by column chromatography, eluting with 
50:8:1 CH2Cl2‒EtOH‒NH4OH, (2R)-2-aminopropanol (0.21 mL, 2.7 mmol) gave the amine 
105 (464 mg, 2.4 mmol, 89%) as an amorphous solid; Rf 0.46 (50:8:1 CH2Cl2‒EtOH‒
NH4OH); [α]D21: 45.0 (c. 0.8, MeOH); δH (300 MHz; CDCl3) 7.23 (2H, d, J 8.6, Ar 2-H and Ar 
6-H), 6.86 (2H, d, J 8.7, Ar 3-H and Ar 5-H), 3.81 (1H, d, J 12.7, CHaAr), 3.79 (3H, s, OMe), 
3.64 (1H, d, J 12.7, CHbAr), 3.57 (1H, dd, J 10.6 and 4.0, 1-Ha), 3.26 (1H, dd, J 10.6, 7.1, 1-Hb), 
2.81 (1H, m, 2-H), 2.32 (2H, s (broad), NH and OH), 1.07 (3H, d, J 6.5, 3-H); δC (75 MHz; 
CDCl3) 159.1 (Ar 4-C), 132.7 (Ar 1-C), 129.7 (Ar 2-C and Ar 6-C), 114.2 (Ar 3-C and Ar 5-C), 
65.9 (1-C), 55.7 (OMe), 54.1 (2-C), 50.9 (CH2Ar), 17.5 (3-C); νmax /cm–1 (film); 3390, 1652, 
1514, 1248; m/z (ESI) 196.1 (100%, MH+). 
(S)-2-(4-Methoxybenzylamino)propan-1-ol, 10660 
 
By general procedure A, followed by purification by column chromatography, eluting with 
50:8:1 CH2Cl2‒EtOH‒NH4OH, (2S)-2-aminopropanol (0.41 mL, 5.3 mmol) gave the amine 
106 (819 mg, 4.2 mmol, 80%) as an amorphous solid; Rf 0.67 (50:8:1 CH2Cl2‒EtOH‒
NH4OH); [α]D20: -48 (c. 1 CHCl3); δH (300 MHz; CDCl3) 7.25 (2H, d, J 8.4, Ar 2-H and Ar 6-H), 
6.88 (2H, d, J 8.6, Ar 3-H and Ar 4-H), 3.82 (1H, d, J 13.0, CHaAr), 3.70 (1H, d, J 12.8, CHbAr), 
3.60 (1H, dd, J  10.6 and 4.6, 1-Ha), 3.27 (1H, dd, J 10.6 and 7.0, 1-Hb), 2.85 (1H, m, 2-H), 
2.12 (2H, s (broad), NH and OH), 1.09 (3H, d, J 6. 4, 3-H); δC (75 MHz; CDCl3) 129.8 (Ar 2-C 
and Ar 6-C), 114.3 (Ar-C3 and Ar-C5), 65.8 (1-C), 55.7 (OMe), 54.1 (2-C), 50.8 (CH2Ar), 17.6 
(3-C); νmax/cm-1 (film) 3300, 2932, 1611, 1585, 1513, 1248, 1036; m/z (ESI) 196.1 (100%, 
MH+); HRMS found MH+, 196.1338. C11H17NO2 requires MH, 196.1332. 
(S)-1-(4-Methoxybenzylamino)propan-2-ol, 107 
 
By general procedure A, (S)-1-amino-2-propanol (1.00 g, 13.3 mmol) gave alcohol 107 
(2.42 g, 12.4 mmol, 93%) as a light brown oil which required no further purification; Rf 
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0.34 (9:1 CH2Cl2‒MeOH); [α] D26: 11.6 (c. 1.3, MeOH); δH (500 MHz; CDCl3) 7.24 (2H, d, J 8.6, 
Ar 2-H and Ar 6-H), 6.87 (2H, d, J 8.7, Ar 3-H and Ar 5-H), 3.75 (5H, m, OMe, 2-H and benzyl 
CHa), 3.72 (1H, d, J 12.8, benzyl CHb), 2.73 (1H, dd, J 12.0, 3.0, 1-Ha), 2.43 (1H, dd, J 12.0, 9.5, 
1-Hb), 2.28 (2H, s (broad), NH and OH), 1.15 (3H, d, J 6.2, 3-H); δC (75 MHz; CDCl3) 129.3 
(Ar 2-C and Ar 6-C), 113.9 (Ar 3-C and Ar 5-C), 65.6 (2-C), 56.1 (1-C), 55.3 (OMe), 53.0 
(CH2 benzyl), 20.4 (3-C) [Ar 1-C and 4-C were not observed]; νmax/cm-1 (film) 3308, 2966, 
1612, 1513; m/z (ESI) 196.1  (100%, MH+); HRMS found MH+, 196.1329. C11H17NO2 
requires MH, 196.1332. 
 (1-(4-Methoxybenzylamino)cyclohexyl)methanol, 11161 
 
1-Amino cyclohexanecarboxylic acid (2.50 g, 17.5 mmol) was slowly added to a stirred 
suspension of LiAlH4 (1.98 g, 52.5 mmol) in THF (175 mL) at 0 °C and the resulting 
suspension was stirred at reflux for 24 h. Reaction was quenched by slow addition of 
Na2CO3 (sat. aq. soln., to pH>11) filtered over celite, washing with EtOAc, the filtrate was 
concentrated in vacuo, extracted with n-butanol (3 × 50 mL), dried (MgSO4) and 
concentrated to give a crude product. Purification by column chromatography, eluting 
with 50:8:1 CH2Cl2‒EtOH‒NH4OH, gave the amine 110 (1.68 g) as a colourless oil which 
was alkylated using general procedure A and gave the amine 111 (425 mg, 1.7 mmol, 43% 
over two steps) as a colourless oil which required no further purification; Rf 0.31 (9:1 
CH2Cl2‒MeOH); δH (500 MHz; CDCl3) 7.25 (2H, d, J 8.5, Ar 2-H and Ar-H6), 6.88 (2H, d, J 8.5, 
Ar 3-H and Ar 5-H), 3.81 (3H, s, OMe), 3.56 (2H, s, CH2Ar), 3.37 (2H, s, CH2OH), 1.64-1.35 
(12H, m, c.Hex and NH and OH); δC (75 MHz; CDCl3) 159.1 (Ar 4-C), 133.2 (Ar 1-C), 129.8 
(Ar 2-C and Ar 6-C), 114.3 (Ar 3-C and Ar 5-C), 65.7 (CH2OH), 55.7 (OMe), 55.6 (1-C), 44.8 
(CH2Ar), 33.1 (c.hex), 26.4 (c.hex), 22.1 (c.hex); νmax /cm–1 (film) 2930, 1613, 1514, 1453, 
1249; m/z (ESI) 250.2 (100%, MH+); HRMS found MH+, 250.1810. C15H23NO2 requires MH, 
250.1802. 
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(1,2-trans)-2-((4-Methoxybenzylamino)methyl)cyclohexanol, 11262 
 
Cyclohexene oxide (1.11 mL, 11.0 mmol) was added to a solution of LiCN⋅(CH3)2CO (2.50 g, 
27.5 mmol) in THF (40 mL) and heated at reflux for 1.5 h. Reaction was quenched with 
water (50 ml), extracted with diethylether (3 × 50 mL), dried (MgSO4) and concentrated to 
give a crude product. Partial purification by column chromatography, eluting with 2:1 
petrol‒EtOAc, gave the nitrile 113 (1.28 g). LiAlH4 (454 mg, 12.0 mmol) was added to a 
stirred solution of nitrile 113 (1.00 g) in THF (80 mL) and heated at reflux for 2.5h. 
Reaction was quenched with water (2 mL), diluted with EtOAc, filtered over celite, 
washing with EtOAc, and solvents removed in vacuo to give a crude product (1.01 g) which 
was used without further purification. Crude amine 114 (≈8.0 mmol) was alkylated using 
general method A to give amine 115 (1.54 g, 6.20 mmol, 77% from epoxide 112) as a 
colourless oil; Rf 0.59 (9:1 CH2Cl2‒MeOH); δH (300 MHz; CDCl3) 7.22 (2H, d, J 8.6, Ar 2-H 
and Ar 6-H), 6.85 (2H, d, J 8.6, Ar 3-H and Ar 5-H), 3.81 (1H, d, J 12.8, CHaAr), 3.80 (3H, s, 
OMe), 3.67 (1H, d, J 12.8, CHbAr), 3.42 (1H, m, 1-H), 2.82 (1H, dd, J 11.9, 2.7, CHaNH), 2.57 
(1H, app. t, J 11.5, CHbNH), 1.94 (1H, m, CH c.hex), 1.67 (2H, m, 2 × CH c.hex), 1.53 (1H, m, 
CH c.hex), 1.40 (1H, m, CH c.hex), 1.21 (3H, m, 3 × CH c.hex), 0.87 (1H, m, CH c.hex); δC (75 
MHz; CDCl3) 159.9 (Ar 4-C), 132.1 (Ar 1-C), 130.5 (Ar 2-C and Ar 6-C), 114.9 (Ar 3-C and Ar 
5-C), 78.7 (1-C), 57.2 (CH2NH), 56.3 (OMe), 54.3 (CH2Ar), 44.4 (2-C), 35.7 (CH c.hex), 30.1 
(CH c.hex), 26.6 (CH c.hex), 25.1 (CH c.hex); νmax /cm-1 (film) 3293, 2928, 2159, 1612, 
1513, 1449; m/z (ESI) 250.2 (100%, MH+); HRMS found MH+, 250.1881. C15H23NO2 
requires MH, 250.1802.  
3-(2-Nitrophenylsulfonamido)propanoic acid, 11699 
 
2-Nitrobenzenesulfonyl chloride (1.62 g, 7.30 mmol) was added to a solution of β-alanine 
(500 mg, 5.6 mmol) and triethylamine (2.40 mL, 16.8 mmol) in THF (2 mL) and water (6 
mL) and stirred at rt for 19h. Reaction mixture was concentrated to half volume, acidified 
with HCl (2 M aq., to pH<2), extracted with EtOAc (3 × 30 mL), dried (MgSO4) and 
concentrated in vacuo to give a crude product. Purification by column chromatography, 
eluting with 9:1 CH2Cl2‒MeOH, gave the acid 116 (705 mg, 2.6 mmol, 46%) as a colourless 
solid; Rf 0.32 (9:1 CH2Cl2‒MeOH); δH (300 MHz; DMSO-D6) 8.15 (1H, t, J 5.6, NH), 8.00 (2H, 
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m, Ar), 7.88 (2H, m, Ar), 3.10 (2H, q, J 6.8, 3-H), 2.42 (2H, t, J 6.9, 2-H);  δC (75 MHz; DMSO-
D6) 172.6 (C1), 148.1 (Ar 2-C), 134.5 (Ar 1-C), 133.1 (Ar), 132.8 (Ar), 129.8 (Ar), 124.8 
(Ar), 40.5 (2-C), 34.4 (3-C); νmax /cm-1 (solid) 1699, 1538, 1428, 1232; m/z (ESI) 297.0 
(100%, MNa+); HRMS found MH+, 275.0334. C9H10N2O6S requires MH, 275.0332. 
 
1-(2-Nitrophenylsulfonamido)cyclohexanecarboxylic acid, 11763 
 
N,O-Bistrimethylsilylacetamide (1.8 mL, 7.2 mmol) was added to 1-
aminocyclohexanecarboxylic acid (500 mg, 3.5 mmol) in CH2Cl2 (15 mL) and stirred at rt 
for 1h. 2-Nitrobenzenesulfonyl chloride (840 mg, 3.8 mmol) in CH2Cl2 (10 mL) was added 
dropwise and the reaction mixture was stirred at rt for a further 16 h. The reaction 
mixture was concentrated in vacuo , treated with NaHCO3 (5% w/w, 15 mL) for 30 min, 
washed with EtOAc (2 × 10 mL), acidified with HCl (2 M aq., to pH<2), extracted with 
EtOAc (3 × 30 mL), washed with brine, dried (MgSO4) and concentrated in vacuo to give 
acid 117 (400 mg, 1.2 mmol, 35%) as a colourless solid which was used without further 
purification; Rf 0.41 (9:1 CH2Cl2‒MeOH); δH (500 MHz; CDCl3) 8.06 (1H, m, Ar), 7.92 (1H, 
m, Ar), 7.83 (2H, m, Ar), 1.87 (2H, m, c.Hex), 1.70 (2H, m, c.Hex), 1.36-1.16 (6H, m, c.Hex); 
δC (75 MHz; CDCl3) 174.9 (CO), 147.1 (Ar 2-C), 134.9 (Ar 1-C), 133.7 (Ar), 132.5 (Ar), 129.5 
(Ar), 124.1 (Ar), 61.6 (1-C), 32.5 (2 × CH2 c.Hex), 24.6 (c.Hex), 20.8 (2 × CH2 c.Hex);  νmax 
/cm–1 (film); 2943, 1709, 1537, 1360; m/z (ESI) 346.3 (100%, MH2O+); HRMS found MNa+, 
351.0637. C13H16N2O2S requires MNa, 351.0627. 
(S)-Methyl-2-(benzylamino)-3-methylbutanoate, 8151 
 
Benzaldehyde (2.05 mL, 20.1 mmol) was added to a solution of L-valine methyl ester·HCl 
(1.70 g, 10.0 mmol), MgSO4 (2.05 g, 17.1 mmol) and triethylamine (1.37 mL, 10.0 mmol) in 
THF (10 mL) at 0 °C and the mixture was stirred at rt for 4.5 h. The reaction mixture was 
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concentrated in vacuo, dissolved in MeOH (30 mL) at 0 °C, NaBH4 (0.76 g, 20.1 mmol) 
added stirred for 45 min, quenched (NaOH 1 M aq., 20 mL), extracted (Et2O, 2 × 100 mL), 
combined organic extracts were washed with brine, dried (MgSO4) and concentrated in 
vacuo to give a crude product. Purification by column chromatography, gradient elution 
9:1→4:1 petrol–EtOAc, gave the amino ester 81 (1.25 g, 5.6 mmol, 56% yield) as 
colourless oil; Rf 0.38 (petrol‒EtOAc 9:1); [α]D26 -13 (c. 1.0 CHCl3) [lit.51[α]D27 -53.9 (c. 1.03 
CHCl3), 24% ee];  δH (500 MHz, CDCl3); 7.40-7.35 (4H, m, Ar-H), 7.35 (1H, m, Ar 4-C), 3.90 
(1H, d, J 13.1 CHaAr), 3.77 (3H, s, OMe), 3.65 (1H, d, J 13.1 CHbAr), 3.08 (1H, d, J 6.1, 2-H), 
1.98 (1H, m, 3-H), 1.81 (1H, s (broad), NH), 1.01 (3H, d, J 6.8, 4-H), 0.99 (3H, d, J 6.8, CH3); 
δC (75 MHz, CDCl3); 176.4 (1-C), 140.6 (Ar 1-C), 128.9 (Ar 3-C and Ar 5-C), 128.8 (Ar 2-C 
and Ar 6-C), 127.5 (Ar 4-C) 67.1 (2-C) 53.1 (CH2Ph), 52.0 (OMe), 32.3 (3-C), 19.9 (4-C), 
19.2 (CH3); νmax/cm–1 (film); 3338, 2961, 1734 and 1454; m/z (ESI) 222.1 (100%, MNH4+); 
HRMS found MH+, 222.1492. C13H19NO2 requires MH, 222.1489. 
(S)-3-Methyl-2-(2-nitrophenylsulfonamido)butanoic acid, 79 
 
2-Nitrobenzenesulfonyl chloride (4.90 g, 22.0 mmol) was slowly added to a stirred 
solution of L-valine (2.00 g, 17.0 mmol) and triethylamine (7.1 mL, 51 mmol) in THF (5 
mL) and water (17 mL) at 0 °C and the resulting mixture was stirred at rt for 22 h. 
Reaction mixture was concentrated to half volume, acidified (HCl, 2 M aq., to pH<2), 
extracted with EtOAc (3 × 50 mL), washed with brine, dried (MgSO4) and concentrated in 
vacuo to give acid 79 (5.07 g, 16.0 mmol, 98%) as a colourless amorphous solid; Rf 0.41 
(9:1 CH2Cl2‒MeOH); [α]D21: -144.1 (c. 0.6, CHCl3); δH (500 MHz; CDCl3) 8.07 (1H, m, Ar), 
7.93 (1H, m, Ar), 7.75 (2H, m, Ar), 7.53 (1H, s (broad), OH), 6.0 (1H, d, J 9.5, NH), 4.05 (1H, 
dd, J 9.5, 4.8,  2-H), 2.20 (1H, m, 3-H), 1.01 (3H, d, J 6.8, 4-H), 0.92 (3H, d, J 6.9, CH3); δC (75 
MHz; CDCl3) 176.3 (1-C), 134.5 (Ar 1-C), 134.3 (Ar), 133.4 (Ar), 130.7 (Ar), 126.1 (Ar), 62.1 
(2-C), 31.7 (3-C), 19.5 (4-C), 17.6 (CH3) [Ar 2-C was not observed]; νmax/cm-1 (solid) 3350, 
2964, 2159, 1715, 1537; m/z (ESI) 320.1 (100%, MNH4+); HRMS found MNH4+, 320.0910. 
C11H14N2O6S requires MNH4, 320.0911. 
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(S)-Methyl-3-methyl-2-(2-nitrophenylsulfonamido)butanoate, 80105 
 
2-Nitrobenzenesulfonyl chloride (2.66 g, 12.0 mmol) was added to a stirred solution of L-
valine methyl ester (2.00 g, 12.0 mmol) and triethylamine (3.85 mL, 27.0 mmol) in CH2Cl2 
(75 mL) and stirred at rt for 22 h. Reaction was quenched with water (10 mL) dried 
(MgSO4) and concentrated in vacuo to give a crude product. Purification by column 
chromatography, eluting with 1:1 petrol‒EtOAc, gave the sulfonamide 80 (3.71 g, 11.7 
mmol >98%) as a light yellow oil; Rf 0.30 (1:1 petrol‒EtOAc); [α]D21: −73.8 (c. 0.7, MeOH); 
δH (300 MHz; CDCl3) 8.11-8.08 (1H, m, Ar), 7.99-7.95 (1H, m, Ar), 7.79-7.75 (2H, m, Ar), 
6.09 (1H, d, J 9.8, NH), 4.05 (1H, dd, J 9.8, 5.2, 2-H), 3.47 (3H, s, OMe), 2.25-2.15 (1H, m, 3-
H), 1.05 (3H, d, J 6.8, 4-H), 0.97 (3H, d, J 6.9, CH3); δC (75 MHz; CDCl3) 171.5 (C1), 134.1 
(Ar), 133.3 (Ar), 130.8 (Ar), 126.1 (Ar), 62.55 (2-C), 52.6 (OMe), 32.0 (3-C), 19.4 (4-C), 17.9 
(CH3) [Ar C-1 and C-2 were not observed]; νmax/cm-1 (film) 3321, 2967, 1741, 1542, 1422, 
1360, 1174; m/z (ESI) 334.1 (100%, MNH4+); HRMS found MH+, 317.0807. C14H23N2O2 
requires MH, 317.0802. 
N-Benzylaniline, 9656 
 
[Cp*IrCl2]2 (20 mg, 0.03 mmol), aniline (0.09 mL, 1.0 mmol), benzylalcohol (0.10 mL, 1.0 
mmol) and K2CO3 (7 mg, 0.05 mmol) were combined in toluene (0.5 mL) under an argon 
atmosphere and the mixture was heated at 110 °C for 24 h. The reaction mixture was 
concentrated in vacuo.  Purification by column chromatography, eluting with 20:1 petrol–
EtOAc, gave the aniline 96 (138 mg, 75%) as a light yellow oil; Rf 0.31 (20:1 petrol‒
EtOAc); δH (500 MHz; CDCl3) 7.44-7.39 (4H, m, Ar), 7.35-7.32 (1H, m, Ar), 7.25-7.22 (2H, m, 
Ar), 6.78 (1H, t, J 7.3, Ar), 6.70 (2H, m, Ar), 4.39 (2H, s, CH2Ph), 4.09 (1H, s (broad), NH); δC 
(75 MHz; CDCl3) 139.8 (Bn 1-C), 129.7 (Ar 3-C and 5-C), 129.0 (Bn 3-C and 5-C), 127.9 (Bn 
2-C and 6-C), 127.7 (Bn 4-C), 118.0 (Ar 4-C), 113.2 (Ar 2-C and 6-C), 48.7 (CH2Ph) [Ar 1-C 
was not observed]; νmax/cm–1 (film) 3419, 3052, 3026, 2849 1602, 1505; m/z (ESI) 184.0 
(100%, MH+). 
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(S)-2-(Benzylamino)-N-(2′-hydroxyethyl)-3-methylbutanamide, 88 
 
Ethanolamine (0.72 mL, 1.2 mmol) was added to a mixture of ester 81 (221 mg, 1.0 mmol) 
and TBD (42 mg, 0.3 mmol) and the mixture heated at 68 °C for 18 h. The cooled reaction 
mixture was purified by column chromatography, eluting with 20:1 CH2Cl2–MeOH, to give 
the amide 88 (221 mg, 88%) as a colourless oil; Rf 0.51 (9:1 CH2Cl2‒MeOH);  δH (500 MHz; 
CDCl3) 7.71 (1H, s (broad), NH), 7.41-7.31 (5H, m, Ar-H), 3.20 (1H, d, J 13.1 CHaPh), 3.76 
(2H, t, J 5.4, 2′-H), 3.72 (1H, d, J 13.1 CHbPh), 3.48 (2H, J 5.4, 1-H′), 3.06 (1H, d, J 4.4, 2-H), 
2.18 (1H, m, 3-H), 1.75 (1H, s (broad), OH), 1.02 (3H, d, J 7.0, 4-H), 0.96 (3H, d, J 7.0, CH3); 
δC (75 MHz; CDCl3) 175.7 (1-C), 140.0 (Ph 1-C), 129.1 (Ph 3-C and Ph 5-C), 128.7 (Ph 2-C 
and Ph 6-C), 127.9 (Ph 4-C), 68.4 (2-C), 63.5 (2-C′), 54.1 (CH2Ph), 42.7 (1-C′), 31.8 (3-C), 
20.1 (4-C), 18.2 (CH3); νmax/cm–1 (film) 3325, 2960, 1651, 1534, 1454, 1362, 1075; m/z 
(ESI) 251.2 (100%, MH+); HRMS found MH+, 251.1754. C14H22N2O2 requires MH, 251.1754. 
(S)-2-(Benzylamino)-N-(2′-hydroxyethyl)-N,3-dimethylbutanamide, 89 
 
N-methylethanolamine (0.2 mL, 0.4 mmol) was added to a mixture of ester 81 (443 mg, 
2.0 mmol) and TBD (84 mg, 0.3 mmol) and the mixture heated to 75 °C for 22 h. The 
cooled reaction mixture was purified by column chromatography, gradient elution 
20:1→9:1 CH2Cl2–MeOH, to give the amide 89 (482 mg, 91%) as a colourless oil; Rf 0.43 
(9:1 CH2Cl2–MeOH); δH (500 MHz; CDCl3) (4.5:1 mixture of rotamers) 7.42-7.27 (10H, m, 
PhrotA+PhrotB), 3.87 (1H, d, J 13.4, CHaPh rotA), 3.84 (2H, t, J 5.1, 2′-HrotA), 3.72 (4H, m, 2′-HrotB 
and 1′-HrotA) 3.64 (2H, m, 1′-HrotB), 3.57 (1H, d, J 13.4, CHaPh rotA), 3.41 (1H, d, J 6.4, 2-HrotB), 
3.26 (1H, d, J 6.4, 2-HrotA), 3.06 (3H, s, NMerotB), 2.97 (3H, s, NMerotA), 2.08 (1H, sept, 3-HrotB) 
1.86 (1H, sept, 6.9, 3-HrotA), 1.05 (6H, d, J 6.5, 4-HrotA+ 4-HrotB), 0.99 (6H, d, J 0.67, CH3rotA+ 
CH3rotB); δC (75 MHz; CDCl3) 177.8 (1-C), 128.7 (Ph), 127.3 (Ph), 62.6 (C), 62.2 (2’-C), 52.6 
(CH2Ph), 42.73 (1’-C), 32.1 (iPr), 20.1 (iPr), 18.7 (iPr); νmax/cm–1 (film) 3401, 2959, 1621, 
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1469, 1404; m/z (ESI) 265.2 (100%, MH+); HRMS found MH+, 265.1928. C15H24N2O2 
requires MH, 265.1928.  
(S)-2-Amino-N-(2′-hydroxyethyl)-3-methylbutanamide, 90 
 
TBD (317 mg, 2.3 mmol) was added to a stirred mixture of ester 86 (1.00 g, 7.6 mmol) and 
ethanolamine (0.55 mL, 9.13 mmol) and the resulting mixture was heated at 60 °C for 16 
h. Reaction mixture was concentrated in vacuo to give a crude product. Purification by 
column chromatography, eluting with 50:8:1 CH2Cl2‒EtOH‒NH4OH, gave the amide 90 
(902 mg, 5.6 mmol, 74%) as a light yellow oil; Rf 0.22 (50:8:1 CH2Cl2‒EtOH‒NH4OH); 
[α]D21: 13.6 (c. 0.6, MeOH); δH (500 MHz; CDCl3) 7.77 (1H, s (broad), OH), 3.75 (2H, t, J 4.9, 
2′-H), 3.51-3.43 (2H, m, 1-H′), 3.29 (1H, d, J 3.8, 2-H), 2.37-2.26 (1H, m, 3-H), 2.20 (1H, s 
(broad), NH), 1.02 (3H, d, J 7.0, 4-H), 0.87 (3H, d, J 6.9, CH3); δC (75 MHz; CDCl3) 175.8 (1-
C), 62.6 (1-C′), 60.1 (2-C′), 42.3 (2-C), 30.8 (3-C), 19.6 (4-C), 16.0 (CH3); νmax/cm-1 (film) 
3294, 2964, 1650, 1465, 1069; m/z (ESI) 161.1 (100%, MH+); HRMS found MH+, 161.1285. 
C7H17N2O2 requires MH, 161.1282. 
(S)-2-Amino-N-(2′-hydroxyethyl)-N-3-dimethylbutanamide, 91 
 
TBD (230 mg, 1.7 mmol) was added to a mixture of L-valine methylester·HCl (924 mg, 5.5 
mmol), N-methylethanolamine (1.33 mL, 16.5 mmol) and triethylamine(0.7 mL, 5.5 mmol) 
and the resulting solution was stirred at 75 °C for 24 h. Analysis (TLC) showed incomplete 
reaction. MeOH (1 mL) added and heated for a further 24 h. Reaction mixture was cooled 
and concentrated in vacuo to give a crude product. Purification by column 
chromatography, eluting with 50:8:1 CH2Cl2‒EtOH‒NH4OH, gave the amide 91 (686 mg, 
72%) as a light yellow oil; Rf 0.12 (9:1 CH2Cl2‒MeOH); [α]D21: 61.1 (c. 1.4, MeOH); δH (300 
MHz; CDCl3) (1:1 mixture of rotamers) 4.02-3.94 (1H, m, 2′-HrotA), 3.89-3.80 (3H, m, 2′-
HrotA and 2′-HrotB), 3.75-3.67 (1H, m), 3.62-3.58 (2H, m), 3.52 (1H, d, J 6.0, 2-HrotA), 3.46 (1H, 
d, J 7.7, 2-HrotB), 3.15 (3H, s, NMerotA), 3.01 (3H, s, NMerotB), 2.08-1.96 (1H, m, 3-HrotA), 1.96-
1.85 (1H, m, 3-HrotB), 1.00 (6H, m, 4-HrotA and CH3), 0.94 (6H, m, 4-HrotB and CH3); δC (75 
  
132 
 
MHz; CDCl3) 60.0 (2’-CrotA), 58.2 (2’-CrotB), 55.5 (2-CrotA), 55.4 (2-CrotB), 51.0 (1’-CrotA), 50.4 
(1’-CrotB), 35.5 (MeNrotA), 32.5 (MeNrotB), 30.8 (3-CrotA), 30.7 (3-CrotB), 16.6 (4-CrotA and CH3 
rotA), 15.7 (4-CrotA and CH3 rotA) [C-1rotA and C-1rotB  were not observed]; νmax/cm-1 (film) 
3361, 2961, 1663, 1470, 1370; m/z (ESI) 197.1 (100%, MNa+); HRMS found MNa+, 
197.1256. C8H18N2O2 requires MNa, 197.1260.  
(S)-N-(2′-Hydroxyethyl)-3-methyl-2-(2-nitrophenylsulfonamido)butanamide, 93 
 
Ethanolamine (0.34 mL, 5.7 mmol) was added to a solution of sulfonamide 80 (1.50 g, 4.70 
mmol) and TBD (198 mg, 1.4 mmol) in MeOH (1 mL) and the resulting solution was stirred 
at 70 °C for 24 h. Incomplete reaction was observed. Ethanolamine (0.34 mL, 5.7 mmol) 
was added and stirred for a further 48 h. Reaction mixture was cooled and concentrated in 
vacuo to give a crude product. Purification by column chromatography, eluting with 9:1 
CH2Cl2‒MeOH, gave the sulfonamide 93 (1.26 g, 3.60 mmol, 78%) as a bright yellow oil; Rf 
0.53 (9:1 CH2Cl2‒MeOH); [α]D21: −106.7 (c. 0.5, MeOH); δH (300 MHz; DMSO-D6) 8.08-8.01 
(2H, m, Ar), 7.84-7.82 (2H, m, Ar), 4.59 (1H, t, J 5.3, OH), 3.59 (1H, t, J 7.7, 2-H), 3.17 (2H, q, 
J 5.8, 2′-H), 3.00-2.85 (2H, m, 1-H′), 1.94-1.83 (1H, m, 3-H), 0.81 (6H, m, 4-H and CH3); δC 
(75 MHz; MeOD) 173.0 (1-C), 135.4 (Ar), 134.0 (Ar), 131.9 (Ar), 126.5 (Ar), 64.6 (2-C), 
61.5 (2’-C), 42.9 (1’-C), 33.0 (3-C), 19.9 (4-C), 18.8 (CH3); νmax/cm-1 (film) 3307, 2966, 
1657, 1541, 1426, 1361, 1171; m/z (ESI) 346.1 (100%, MH+); HRMS found MH+, 346.1072. 
C13H19N3O6S requires MH, 346.1067. 
(S)-3-iso-Propyl-1-methylpiperazin-2-one, 101 
 
Diethyl azodicarboxylate (0.9 mL, 5.0 mmol) was added to an ice cold solution of amine 91 
(650 mg, 3.7 mmol) and triphenylphosphine (1.36 g, 5.20 mmol) in THF (30 mL) and the 
resulting solution was allowed to warm to rt and stirred for 16 h. Reaction mixture was 
concentrated in vacuo to give a crude product. Purification by column chromatography 
eluting with 20:1 CH2Cl2‒MeOH, gave the ketopiperazine 101 (319 mg, 2.0 mmol, 55%) as 
a light yellow oil; Rf 0.42 (9:1 CH2Cl2‒MeOH); [α]D21: −127.8 (c. 0.7, MeOH); δH (300 MHz; 
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CDCl3) 3.45-3.36 (1H, m, 6-Ha), 3.26 (1H, d, J 3.0, 3-H), 3.14-3.03 (2H, m, 5- Ha), 2.98-2.90 
(1H, m, 6-Hb), 2.90 (3H, s, NMe), 2.47 (1H, d sept, J 3.1, 7.0, iPr), 1.67 (1H, s (broad), NH), 
0.94 (3H, d, J 7.1, iPr), 0.80 (3H, d, J 6.8, iPr); δC (75 MHz; CDCl3) 170.5 (2-C), 64.7 (3-C), 
50.6 (6-C), 42.8 (5-C), 35.1 (iPr), 30.2 (NMe), 20.0 (iPr), 17.1 (iPr); νmax/cm-1 (film) 3322, 
2960, 2871, 1634, 1503, 1336; m/z (ESI) 157.1 (100%, MH+); HRMS found MH+, 157.1339. 
C8H16N2O requires MH, 157.1335. 
(S)-2-Amino-N-(2′-hydroxyethyl)-N-(4-methoxybenzyl)-3-methylbutanamide, 92 
 
By general method B, the ester 86 (483 mg, 3.7 mmol) and amine 84 followed by 
purification by column chromatography, eluting with 9:1 CH2Cl2‒MeOH, gave the amide 
92 (573 mg, 2.0 mmol, 56%, 1:1 mixture of rotamers) as a light yellow oil; Rf 0.46 (50:8:1 
CH2Cl2‒EtOH‒NH4OH); [α]D22: -22.2 (c. 0.9, CHCl3); δH (300 MHz; CDCl3) 7.17 (2H, d, J 8.6, 
Ar 2 -HrotA and Ar 6-HrotA), 7.12 (2H, d, J 8.7, Ar 2-H rotB and Ar 6-HrotB), 6.90 (2H, d, J 8.7, Ar 
3-HrotA and Ar 5-HrotA), 6.86 (2H, d, J 8.6, Ar 3-H rotB and Ar 5-HrotB), 5.26 (1H, d, J 14.6, 
CHaArrotA), 4.71 (1H, d, J 16.6, CHaArrotB), 4.46 (1H, d, J 16.6, CHbArrotB), 4.00 (1H, d, J 14.6, 
CHbArrotA), 3.79 (3H, s, OMerotA), 3.77-3.72 (3H, m, 2’-HrotA+ 2’-Ha rotB), 3.68-3.61 (2H, m, 2’-
Hb rotB), 3.47 (3H, s, OMerotB), 3.45-3.39 (1H, m, 1’-Ha rotB), 3.18-3.12 (1H, m, 1’-Ha rotB), 2.66 
(6H, s (broad), NH2+OHrotB +rotA), 2.02 (1H, m, iPrrotA), 1.92 (1H, m, iPr rotB), 0.94 (12H, m, iPr 
rotB +rotA); δC (75 MHz; CDCl3) 129.5 (Ar), 127.9 (Ar), 114.5 (Ar), 114.1 (Ar), 61.9 
(CH2OHrotA), 59.6 (CH2OH rotB), 57.1 (CHCO rotA), 56.8 (CHCO rotB), 55.4 (OMe rotA), 55.4 (OMe 
rotB), 51.9 (NCH2 rotA), 49.9 (NCH2 rotB), 49.0 (Bn rotA), 47.7 (Bn rotB), 32.5 (iPr rotA), 32.1 (iPr 
rotB), 20.2 (iPr rotA), 20.0 (iPr rotB), 17.8 (iPr rotA), 17.2 (iPr rotB) [Quaternary Ar-C, 1-CrotA and 
1-CrotB were not observed]; νmax/cm-1 (film) 3368, 1738, 1614, 1365; m/z (ESI) 281.2 
(100%, MH+); HRMS found MH+, 281.1869. C15H24N2O3 requires MH, 281.1860.  
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(S)-N-(2′-Hydroxyethyl)-N-(4-methoxybenzyl)-3-methyl-2-(2- 
nitrophenylsulfonamido)butanamide, 94 
 
By general method B, the ester 80 (1.16 g, 3.70 mmol) and the amine 84 followed by 
purification by column chromatography, eluting with 50:8:1 CH2Cl2‒EtOH‒NH4OH, gave 
the amide 94 (300 mg, 0.6 mmol, 18%, 1:1 mixture of rotamers) as a light yellow oil; Rf 
0.53 (9:1 CH2Cl2‒MeOH); [α]D21: -44.6 (c. 2.7, CHCl3); δH (300 MHz; CDCl3) 8.08 (1H, m, Ns 
rotA), 7.91 (3H, m, Ns rotA+ rotB), 7.69 (4H, m, Ns rotA+ rotB), 7.01 (2H, d, J 8.7, ArrotA), 6.97 (2H, d, 
J 8.7, Ar rotB), 6.87 (2H, d, J 8.7, ArrotA), 6.76 (2H, d, J 8.7, ArrotB), 4.68 (1H, d, J 14.7, BnrotA), 
4.56 (1H, d, J 16, BnrotB), 4.49 (1H, d, J 3.8, NH rotA), 4.44 (1H, d, J 3.8, NHrotB), 4.39 (1H, d, J 
15.9, BnrotB), 4.03 (1H, d, J 14.7, BnrotA), 3.83 (3H, a, OMerotA), 3.80 (1H, m, CHCO rotA), 3.77 
(3H, s, OMe rotB), 3.65 (2H, m, CH2OHrotA), 3.44 (4H, m, CH2OHrotB and CH2NHrotA), 3.34 (1H, 
m, CHCOrotB), 3.21 (2H, m, CH2NHrotA), 2.01 (2H, m, iPr rotA+ rotB), 1.06 (7H, m, iPr rotA+ rotB), 
0.91 (7H, m, iPr rotA+ rotB); δC (75 MHz; CDCl3) 172.3 (COrotA), 171.2 (COrotB), 159.9 (iNO2 rotA), 
159.4 (iNO2 rotB), 148.0 (iSO2 rotA+ rotB), 134.9 (iOMe rotA), 134.0 (Ns), 133.8 (Ns), 133.2 (Ns), 
133.1 (Ns), 130.8 (Ns), 130.4 (Ns), 129.7 (mOMe rotA), 129.4 (iOMe), 128.9 (mOMe rotB), 
127.7 (pOMe), 126.2 (Ns), 125.9 (Ns), 114.8 (oOMe rotA), 114.5 (oOMe rotB), 61.6 (CH2OH 
rotA), 59.9 (COCH rotA), 59.8 (CH2OH rotB), 59.5 (COCH rotB), 55.8 (OMe rotA), 55.7 (OMerotB), 52.2 
(CH2HrotA), 49.5 (CH2N rotA), 48.7 (Bn rotA), 48.4 (Bn rotA), 31.8 (iPr rotA), 31.6 (iPr rotA+ rotB), 20.3 
(iPr rotA+ rotB), 16.6 (iPr rotA+ rotB); νmax/cm-1 (film) 3304, 2967, 1634, 1541, 1513, 1464; m/z 
(ESI) 466.2 (100%, MH+); HRMS found MNa+, 466.1644. C21H27N3O7S requires MNa, 
466.1642. 
(S)-3-iso-Propyl-1-(4-methoxybenzyl)-4-(2-nitrophenylsulfonyl)piperazin-2-one, 
103 
 
By general procedure C, the alcohol 94 (200 mg, 0.4 mmol) gave a crude product. 
Purification by column chromatography, eluting with 1:1 petrol‒EtOAc, gave sulfonamide 
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103 (173 mg, 0.4 mmol, 90%) as a light yellow gum; Rf 0.57 (50:8:1 CH2Cl2‒MeOH‒
NH4OH); [α]D21: 102.7  (c. 1.1 CHCl3); δH (500 MHz; CDCl3) 7.98 (1H, m, Ns), 7.62 (3H, m, 
Ns), 7.04 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.77 (2H, d, J 8.6, Ar 3-H and Ar 5-H), 4.48 (1H, d, 
J 14.4, CHaAr), 4.35 (1H, d, J 14.4, CHbAr), 4.22 (1H, d, J 7.4, 3-H), 3.99 (1H, dd, J 15.0, 5.4, 
CH), 3.79 (3H, s, OMe), 3.53 (1H, ddd, J 15.0, 11.1, 5.0, CH), 3.17 (1H, dd, J 12.5, 5.4, CH), 
3.04 (1H, dd, J 12.5, 5.0, CH), 2.31 (1H, m, iPr), 1.10 (3H, d, J 6.7, iPr), 0.96 (3H, d, J 6.9, iPr); 
δC (75 MHz; CDCl3) 166.9 (1-C), 159.5 (Ar 4-C), 148.2 (Ns 2-C), 134.3 (Ns), 133.6 (Ns 1-C), 
132.4 (Ns), 131.3 (Ns), 130.0 (Ar 2-C and Ar 6-C), 128.6 (Ar 1-C), 124.7 (Ns), 114.4 (Ar 3-C 
and Ar 5-C), 64.6 (3-C), 55.7 (OMe), 49.9 (CH2Ar), 45.1 (CH2), 40.1 (CH2), 31.8 (iPr), 20.5 
(iPr), 20.4 (iPr); νmax/cm-1 (film) 2966, 1711, 1650, 1544, 1513, 1370; m/z (ESI) 448.1 
(100%, MH+); HRMS found MNa+, 470.1367. C21H25N3O6S requires MNa, 470.1356.  
(S)-3-iso-Propyl-1-(4-methoxybenzyl)piperazin-2-one, 102 
 
Compound 102 was synthesised by the three methods outlined below.  
1. General method C  
By general method C, followed by purification by column chromatography, eluting with 
8:1 EtOAc‒MeOH, the alcohol 93 (540 mg, 1.9 mmol gave the ketopiperazine 102 (370 mg, 
1.4 mmol, 73%) as a light yellow oil. 
2. Deprotection of 103 
Thiophenol (0.03 mL, 0.3 mmol) was added to a solution of sulfonamide 103 (100 mg, 0.2 
mmol) and K2CO3 (93 mg, 0.7 mmol) in DMF (4 mL) and stirred at rt for 1.5h. Reaction 
mixture was concentrated in vacuo , diluted with EtOAc (10 mL), washed with water (5 
mL) and K2CO3 (aq. sat. soln. 5 mL), dried (MgSO4) and concentrated in vacuo to give a 
crude product.  Purification by ion exchange chromatography (Supelco DSC-SCX resin) 
gave ketopiperazine 102 (47 mg, 0.18 mmol, 80%) as a light yellow oil. 
3. By general method D 
By general procedure D, acid 79 (500 mg, 1.7 mmol) and amine 84 gave the 
ketopiperazine 102 (94 mg, 0.4 mmol, 22%) as a light yellow oil. 
In all cases the resulting material was spectroscopically identical. 
  
136 
 
Rf 0.41 (9:1 CH2Cl2‒MeOH); [α]D22: -81.6  (c. 1 CHCl3); δH (500 MHz; CDCl3) 7.20 (2H, d, J 
8.6, Ar 2-C and Ar 6-C), 6.85 (2H, d, J 8.6, Ar 3-C and Ar 5-C), 4.58 (1H, d, J 14.4, CHaAr), 
4.51 (1H, d, J 14.4, CHbAr), 3.80 (3H, s, OMe), 3.42 (1H, d, J 3.0, 3-H), 3.31 (1H, dt, J 11.0, 5.0, 
6-Ha), 3.10 (2H, m, 6-Hb and 5-Ha), 2.93 (1H, dt, J 12.1, 3.8, 5-Ha), 2.61 (1H, dsept, J 7.0, 3.1, 
iPr), 1.64 (1H, s (broad), NH), 1.02 (3H, d, J 7.1, iPr), 0.91 (3H, d, J 6.8, iPr); δC (75 MHz; 
CDCl3) 170.3 (2-C), 159.4 (Ar 4-C), 129.9 (Ar 2-C and Ar 6-C), 129.6 (Ar 4-C), 114.4 (Ar 3-C 
and Ar 5-C), 64.8 (3-C), 55.7 (OMe), 50.0 (CH2Ar), 47.7 (6-C), 42.9 (5-C), 30.4 (iPr), 20.0 
(iPr), 17.1 (iPr); νmax/cm-1 (film) 3436, 2961, 1631, 1513, 1247; m/z (ESI) 263.2 (100%, 
MH+); HRMS found MH+, 263.1756. C15H22N2O2 requires MH, 263.1754.  
(3S,6R)-3-iso-Propyl-1-(4-methoxybenzyl)-6-methylpiperazin-2-one, 120 
 
By general method D, acid 79 (387 mg, 1.3 mmol) and the amine 105 gave the 
ketopiperazine 120 (18 mg, 65 μmol, 5%) as a colourless oil; Rf 0.60 (9:1 CH2Cl2‒MeOH); 
[α]D21: -162.2 (c. 1.5, CHCl3); δH (300 MHz; CDCl3) 7.21 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 
6.84 (2H, d, J 8.7, Ar 3-H and Ar 5-H), 5.23 (1H, d, J 14.7, CHaAr), 3.85 (1H, d, J 14.7, CHbAr), 
3.79 (3H, s, OMe), 3.45 (1H, d, J 3.0, 3-H), 3.30 (1H, m, 6-H), 2.98 (1H, dd, J 12.4, 3.6, 5-Ha), 
2.86 (1H, dd, J 12.3, 1.2, 5-Hb), 2.59 (1H, d sept, J 3.0, 7.0, iPr), 1.76 (1H, s (broad), NH), 
1.29 (3H, d, J 6.4, CH3), 1.03 (3H, d, J 7.1, iPr), 0.93 (3H, d, J 6.8, iPr); δC (75 MHz; CDCl3) 
170.6 (2-C), 159.3 (Ar 4-C), 130.2 (Ar 1-C), 129.8 (Ar 2-C and Ar 6-C), 114.3 (Ar 3-C and Ar 
5-C), 64.9 (3-C), 55.7 (OMe), 51.1 (6-C), 48.6 (CH2Ar), 47.6 (5-C), 30.4 (iPr), 19.9 (Me), 18.3 
(iPr), 17.0 (iPr);  νmax/cm-1 (film) 2962, 1634, 1531, 1463, 1245, 1175; m/z (ESI) 277.2 
(100%, MH+); HRMS found MH+, 277.1915. C16H24N2O2 requires MH, 277.1911. 
(3S,6S)-3-iso-Propyl-1-(4-methoxybenzyl)-6-methylpiperazin-2-one, 121 
 
By general method D, acid 79 (200 mg, 0.7 mmol) and the amine 106 gave the 
ketopiperazine 121 (32 mg, 0.1 mmol, 18%) as a colourless oil; Rf 0.43 (50:1, EtOAc‒
petrol); [α]D21: -151 (c. 3.1 CHCl3); δH (300 MHZ; CDCl3) 7.21 (2H, d, J 8.6, Ar 2-H and Ar 6-
H), 6.85 (2H, d, J 8.6, Ar 3-H and Ar 5-H), 5.23 (1H, d, J 14.7, CHaAr), 3.85 (1H, d, J 14.7, 
CHbAr), 3.79 (3H, s, OMe), 3.45 (1H, d, J 3.4, 3-H), 3.30 (1H, m, 6-H), 2.98 (1H, dd, J 12.4, 
3.6, 5-Ha), 2.86 (1H, d, J 11.7, 55-Hb), 2.59 (1H, d sept, J 3.0, 7.0, iPr), 1.66 (1H, s (broad), 
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NH), 1.29 (3H, d, J 6.4, Me), 1.03 (3H, d, J 7.1, iPr), 0.93 (3H, d, J 6.8, iPr); δC (75 MHz; CDCl3) 
170.6 (2-C), 159.3 (Ar 4-C), 130.2 (Ar 1-C), 129.8 (Ar 2-C and 6-C), 114.3 (Ar 3-C and Ar 5-
C), 64.9 (3-C), 55.7 (OMe), 51.1 (6-C), 48.7 (CH2Ar), 47.6 (5-C), 30.4 (iPr), 19.9 (Me), 18.3 
(iPr), 17.0 (iPr), ; νmax/cm-1 (film) 3337, 2965, 1633, 1513, 1246; m/z (ESI) 277.2 (100%, 
MH+); HRMS found MH+, 277.1901. C16H24N2O2 requires MH, 277.1911.  
(3S,5R)-3-iso-Propyl-1-(4-methoxybenzyl)-5-methylpiperazin-2-one, 122 
 
By general method D, acid 79 (250 mg, 0.8 mmol) and the amine 79 gave the 
ketopiperazine 122 (95 mg, 0.3 mmol, 42%) as a colourless oil; Rf 0.57 (9:1 CH2Cl2‒
MeOH); [α]D21: -82.9 (c. 0.8, CHCl3); δH (400 MHz; CDCl3) 7.19 (2H, d, J 8.5, Ar 2-H and Ar 6-
H), 6.85 (2H, d, J 8.6, Ar 3-H and Ar 5-H), 4.56 (1H, d, J 14.4, CHaAr), 4.47 (1H, d, J 14.4, 
CHbAr), 3.97 (3H, s, OMe), 3.48 (1H, d, J 2.8, 3-H), 3.05 (1H, m, 5-H), 2.98 (1H, dd, J 3.5, 
11.3, 6-Ha), 2.91 (1H, m, 6-Hb), 2.67 (1H, d sept, J 7.0, 2.9, iPr), 1.42 (1H, s (broad), NH), 
1.09 (3H, d, J 6.2, Me), 1.01 (3H, d, J 7.2, iPr), 0.91 (3H, d, J 6.8, iPr); δC (75 MHz; CDCl3) 
170.2 (2-C), 129.9 (Ar 2-C and Ar 6-C), 129.6 (Ar 1-C), 114.3 (Ar 3-C and Ar 5-C), 64.7 (3-
C), 55.7 (OMe), 54.2 (6-C), 50.0 (CH2Ar), 48.3 (5-C), 30.6 (iPr), 19.9 (CH3), 19.7 (iPr), 17.0 
(iPr) [Ar 4-C was not observed]; νmax/cm-1 (film) 3436, 2965, 1709, 1630, 1513, 1247; m/z 
(ESI) 277.2 (100%, MH+); HRMS found MH+, 277.1919. C16H24N2O2 requires MH, 277.1911.  
4-(4-Methoxybenzyl)-1,4-diazaspiro[5.5]undecan-5-one, 125 
 
By general method D, acid 117 (200 mg, 0.6 mmol) and the amine 84 gave the 
ketopiperazine 125 (27 mg, 0.1 mmol, 15%) as a colourless oil; Rf 0.47 (100%, EtOAc); δH 
(500 MHz; CDCl3) 7.16 (2H, d, J 8.5, Ar 2-H and Ar 6-H), 6.84 (2H, d, J 8.5, Ar 3-H and Ar 5-
H), 4.51 (2H, s, CH2Ar), 3.79 (3H, s, OMe), 3.19 (2H, t, J 5.5, 3-H), 3.00 (2H, t, J 5.5, 2-H), 2.00 
(2H, dt, J 13.5, 3.9, 2 × CH c. hex), 1.92 (1H, s (broad), NH), 1.72 (2H, d, J 13.2, 2 × CH c. 
hex), 1.63 (2H, m, 2 × CH c. hex), 1.45 (2H, app. q, J 13.0, 2 × CH c. hex), 1.31 (2H, m, 2 × CH 
c. hex); δC (75 MHz; CDCl3) 174.2 (5-C), 159.3 (Ar 4-C), 129.7 (Ar 2-C and Ar 6-C), 114.4 
(Ar 3-C and Ar 5-C), 59.2 (6-C), 55.7 (OMe), 50.1 (CH2Ar), 48.0 (2-C), 38.3 (3-C), 33.5 (2 × 
CH2 c.hex), 25.7 (CH2 c.hex), 21.1 (2 × CH2 c.hex) [Ar 1-C was not observed]; νmax/cm–1 
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(film); 2929, 1736, 1629, 1513, 1248; m/z (ESI) 289.2 (100%, MH+); HRMS found MH+, 
289.1920. C17H24N2O2 requires MH, 289.1911.  
(S)-3-iso-Propyl-1-(4-methoxybenzyl)-1,4-diazepan-2-one, 118 
 
By general method D, acid 79 (1.00 g, 3.3 mmol) and the amine 84 gave the ketodiazepane 
118 (111 mg, 0.4 mmol, 12%) as a colourless oil; Rf 0.53 (9:1 CH2Cl2‒MeOH); [α]D21: -28.6 
(c. 0.8, CHCl3); δH (500 MHz; CDCl3) 7.21 (2H, d, J 8.7, Ar 2-H and Ar 6-H), 6.85 (2H, d, J 8.7, 
Ar 3-H and Ar 5-H), 4.63 (1H, d, J 14.4, CHaAr), 4.42 (1H, d, J 14.4, CHbAr), 3.80 (3H, s, 
OMe), 3.51 (1H, dd, J 15.5, 11.5, 7-Ha), 3.30 (2H, m, 5-H), 3.09 (1H, d, J 6.7, 3-H), 2.80 (1H, 
dd, J 11.0 and 3.7, 7-Hb), 2.21 (1H, m, iPr), 1.68 (1H, s (broad), NH), 1.55 (1H, m, 6-Ha), 1.41 
(1H, m, 6-Hb), 1.02 (6H, d, J 6.9, iPr); δC (75 MHz; CDCl3) 175.6 (2-C), 159.3 (Ar 4-C), 130.5 
(Ar 1-C), 130.0 (Ar 2-C and Ar 6-C), 114.3 (Ar 3-C and Ar 5-C), 66.9 (3-C), 55.7 (OMe), 51.0 
(CH2Ar), 50.1 (7-C), 47.3 (5-C), 30.1 (6-C), 29.7 (iPr), 21.1 (iPr), 18.7 (iPr); νmax/cm-1 (film) 
3444, 1707, 1634, 1513, 1365, 1244; m/z (ESI) 277.2 (100%, MH+); HRMS found MH+, 
277.1919. C16H24N2O2 requires MH, 277.1911. 
4-(4-Methoxybenzyl)-1,4-diazepan-5-one, 119 
 
By general method D, acid 116 (260 mg, 0.9 mmol) and the amine 84 gave the 
ketodiazepane 119  (21 mg, 89 μmol, 9%) as a colourless oil Rf 0.25 (9:1 CH2Cl2‒MeOH); 
δH (500 MHz; CDCl3) 7.19 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.85 (2H, d, J 8.6, Ar 3-H and Ar 
5-H), 4.63 (2H, s, CH2Ar), 3.80 (3H, s, OMe), 3.35 (2H, t, J 4.4, 6-H), 2.98 (2H, t, J 5.1, 3-H), 
2.74 (2H, t, J 4.5, 7-H), 2.73 (2H, t, J 5.3, 2-H), 1.91 (1H, s (broad), NH); δC (75 MHz; CDCl3) 
175.5 (5-C), 159.4 (Ar 4-C), 130.0 (Ar 2-C and Ar 6-C), 114.4 (Ar 3-C and Ar 5-C), 55.7 
(OMe), 51.3 (6-C), 51.2 (3-C), 49.4 (CH2Ar), 44.5 (2-C), 41.4 (7-C) [Ar 1-C was not 
observed]; νmax/cm-1 (film) 3444,  1738, 1626, 1513, 1217; m/z (ESI) 257.1 (100%, MNa+); 
HRMS found MNa+, 257.1206. C13H18N2O2 requires MNa, 257.1260.  
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3-[(4-Methoxyphenyl)methyl]-1,2,3- oxathiazolidine-2,2-dione, 13064 
 
By general procedure F, the amino alcohol 130 (5.93 g, 33.0 mmol) gave cyclic sulfamidate 
130 (7.09 g, 29.2 mmol, 89%) as a light brown oil which solidified upon standing; Rf 0.56 
(1:1, petrol‒EtOAc); δH (500 MHz; CDCl3) 7.30 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 8.90 (2H, d, 
J 8.6, Ar 3-H and Ar 4-H), 4.50 (2H, t, J 6.5, 5-H), 4.18 (2H, s, CH2 benzyl), 3.81 (3H, s, OMe), 
3.39 (2H, t, J 6.5, 4-H); δC (75 MHz; CDCl3) 160.2 (Ar4-C), 136.0 (Ar 2-C and Ar 6-C), 126.6 
(Ar6-C), 114.7 (Ar 3-C and Ar 5-C), 67.2 (5-C), 55.8 (OMe), 51.4 (CH2 benzyl), 47.4 (4-C); 
νmax/cm-1 (film) 2962, 1612, 1584, 1455, 1301; m/z (ESI) 266.0 (100%, MNa+); HRMS 
found MNa+, 266.0465. C10H13NO4S requires MNa, 266.0457. 
N-(2-Hydroxyethyl)-2-nitrobenzenesulfonamide, 131106 
 
By general procedure E, 2-aminoethanol (1.22 g, 20.0 mmol) gave sulfonamide 131 (3.99 
g, 16.2 mmol, 81%) as a light yellow oil which solidified upon standing; Rf 0.57 (50:5:1 
CH2Cl2‒EtOH‒NH4OH); δH (500 MHz; CDCl3) 8.20 (1H, m, Ar 3-H), 7.93 (1H, m, Ar 6-H), 
7.80 (2H, m, Ar 5-H and Ar 5-H), 5.81 (1H, t (broad), J 4.7, NH), 3.81 (2H, app. q, J 5.0, 2-H), 
3.32 (2H, app. q, J 4.8, 1-H), 1.92 (1H, t, J 5.1, OH); δC (75 MHz; CDCl3) 133.7 (Ar 3-C), 132.8 
(Ar 6-C), 131.1 (Ar 4-C), 125.5 (Ar 5-C), 61.3 (2-C), 45.7 (1-C); νmax/cm-1 (film) 3257, 1540, 
1439, 1360; m/z (ESI) 269.0 (100%, MNa+); HRMS found MNa+, 269.0211. C8H10N2O5S 
requires MNa, 269.0203. 
N-(2'-Hydroxyethyl)-N-(2-(4-methoxybenzylamino)ethyl)-2'-
nitrobenzenesulfonamide, 132 
 
By general procedure G, the cyclic sulfamidate 130 (1.00 g, 4.1 mmol) and sulfonamide 
131 gave sulfonamide 132 (1.25 g, 3.00 mmol, 74%) as a colourless oil; Rf 0.58 (1:1, 
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petrol‒EtOAc); δH (500 MHz; CDCl3) 8.00 (1H, m, Ar 3’-H), 7.74 (2H, m, Ar 5’-H and Ar H-
'6), 7.65 (1H, m, Ar 4’-H), 7.26 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.92 (2H, d, J 8.7, Ar 3-H 
and Ar 4-H), 3.87-3.85 (5H, m, OMe and 2-H), 3.80 (2H, s, CH2 benzyl), 3.50 (2H, t, J 5.5, 
H1'), 3.47 (2H, t, J 4.7, 1-H), 2.99 (2H, t, J 6.5, 2'-H); δC (75 MHz; CDCl3) 155.7 (Ar 4-C), 
133.8 (Ar 4’-C), 131.7 (Ar 5’-C), 130.8 (Ar 6’-C), 129.9 (Ar 2-C and Ar 6-C), 124.2 (Ar 3’-C), 
114.1 (Ar 3-C and Ar 5-C), 62.4 (2-C), 55.3 (1’-C), 54.0 (OMe), 52.7 (CH2 benzyl), 49.7 (1-C), 
47.5 (2’-C) [Ar 1-C, Ar 1’-C and Ar 2’-C were not observed]; νmax/cm-1 (film) 3320, 1611, 
1543, 1345, 1249; m/z (ESI) 410.1 (100%, MH+). 
4-(4-Methoxybenzyl)morpholine, 13466 
 
The morpholine 134 was prepared as reported by Fujita and colleagues.66 4-
Methoxybenzylamine (0.42 g, 3.0 mmol), diethylene glycol (0.21 g, 2.0 mmol), [Cp*IrCl2]2 
(40.0 mg, 50.0 μmol) and NaHCO3 (1 mg, 1.0 μmol) were combined in toluene (1 mL), 
degassed (4 cycles of vacuum and argon, ending under positive pressure of argon), and 
heated at 100 °C for 24 h. The reaction mixture was cooled to room temperature and 
concentrated in vacuo to give a crude product. Purification by column chromatography, 
gradient elution  100% CH2Cl2 to 20:1 CH2Cl2‒MeOH,  followed by a second column eluting 
with EtOAc‒petrol 2:1, gave morpholine 134 (212 mg, 1.1 mmol, 51%) as a light yellow 
oil; δH (500 MHz; CDCl3) 7.23 (2H, d, J 8.5, Ar 2-H and Ar 6-H), 6.85 (2H, d, J 8.6, Ar 3-H and 
Ar 5-H), 3.80 (3H, s, OMe), 3.70 (4H, t, J 4.7, 2-H and 6-H), 3.43 (2H, s, CH2 benzyl), 2.42 
(4H, t (broad), J 4.1, 3-H and 5-H); δC (75 MHz; CDCl3) 158.8 (Ar 4-C), 130.4 (Ar 2-C and Ar 
6-C), 113.6 (3-C and Ar 5-C), 67.0 (CH2), 62.8 (CH2), 55.3 (OMe), 53.5 (CH2) [Ar 1-C was not 
observed]; m/z (ESI) 208.0 (100%, MH+). 
1-(4-Methoxybenzyl)-4-(2'-nitrophenylsulfonyl)piperazine, 78  
 
By general procedure C, the sulfonamide 132 (0.40 g, 1.0 mmol), gave piperazine 78 (0.36 
g, 0.90 mmol, 94%) as a light yellow oil; Rf 0.80 (9:1 CH2Cl2‒MeOH); δH (500 MHz; CDCl3) 
7.94 (1H, dd, J 7.5, 1.6, Ar 3’-H), 7.68 (2H, m, Ar 5’-H and Ar 6’-H), 7.60 (1H, dd, J 7.5, 1.7, Ar 
4’-H), 7.18 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.84 (2H, d, J 8.6, Ar 3-H and Ar 5-H), 3.79 (3H, 
s, OMe), 3.45 (2H, s, CH2 benzyl), 3.30 (4H, t (broad), J 4.6, 3-H and 5-H), 2.50 (4H, t 
(broad), J 4.8, 2-H and 6-H); δC (75 MHz; CDCl3) 133.7 (Ar 5’-C), 131.4 (Ar 4’-C), 130.9 (Ar 
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6’-C), 130.3 (Ar 2-C and Ar 6-C), 124.0 (Ar 4’-C), 113.7 (Ar 3-C and Ar 5-C), 62.0 (3-C and 5-
C), 55.3 (OMe), 52.19 (CH2 benzyl), 46.0 (2-C and 6-C) [quaternary Ar-C were not 
observed]; νmax/cm-1 (film) 2937, 1612, 1546, 1513, 1373, 1249, 1174; m/z (ESI) 392.1 
(100%, MH+); HRMS found MH+, 392.1285. C18N21N3O5S requires MH, 392.1275. 
N-(3-Hydroxypropyl)-2-nitrobenzenesulfonamide, 15198 
 
By general procedure E, 3-aminopropanol (1.58 g, 21.0 mmol) gave sulfonamide 151 (5.38 
g, 20.7 mmol, 98%) as a light yellow semi solid which required no further purification; Rf 
0.14 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3) 8.14 (1H, m, Ar 3-H), 7.56 (1H, m, Ar 6-H), 
7.75 (2H, m, Ar 4-H and Ar 5-H), 5.87 (1H, s (broad), NH) 3.76 (2H, t, J 5.7, 3-H), 3.26 (2H, t, 
J 6.3, 1-H), 2.09 (1H, s (broad), OH), 1.78 (2H, app. pent., J 5.8, 2-H); δC (75 MHz; CDCl3) 
148.1 (Ar 2-C), 133.6 (Ar 5-C), 133.5 (Ar 1-C), 132.8 (Ar 4-C), 131.1 (Ar 6-C), 125.4 (Ar 3-
C), 60.4 (3-C), 41.5 (1-C), 31.6 (2-C); νmax /cm-1 (film) 3328, 2965, 1537, 1414, 1362; m/z 
(ESI) 283.0 (100%, MNa+); HRMS found MNa+, 283.0360. C9H12N2O5S requires MNa, 
283.0359. 
(S)-N-(2-Hydroxypropyl)-2-nitrobenzenesulfonamide, 152 
 
By general procedure E, (S)-1-amino-2-propanol (1.00 g, 13.3 mmol) gave sulfonamide 
152 (3.29 g, 12.5 mmol, 94%) as a light yellow amorphous solid which required no further 
purification;  Rf 0.73 (50:8:1 CH2Cl2‒EtOH‒NH4OH); [α]D26: -20.5 (c. 1.3, MeOH); δH (300 
MHz; CDCl3) 8.14 (1H, m, Ar 3-H), 7.88 (1H, m, Ar 6-H), 7.76 (2H, m, Ar 4-H and Ar 5-H), 
5.78 (1H, t (broad), J 5.7, NH), 3.97 (1H, m, 2-H), 3.23 (1H, ddd, J 12.9, 7.1, 3.3, 1-Ha), 2.94 
(1H, ddd, J 13.1, 8.0, 5.3, 1-Hb), 1.98 (1H, s (broad), OH), 1.20 (3H, d, J 6.3, 3-H); δC (75 MHz; 
CDCl3) 134.1 (Ar 5-C), 133.3 (Ar 4-C), 131.5 (Ar 6-C), 125.9 (Ar 3-C), 66.9 (2-C), 50.9 (1-C), 
21.1 (3-C) [Ar 1-C and Ar 2-C were not observed]; νmax/cm-1 (film) 3340, 1538, 1361; m/z 
(ESI) 283.0 (100%, MNa+); HRMS found MNa+, 283.0346. C9H12N2O5S requires MNa, 
283.0359. 
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(R)-N-(2-Hydroxypropyl)-2-nitrobenzenesulfonamide, 153  
 
By general procedure E, (R)-1-amino-2-propanol (1.00 g, 13.3 mmol) gave sulfonamide 
153 (3.30 g, 12.7 mmol, 95%) as a light yellow amorphous solid which required no further 
purification; Rf 0.65 (50:8:1 CH2Cl2‒EtOH‒NH4OH); [α]D26: 16.6 (c. 0.9, MeOH); δH (300 
MHz; CDCl3) 8.14 (1H, m, Ar 3-H), 7.88 (1H, m, Ar 6-H), 7.76 (2H, m, Ar 4-H and Ar 5-H), 
5.77 (1H, t (broad), J 5.8, NH), 3.97 (1H, m (broad), 2-H), 3.22 (1H, ddd, J 13.0, 7.0, 3.2, 1-
Ha), 2.94 (1H, ddd, J 13.1, 7.9, 5.2, 1-Hb), 1.95 (1H, d (broad), J 2.8, OH), 1.20 (3H, d, J 6.2, 3-
H); δC (75 MHz; CDCl3) 134.1 (Ar 5-C), 133.3 (Ar 4-C), 131.5 (Ar 6-C), 125.9 (Ar 3-C), 66.9 
(2-C), 50.9 (1-C), 21.1 (3-C) [Ar 1-C and Ar 2-C were not observed]; νmax/cm-1 (film) 3339, 
1538, 1411, 1362; m/z (ESI) 283.0 (100%, MNa+); HRMS found MNa+, 283.0364. 
C9H12N2O5S requires MNa, 283.0359. 
(S)-N-(1-Hydroxy-3-methylbutan-2-yl)-2-nitrobenzenesulfonamide, 154 
 
By general procedure E, (2S)-2-amino-3-methyl butanol (1.00 g, 9.7 mmol) gave 
sulfonamide 154 (2.47 g, 12.7 mmol, 88%) as a light yellow amorphous solid which 
required no further purification; Rf 0.39 (9:1 CH2Cl2‒MeOH); [α]D26: -29.6 (c. 1.1, MeOH); 
δH (300 MHz; CDCl3) 8.14 (1H, m, Ar 3-H), 7.87 (1H, m, Ar 6-H), 7.72 (2H, m, Ar 4-H and Ar 
5-H), 5.52 (1H, d (broad), J 8.24, NH), 3.62 (2H, m, 1-H), 3.30 (1H, m, 2-H), 1.89 (1H, app. 
oct, J 6.7, 3-H), 1.76 (1H, t, J 5.7, OH), 0.88 (6H, d, J 6.8, 4-H and Me); δC (75 MHz; CDCl3) 
134.9 (Ar 1-C), 133.4 (Ar 5-C), 132.9 (Ar 4-C), 130.6 (Ar 6-C), 125.3 (Ar 3-C), 63.3 (1-C), 
62.3 (2-C), 29.5 (3-C), 19.3 (4-C), 18.3 (Me) [Ar 2-C was not observed]; νmax/cm-1 (film) 
3327, 2963, 1538, 1360; m/z (ESI) 311.1  (100%, MNa+); HRMS found MNa+, 311.0677. 
C11H16N2O5S requires MNa, 311.0672. 
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 (R)-1-(4-Methoxybenzylamino)propan-2-ol, 140 
 
By general procedure A, (R)-1-amino-2-propanol (1.00 g, 13.3 mmol) gave alcohol 140 
(2.57 g, 13.2 mmol, 98%) as a light brown oil which required no further purification; Rf 
0.39 (9:1 CH2Cl2‒MeOH); [α]D26: -18.6 (c. 1.4, MeOH); δH (500 MHz; CDCl3) 7.24 (2H, d, J 
8.6, Ar 3-H and Ar 5-H), 6.87 (2H, d, J 8.7, Ar 2-H and Ar 6-H), 3.80 (5H, m, OMe, benzyl CHa 
and 2-H), 3.73 (1H, d, J 13.0, benzyl CHb), 2.73 (1H, dd, J 12.1, 3.0, 1-Ha), 2.43 (1H, dd, J 
12.0, 9.5, 2-Hb), 2.38 (2H, s (broad), NH and OH), 1.15 (3H, d, J 6.2, 3-H); δC (75 MHz; 
CDCl3) 129.3 (Ar 2-C and Ar 6-C), 113.9 (Ar 3-C and Ar 5-C), 65.5 (2-C), 56.1 (1-C), 55.3 
(OMe), 53.0 (CH2 benzyl), 20.4 (3-C) [Ar 1-C and Ar 4-C were not observed]; νmax/cm-1 
(film) 3392, 2968, 1613, 1514, 1249; m/z (ESI) 196.1  (100%, MH+); HRMS found MH+, 
196.1324. C11H17NO2 requires MH, 196.1332. 
 (S)-2-(4-Methoxybenzylamino)-3-methylbutan-1-ol, 141 
 
By general procedure A, (2S)-2-amino-3-methyl butanol (1.00 g, 6.1 mmol) gave the 
alcohol 141 (1.78 g, 8.00 mmol, 80%) as a light brown oil which required no further 
purification; Rf 0.39 (9:1 CH2Cl2‒MeOH); [α]D26: 0.5 (c. 1.1, MeOH); δH (500 MHz; CDCl3) 
7.25 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.87 (2H, d, J 8.6, Ar 3-H and Ar 5-H), 3.80 (3H, s, 
OMe), 3.77 (1H, d, J 12.7, benzyl CHa), 2.70 (1H, d, J 12.7, benzyl CHb), 3.63 (1H, dd, J 10.5, 
4.2, 1-Ha), 3.35 (1H, dd, J 15.6, 7.0, 1-Hb), 2.47 (1H, m, 2-H), 1.86 (1H, m, 3-H), 0.97 (3H, d, J 
6.9, 4-H), 0.91 (3H, d, J 6.9, methyl); δC (75 MHz; CDCl3) 129.9 (Ar 2-C and Ar 6-C), 114.0 
(Ar 3-C and Ar 5-C), 63.8 (1-C), 60.1 (2-C), 55.3 (OMe), 50.6 (CH2 benzyl), 28.6 (3-C), 19.6 
(4-C), 18.4 (methyl) [Ar 1-C and Ar 4-C were not observed];  νmax/cm-1 (film) 3367, 2957, 
1612, 1513, 1248; m/z (ESI) 224.1  (100%, MH+); HRMS found MH+, 224.1645. C13H21NO2 
requires MH, 224.1645. 
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3-[(4-Methoxyphenyl)methyl]-1,2,3- oxathiazinane-2,2-dione, 144 
 
By general procedure F, alcohol 108 (1.00 g, 5.1 mmol) gave cyclic sulfamidate 144 (1.08 
g, 4.20 mmol, 83%) as a light brow oil which solidified upon standing; Rf 0.67 (1:1, petrol‒
EtOAc); δH (500 MHz; CDCl3) 7.26 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.89 (2H, d, J 8.6, Ar3-H 
and Ar 5-H), 4.65 (2H, t, J 5.6, 6-H), 4.28 (2H, s, CH2 benzyl), 3.81 (3H, s, OMe), 3.39 (2H, t, J 
5.7, 4-H), 1.81 (2H, app. pent, J 5.7, 5-H); δC (75 MHz; CDCl3) 159.6 (Ar 4-C), 130.1 (Ar 3-C 
and Ar 5-C), 126.8 (Ar 1-C), 114.2 (Ar 2-C and Ar 6-C), 73.2 (6-C), 55.3 (OMe), 51.8 (CH2 
benzyl), 46.7 (4-C), 20.2 (5-C); νmax/cm-1 (film) 2963, 1614, 1514, 1300, 1243; m/z (ESI) 
280.1 (100%, MNa+); HRMS found MNa+, 280.0630. C11H15NO4S requires MNa, 280.0614. 
(5S)-3-[(4-Methoxyphenyl)methyl]-5-methyl- 1,2,3-oxathiazolidine-2,2-dione, 145 
 
By general procedure F, alcohol 152 (1.00 g, 5.1 mmol) gave cyclic sulfamidate 145 (1.25 
g, 4.80 mmol, 95%) as a light brow oil which solidified upon standing; Rf 0.69 (1:1, petrol‒
EtOAc); [α]D26: -21.8 (c. 1.0, MeOH); δH (500 MHz; CDCl3) 7.29 (2H, d, J 8.7, Ar 2-H and Ar 6-
H), 6.90 (2H, d, J 8.7, Ar 3-H and Ar 5-H), 4.87 (1H, m, 5-H), 4.27 (1H, d, J 13.4, benzyl CHa), 
4.05 (1H, d, J 13.4, benzyl CHb), 3.81 (3H, s, OMe), 3.40 (1H, dd, J 9.4, 6.1, 4-Ha), 3.03 (1H, 
dd, J 9.5, 8.0, 4-Hb), 1.49 (3H, d, J 6.3, CH3); δC (75 MHz; CDCl3) 159.7 (Ar 4-C), 130.1 (Ar 2-C 
and Ar 6-C), 126.3 (Ar 1-C), 114.2 (Ar 3-C and Ar 5-C), 76.6 (5-C), 55.3 (OMe), 53.6, 50.7, 
19.4 (CH3); νmax/cm-1 (film) 2986, 1611, 1515, 1333, 1253; m/z (ESI) 280.1 (100%, MNa+); 
HRMS found MNa+, 280.0621. C11H15NO4S requires MNa, 280.0614. 
(5R)-3-[(4-Methoxyphenyl)methyl]-5-methyl- 1,2,3-oxathiazolidine-2,2-dione, 146 
 
By general procedure F, alcohol 153 (1.00 g, 5.1 mmol) gave cyclic sulfamidate 146 (1.15 
g, 4.50 mmol, 88%) as a light brow oil which solidified upon standing; Rf 0.72 (1:1, petrol‒
EtOAc); [α]D26: 16.4 (c. 1.5, MeOH); δH (500 MHz; CDCl3) 7.29 (2H, d, J 8.5, Ar 2-H and Ar 6-
H), 6.90 (2H, d, J 8.7, Ar 3-H and Ar 5-H), 4.86 (1H, m, 5-H), 4.27 (1H, d, J 13.5, benzyl CHa), 
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4.05 (1H, d, J 13.5, benzyl CHb), 3.81 (3H, s, OMe), 3.40 (1H, dd, J 9.5, 6.1, 4-Ha), 3.02 (1H, 
dd, J 9.5, 8.0, 4-Hb), 1.49 (3H, d, J 6.3, CH3); δC (75 MHz; CDCl3) 130.1 (Ar 2-C and Ar 6-C), 
126.4 (Ar 1-C), 114.3 (Ar 3-C and Ar 5-C), 76.8 (5-C), 55.3 (OMe), 53.6, 50.7, 19.4 (CH3) [Ar 
4-C was not observed]; νmax/cm-1 (film) 2961, 1612, 1586, 1456, 1302; m/z (ESI) 280.1 
(100%, MNa+); HRMS found MNa+, 280.0619. C11H15NO4S requires MNa, 280.0614. 
(4S)-3-[(4-Methoxyphenyl)methyl]-4-(propan-2-yl)-1,2,3-oxathiazolidine-2,2-dione, 
147 
 
By general procedure F, alcohol 141 (1.60 g, 7.20 mmol) gave the cyclic sulfamidate 147 
(1.81 g, 6.30 mmol, 89%) as a light brow oil which solidified upon standing; Rf 0.85 (9:1 
CH2Cl2‒MeOH); [α] D26: -7.6 (c. 2.2, MeOH); δH (500 MHz; CDCl3) 7.33 (2H, d, J 8.7, Ar 2-H 
and Ar 6-H), 6.89 (2H, d, J 8.7, Ar 3-H and Ar 5-H), 4.38 (1H, dd, J 8.9, 7.4, 5-Ha), 4.33 (1H, d, 
J 14.6, benzyl CHa), 4.25 (1H, dd, J 8.9, 5.7, 5-Hb), 4.23 (1H, dd, J 14.6, benzyl CHb), 3.81 (3H, 
s, OMe), 3.41 (1H, m, 4-H), 1.90 (1H, d sept., J 1.2, 5.6, propyl 2-H), 0.91 (3H, d, J 6.8, propyl 
1-H), 0..87 (3H, d, J 7, propyl 3-H); δC (75 MHz; CDCl3) 159.6 (Ar 4-C), 130.4 (Ar 2-C and Ar 
6-C), 126.6 (Ar 1-C), 114.1 (Ar 3-C and Ar 5-C), 67.0 (5-C), 64.0 (4-C), 55.3 (OMe), 51.4 
(CH2 benzyl), 29.6 (2-C propyl), 18.2 (1-C propyl), 15.9 (3-C propyl); νmax/cm-1 (film) 2965, 
1613, 1515, 1346, 1185; m/z (ESI) 308.1 (100%, MNa+); HRMS found MNa+, 308.0932. 
C13H19NO4S requires MNa, 308.0927. 
(2S)-1-Hydroxy-N-(2’-{[(4-methoxyphenyl)methyl]amino}ethyl)-3-methyl-S-(2’-
nitrophenyl) butane-2-sulfonamide, 156 
 
By general procedure G, cyclic sulfamidate 130 (219 mg, 0.9 mmol) and sulfonamide  gave 
the sulfonamide 156 (294 mg, 0.7 mmol, 72%) as a light yellow oil; Rf 0.50 (9:1 CH2Cl2‒
MeOH); [α] D24: 58.3 (c. 0.5, CHCl3); δH (500 MHz; CDCl3) 8.09 (1H, m, Ar 3’-H), 7.62 (2H, m, 
Ar 5'-H and Ar 6'-H), 7.47 (1H, m, Ar 4'-H), 7.14 (2H, d, J 8.5, Ar 2-H and Ar 6-H), 6.84 (2H, 
d, J 8.6, Ar 3-H and Ar 5-H), 3.91 (1H, m, 1-Ha), 3.84 (1H, m, 1-Hb), 3.80 (3H, s, OMe), 3.66-
3.58 (4H, m, CH2 benzyl and 1’-H), 3.26 (1H, ddd, J 15.8, 8.4, 4.4, 2-H), 3.03 (1H, ddd, J 13.2, 
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7.9, 4.0, 2’-Ha), 2.82 (1H, m, 2’-Hb), 1.93 (1H, m, 3-H), 1.64 (2H, s, NH and OH), 0.96 (3H, d, J 
6.5, 4-H), 0.60 (3H, d, J 6.7, methyl); δC (75 MHz; CDCl3) 133.4 (Ar 5-C′), 131.1 (Ar 4’-C), 
129.7 (Ar 2-C and Ar 6-C), 124.2 (Ar 3’-C), 123.5 (Ar 6’-C), 114.1 (Ar 3-C and Ar 5-C), 61.5 
(2-C), 55.3 (OMe), 54.2 (1-C), 52.7 (CH2 benzyl), 52.0 (1’-C), 50.8 (2’-C), 27.2 (3-C), 20.1 (4-
C), 19.9 (Me) [Quaternary Ar-C were not observed]; νmax/cm-1; 2964, 1611, 1544, 1513, 
1344, 1249; m/z (ESI) 452.1 (100%, MH+). 
(S)-2-Isopropyl-4-(4-methoxybenzyl)-1-(2'-nitrophenylsulfonyl)piperazine, 172 
 
By general procedure C, sulfonamide 156 (282 mg, 0.6 mmol) gave piperazine 172 (256 
mg, 0.6 mmol, 95%) as a yellow oil; Rf 0.70 (1:1, petrol‒EtOAc); [α] D24: 13.8 (c. 0.6, CHCl3); 
δH (500 MHz; CDCl3) 8.03 (1H, m, Ar 3’-H), 7.66 (2H, m, Ar 5’-H and Ar 6’-H), 7.61 (1H, m, 
Ar 4’-H), 7.17 (2H, d, J 8.4, Ar 2-H and Ar 6-H), 6.83 (2H, d, J 8.5, Ar 3-H and Ar 5-H), 3.84 
(1H, m, 2-H), 3.80 (3H, s, OMe), 3.44-3.40 (2H, m, benzyl CHa and 6-Ha), 3.30 (1H, dt, J 15.5, 
2.8, 6-Hb), 3.22 (1H, d, J 12.9, benzyl CHb), 2.86 (1H, d, J 11.7, 3-Ha), 2.73 (1H, d, J 10.9, 5-
Ha), 2.42 (1H, m, isopropyl CH), 2.00 (1H, dd, J 11.8, 3.4, 3-Hb), 1.95 (1H, dt, J 12.1, 3.3, 5-
Hb), 0.76 (3H, d, J 6.5, methyl), 0.73 (3H, d, J 6.8, methyl); δC (75 MHz; CDCl3) 158.8 (Ar 4-
C), 147.6 (Ar 2-C′), 134.9 (Ar 1-C′), 133.2 9 (Ar 5-C′), 131.7 (Ar 6-C′), 130.0 (Ar 3-C and Ar 
5-C), 124.1 (Ar 3-C′), 113.6 (Ar 2-C and Ar 6-C), 62.1, 61.4 (2-C), 55.3 (OMe), 53.2, 53.1, 
42.1, 26.1 (isopropyl CH), 19.9 (Me), 19.5 (Me); νmax/cm-1 (film) 2964, 1612, 1545, 1512, 
1358, 1248; m/z (ESI) 434.2 (100%, MH+); HRMS found MH+, 434.1765. C21H27N3O5S 
requires MH, 434.1765.  
2-Hydroxy-N-(3’-{[(4-methoxyphenyl)methyl]amino}propyl)-N-(2’-
nitrophenyl)ethane-1-sulfonamide, 157 
 
By general procedure G (heating at 80 °C), cyclic sulfamidate 144 (206 mg, 0.8 mmol) and 
sulfonamide 131 gave 157 (165 mg, 0.4 mmol, 49%) as a light yellow oil; Rf 0.19 (9:1 
CH2Cl2‒MeOH); δH (500 MHz; CDCl3) 7.96 (1H, dd, J 7.4, 1.4, Ar 3’-H), 7.68 (2H, m, Ar 5’-H 
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and Ar 6’-H), 7.60 (1H, dd, J 7.0, 1.8, Ar 4’-H), 7.22 (2H, d, J 8.7, Ar 2-H and Ar 6-H), 6.86 
(2H, d, J 8.7, Ar 3-H and Ar 5-H), 3.79 (3H, s, OMe), 3.76 (2H, t, J 4.8, 2-H), 3.70 (2H, s, CH2 
benzyl), 3.43 (2H, t, J 6.6, 1’-H), 3.40 (2H, t, J 5.0, 1-H), 2.76 (2H, t, J 6.1, 3’-H), 1.88 (2H, 
pent, J 6.2, 2’-H); δC (75 MHz; CDCl3) 158.8 (Ar 4-C), 148.4 (Ar 2’-C), 133.7 (Ar 1’-C), 132.0 
(Ar 1-C), 131.6 (Ar 5’-C), 131.1 (Ar 4’-C), 130.8 (Ar 6’-C), 129.6 (Ar 2-C and Ar 6-C), 124.1 
(Ar 3’-C), 113.9 (Ar 3-C and Ar 5-C), 61.5 (2-C), 55.3 (OMe), 53.4 (1-C), 52.6 (1’-C), 48.4 
(CH2 benzyl), 46.2 (3’-C), 28.5 (2’-C); νmax/cm-1 (film) 2963, 1612, 1544, 1515, 1341, 1249; 
m/z (ESI) 424.1 (100%, MH+). 
1-(4-Methoxybenzyl)-4-(2'-nitrophenylsulfonyl)-1,4-diazepane, 170 
 
By general procedure C, followed by purification by column chromatography, eluting with 
50:1 CH2Cl2‒MeOH, 157 (120 mg, 0.3 mmol) gave diazepane 170 (91 mg, 0.02 mmol, 
80%) as a yellow oil; Rf 0.26 (1:1, petrol‒EtOAc); δH (500 MHz; CDCl3) 7.99 (1H, m, Ar H-
'3), 7.67 (2H, m, Ar 5’-H and Ar 6-H), 7.60 (1H, m, Ar 4’-H), 7.22 (2H, d, J 8.6, Ar 2-H and Ar 
6-H), 6.84 (2H, d, J 8.7, Ar 3-H and Ar 5-H), 3.80 (3H, s, OMe), 3.58 (2H, s, CH2 benzyl), 3.49 
(4H, m, 3-H and 5-H), 2.71 (4H, m, 2-H and 7-H), 1.89 (2H, m, 6-H); δC (75 MHz; CDCl3) 
133.3, 131.5, 130.8, 129.9 (Ar 2-C and Ar 6-C), 124.0, 113.7 (Ar 3-C and Ar 5-C), 61.5, 55.9, 
55.3, 54.4, 47.2; νmax/cm-1 (film); 3393, 1543, 1511, 1341, 1247, 1164; m/z (ES) 406.1 
(MH+); m/z (ESI) 406.1 (100%, MH+); HRMS found MH+, 406.1445. C19H23N3O5S requires 
MH, 406.1431.  
3-Hydroxy-N-(2’-{[(4-methoxyphenyl)methyl]amino}ethyl)-N-(2’-
nitrophenyl)propane-1-sulfonamide, 158 
 
By general procedure G (heating at 80 °C), cyclic sulfamidate 144 (206 mg, 0.8 mmol) and 
sulfonamide 151 gave 158 (209 mg, 0.5 mmol, 60%) as a light yellow oil; Rf 0.19 (9:1 
CH2Cl2‒MeOH); δH (500 MHz; CDCl3) 7.98 (1H, dd, J 7.4, 2.0, Ar 3’-H), 7.66 (2H, m, Ar 5’-H 
and Ar H6'), 7.60 (1H, dd, J 7.7, 1.8, Ar 4’-H), 7.19 (2H, d, J 8.7, Ar 2-H and Ar 6-H), 6.85 
(2H, d, J 8.7, Ar 3-H and Ar 6-H), 3.79 (3H, s, OMe), 3.65 (2H, s, CH2 benzyl), 3.64 (2H, t, J 
5.9, 3-H), 3.43 (2H, t, J 6.9, 1’-H), 3.38 (2H, t, J 7.4, 1’-H), 2.60 (2H, t, J 6.8, 3’-H), 2.12 (2H, s 
(broad), NH and OH), 1.76 (4H, m, H2 and H2'); δC (75 MHz; CDCl3) 158.7 (Ar 4-C), 148.1 
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(Ar 2’-C), 133.5 (Ar 5’-C), 133.2 (Ar 1’-C), 131.9 (Ar 1’-C), 131.7 (Ar 4'-C), 130.6 (Ar 6’-C), 
129.4 (Ar 2-C and Ar 6-C), 124.2 (Ar 3’-C), 113.8 (Ar 3-C and Ar 5-C), 58.9 (3-C), 55.3 
(OMe), 53.3 (1’-C), 46.0 (CH2 benzyl), 44.7 (1’-C), 31.0 (3’-C), 28.5 (2-C); νmax/cm-1 (film) 
2963, 1612, 1544, 1515, 1341, 1249; m/z (ESI) 438.2 (100%, MH+). 
1-(4-Methoxybenzyl)-5-(2'-nitrophenylsulfonyl)-1,5-diazocane, 179 
 
By general procedure C, followed by purification by column chromatography, eluting with 
50:1 CH2Cl2‒MeOH, 158 (282 mg, 0.6 mmol) gave diazocane 179 (256 mg, 0.6 mmol, 
95%) as a yellow oil; Rf 0.21 (1:1, petrol‒EtOAc); δH (500 MHz; CDCl3) 7.91 (1H, m, Ar 3’-
H), 7.66 (2H, m, Ar 5’-H and Ar 6-H), 7.61 (1H, m, Ar 4’-H), 7.21 (2H, d, J 8.6, Ar 2-H and Ar 
6-H), 6.84 (2H, d, J 8.6, Ar 3-H and Ar 5-H), 3.79 (3H, s, OMe), 3.60 (2H, s, CH2 benzyl), 3.43 
(4H, app. t, J 5.3), 2.66 (4H, t, J 6.3), 2.77 (4H, pent (broad), J 5.4); δC (75 MHz; CDCl3) 158.6 
(Ar 4-C), 113.1, 132.0, 131.4, 130.3, 130.1 (Ar 2-H and Ar 6-H), 124.1, 113.6 (Ar 3-H and Ar 
5-H), 61.1 (OMe), 55.2 (CH2 benzyl), 49.8, 49.5, 29.4; νmax/cm-1 (film); 3399, 2933, 1611, 
1543, 1371, 1246; m/z (ESI) 420.2 (100%, MH+); HRMS found MH+, 420.1602. C20H25N3O5S 
requires MH, 420.1588.  
 
(2R)-2-Hydroxy-N-[(2’R)-1’-{[(4-methoxyphenyl)methyl]amino}propan-2-yl]-S-(2’-
nitrophenyl) propane-1-sulfonamide, 160 
 
By general procedure G, cyclic sulfamidate 145 (206 mg, 0.8 mmol)  and sulfonamide 153 
gave 160 (238 mg, 0.5 mmol, 68%) as a light yellow oil; Rf 0.45 (9:1 CH2Cl2‒MeOH); [α] D24: 
-48.5 (c. 3.1 CHCl3); δH (500 MHz; CDCl3) 8.02 (1H, m, Ar 3’-H), 7.65 (2H, m, Ar 5’-H and Ar 
6’-H), 7.53 (1H, m, Ar 4’-H), 7.16 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.86 (2H, d, J 8.7, Ar 3-H 
and Ar 5-H), 4.23 (1H, m, 2-H), 4.08 (1H, m, 2’-H), 3.80 (4H, m, OMe and 1-Ha), 3.75 (1H, d, 
J 13.0, benzyl CHa), 3.57 (1H, d, J 13.0, benzyl CHb), 3.55 (1H, dd, J 15.2, 1.7, 1-Hb), 2.76 (1H, 
dd, J 15.2, 9.9, 1'-Ha), 2.65 (2H, m, 1'-Hb and OH), 1.17 (3H, d, J 6.3, 3-H), 0.93 (3H, d, J 6.6, 
3’-H); δC (75 MHz; CDCl3) 158.9 (Ar 4-C), 133.7 (Ar 5’-C), 133.3 (Ar 2’-C), 131.6 (Ar 4’-C), 
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130.8 (Ar 6’-C), 130.5 (Ar 1’-C), 129.5 (Ar 2-C and Ar 6-C), 123.8 (Ar 3’-C), 114.0 (Ar 3-C 
and Ar 5-C), 66.9 (2-C), 55.3 (OMe), 52.8 (CH2 benzyl), 52.0 (1-C), 51.7 (2-C), 51.3 (2’-C), 
20.1 (3-C), 15.9 (3’-C) [Ar 1-C was not observed]; νmax/cm-1 (film); 3313, 2973, 1612, 1545, 
1347, 1249; m/z (ESI) 438.1 (100%, MH+). 
(2S,5R)-1-(4-Methoxybenzyl)-2,5-dimethyl-4-(2'-nitrophenylsulfonyl)piperazine, 
173 
 
By general procedure C, followed by purification by column chromatography, eluting with 
50:1 CH2Cl2‒MeOH, 160 (219 mg, 0.5 mmol) gave piperazine 173 (100 mg, 0.2 mmol, 
48%) as a yellow oil; Rf 0.70 (1:1, petrol‒EtOAc); [α] D24: -82.7 (c. 1.9, CHCl3); (500 MHz; 
CDCl3) 8.03 (1H, m, Ar 3’-H), 7.69-7.62 (3H, m, Ar 4’-H, Ar 5’-H and Ar 6’-H), 7.23 (2H, d, J 
8.4, Ar 2-H and Ar 6-H), 6.84 (2H, d, J 8.6, Ar 3-H and Ar 5-H), 4.05 (1H, s (broad), 5-H), 
3.79  (3H, s, OMe), 3.60 (1H, d, J 13.1, 3-Ha), 3.52 (1H, d, J 13.3, benzyl CHa), 3.43 (1H, d, J 
13.2, benzyl CHb), 3.37 (1H, d, J 13.4, 3-Hb), 2.96 (1H, s (broad), 2-H), 2.84 (1H, dd, J 11.8, 
3.8, 6-Ha), 2.20 (1H, d, J 11.7, 6-Hb), 1.18 (3H, d, J 6.7, methyl 5-C), 0.91 (3H, d, J 6.4, methyl 
2-C); δC (75 MHz; CDCl3) 158.7 (Ar 4-C), 147.8 (Ar 2’-C), 134.2 (Ar 1’-C), 133.3 (Ar 5’-C), 
132.0 (Ar 1-C), 131.6 (Ar 4’-C), 130.8 (Ar 6’-C), 129.6 (Ar 2-C and Ar 6-C), 124.2 (Ar 3’-C), 
113.6 (Ar 3-C and Ar 4-C), 58.0 (3-C), 55.2 (5-C), 51.9 (OMe), 50.1 (6-C), 49.6 (CH2 benzyl), 
47.1 (C1), 15.9 (methyl), 7.5 (methyl); νmax/cm-1 (film) 3383, 2974, 1612, 1544, 1372, 
1248; m/z (ESI) 420.2 (100%, MH+); HRMS found MH+, 420.1601. C20H25N3O5S requires 
MH, 420.1588.  
(2S)-2-Hydroxy-N-[(2’R)-1’-{[(4-methoxyphenyl)methyl]amino}propan-2-yl]-S-(2’-
nitrophenyl) propane-1-sulfonamide, 161 
 
By general procedure G, cyclic sulfamidate 145 (206 mg, 0.8 mmol) and sulfonamide 153 
gave 161 (247 mg, 0.6 mmol, 71%) as a light yellow oil; Rf 0.50 (9:1 CH2Cl2‒MeOH); [α] D24:  
-11.5 (c. 3.2, CHCl3); δH (500 MHz; CDCl3) 8.02 (1H, m, Ar 3’-H), 7.65 (2H, m, Ar 5’-H and Ar 
6’-H), 7.56 (1H, m, Ar 3’-H), 7.20 (2H, d, J 8.7, Ar 2-H and Ar 6-H), 6.85 (2H, d, J 8.7, Ar 3-H 
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and Ar 5-H), 4.17 (1H, m, 2-H), 3.90 (1H, m, 2’-H), 3.81-3.75 (4H, m (broad), OMe, benzyl 
CHa), 3.70 (1H, d,  J 13.0, benzyl CHb), 3.44 (1H, dd, J 14.8, 10.3, 1-Ha), 3.25 (1H, dd, J 14.8, 
3.0, 1-Hb), 2.76 (1H, app. t, J 12.2, 1'-Ha), 2.68 (1H, dd, J 12.3, 5.9, 1'-Hb), 1.18 (3H, d, J 6.2, 3-
H), 1.05 (3H, d, J 6.8, 3’-H); δC (75 MHz; CDCl3) 158.9 (Ar 4-C), 134.1 (Ar 2’-C), 133.4 (Ar 5’-
C), 131.5 (Ar 4’-C), 140.0 (Ar 6’-C), 130.7 (Ar 1’-C), 130.0 (Ar 1’-C), 129.5 (Ar 2-C and Ar 6-
C), 124.0 (Ar 3’-C), 113.9 (Ar 3-C and Ar 5-C), 65.7 (2-C), 55.3 (OMe), 54.0 (CH2 benzyl), 
53.5 (1-C), 53.3 (1’-C), 52.8 (2’-C), 20.4 (3-C), 15.9 (3’-C); νmax/cm-1 (film) 3316, 2935, 
1611, 1544, 1249; m/z (ESI) 438.1 (100%, MH+). 
(2R,5R)-1-(4-Methoxybenzyl)-2,5-dimethyl-4-(2'-nitrophenylsulfonyl)piperazine, 
176 
 
By general procedure C, followed by purification by column chromatography, eluting with 
50:1 CH2Cl2‒MeOH, 161 (208 mg, 0.5 mmol) gave piperazine 176 (82 mg, 0.2 mmol, 41%) 
as a yellow oil; Rf 0.78 (1:1, petrol‒EtOAc); [α] D24: -65.3 (c. 0.4, CHCl3); δH (500 MHz; 
CDCl3) 8.05 (1H, m, Ar 3’-H), 7.68-7.62 (3H, m, Ar 4’-H, Ar 5’-H and Ar 6’-H), 7.18 (2H, d, J 
8.5, Ar 2-H and Ar 6-H), 6.83 (2H, d, J 8.7, Ar 3-H and Ar 5-H), 4.06 (1H, d, J 13.3, benzyl 
CHa), 3.99 (1H, s (broad), 5-H), 3.79 (3H, s, OMe), 3.50 (1H, dd, J 12.3, 3.5, 3-Ha), 3.05 (1H, 
dd, J 13.3, 11.0, 3-Hb), 2.88 (1H, d, J 13.3, benzyl CHb), 2.51 (1H, dd, J 11.7, 1.9, 6-Ha), 2.32 
(1H, m, 2-H), 2.14 (1H, dd, J 11.6, 3.3, 6-Hb), 1.21 (3H, d, J 6.7, methyl), 1.16 (3H, d, J 6.1, 
methyl); δC (75 MHz; CDCl3) 158.6 (Ar 4-C), 133.9 (Ar 2’-C), 133.3, 132.0, 131.7, 130.9, 
130.8, 129.7 (Ar 2-C and Ar 6-C), 124.3, 113.7 (Ar 3-C and Ar 5-C), 56.4, 56.3, 56.2, 55.2, 
50.2, 47.3, 17.5 (methyl), 15.8 (methyl); νmax/cm-1 (film) 2937, 1611, 1544, 1512, 1373, 
1249; m/z (ESI) 420.2 (100%, MH+); HRMS found MH+, 420.1607. C20H25N3O5S requires 
MH, 420.1593. 
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(2R)-2-Hydroxy-N-[(2’S)-1’-{[(4-methoxyphenyl)methyl]amino}propan-2-yl]-S-(2’-
nitrophenyl) propane-1-sulfonamide, 163 
 
By general procedure G, cyclic sulfamidate 146 (206 mg, 0.8 mmol) and sulfonamide 153 
gave 163 (265 mg, 0.6 mmol, 76%) as a light yellow oil; Rf 0.50 (9:1 CH2Cl2‒MeOH); [α] D24: 
12.3 (c. 4.1 CHCl3); δH (500 MHz; CDCl3) 8.01 (1H, m, Ar 3’-H), 7.65 (2H, m, Ar 5’-H and Ar 
6’-H), 7.55 (1H, m, Ar 4’-H), 7.20 (2H, d, J 8.7, Ar 2-H and Ar 6-H), 6.84 (2H, d, J 8.7, Ar 3-H 
and Ar 5-H), 4.17 (1H, m, 2-H), 3.90 (1H, m, 2’-H), 3.81-3.75 (4H, m (broad), OMe and 
benzyl CHa), 3.70 (1H, d, J 13.0, benzyl CHb), 3.44 (1H, dd, J 14.8, 10.3, 1-Ha), 3.25 (1H, dd, J 
14.8, 3.0, 1-Hb), 2.76 (1H, app. t, J 12.3, 1'-Ha), 2.68 (1H, dd, J 12.3, 5.9, 1'-Hb), 1.18 (3H, d, J 
6.2, 3-H), 1.05 (3H, d, J 6.9, 3’-H); δC (75 MHz; CDCl3) 158.8 (Ar 4-C), 147.9 (Ar 2’-C), 134.1 
(Ar 1’-C), 133.4 (Ar 5’-C), 131.6 (Ar 4’-C), 131.0 (Ar 4-C), 130.9 (Ar 6-C), 129.5 (Ar 2-C and 
Ar 6-C), 124.0 (Ar 3’-C), 113.9 (Ar 3-C and Ar 5-C), 65.7 (2-C), 55.3 (OMe), 53.9 (2’-C), 53.5 
(CH2 benzyl), 53.2 (1-C), 52.8 (1’-C), 20.3 (3-C), 15.9 (3’-C); νmax/cm-1 (film) 3391, 2973, 
1612, 1543, 1374, 1342, 1249; m/z (ESI) 438.2 (100%, MH+). 
(2S,5S)-1-(4-Methoxybenzyl)-2,5-dimethyl-4-(2'-nitrophenylsulfonyl)piperazine, 
174 
 
By general procedure C, followed by purification by column chromatography, eluting with 
50:1 CH2Cl2‒MeOH, 163 (240 mg, 0.6 mmol) gave piperazine 174 (112 mg, 0.3 mmol, 
48%) as a yellow oil; Rf 0.67 (1:1, petrol‒EtOAc); [α] D24: 64.8 (c. 0.3, CHCl3); δH (500 MHz; 
CDCl3) 8.04 (1H, m, Ar 3’-H), 7.70-7.62 (3H, m, Ar 4’-H, Ar 5’-H and Ar 6’-H), 7.18 (2H, d, J 
8.5, Ar 2-H and Ar 6-H), 6.83 (2H, d, J 8.7, Ar 3-H and Ar 5-H), 4.05 (1H, d, J 13.2, benzyl 
CHa), 3.99 (1H, m, 5-H), 3.79 (3H, s, OMe), 3.50 (1H, ddd, J 13.2, 3.4, 1.1, 3-Ha), 3.05 (1H, 
ddd, J 13.2, 10.9, 3-Hb), 2.88 (1H, d, J 13.2, benzyl CHb), 2.51 (1H, dd, J 11.7, 1.9, 6-Ha), 2.32 
(1H, m, 2-H), 2.14 (1H, dd, J 11.7, 3.6, 6-Hb), 1.21 (3H, d, J 6.7, methyl), 1.16 (3H, d, J 6.1, 
methyl); δC (75 MHz; CDCl3) 158.6 (Ar 4-C), 133.9 (Ar 2’-C), 133.3, 132.0, 131.7, 130.8, 
130.8, 129.7 (Ar 2-C and Ar 6-C), 124.3, 113.7 (Ar 3-C and Ar 5-C), 56.4, 56.3, 56.2, 55.2, 
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50.2, 47.3, 17.5 (methyl), 15.8 (methyl); νmax/cm-1 (film) 2909, 2938, 1611, 1512, 1372, 
1193; m/z (ESI) 420.2 (100%, MH+); HRMS found MH+, 420.1605. C20H25N3O5S requires 
MH, 420.1588. 
(2S)-2-Hydroxy-N-[(2’S)-1’-{[(4-methoxyphenyl)methyl]amino}propan-2-yl]-S-(2’-
nitrophenyl) propane-1-sulfonamide, 164 
 
By general procedure G, cyclic sulfamidate 148 (206 mg, 0.8 mmol) and sulfonamide 152 
gave 164 (257 mg, 0.6 mmol, 74%) as a light yellow oil; Rf 0.63 (9:1 CH2Cl2‒MeOH); [α] D24: 
47.6 (c. 4.1 CHCl3); δH (500 MHz; CDCl3) 8.01 (1H, m, Ar 3’-H), 7.64 (2H, m, Ar 5’-H and Ar 
6’-H), 7.52 (1H, m, Ar 4’-H), 7.17 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.86 (2H, d, J 8.7, Ar 3-H 
and Ar 6-H), 4.23 (1H, m, 2-H), 4.09 (1H, m, 2’-H), 3.80 (4H, m (broad), OMe and 1-Ha), 
3.74 (1H, d, J 13.0, benzyl CHa), 3.58 (1H, d, J 13.0, benzyl CHb), 3.55 (1H, dd, J 15.4, 1.7, 1-
Hb), 2.76 (1H, dd, J 15.2, 9.9, H1'-Ha), 2.65 (1H, m, 1'-Hb), 1.17 (3H, d, J 6.3, 3-H), 0.92 (3H, 
d, J 6.6, 3’-H); δC (75 MHz; CDCl3) 158.9 (Ar 1-C), 148.2 (Ar 2’-C), 133.7 (Ar 5’-C), 133.3 (Ar 
1’-C), 131.6 (Ar 6’-C), 130.8 (Ar 4’-C), 130.6 (Ar 1-C), 129.6 (Ar 2-C and Ar 6-C), 123.9 (Ar 
3’-C), 114.0 (Ar 3-C and Ar 5-C), 66.9 (2-C), 55.3 (OMe), 52.8 (2’-C), 52.1 (CH2 benzyl), 51.6 
(1-C), 51.3 (C1-1'), 20.0 (3’-C), 15.9 (3’-C); νmax/cm-1 (film) 2973, 1612, 1545, 1513, 1371, 
1249; m/z (ES) 438.2 (MH+). 
(2R,5S)-1-(4-Methoxybenzyl)-2,5-dimethyl-4-(2'-nitrophenylsulfonyl)piperazine, 
177 
 
By general procedure C, followed by purification by column chromatography, eluting with 
50:1 CH2Cl2‒MeOH, 164 (223 mg, 0.5 mmol) gave piperazine 177 (118 mg, 0.3 mmol, 
55%) as a yellow oil; Rf 0.71 (1:1, petrol‒EtOAc); [α] D24: 94.9 (c. 0.4, CHCl3); δH (500 MHz; 
CDCl3) 8.03 (1H, m, Ar 3’-H), 7.69-7.62 (3H, m, Ar 4’-H, Ar 5’-H and Ar 6’-H), 7.23 (2H, d, J 
8.4, Ar 2-H and Ar 6-H), 6.84 (2H, d, J 8.6, Ar 3-H and Ar 5-H), 4.05 (1H, m, 5-H), 3.79 (3H, 
s, OMe), 3.60 (1H, dd, J 12.9, 3.3, 3-Ha), 3.53 (1H, d, J 13.2, benzyl CHa), 3.43 (1H, d, J 13.2, 
benzyl CHb), 3.38 (1H, d, J 13.9, 3-Hb), 2.96 (1H, m, 2-H), 2.83 (1H, dd, J 11.8, 3.9, 6-Ha), 2.19 
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(1H, dd, J 11.8, 2.0, 6-Hb), 1.17 (3H, d, J 6.7, methyl), 0.91 (3H, d, J 6.6, methyl); δC (75 MHz; 
CDCl3) 158.7 (Ar 4-C), 147.8 (Ar 2’-C), 134.2, 133.3, 132.0, 131.6, 130.7, 129.6 (Ar 2-C and 
Ar 6-C), 124.2, 113.7 (Ar 3-C and Ar 5-C), 57.9, 55.2, 51.9, 50.1, 49.6, 47.1, 15.9, 7.5; 
νmax/cm-1 (film) 2973, 1544, 1512, 1372, 1248; m/z (ESI) 420.2 (100%, MH+); HRMS found 
MH+, 420.1588. C20H25N3O5S requires MH, 420.1588. 
2-Hydroxy-N-[(2’S)-2’-{[(4-methoxyphenyl)methyl]amino}-3-methylbutyl]-S-(2’-
nitrophenyl) ethane-1-sulfonamide, 165 
 
By general procedure G, cyclic sulfamidate 147 (257 mg, 0.9 mmol) and sulfonamide  131 
gave 165 (306 mg, 0.7 mmol, 75%) as a light yellow oil; Rf 0.50 (9:1 CH2Cl2‒MeOH); [α] D24: 
58.3 (c. 0.6, CHCl3); δH (500 MHz; CDCl3) 7.95 (1H, dd, J 7.2, 2.0, Ar 3’-H), 7.69 (2H, m, Ar 5’-
H and Ar 6’-H), 7.60 (1H, dd, J 7.2, 1.7, Ar 4’-H), 7.27 (2H, d, J 8.5, Ar 2-H and Ar 6-H), 6.88 
(2H, d, J 8.4, Ar 3-H and Ar 5-H), 3.90 (1H, ddd, J 12.4, 8.2, 2.4, 1-Ha), 3.86 (1H, d, J 12.4, 
benzyl CHa), 3.83-3.80 (4H, m, OMe and benzyl CHb), 3.74 (1H, ddd, J 12.6, 5.0, 2.4, 1-Hb), 
3.67 (1H, ddd, J 14.4, 5.0, 2.4, 1'-Ha), 3.55 (1H, dd, J 14.1, 2.9, 1'-Hb), 3.16-3.10 (2H, m, 2-H), 
3.07 (1H, m, 2’-H), 1.91 (1H, m, 3’-H), 1.60 (2H, s broad, NH and OH), 0.92 (3H, d, J 7, 4’-H), 
0.89 (3H, d, J 6.9, methyl); δC (75 MHz; CDCl3) 133.7 (Ar 5’-C), 131.6 (Ar 6’-C), 130.7 (Ar 4’-
C), 129.9 (Ar 2-C and Ar 6-C), 124.2 (Ar 3’-C), 114.1 (Ar 3-C and Ar 5-C), 62.4 (2-C), 61.7 
(3’-C), 55.3 (1-C), 54.8 (OMe), 52.7 (CH2 benzyl), 52.0 (1’-C), 29.1 (3’-C), 18.5 (4’-C), 17.8 
(methyl) [Quaternary Ar-C were not observed];  νmax/cm-1 (film) 2965, 1606, 1543, 1513, 
1346, 1250; m/z (ES) 452.1 (MH+). 
(S)-2-Isopropyl-1-(4-methoxybenzyl)-4-(2'-nitrophenylsulfonyl)piperazine, 171 
 
By general procedure C, 165 (289 mg, 1.0 mmol) gave piperazine 171 (260 mg, 0.6 mmol, 
96%) as a yellow oil; Rf 0.63 (1:1, petrol‒EtOAc); [α] D24: 19.2 (c. 0.4, CHCl3); δH (500 MHz; 
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CDCl3) 7.93 (1H, m, Ar 3’-H), 7.69 (2H, m, Ar 5’-H and Ar 6’-H), 7.61 (1H, m, Ar 4-H), 7.18 
(2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.83 (2H, d, J 8.6, Ar 3-H and Ar 5-H), 4.03 (1H, d, J 13.0, 
benzyl CHa), 3.79 (3H, s, OMe), 3.61 (1H, dt, J 12.2, 2.7, 5-Ha), 3.47 (1H, m, 3-Ha), 3.06 (1H, 
d, J 13.0, benzyl CHb), 2.86-2.79 (3H, m, 5-Hb, 3-Hb and 2-H), 2.36 (1H, m, isopropyl CH), 
2.25-2.23 (1H, m, 6-Ha), 2.17 (1H, m, 6-Hb), 1.03 (3H, d, J 6.8, methyl), 0.95 (3H, d, J 6.8, 
methyl); δC  (75 MHz, CDCl3) 158.7 (Ar 4-C), 133.7 (Ar 5-C′), 131.4 (Ar 3-C′), 130.9 (Ar 6-
C′), 129.9 (Ar 3-C and Ar 5-C), 124.0 (Ar 3-C′), 113.7 (Ar 2-C and Ar 6-C),  64.3 (2-C), 55.4, 
55.3 (OMe), 49.7, 44.7, 44.4, 26.5 (isopropyl CH), 19.7 (Me), 16.2 (Me); νmax/cm-1 (film) 
2964, 1611, 1546, 1373, 1173 [Ar 1-C, Ar 1’-C and Ar 2’-C were not observed]; m/z (ESI) 
434.2 (100%, MH+); HRMS found MH+, 434.1764. C21H27N3O5S requires MH, 434.1744. 
(2R)-2-Hydroxy-N-[(2’S)-2-{[(4-methoxyphenyl)methyl]amino}-3-methylbutyl]-S-
(2’-nitrophenyl)propane-1-sulfonamide, 167 
 
By general procedure G, cyclic sulfamidate 147 (228 mg, 0.8 mmol) and sulfonamide 153 
gave 167 (323 mg, 0.7 mmol, 87%) as a light yellow oil; Rf 0.63 (9:1 CH2Cl2‒MeOH); [α] D24: 
32.9 (c. 6.8, CHCl3); δH (500 MHz; CDCl3) 7.96 (1H, m, Ar 3’-H), 7.68 (2H, m, Ar 5’-H and Ar 
6’-H), 7.56 (1H, m, Ar 4’-H), 7.25 (2H, d, J 8.7, Ar 2-H and Ar 6-H), 6.86 (2H, d, J 8.7, Ar 3-H 
and Ar 5-H), 4.04 (1H, m, 2-H), 3.79 (3H, s, OMe), 3.79 (1H, d, J 12.2, benzyl CHa), 3.65 (1H, 
d, J 12.2, benzyl CHb), 3.28-3.20 (3H, m, 1-H and 1'-Ha), 3.13 (1H, dd, J 14.3, 8.4, 1'-Hb), 2.96 
(1H, m, 2’-H), 2.04 (1H, m, H3'), 1.18 (3H, d, J 6.3, 3-H), 0.95 (3H, d, J 7, 4’-H), 0.90 (3H, d, J 
6.9, methyl); δC (75 MHz, CDCl3) 158.8 (Ar 4-C), 148.6 (Ar 2’-C), 133.7 (Ar 5’-C), 131.6 (Ar 
1’-C), 131.5 (Ar 1’-C), 131.4 (Ar 6’-C), 130.8 (Ar 4’-C), 129.7 (Ar 2-C and Ar 6-C), 124.0 (Ar 
3’-C), 114.0 (Ar 3-C and Ar 5-C), 63.3 (2-C), 59.7 (2’-C), 57.8 (CH2 benzyl), 55.3 (OMe), 50.4 
(1-C), 50.1 (1’-C), 28.4 (3’-C), 20.1 (3-C), 19.0 (4’-C), 16.9 (methyl); νmax/cm-1 (film) 2965, 
1611, 1546, 1373, 1249; m/z (ES) 466.2 (MH+). 
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(2S,6S)-2-isoPropyl-1-(4-methoxybenzyl)-6-methyl-4-(2'-
nitrophenylsulfonyl)piperazine, 175 
 
By general procedure C, followed by purification by column chromatography, eluting with 
50:1 CH2Cl2‒MeOH, 167 (280 mg, 0.6 mmol) gave piperazine 175 (123 mg, 0.3 mmol, 
46%) as a yellow oil; Rf 0.78 (1:1, petrol‒EtOAc); [α] D24: -251.3 (c. 0.5, CHCl3); δH (500 
MHZ; CDCl3) 7.93 (1H, m, Ar 3’-H), 7.70 (2H, m, Ar 5’-H and Ar 6’-H), 7.60 (1H, m, Ar 4’-H), 
7.20 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.83 (2H, d, J 8.7, Ar 3-H and Ar 5-H), 3.78 (3H, s, 
OMe), 3.67 (1H, d, J 13.6, benzyl CHa), 3.53 (1H, d, J 13.6, benzyl CHb), 3.44 (1H, dd, J 12.1, 
3.0, 3-Ha), 3.14-3.05 (3H, m, 3-Hb and 5-H), 3.00 (1H, dd, J 12.0, 7.1, 2-H), 2.54 (1H, dt, J 7.2, 
3.1, 6-H), 2.14 (1H, m, isopropyl CH), 1.07 (3H, d, J 6.6, Methyl), 0.95 (3H, d, J 6.8, Methyl), 
0.87 (3H, d, J 6.7, Methyl); δC (75 MHz, CDCl3) 158.6 (Ar 4-C), 148.5 (Ar 3’-C), 133.6, 133.6, 
131.5, 131.2, 130.9, 129.4 (Ar 2-C and Ar 6-C), 124.0, 113.7 (Ar 3-C and Ar 5-C), 58.9, 55.3, 
49.1, 48.3, 47.7, 42.3, 26.3, 19.8, 18.0, 13.2; νmax/cm-1 (film) 2966, 1611, 1546, 1511, 1373, 
1248; m/z (ESI) 448.1 (100%, MH+); HRMS found MH+, 448.1922. C22H29N3O5S requires 
MH, 448.1901. 
(2S)-2-Hydroxy-N-[(2’S)-2’-{[(4-methoxyphenyl)methyl]amino}-3-methylbutyl]-S-
(2’-nitrophenyl)propane-1-sulfonamide, 168 
 
By general procedure G, cyclic sulfamidate 147 (228 mg, 0.8 mmol) and sulfonamide 152  
gave 168 (319 mg, 0.7 mmol, 86%) as a light yellow oil Rf 0.65 (9:1 CH2Cl2‒MeOH); [α] D24: 
27.2 (c. 5.2, CHCl3); δH (500 MHz; CDCl3) 7.96 (1H, m, Ar 3’-H), 7.68 (2H, m, Ar 5’-H and Ar 
6’-H), 7.56 (1H, m, Ar 4’-H), 7.25 (2H, d, J 8.7, Ar 2-H and Ar 6-H), 6.86 (2H, d, J 8.7, Ar 3-H 
and Ar 5-H), 4.04 (1H, m, 2-H), 3.79 (3H, s, OMe), 3.79 (1H, d, J 12.2, benzyl CHa), 3.65 (1H, 
d, J 12.2, benzyl CHb), 3.28-3.20 (3H, m, 1-H and 1'-Ha), 3.13 (1H, dd, J 14.3, 8.4, 1'-Hb), 2.96 
(1H, m, 2’-H), 2.04 (1H, m, 3'-H), 1.18 (3H, d, J 6.3, 3-H), 0.95 (3H, d, J 7, 4’-H), 0.90 (3H, d, J 
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6.9, methyl); δC (75 MHz, CDCl3) 158.8 (Ar 4-C), 148.6 (Ar 2’-C), 133.7 (Ar 5’-C), 131.6 (Ar 
1’-C), 131.5 (Ar 1’-C), 131.4 (Ar 6’-C), 130.8 (Ar 4’-C), 129.7 (Ar 2-C and Ar 6-C), 124.0 (Ar 
3’-C), 114.0 (Ar 3-C and Ar 5-C), 63.3 (2-C), 59.7 (2’-C), 57.8 (CH2 benzyl), 55.3 (OMe), 50.4 
(1-C), 50.1 (1’-C), 28.4 (3’-C), 20.1 (3-C), 19.0 (4’-C), 16.9 (methyl); νmax/cm-1 (film) 3096, 
2964, 1611, 1546, 1373, 1249; m/z (ESI) 466.2 (100%, MH+). 
 
(2S,6R)-2-isoPropyl-1-(4-methoxybenzyl)-6-methyl-4-(2'-
nitrophenylsulfonyl)piperazine, 178 
 
By general procedure C, followed by purification by column chromatography, eluting with 
50:1 CH2Cl2‒MeOH, 168 (280 mg, 0.6 mmol) gave piperazine 178 (126 mg, 0.3 mmol, 
47%) as a yellow oil; Rf 0.72 (1:1, petrol‒EtOAc); [α] D24: 1.5 (c. 4, CHCl3); δH (500 MHz; 
CDCl3) 7.95 (1H, m, Ar 3-H), 7.70 (2H, m, Ar 4-H and Ar 6-H), 7.60 (1H, m, Ar 5-H), 7.20 
(2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.81 (2H, d, J 8.7 Ar 3-H and Ar 5-H), 3.78 (3H, s, OMe), 
3.74 (1H, d, J 16.4 benzyl CHa), 3.60 (1H, d, J 16.5, benzyl CHb), 3.61 (1H, dt, J 11.9, 2.5, 5-
Ha), 3.54 (1H, dt, J 11.9, 2.2, 3-Ha), 2.77 (1H, m, 6-H), 2.73 (1H, dd, J 12.0, 10.0, 5-Hb), 2.62 
(1H, dd, J 12.0, 10.1, 3-Hb), 2.48 (1H, m, 1-H), 2.11 (1H, m, CH isopropyl), 1.10 (3H, d, J 6.3, 
Me), 0.94 (3H, d, J 6.9, Me (isopropyl)), 0.76 (3H, d, J 6.8, Me (isopropyl)); δC (75 MHz, 
CDCl3) 158.3 (Ar 4-C), 148.6 (Ar 2’-C), 133.7, 132.3, 132.0, 131.5, 130.9, 128.9 (Ar 2-C and 
Ar 6-C), 124.0, 113.5 (Ar 3-C and Ar 5-C), 65.2, 55.4, 55.2, 52.7, 50.8, 44.8, 27.9 (CH 
isopropyl), 20.2 (Me), 19.0 (Me (isopropyl)), 16.6 (Me (isopropyl)); νmax/cm-1 (film) 2965, 
1610, 1546, 1511, 1373, 1246; m/z (ESI) 448.2 (100%, MH+); HRMS found MH+, 448.1922. 
C22H29N3O5S requires MH, 448.1901. 
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3-Hydroxy-N-[(2’S)-2’-{[(4-methoxyphenyl)methyl]amino}-3-methylbutyl]-S-(2’-
nitrophenyl) propane-1-sulfonamide, 169 
 
By general procedure G, cyclic sulfamidate 147 (228 mg, 0.8 mmol) and sulfonamide 151 
gave 169 (290 mg, 0.6 mmol, 78%) as a light yellow oil; Rf 0.50 (9:1 CH2Cl2‒MeOH); [α] D24: 
10.4 (c. 0.3, CHCl3); δH (500 MHz; CDCl3) 8.02 (1H, m, Ar 3’-H), 7.62 (2H, m, Ar 5’-H and Ar 
6’-H), 7.53 (1H, m, Ar 4’-H), 7.14 (2H, d, J 8.5, Ar 2-H and Ar 6-H), 6.82 (2H, d, J 8.6, Ar 3-H 
and Ar 5-H), 3.80 (3H, s, OMe), 3.71 (1H, d, J 12.7, benzyl CHa), 3.63 (2H, app. t, J 5.8, 3-H), 
3.57 (1H, d, J 12.8, benzyl CHb), 3.55 (1H, m, 1-Ha), 3.34-3.26 (3H, m, 1-Hb and 1’-H), 2.66 
(1H, m, 2’-H), 1.97 (1H, m, 3’-H), 1.72 (4H, m broad, 2-H, NH and OH), 0.90 (3H, d, J 4.1, 4-
H), 0.89 (3H, d, J 4.1, methyl); δC (75 MHz, CDCl3) 131.6 (Ar 4’-C), 131.0 (Ar 5’-C), 129.7 (Ar 
2-C and Ar 6-C), 124.2 (Ar 3’-C), 113.8 (Ar 3-C and Ar 5-C), 59.2 (3-C), 55.3 (OMe), 48.5 (1-
C), 30.7 (C1'), 27.9, 18.3 (4’-C), 17.1 (methyl) [Quaternary Ar-C were not observed]; 
νmax/cm-1 (film) 3363, 2960, 1606, 1543, 1250; m/z (ESI) 466.2 (100%, MH+). 
(S)-2-Isopropyl-1-(4-methoxybenzyl)-4-(2'-nitrophenylsulfonyl)-1,4-diazepane, 180 
 
By general procedure C, followed by purification by column chromatography, eluting with 
50:1 CH2Cl2‒MeOH, 169 (270 mg, 0.6 mmol) gave the diazepane 180 (145 mg, 0.3 mmol, 
56%) as a yellow oil; Rf 0.46 (1:1, petrol‒EtOAc); [α] D24: 15.4 (c. 1 CHCl3); δH (500 MHz; 
CDCl3) 7.99 (1H, m, Ar 2’-H), 7.69 (2H, m, Ar 5’-H and Ar 6-H), 7.62 (1H, m, Ar 4’-H), 7.27 
(2H, d, J 8.6, Ar 2-H and Ar 6-H), 6.85 (2H, d, J 8.6, Ar 3-H and Ar 5-H), 3.93 (1H, d, J 13.8, 
benzyl CHa), 3.80 (3H, s, OMe), 3.78 (1H, d, J 14.1 benzyl CHb), 3.66 (1H, dd, J 14.3, 4.9, 3-
Ha), 3.56 (1H, m, 5-Ha), 30 (1H, dd, J 14.2, 10.4, 3-Hb), 3.23 (1H, m, 5-Hb), 2.93 (1H, ddd, J 
15.3, 8.7, 3.3, 7-Ha), 2.78 (1H, ddd, J 15.7, 7.9, 3.4, 7-Hb), 2.70 (1H, m, H2), 1.92 (1H, m, 6-
Ha), 1.76 (1H, m, CH isopropyl), 1.65 (1H, m, 6-Hb), 1.02 (3H, d, J 6.7, methyl), 0.92 (3H, d, J 
6.7, methyl); δC (75 MHz, CDCl3) 133.3, 131.6, 130.6, 129.7 (Ar 2-C and Ar 6-C), 124.1, 
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113.5 (Ar 3-C and Ar 5-C), 68.13, 55.3, 53.9, 51.6, 49.4, 47.6, 31.0, 26.2 (CH isopropyl), 20.5 
(Me), 19.8 (Me) [Quaternary Ar-C were not observed]; νmax/cm-1 (film) 3374, 2960, 1711, 
1544, 1511, 1373, 1249; m/z (ESI) 448.2 (100%, MH+); HRMS found MH+, 448.1912. 
C22H29N3O5S requires MH, 448.1901. 
tert-Butyl-N-[(2-nitrobenzene)sulfonyl]carbamate, o-203100 
 
DMAP (10.0 mg, 0.08 mmol) was added to a stirred suspension of 2-
nitrobenzenesulfonamide (5.00 g, 24.7 mmol) and Boc2O (5.40 g, 24.7 mmol) and NEt3 
(5.00 mL, 35.9 mmol) in CH2Cl2 (25 mL) and the resulting solution stirred at rt for 16h. 
The reaction mixture was quenched with HCl (1 M aq. to pH<2), extracted with CH2Cl2 (2 × 
20 mL), washed with brine (20 mL) dried (MgSO4) and concentrated in vacuo . Purification 
by crystallisation, from toluene‒EtOAc, gave the carbamate o-203 (6.42 g, 21.3 mmol, 
86%) as colourless plates; Rf 0.59 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3); 8.35 (1H, m, Ar 
3-H), 7.87 (1H, m, Ar 6-H), 7.80 (2H, m, Ar 4-H and Ar 5-H), 1.43 (9H, s, tBu); δC (75 MHz, 
CDCl3); 134.7 (Ar 4-C), 133.3 (Ar 5-C), 132.5 (Ar 6-C), 125.1 (Ar 3-C), 84.9 (tBu), 27.9 
(tBu);  νmax/cm−1 (solid); 3248, 2980, 1747, 1546, 1358, 1147; m/z (ESI) 325.0 (100%, 
MNa+); HRMS found MNa+, 325.0473. C11H14N2O6S requires MNa, 325.0465. 
tert-Butyl-N-[(4-nitrobenzene)sulfonyl]carbamate, p-203 
 
 
DMAP (10.0 mg, 0.08 mmol) was added to a stirred suspension of 4-
nitrobenzenesulfonamide (5.00 g, 24.7 mmol) and Boc2O (5.40 g, 24.7 mmol) and NEt3 
(5.00 mL, 35.9 mmol) in CH2Cl2 (25 mL) and the resulting solution stirred at rt for 16h. 
The reaction mixture was quenched with HCl (1 M aq. to pH<2), extracted with CH2Cl2 (2 × 
20 mL), washed with brine (20 mL) dried (MgSO4) and concentrated in vacuo . Purification 
by crystallisation, from toluene‒EtOAc, gave the carbamate p-203 (5.68 g, 18.8 mmol, 
76%) as colourless plates; Rf 0.68 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3); 8.41 (2H d, J 
9.0, Ar 3-H and Ar 4-H), 8.25 (2H, d, J 9.0, Ar 2-H and Ar 6-H), 1.48 (9H, s, tBu); δC (75 MHz, 
CDCl3); 148.6 (Ar 4-C), 144.2 (Ar 1-C), 129.8 (Ar 2-C and Ar 6-C), 124.2 (Ar 3-C and Ar 5-
  
159 
 
C), 85.2 (tBu), 28.9 (tBu); νmax/cm−1 (film) 3253, 2982, 1748, 1545, 1361; m/z (ESI) 301.1 
(100%, M−).  
N-Benzyl-2-nitrobenzene-1-sulfonamide, 221107 
 
2-Nitrobenzenesulfonyl chloride (4.14 g, 18.7 mmol) was added to a stirred solution of 
benzylamine (2.04 mL, 18.7 mmol) and NEt3 (7.80 mL, 56.0 mmol) in CH2Cl2 and the 
resulting solution was stirred at rt for 2 h. The reaxtion mixture was acidified with HCl 
(2M aq. soln, to pH<2), extracted with CH2Cl2 (3 × 20 mL), organics washed with brine and 
dried (MgSO4) to give a crude product. Purification by column chromatography, gradient 
elution 9: to 1:1 petrol‒EtOAc, gave the sulfonamide 221 (4.94 g, 16.9 mmol, 90%) as 
colourless oil which solidified upon standing; Rf 0.49 (1:1 petrol‒EtOAc); δH (300 MHz, 
CDCl3); 8.00 (1H, dd, J 7.3 and 1.9, Ar 3-H), 7.83 (1H, dd, J 7.5 and 1.7, Ar 6-H), 3.66 (2H, m,  
Ar 4-H and Ar 5-H), 7.22 (5H, m, Phenyl), 5.73 (1H, br t, J 6.9, NH), 4.32 (2H, d, J 6.3, CH2); 
δC (75 MHz, CDCl3); 135.6 (Ph 1-C), 134.0 (Ar-C), 133.4 (Ar 1-C), 132.8 (Ar 4-C), 131.1 (Ar 
5-C), 128.7 (Ph 3-C and Ph 5-C), 128.1 (Ph 4-C), 127.9 (Ph 2-C and Ph 6-C), 125.3 (Ar 3-C), 
47.9 (CH2); νmax/cm−1 (solid); 3031, 1539, 1362, 1219, 1167; m/z (ESI) 315.0 (100%, 
MNa+); HRMS found MNa+, 315.0422. C13H12N2O4S requires MNa, 315.0410.  
2-Nitro-N-(prop-2-yn-1-yl)benzene-1-sulfonamide, o-202101 
 
By general procedure J, propargyl alcohol (1.16 mL, 19.9 mmol) and sulfonamide 0-203 
(6.63 g, 21.9 mmol) gave the sulfonamide o-202 (4.21 g, 17.5 mmol, 88%) as a colourless 
solid; Rf 0.62 (1:1 petrol‒EOAc); δH (300 MHz, CDCl3); 8.26-8.16 (1H, m, Ar 3-H), 7.96-7.91 
(1H, m, Ar 5-H), 7.81-7.73 (2H, m, Ar 4-H and 6-H), 5.71 (1H, br t, J 6.3, N-H), 4.03 (2H, dd, J 
6.3 and 2.5, 1-H), 1.97 (1H, t, J 2.5, 3-H); δC (75 MHz, CDCl3); 134.0 (Ar 1-C), 133.9 (Ar 4-C), 
133.0 (Ar 5-C), 131.6 (Ar 6-C), 125.7 (Ar 3-C), 80.7 (2-C), 73.3 (3-C), 33.4 (1-C); νmax/cm−1 
(film); 3299, 2126, 1540, 1335; m/z (ESI) 241.8 (100%, MH+). 
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4-Nitro-N-(prop-2-yn-1-yl)benzene-1-sulfonamide, p-202 
 
By general procedure J, propargyl alcohol (0.88 mL, 15.1 mmol) and sulfonamide p-203 
(5.00 g, 16.5 mmol) gave the sulfonamide p-202 (3.16 g, 13.2 mmol, 87%) as a colourless 
solid; Rf 0.68 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3) 8.37 (2H, d, J 8.8, Ar 3-H and Ar 5-
H), 8.10 (2H, d, J 8.8, Ar 2-H and Ar 6-H), 4.76 (1H, br s, N-H), 3.97 (2H, dd, J 7.2 and 2.5 , 1-
H), 2.09 (1H, t, J 2.5, 3-H); δC (75 MHz, MeOD); 151.4 (Ar 4-C), 147.9 (Ar 1-C), 129.7 (Ar 2-C 
and 6), 125.1 (Ar 3-C and 5), 82.2 (3-C), 79.1 (2-C), 33.1 (1-C); νmax/cm−1 (solid); 3275, 
2978, 2121, 1607, 1537, 1350, 1069; m/z (ESI) 263.0 (100%, MNa+); HRMS found MNa+, 
263.0105. C9H8N2O4S requires MNa, 263.0097.  
2-Nitro-N-(pent-2-yn-1-yl)benzene-1-sulfonamide, o-235 
 
By general procedure J, 2-pentyn-1-ol (0.87 mL, 9.35 mmol) and sulfonamide o-203 (4.26 
g, 14.1 mmol) gave the sulfonamide o-235 (2.17 g, 8.09 mmol, 82%) as a colourless solid; 
Rf 0.68 (1:1 petrol‒EtOAc); δH (500 MHz, CDCl3); 8.25-8.17 (1H, m, Ar 3-H), 7.94-7.89 (1H, 
m, 5-H), 7.80-7.72 (2H, m, Ar 4-H and 6-H), 5.61 (1H, br t, J 5.8, N-H), 3.97 (2H, dt, J 6.2 and 
2.2, 1-H), 1.83 (2H, qt, J 7.5 and 2.2, 4-H), 0.82 (3H, t, J 7.5, 5-H),  δC (75 MHz, CDCl3); 147.9 
(Ar 2-C), 134.3 (Ar 1-C), 133.6 (Ar 4-C), 132.9 (Ar 5-C), 131.7 (Ar 6-C), 125.4 (Ar 3-C), 87.3 
(2-C), 72.9 (3-C), 34.0 (1-C), 13.4 (5-C), 12.0 (4-C), νmax/cm−1 (film); 3347, 2979, 2238, 
1542, 1362, 1168; m/z (ESI) 267.1 (100%, M−). 
4-Nitro-N-(pent-2-yn-1-yl)benzene-1-sulfonamide, p-235 
 
By general procedure J, 2-pentyn-1-ol (0.5 mL, 5.40 mmol) and sulfonamide p-203 (1.80 g, 
5.95 mmol) gave the sulfonamide p-235 (1.42 g 5.31 mmol, 98%) as a colourless solid; Rf 
0.73 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3); 8.38 (2H, d, J 9.0, Ar 3-H and Ar 5-H), 8.12 
(2H, d, J 9.0, Ar 2-H and Ar 6-H), 4.85 (1H, t, J 6.0, NH), 3.92 (2H, dt, J 6.0 and 2.2, 1-H), 1.92 
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(2H, qt, J 7.5 and 2.3, 4-H), 0.91 (3H, t, J 7.5, 5-H); δC (75 MHz, CDCl3); 150.1 (Ar 3-c), 146.0 
(Ar 1-C), 128.8 (Ar 2-C and Ar 6-C), 124.2 (Ar 3-C and Ar 5-C), 87.5 (3-C), 72.9 (2-C), 33.5 
(1-C), 13.4 (4-C), 12.1 (5-C); νmax/cm−1 (film); 3255, 1605, 1531, 1348, 1160; m/z (ESI) 
291.0 (100%, MNa+); HRMS found MNa+, 291.0410, C11H12N2O4S requires MNa, 291.0410. 
(±)-2-Nitro-N-(pent-1-yn-3-yl)benzene-1-sulfonamide, o-236 
 
By general procedure J, 1-pentyn-3-ol (0.51 mL, 5.94 mmol) and sulfonamide o-203 (2.70 
g, 8.93 mmol) gave the sulfonamide o-236 (1.29 g, 4.81 mmol, 81%) as a colourless solid; 
Rf 0.62 (1:1 petrol‒EtOAc); δH (500 MHz, CDCl3); 8.24-8.17 (1H, m, Ar 3-H), 7.95-7.89 (1H, 
m, Ar 5-H), 7.78-7.71 (2H, m, Ar 4-H and 6-H), 5.61 (1H, br d, J 9.5, N-H), 4.16 (1H, dtd, J 
9.4, 6.9 and 2.2, 3-H), 1.96 (1H, d, J 2.2, 1-H), 1.86-1.72 (2H, m, 4-H), 1.05 (3H, t, J 7.4, 5-H); 
δC (75 MHz, CDCl3); 133.7 (Ar 4-C), 132.9 (Ar 5-C), 131.6 (Ar 6-C), 125.5 (Ar 3-C), 80.7 (1-
C), 73.0 (2-C), 47.5 (3-C), 29.6 (4-C), 9.8 (5-C) [Ar 1-C and Ar 2-C were not observed]; 
νmax/cm−1 (film); 3292, 2122, 1541, 1354, 1172; m/z (ESI) 267.0 (100%, M−). 
(±)-4-Nitro-N-(pent-1-yn-3-yl)benzene-1-sulfonamide, p-236 
 
By general procedure J, 1-pentyn-3-ol (0.47 mL, 5.45 mmol) and sulfonamide p-203 (1.80 
g, 5.95 mmol) gave the sulfonamide p-236 (1.21 g, 4.50 mmol, 83%) as a colourless solid; 
Rf 0.76 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3); 8.37 (2H, d, J 8.8, Ar 3-H and Ar 5-H), 8.10 
(2H, d, J 8.8, Ar 2-H and Ar 6-H), 4.37 (1H, d, J 9.1, N-H), 4.10 (1H, m, 3-H), 2.08 (1H, d, J 2.3, 
1-H), 1.36 (2H, m, 4-H), 1.03 (3H, t, J 7.4, 5-H); δC (75 MHz, CDCl3); 128.7 (Ar 2-C and Ar 6-
C), 124.2 (Ar 3-C and Ar 5-C), 80.92 (1-C), 41.2 (3-C), 29.9 (4-C), 9.8 (5-C) [Ar 1-C and Ar 4-
C were not observed]; νmax/cm−1 (solid); 3275, 2984, 2345, 1519, 1167; m/z (ESI) 291.0 
(100%, MNa+); (Found MNa+, 291.0419. C11H12N2O4S requires MNa, 291.0410).  
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2-Nitro-N-(pent-4-yn-1-yl)benzene-1-sulfonamide,  o-237 
 
By general procedure J, 4-pentyn-1-ol (0.70 mL, 7.52 mmol) and sulfonamide o-203 (3.39 
g, 11.2 mmol) gave the sulfonamide o-237 (1.70 g, 6.32 mmol, 84%) as a colourless oil; Rf  
0.27 (7:3 petrol‒EtOAc); δH (500 MHz, CDCl3); 8.19-8.12 (1H, m, Ar 3-H), 7.91-7.83 (1H, m, 
Ar 6-H), 7.79-7.71 (2H, m, Ar 4-H and 5-H), 5.43 (1H, br t, J 5.5, N-H), 3.26 (2H, q, J 6.7, 1-
H), 2.27 (2H, td, J 6.8 and 2.7, 3-H), 1.96 (1H, t, J 2.7, 5-H), 1.78 (2H, pentet, J 6.8, 2-H); δC 
(75 MHz, CDCl3); 148.1 (Ar 2-C), 133.8 (Ar 1-C), 133.6 (Ar 4-C), 132.8 (Ar 5-C), 131.1 (Ar 
6-C), 125.4 (Ar 1-C), 82.5 (4-C), 69.7 (5-C), 42.7 (1-C), 28.2 (2-C), 15.7 (3-C); νmax/cm−1 
(film) 3297, 2346, 1541, 1364, 1341, 1165; m/z (ESI) 291.3 (100%, MNa+). 
Benzyl N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]carbamate, 247 
 
By general procedure H, (S)-2-amino-3-phenyl-1-propanol (1.0 g, 6.6 mmol), gave the 
carbamate 247 (1.7 g, 6.2 mmol, 93%) as a colourless oil which solidified on standing; Rf 
0.44 (1:1 petrol–EtOAc); [α]D19 −28.5 (c 1.0, CHCl3); δH (500 MHz, CHCl3); 7.35-7.18 (10H, 
m, Benzyl-H and Phenyl-H), 5.06 (3H, br s, N-H and Benzyl-H), 3.94 (1H, m, 2-H), 3.68 (1H, 
br m, 1-Ha), 3.57 (1H, br m, 1-Hb), 2.85 (2H, d, J 6.7, 3-H), 2.34 (1H, br s, O-H); δC (75 MHz, 
CHCl3); 156.5 (Carbonyl-C), 137.7 (Phenyl 1-C), 136.3 (Benzyl 1-C), 129.3 (Phenyl 2-C and 
Phenyl 6-C), 128.6 (Phenyl 3-C and Phenyl 5-C), 128.6 (Benzyl Ar 2-C and Benzyl Ar 6-C), 
128.2 (Benzyl Ar 3-C and Benzyl Ar 5-C), 128.1 (Benzyl Ar 4-C), 126.7 (Phenyl 4-C), 66.9 
(Benzyl-C), 64.0 (1-C), 54.1 (2-C), 37.3 (3-C); νmax/cm−1 (film); 3366, 2880, 1691, 1542, 
1454, 1262, 1019; m/z (ESI) 308.1 (100%, MNa+); HRMS found MNa+, 308.1270. 
C17H19NO3 requires MNa, 308.1257.  
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tert-Butyl-N-[(1S)-2-hydroxy-1-phenylethyl]carbamate, 246 
 
By general procedure I, (2S)-2-amino-2-phenylethanol (2.00 g, 14.6 mmol), gave the 
carbamate 246 (3.18 g, 13.4 mmol, 92%) as a colourless soild; Rf 0.50 (1:1 petrol–EtOAc); 
[α]D19 +39.6 (c 0.5, CHCl3); δH (300 MHz, CDCl3); 7.39- 7.26 (5H, m, Ar-H), 5.19 (1H, br s, N-
H), 4.77 (1H, br m, 1-H), 3.85 (2H, br m, 2-H), 2.25 (1H, br s, O-H), 1.43 (9H, s, tBu-H); δC 
(75 MHz, CDCl3); 128.8 (Ar 3-C and Ar 5-C), 127.8 (Ar 4-C), 126.6 (Ar 2-C and Ar 6-C), 80.1 
(tBu-C), 67.1 (2-C), 56.9 (1-C), 28.3 (tBu-C) [Ar 1-C was not observed]; νmax/cm−1 (solid); 
3312, 3248, 2977, 1672, 1555, 1367, 1219; m/z (ESI) 260.1 (100%, MNa+); HRMS found 
MNa+, 260.1263. C13H19NO3 requires MNa, 260.1257.  
Benzyl-N-[(2S)-2-hydroxypropyl]carbamate, 248 
 
By general procedure H, (2S)-1-amino-2-propanol (500 mg, 6.66 mmol), gave the 
carbamate 248 (1.32 g, 6.28 mmol, 95%) as a colourless oil; Rf 0.26 (1:1 petrol–EtOAc); 
[α]D19 +21.5 (c 0.5, CHCl3); δH (500 MHz, CDCl3); 7.36-7.26 (5H, m, Benzyl Ar-H), 5.15 (1H, 
br s, N-H), 5.11 (2H, s, Benzyl-H), 3.93 (1H, m, 2-H), 3.36 (1H, m, 1-Ha), 3.07 (1H, dd, J 13.4 
and 6.0 , 1-Hb), 2.10 (1H, s, O-H), 1.20 (3H, d, J 6.2, 3-H); δC (75 MHz, CDCl3); 136.4 (benzyl 
Ar 1-C), 128.6 (benzyl Ar 3-C and benzyl Ar 5-C), 128.2 (benzyl Ar 2-C and benzyl Ar 6-C), 
128.2 (benzyl Ar 4-C), 67.5 (2-C), 66.9 (benzyl-C), 48.3 (1-C), 20.7 (3-C); νmax/cm−1 (film); 
3308, 1681, 1526, 1261, 1150; m/z (ESI) 232.1 (100%, MNa+); HRMS found MNa+, 
232.0946. C11H15NO3 requires MNa, 232.0944).  
tert-Butyl-N-(1,3-dihydroxypropan-2-yl)carbamate, 25887 
 
By general procedure I, 2-amino-1,3-propanediol (4.00 g, 43.9 mmol), gave the carbamate 
258 (7.46 g, 39.0 mmol, 89%) as a colourless solid; Rf 0.12 (1:1 petrol–EtOAc);  δH (300 
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MHz, CDCl3); 5.32 (1H, d, J 7.5, N-H), 3.85-3.65 (5H, m, 1-H, 2-H and 3-H), 2.97 (2H, br s, 2 × 
O-H), 1.45 (9H, s, tBu-H); δC (75 MHz, CDCl3); 154.0 (carbamate-C), 80.2 (tBu-C), 63.5 (1-C 
and 3-C), 53.0 (2-C), 28.4 (tBu-C); νmax/cm−1 (film);3324, 2943, 1686, 1536, 1366, 1171; 
m/z (ESI) 214.1 (100%, MNa+); HRMS found MNa+, 214.1050. C8H17NO4 requires MNa, 
214.1050.  
(2R)-2-{[(tert-Butoxy)carbonyl]amino}-3-hydroxypropyl acetate, 25987 
 
Porcine pancreatic lipase (PPL, 2.93 g) was added to a solution of the carbamate 258 (4.00 
g, 20.9 mmol) in vinyl acetate (100 mL) and the resulting suspension was stirred at rt for 2 
h. The reaction mixture was filtered and the filtrate concentrated in vacuo to give a crude 
product. Purification by column chromatography, eluting with 1:1 petrol–EtOAc, gave the 
acetate 259 (4.80 g, 20.6 mmol, 98%) as a colourless oil; Rf 0.38 (1:1 petrol–EtOAc); [α]D19 
+4.8 (c 0.4, CHCl3); δH (300 MHz, CDCl3); 4.98 (1H, br d, J 7.8, N-H), 4.20 (2H, d, J 5.7, 1-H), 
3.89 (1H, m, 2-H), 3.66 (2H, m, 3-H), 2.52 (1H, br s, O-H), 2.10 (3H, s, acetate-H), 1.45 (9H, 
s, tBu-H); δC (75 MHz, CDCl3); 171.5 (acetate), 80.2 (tBu-C), 63.0 (1-C), 62.0 (3-C), 51.0 (2-
C), 28.3 (tBu-C), 20.9 (acetate-C); νmax/cm−1 (film); 3374, 2979, 1693, 1525, 1376, 1244, 
1170; m/z (ESI) 256.1 (100%, MNa+); HRMS found MNa+, 256.1165. C10H19NO5 requires 
MNa, 256.1155.  
(±)-2-{[(tert-Butoxy)carbonyl]amino}-3-hydroxypropyl acetate, 259-rac 
 
Acetic anhydride (0.11 mL, 1.16 mmol) was added dropwise to a solution of the carbamate 
258 (191 mg, 1.00 mmol) and triethylamine (0.28 mL, 2.01 mmol) in CH2Cl2 (10 mL) at 0 
°C and the resulting solution stirred for 2 h. The reaction mixture was warmed to rt, 
quenched by the addition of HCl (1 M aq., to pH <2), extracted with CH2Cl2 (3 × 10 mL), 
combined organics washed with brine (20 mL), dried (MgSO4), and concentrated in vacuo 
to give a crude product. Purification by column chromatography, elution with 6:4 petrol–
EtOAc, gave the acetate 259-rac (112 mg, 0.48 mmol, 48%) as a colourless oil; Rf 0.38 (1:1 
petrol–EtOAc); δH (300 MHz, CDCl3); 4.98 (1H, br d, J 7.8, N-H), 4.20 (2H, d, J 5.7, 1-H), 3.89 
(1H, m, 2-H), 3.66 (2H, m, 3-H), 2.52 (1H, br s, O-H), 2.10 (3H, s, acetate-H), 1.45 (9H, s, 
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tBu-H); δC (75 MHz, CDCl3); 171.5 (acetate carbonyl-C), 80.2 (tBu-C), 63.0 (1-C), 62.0 (3-C), 
51.0 (2-C), 28.3 (tBu-C), 20.9 (acetate-C); νmax/cm−1 3372, 2978, 1695, 1525, 1376, 1243, 
1170; m/z (ESI) 256.1 (100%, MNa+); HRMS found MNa+, 256.1165. C10H19NO5 requires 
MNa, 256.1155.  
(2S)-3-(Acetyloxy)-2-{[(tert-butoxy)carbonyl]amino}propyl-(2’S)-3’,3’,3’-trifluoro-
2’-methoxy-2’-phenylpropanoate, 260 
 
(+)-MTPA chloride (37μL, 0.19 mmol) was added to a stirred solution of acetate 259 (23 
mg, 0. 9 mmol), triethylamine (28 μL, 2.0 mmol) and DMAP (1.0 mg, 8.0 mmol) in CH2Cl2 (2 
mL) at 0 °C and the resulting solution stirred for 1 h. The reaction mixture was 
concentrated in vacuo to give a crude product. Purification by column chromatography, 
eluting with 7:3 petrol–EtOAc, gave the ester 260 (33 mg, 0.7 mg, 75%) as a colorless oil; 
Rf 0.85 (1:1 petrol–EtOAc); δH (500 MHz, CDCl3); 7.50-7.49 (2H, m, phenyl 3-H and phenyl 
5-H), 7.43-7.40 (3H, m, phenyl 2-H, phenyl 4-H and phenyl 6-H), 7.60 (1H, br d, J 8.3, N-H), 
4.39 (2H, d, J 5.1, 3-H), 4.20 (1H, m, 2-H), 4.10 (1H, dd, J 11.4 and 5.1, 1-Ha), 4.05 (1H, dd, J 
11.4 and 5.5, 1-Hb), 3.54 (3H, s, OMe-H), 2.05 (3H, s, acetate-H), 1.43 (9H, s, tBu -H); δC (75 
MHz, CDCl3); 170.6 (acetate carbonyl-C), 166.3 (1’-C), 154.9 (tBu carbonyl-C), 131.9 
(phenyl 1-C), 129.8 (ester-C), 128.6 (phenyl 2-C and phenyl 6-C), 127.2 (phenyl 3-C and 
phenyl 5-C), 125.1 (phenyl 4-C), 125.1 (q, 1JC-F 288, 3’-C), 80.3 (tBu-C), 64.5 (1-C), 63.0 (3-
C), 55.5 (OMe-C), 48.2 (2-C), 28.3 (tBu-C), 20.7 (acetate-C); νmax/cm−1 (film); 3363, 2979, 
1751, 1717, 1513, 1237, 1169; m/z (ESI) 472.2 (100%, MNa); HRMS found MNa+, 
472.1569, C20H26F3NO7 requires MNa, 472.1554. 
3-(Acetyloxy)-2-{[(tert-butoxy)carbonyl]amino}propyl(2’S)-3’,3’,3’-trifluoro-2’-
methoxy-2’-phenylpropanoate, 260-rac 
 
(+)-MTPA chloride (37μL, 0.19 mmol) was added to a stirred solution of acetate 259-rac 
(23 mg, 0. 9 mmol), triethylamine (28 μL, 2.0 mmol) and DMAP (1.0 mg, 8.0 mmol) in 
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CH2Cl2 (2 mL) at 0 °C and the resulting solution stirred for 1 h. The reaction mixture was 
concentrated in vacuo to give a crude product. Purification by column chromatography, 
eluting with 7:3 petrol–EtOAc, gave the ester 260-rac (33 mg, 0.7 mmol, 75%, 1:1 mixture 
of diasteroisomers) as a colorless oil; Rf 0.85 (1:1 petrol–EtOAc);  δH (500 MHz, CDCl3) 
7.55-7.45 (4H, m, D1 and D2  Ar 2-H and 6), 7.46-7.36 (6H, m, D1 and D2 Ar 3-H, 4 and 5), 
4.73 (1H, d, J 8.2, D2 NH), 4.69 (1H, d, J 8.5, D1 NH), 4.44 (1H, dd, J 11.2 and 5.0, D2 3-Ha), 
4.38 (2H, app. d, J 5.1, D1 3-H), 4.33 (1H, dd, J 10.9 and 5.3, D2 3-Hb), 4.20-4.19 (2H, m, D1 
and D2 2-H), 4.13-4.01 (4H, m, D1 and D2 1-H), 3.54 (3H, d, J 0.8, D1 OMe), 3.53 (3H, d, J 
0.7, D2 OMe), 2.05 (6H, s, D1 and D2 OAc), 1.43 (18H, s, D1 and D2 tBu); δC (75 MHz, 
CDCl3) 170.6 (C-OAc), 166.3 (1’-C), 154.9 (carbamate), 131.9 (Ar 1-C), 129.8 (Ar 2-C and 
6), 128.6 (Ar 3-C and 5), 127.3 (Ar C- 4), 123.2  (q, J 77.9, CF3), 84.9 (C’-C), 80.3 (tBu), 64.5 
(1-C), 63.0 (3-C), 55.5 (OMe), 48.2 (2-C), 28.3 (tBu-C), 20.7 (C-OAc); νmax/cm−1 (film); 3364, 
2980, 1750, 1717, 1516, 1368, 1236, 1169; m/z (ESI) 472.2 (100%, MNa); HRMS found 
MNa+, 472.1568, C20H26F3NO7 requires MNa, 472.1559. 
tert-Butyl-N-(1,3-dihydroxypropan-2-yl)carbamate, 254a 
 
By general procedure I, (2R)-3-amino-1,2-propanediol (4.00 g, 43.9 mmol), gave the 
carbamate 254a (7.79 g, 40.7 mmol, 93%) as colourless oil; Rf 0.10 (1:1 petrol–EtOAc); 
[α]D19 −8.3 (c 1.4, CHCl3); δH (300 MHz, CDCl3); 5.10 (1H, br s, NH), 3.82-3.69 (1H, m, 2-H), 
3.68-3.48 (2H, m, 3-H), 3.33-3.18 (4H, m, 1-H and 2 × OH), 1.45 (9H, s, tBu); δC (75 MHz, 
CDCl3) 80.2 (C-tBu), 71.4 (2-C), 63.6 (3-C), 42.8 (1-C), 28.3 (C-tBu) [Carbonyl was not 
observed]; νmax/cm−1 (film); 3357, 2978, 1689, 1528, 1367, 1172; m/z (ESI) 214.1 (100%, 
MNa+); HRMS found MNa+, 214.1052. C8H17NO4 requires MNa, 214.1050.  
tert-Butyl-N-[(2R)-3-[(tert-butyldimethylsilyl)oxy]-2-hydroxypropyl]carbamate, 
254 
 
TBSCl (7.02 g, 46.6 mmol) was slowly added to a stirred solution of the carbamate 254a 
(7.79 g, 40.7 mmol) and imidazole (4.50 g, 66.1 mmol) in CH2Cl2 (55 mL) at 0 °C and the 
resulting solution was stirred at rt for 2 h. The reaction was quenched with HCl (1 M, aq., 
to pH<2), extracted with CH2Cl2 (3 × 20 mL), dried (MgSO4) and concentrated in vacuo to 
give a crude product. Purification by column chromatography, gradient elution with 9:1 to 
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7:3 petrol–EtOAc, gave the carbamate 254 (12.4 g, 40.7 mmol, >98%.) as a colourless oil; 
Rf 0.77 (1:1 petrol–EtOAc); [α]D19 +9.5 (c 0.9, CHCl3); δH (500 MHz, CDCl3); 4.88 (1H, br s, N-
H), 3.66 (1H, m, 2-H), 3.57 (1H, dd, J 10.1 and 4.6, 3-Ha), 3.46 (1H, dd, J 10.1 and 6.2, 3-Hb), 
3.27 (1H, m, 1-Ha), 3.06 (1H, ddd, J 12.0, 6.7 and 5.3, 1-Hb), 2.75 (1H, d, J 3.8, O-H), 1.37 
(9H, s, tBuO-H), 0.84 (9H, s, tBuSi -H), 0.00 (6H, s, 2 × MeSi-H); δC (75 MHz, CDCl3); 80.2 
(tBuO -C), 71.2 (2-C), 64.8 (3-C), 43.3 (1-C), 28.4 (tBuO-C), 25.9 (tBuSi-C), 18.3 (tBuSi-C), -
5.44 (2 × MeSi-C); νmax/cm−1 (solid); 3375, 2930, 1694, 1515, 1253, 1173; m/z (ESI) 328.2 
(100%, MNa+); HRMS found MNa+, 328.1917. C14H31NO4Si requires MNa, 328.1915.  
Benzyl-N-[(2R)-2,3-dihydroxypropyl]carbamate, 256a 
 
By general procedure H, (2R)-3-amino-1,2-propanediol (2.00 g, 22.0 mmol), gave the 
carbamate 256a (3.84 g, 17.0 mmol, 78%) as colourless soild; Rf 0.08 (1:1 petrol–EtOAc); 
δH (500 MHz, CDCl3) 7.39-7.27 (5H, m, Ar-H), 5.37 (1H, br s, N-H), 5.09 (2H, s, benzyl-H), 
3.75 (1H, m, 2-H), 3.65-3.56 (1H, m, 3-Ha), 3.56-3.48 (1H, m, 3-Hb), 3.37-3.30 (1H, m, 1-Ha), 
3.30-3.20 (2H, m, 3-Hb and OH), 3.07 (1H, s, OH); δC (75 MHz, CDCl3) 157.7 (carbamate), 
136.2 (Ar 1-C), 128.6 (Ar C), 128.3 (Ar C), 128.2 (Ar C), 71.2 (2-C), 67.2 (benzyl C), 63.7 (3-
C), 43.2 (1-C); νmax/cm−1 (solid); 3333, 2933, 1691, 1539, 1219; m/z (ESI) 248.1 (100%, 
MNa+); HRMS found MNa+, 248.0896. C11H15NO4 requires MNa, 248.0893.  
 
Benzyl-N-[(2R)-3-[(tert-butyldimethylsilyl)oxy]-2-hydroxypropyl]carbamate, 256 
 
TBSCl (3.31 g, 22.0 mmol) was slowly added to a stirred solution of the carbamate 256a 
(4.71 g, 20.9 mmol) and imidazole (2.14 g, 31.4 mmol) in CH2Cl2 (45 mL) at 0 °C and the 
resulting solution was stirred at rt for 2h. The reaction was quenched with HCl (1 M, aq., to 
pH<2), extracted with CH2Cl2 (3 × 20 mL), dried (MgSO4) and concentrated in vacuo to give 
a crude product. Purification by column chromatography, gradient elution with 9:1 to 7:3 
petrol–EtOAc, gave the carbamate 256 (6.10 g, 18.0 mmol, 83%) as a colourless oil; Rf 0.64 
(1:1 petrol–EtOAc); [α]D19 +9.4 (c 1.5, CHCl3); δH (300 MHz, CDCl3); 7.28 (5H, m, benzyl Ar-
H), 5.12 (1H, br s, N-H), 5.04 (2H, s, benzyl-H), 3.68 (1H, m, 2-H), 3.58 (1H, dd, J 10.1 and 
4.4, 3-Ha), 3.46 (1H, dd, J 10.1 and 6.2, 3-Hb), 3.36 (1H, ddd, J 13.9, 6.7 and 3.67, 1-Ha), 3.12 
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(1H, ddd, J 13.9, 6.9, 5.2, 1-Hb), 2.68 (1H, d, J 4.3, O-H), 0.83 (9H, s, tBu-H), 0.00 (6H, s, 2 × 
MeSi-H); δC (75 MHz, CDCl3); 136.5 (Ar 1-C), 128.5 (Ar  3-C and Ar 5-C), 128.1 (Ar 2-C and 
Ar-6C), 128.1 (Ar 5-C), 71.0 (2-C), 66.8 (benzyl-C), 64.7 (3-C), 43.7 (1-C), 25.8 (tBu-C), 18.2 
(tBu-C), -5.5 (2 × MeSi-C); νmax/cm−1 (solid) [carbonyl was not observed]; 3346, 2929, 
1706, 1532, 1256; m/z (ESI) 362.2 (100%, MNa+); HRMS found MNa+, 362.1773. 
C17H29NO4Si requires MNa, 362.1758.  
tert-Butyl-N-(3-hydroxypropyl)carbamate, 245102 
 
By general procedure I, 3-amino-1-propanol (756 mg, 10.0 mmol), gave the carbamate 
245 (1.76 g, 9.54 mmol, 97%) as a colourless oil; Rf 0.36 (1:1 petrol–EtOAc); δH (300 MHz, 
CDCl3); 4.78 (1H, br s, N-H), 3.67 (2H, br s, 3-H), 3.28 (2H, q, J 6.05, 1-H), 2.97 (1H, br s, O-
H), 1.67 (2H, app. q, J 5.9, 2-H), 1.45 (9H, s, tBu-H); δC (75 MHz, CDCl3); 79.6 (tBu-C), 59.2 
(3-C), 36.9 (1-C), 32.9 (2-C), 28.4 (tBu-C) ; νmax/cm−1 (film); 3355, 2978, 1690, 1528, 1367, 
1173; m/z (ESI) 198.1 (100%, MNa+); HRMS found MNa+, 198.1106. C8H17NO3 requires 
MNa, 198.1101.  
tert-Butyl-2,2-dioxo-1,2,3-oxathiazolidine-3-carboxylate, 200103 
 
By general procedure F, the carbamate 197 (3.00 g, 18.6 mmol) gave the sulfamidate 200 
(3.56 g, 15.9 mmol, 86%) as a colourless oil (solidified on standing) which required no 
further purification; Rf  0.74 (1:1 petrol–EtOAc); δH (300 MHz, CDCl3); 4.62 (2H, t, J 6.4, 5-
H), 4.05 (2H, t, J 6.4, 4-H), 1.56 (9H, s, tBu-H); δC (75 MHz, CDCl3); 148.6 (carbamate 
carbonyl-C), 85.6 (tBu-C), 65.6 (5-C), 45.3 (4-C), 27.9 (tBu-C); νmax/cm−1 (film) 2989, 1719, 
1477, 1373, 1156; m/z (ESI) 246.0 (100%, MNa+);  HRMS found MNa+, 246.0411. 
C7H13NO5S requires MNa, 246.0407.  
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Benzyl-2,2-dioxo-1,2,3-oxathiazolidine-3-carboxylate, 199103 
 
By general procedure F, the carbamate 196 (6.00 g, 30.7 mmol) gave the sulfamidate 199 
(6.85 g, 26.6 mmol, 87%) as a colourless oil (solidified on standing) which required no 
further purification; Rf  0.72 (1:1 petrol–EtOAc); δH (500 MHz, CDCl3); 7.42-7.34 (5H, m, Ar-
H), 5.32 (2H, s, benzyl-H), 4.63 (2H, t, J 6.5, 5-H), 4.09 (2H, t, J 6.5, 4-H); δC (75 MHz, CDCl3); 
149.8 (carbamate carbonyl-C), 134.4 (Ar 1-C), 128.8 (Ar 3-C and Ar 5-C), 128.7 (Ar 2-C and 
Ar 6-C), 128.1 (Ar 4-C), 69.5 (benzyl-C), 66.0 (5-C), 45.6 (4-C); νmax/cm−1 (film) 3035, 2983, 
1732, 1454, 1323, 1144; m/z (ESI) 280.0 (100%, MNa); HRMS found MNa+, 280.0257. 
C10H11NO5S requires MNa, 280.0250.  
3-Benzyl-1,2,3-oxathiazolidine-2,2-dione, 198 
 
By general procedure F, the amine 195 (3.00 g, 19.8 mmol) gave the sulfamidate 198 
(2.62 g, 12.3 mmol, 66%) as a colourless oil (solidified on standing) which required no 
further purification; Rf  0.77 (1:1 petrol–EtOAc);  δH (300 MHz, CDCl3); 7.38 (5H, m, Ar-H), 
4.52 (2H, t, J 6.5, 5-H), 4.24 (2H, s, X-H), 3.39 (2H, t, J 6.5, 4-H); δC (75 MHz, CDCl3); 134.3 
(Ar 1-C), 128.9 (Ar 3-C and Ar 5-C), 128.7 (Ar 2-C and Ar 6-C), 128.6 (Ar 4-C), 66.8 (5-C), 
51.5 (benzyl), 47.2 (4-C); νmax/cm−1 (film) 3034, 2914, 1456, 1331, 1214; m/z (ESI) 236.0 
(100%, MNa+); HRMS found MNa+, 236.0352. C9H11NO3S requires MNa, 236.0352.  
Benzyl(4S)-4-benzyl-2,2-dioxo-1,2,3- oxathiazolidine-3-carboxylate, 251 
 
By general procedure F, the carbamate 247 (1.50 g, 5.26 mmol) gave the sulfamidate 251 
(1.63 g, 4.90 mmol, 93%) as a colourless oil (solidified on standing) which required no 
further purification; Rf  0.67 (1:1 petrol–EtOAc); [α]D22 -34.5 (c 1.7, MeOH); δH (500 MHz, 
CDCl3); 7.45-7.24 (9H, m, 9 × Ph-H), 7.20 (1H, m, Ph-H), 5.33 (2H, s, Cbz benzyl-H), 4.50 
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(1H, app. d, J 3.0, 4-H), 4.48 (1H, app. d, J 2.6, 5-Ha), 4.40-4.32 (1H, m, 5-Hb),  3.38 (1H, br d, 
J 13.7, benzyl-Ha), 2.94 (1H, dd, J 13.4 and 10.0, benzyl-Ha); δC (75 MHz, CDCl3); 149.7 (Ar-
C), 134.8 (Ar -C), 134.4 (Ar -C), 129.4 (Ar -C), 129.1 (Ar -C), 128.7 (Ar -C), 128.0 (Ar -C), 
127.6 (Ar -C), 69.5 (Cbz benzyl-C), 69.0 (5C), 59.0 (4-C), 37.7 (benzyl-C); νmax/cm−1 (film) 
3032, 2928, 1740, 1383, 1308, 1193; m/z (ESI) 370.2 (100%, MNa+). 
 
tert-Butyl-2,2-dioxo-3-oxa-2-thia-1-azaspiro[5.5]nonane-1-carboxylate, 256   
 
By general procedure F, the carbamate 246 (3.00 g, 12.6 mmol) gave the sulfamidate 256 
(3.62 g, 12.1 mmol, 96%) as a colourless oil (solidified on standing) which required no 
further purification; Rf 0.87 (1:1 petrol‒EtOAc); [α]D19 +47.7 (c 0.5, CHCl3); δH (300 MHz, 
CDCl3); 7.42-7.39 (5H, m, phenyl-H), 5.28 (1H, dd, J 6.7 and 4.3, 4-H), 4.88 (1H, dd, J 6.7 and 
9.2, 5-Ha), 4.41 (1H, dd, J 9.3 and 4.3, 5-Hb), 1.44 (9H, s, tBu-H); δC (75 MHz, CDCl3); 129.3 
(Ar 3-C and Ar 5-C), 129.1 (Ar 4-C), 126.2 (Ar 2-C and Ar 6-C), 85.6 (tBu-C), 71.8 (5-C), 
60.8 (4-C), 27.8 (tBu-C) [Ar 1-C was not observed]; νmax/cm−1 (film) 2976, 1723, 1326, 
1189, 1155; m/z (ESI) 322.1 (100%, MNa+); HRMS found MNa+, 322.0727. C13H17NO5S 
requires MNa, 322.0720. 
Benzyl-(5S)-5-methyl-2,2-dioxo-1,2,3-oxathiazolidine-3-carboxylate, 252 
 
By general procedure F, the carbamate 248 (1.20 g, 5.74 mmol) gave the sulfamidate 252 
(1.43 g, 5.28 mmol, 89%) as a colourless oil (solidified on standing) which required no 
further purification; Rf 0.72 (1:1 petrol‒EtOAc); [α]D19 −36.0 (c 0.5, CHCl3); δH (300 MHz, 
CDCl3); 7.43-7.34 (5H, m, Ar-H), 5.32 (2H, s, benzyl-H), 5.01 (1H, m, 5-H), 4.15 (1H, dd, J 5.6 
and 10.0, 4-Ha), 3.7 (1H, app. t, J 9.8, 4-Hb), 1.60 (3H, d, J 6.2, Me-H); δC (75 MHz, CDCl3); 
128.7 (Ar 2-C, Ar 3-C, Ar 5-C and Ar 6-C), 128.1 (Ar 4-C), 80.3 (5-C), 69.4 (benzyl-C), 52.0 
(4-C), 18.0 (Me-C) [Ar 1-C was not observed]; νmax/cm−1 (film) 2926, 1743, 1403, 1323, 
1196; m/z (ESI) 289.1 (100%, MNH4+); HRMS found MNH4+, 289.0861. C11H13NO5S 
requires MNH4, 289.0853.  
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tert-Butyl-(4S)-4-[(acetyloxy)methyl]-2,2-dioxo-1,2,3-oxathiazolidine-3-
carboxylate, 243 
 
By general procedure F, the carbamate 259 (1.17 g, 5.02 mmol) gave the sulfamidate 242 
(1.03 g, 3.49 mmol, 69%) as a colourless oil (solidified on standing) which required no 
further purification; Rf 0.69 (1:1 petrol‒EtOAc); [α]D19 15.4 (c 0.6, MeOH); δH (300 MHz, 
CDCl3); 4.68 (1H, dd, J 9.7 and 6.3, 5-Ha), 4.57-4.40 (3H, m, 5-Hb, 4-H and methylene-Ha), 
4.30 (1H, dd, J 11.3 and 3.6, methylene-Hb), 2.12 (3H, s, acetyl-H), 1.57 (9H, s, tBu-H); δC 
(75 MHz, CDCl3); 170.6 (acetyl carbonyl-C), 148.3 (carbamate carbonyl-C), 86.1 (tBu-C), 
67.6 (5-C), 61.5 (methylene-C), 55.0 (4-C), 27.9 (tBu-C), 20.7 (acetyl-C); νmax/cm−1 (film) 
2984, 1727, 1530, 1336, 1219; m/z (ESI) 318.1 (100%, MNa+); HRMS found MNa+, 
318.0626. C10H17NO7S requires MNa, 318.0618.  
tert-Butyl-(5R)-5-{[(tert-butyldimethylsilyl)oxy]methyl}-2,2-dioxo-1,2,3-
oxathiazolidine-3-carboxylate, 242 
 
By general procedure F, the carbamate 256 (10.0 g, 32.7 mmol) gave the sulfamidate 242 
(10.89 g, 29.6 mmol, 90%) as a colourless oil (solidified on standing) which required no 
further purification; Rf 0.95 (1:1 petrol‒EtOAc); [α]D19 +10.6 (c 0.6, CHCl3); δH (500 MHz, 
CDCl3); 4.71 (1H, m, 5-H), 3.90 (1H, dd, J 10.0, 6.4, methylene-Ha), 3.85-3.79 (3H, m, 4-H 
and methylene-Hb), 1.46 (9H, s, tBuO-H), 0.81 (9H, s, tBuSi-H), 0.00 (6H, s, 2 × CH3Si-H); δC 
(75 MHz, CDCl3); 85.5 (tBuO-C), 78.0 (5-C), 61.7 (methylene-C), 45.6 (4-C), 27.9 (tBuO-C), 
25.7 (tBuSi-C), 18.2 (tBuSi-C), -5.45 (2 × CH3Si -C); νmax/cm−1 (film) 2932, 1747, 1475, 
1397, 1261, 1105; m/z (ESI) 385.2 (100%, MNH4+); HRMS found MNH4+, 385.1843. 
C14H29NO6SSi requires MNH4, 385.1823.  
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tert-Butyl-(5R)-5-{[(tert-butyldimethylsilyl)oxy]methyl}-2,2-dioxo-1,2,3-
oxathiazolidine-3-carboxylate, 244 
 
By general procedure F, the carbamate 256 (6.03 g, 17.7 mmol) gave the sulfamidate 244 
(6.51 g, 16.2 mmol, 92%) as a colourless oil (solidified on standing) which required no 
further purification; Rf 0.92 (1:1 petrol‒EtOAc); [α]D22 7.7 (c 1.3, CHCl3); δH (500 MHz, 
CDCl3); 7.39-7.19 (5H, m, Ar-H), 5.33 (1H, s, benzyl-H), 4.77 (1H, ddt, J 8.7, 6.3, 4.5, 5-H), 
4.00-3.87 (2H, m, methylene-H), 3.87-3.78 (2H, m, 4-H), 0.81 (9H, s, tBu-H), 03.00 (6H, s, 2 
× CH3Si-H); δC (75 MHz, CDCl3); 148.8 (carbamate carbonyl-C), 133.3 (Ar 1-C), 127.8 (Ar 3-
C and Ar 50C), 127.7 (Ar 2-C and Ar 6-C), 127.1 (Ar 4-C), 78.1 (5-C), 68.6 (benzyl-C), 60.0 
(methylene-C), 45.2 (4-C), 24.7 (tBu-C), -3.93 (2 × CH3Si-C); νmax/cm−1 (film) 3523, 2932, 
1716, 1373, 1335, 1196; m/z (ESI) 424.1 (100%, MNa+); HRMS found MNa+, 424.1227. 
C17H27NO6S requires MNa, 424.1221.  
tert-Butyl-2,2-dioxo-1,2,3-oxathiazinane-3-carboxylate, 249103 
 
By general procedure F, the carbamate 245 (1.77 g, 10.1 mmol) gave the sulfamidate 249 
(1.97 g, 8.32 mmol, 82%) as a colourless oil (solidified on standing) which required no 
further purification; Rf 0.74 (1:1 petrol‒EtOAc); δH (500 MHz, CDCl3); 4.67 (2H, t, J 6.0, 6-
H), 4.03-3.98 (2H, m, 4-H), 2.12-2.06 (2H, m, 5-H), 1.53 (9H, s, tBu-H); δC (75 MHz, CDCl3); 
150.4 (carbonyl), 85.0 (tButyl-C), 73.2 (6-C), 45.9 (4-C), 27.9 (tBu-C), 23.7 (5-C); νmax/cm−1 
(film)2983, 1728, 1426, 13872, 1065; m/z (ESI) 260.1 (100%, MNa+); HRMS found MNa+, 
260.0564. C8H15NO5S requires MNa, 260.0563.  
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Benzyl(pent-4-yn-1-yl)amine, 21077 
 
DEAD (3.67 mL, 23.2 mmol) was added dropwise to a solution of 4-pentyn-1-ol (2.16 mL, 
23.2 mmol), the sulfonamide 221 (4.52 g, 15.5 mmol) and triphenylphosphine (6.08 g, 
23.2 mmol) in THF (30 mL) at 0 °C and the resulting solution was warmed to rt and stirred 
for 6 h. Th reaction mixture was concentrated in vacuo to give a crude intermediate. 
Partial purification by filtration over SiO2, eluting with CH2Cl2 gave an intermediate 
sulfonamide. PhSH (6.37 mL, 62.0 mmol) was added to a suspension of the sulfonamide 
intermediate and K2CO3 (8.60 g, 62.0 mmol) in MeCN (30 mL) and the resulting mixture 
was stirred for 24 h. The reaction mixture was acidified with HCl (2M aq. soln., to pH<2) 
extracted with EtOAc (3 × 20 mL), basified with K2CO3 (sat. aq. soln., to pH >12) extracted 
with CH2Cl2 (3 × 20 mL), washed with brine, dried (MgSO4) and concentrated in vacuo to 
give a crude product. Purification by column chromatography, gradient elution 100% 
CH2Cl2 to 10:1 CH2Cl2‒MeOH, gave the amine 210 (1.95 g, 11.3 mmol, 73% over two steps) 
as a light brown oil: Rf  0.40 (EtOAc); δH (500 MHz, CDCl3); 7.37-7.28 (4H, m, Ar 2-H, Ar 3-H, 
Ar 5-H and Ar 6-H), 7.28-7.20 (1H, m, 4-H), 3.80 (2H, s, benzyl-H), 2.75 (2H, t, J 7.0, 1-H), 
2.27 (2H, td,  J 7.1, 2.1, 3-H), 1.94 (1H, t, J 2.7, 5-H), 1.73 (2H, p, J 7.0, 2-H), 1.42 (1H, br s, N-
H); δC (75 MHz, CDCl3); δ 140.5 (Ar-C), 128.4 (Ar-C), 128.0(Ar-C), 126.9(Ar-C), 84.1(4-C), 
68.5 (5-), 53.9 (benzyl), 48.2 (1-C), 28.7 (2-C), 16.3 (3-C); νmax/cm−1 (film) 3300, 2938, 
1648, 1495, 1453, 1217; m/z (ESI) 174.1 (100%, MH+); HRMS found MH+, 174.1278. 
C12H15N requires MH, 174.1277.  
tert-Butyl-N-[2-(prop-2’-yn-1’-yloxy)ethyl]carbamate, 205 
 
By general procedure G, the sulfamidate 200 (1.00 g, 4.50 mmol) and propargyl alcohol 
(0.4 mL mg, 6.7 mmol) gave a crude product. Purification by column chromatography, 
eluting with 7:3 petrol–EtOAc, gave the carbamate 205 (684 mg, 3.43 mmol, 77%) as a 
colourless oil; Rf 0.76 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3); 4.92 (1H, br s, N-H), 4.16 
(2H, d, J 2.4, 1’-H), 3.59 (2H, t, J 5.1, 2-H), 3.34 (2H, dd, J 10.6, 5.3, 1-H), 2.45 (1H, t, J 2.4, 3’-
H), 1.45 (9H, s, tBu-H); δC (75 MHz, CDCl3); 155.9 (carbamate-C), 79.4 (2’-C), 79.3 (tBu-C), 
74.6 (3’-C), 69.1 (2-C), 58.3 (1’-C), 40.3 (1-C), 28.4 (tBu-C); νmax/cm−1 (film) 3357, 2933, 
2116, 1708, 1514, 1366, 1215, 1173; m/z (ESI) 222.1 (100%, MNa+); HRMS found MNa+, 
222.1099. C10H17NO3 requires MNa, 222.1101.  
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tert-Butyl-N-{2-[N-(prop-2’-yn-1’-yl)(2-nitrobenzene)sulfonamido]ethyl}carbamate, 
208 
 
 
By general procedure G, the sulfamidate 200 (1.00 g, 4.48 mmol) and the sulfonamide o-
202 (1.61 g, 6.70 mmol) gave a crude product. Purification by column chromatography, 
eluting with 50:1 CH2Cl2–MeOH, gave the carbamate 208 (1.72 g, 4.49 mmol, >98%) as a 
light brown oil; Rf 0.52 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3); 8.11-8.00 (1H, m, Ar 3-H), 
7.77-7.59 (3H, m, Ar 4-H, Ar 5-H and Ar 6-H), 4.80 (1H, br s, N-H), 4.26 (2H, d, J 2.3, 1’-H), 
3.53 (2H, t, J 5.9, 2-H), 3.37 (2H, dd, J 11.4 and 5.6, 1-H), 2.20 (1H, t, J 2.20, 3’-H), 1.43 (9H, 
s, tBu-H); δC (75 MHz, CDCl3); 156.0 (carbamate-C), 148.2 (sulfonamide 2-C), 133.9 
(sulfonamide 4-C), 132.5 (sulfonamide 1-C), 131.8 (sulfonamide 5-C), 131.0 (sulfonamide 
6-C), 124.2 (sulfonamide 3-C), 79.7 (tBu-C), 77.2 (2’-C), 74.2 (3’-C), 46.6 (2-C), 37.9 (1-C), 
36.9 (1’-C), 28.3 (tBu-C); νmax/cm−1 (film) 3407, 3265, 2123, 1711, 1532, 1360, 1143; m/z 
(ESI) 406.1 (100%, MNa+); HRMS found MNa+, 406.1060. C16H21N3O6S requires MNa, 
406.1043.  
Benzyl[2-(prop-2’-yn-1’-yloxy)ethyl]amine, 204 
 
By general procedure G, the sulfamidate 198 (1.00 g, 4.48 mmol) and propargyl alohol 
(0.40 mL, 6.87 mmol) gave a crude product. Purification by SCX gave the amine 204 (684 
mg, 3.43 mmol, 77%) as a colourless oil; Rf 0.1 (1:1 petrol‒EtOAc); δH (500 MHz, CDCl3); 
7.38-7.29 (5H, m, Ar-H), 4.16 (2H, d, J 2.4, 1’-H), 3.87 (2H, s, benzyl-H), 3.67 (2H, app. t, J 
5.2, 2-H), 2.88 (2H, app. t, J 5.1 1-H), 2.42 (1H, t, J 2.3, 3’-H); δC (75 MHz, CDCl3); 138.8 (Ar 
1-C), 128.5 (Ar 3-C and Ar 5-C), 128.5 (Ar 2-C and Ar 6-C), 127.3 (Ar4-C), 79.6 (2’-C), 74.5 
(3’-C), 68.7 (2-C), 58.3 (1’-C), 53.4 (benzyl-C), 48.1 (1-C); νmax/cm−1 (film)3288, 2924, 
1605, 1454, 1103; m/z (ESI) 190.1 (100%, MH+); HRMS found MH+, 190.1235. C12H15NO 
requires MH, 190.1226.  
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N-[2-(Benzylamino)ethyl]-2-nitro-N-(prop-2’-yn-1’-yl)benzene-1-sulfonamide, 207 
 
By general procedure G, the sulfamidate 198 (300 mg, 1.52 mmol) and sulfonamide o-202 
(731 mg, 3.04 mmol) gave a crude product. Purification by SCX gave the carbamate 207 
(154 mg, 0.41 mmol, 27%) as a colourless oil; Rf 0.61 (1:1 petrol‒EtOAc); δH (500 MHz, 
CDCl3); 8.06 (1H, dd, J 7.0 and 2.1, Ar 3-H), 7.71-7.62 (2H, m, Ar 5-H and Ar-6H), 7.62-7.56 
(1Hm, Ar 4-H), 7.35-7.21 (5H, m, Ph-H), 4.25 (2H, d, J 2.2, 1’-H), 3.77 (2H, s, benzyl-H), 3.56 
(2H, t, J 6.1, 1-H), 2.87 (2H, t,  J 6.1, 2-H), 2.16 (2H, t, J 2.2, 3’-H); δC (75 MHz, CDCl3); 148.2 
(sulfonamide 2-C),140.1 (Ph 1-C), 133.9 (sulfonamide 4-C), 132.4 (sulfonamide 1-C), 131.8 
(sulfonamide 5-C), 131.0 (sulfonamide 6-C), 128.5 (Ph-C), 128.1 (Ph-C), 127.1 (Ph-C), 
124.3 (sulfonamide 3-C), 76.8 (2’-C), 74.2 (3’-C), 61.0 (Bn-C), 50.5 (1-C), 46.6 (2-C); 
νmax/cm−1 (film) 3294, 3106, 2125, 1538, 1366, 1163; m/z (ESI) 374.1 (100%, MH+); 
(Found MH+, 374.1166 C18H19N3O4S requires MH, 374.1169). 
Benzyl-N-{2-[N-(prop-2’-yn-1’-yl)(2-nitrobenzene)sulfonamido]ethyl}carbamate, 
209 
 
By general procedure G, the sulfamidate 199 (1.00 g, 3.90 mmol) and sulfonamide o-202 
(1.40 g, 5.83 mmol) gave a crude product. Purification by column chromatography, eluting 
with 7:3 petrol–EtOAc, gave the carbamate 209 (1.54 g, 3.69 mmol, 95%) as a colourless 
solid; Rf 0.39 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3); 8.03 (1H, m, Ar 3-H), 7.67-7.57 (3H, 
m, Ar 4-H, Ar 5-H and Ar 6-H), 7.42-7.27 (5H, m, benzyl-H), 5.05 (3H, br s, N-H and benzyl), 
4.24 (2H, d, J 1.8, 1’-H), 3.62-3.49 (2H, m, 2-H), 3.44 (2H, m, 1-H), 2.20 (1H, br s, 3’-H); δC 
(75 MHz, CDCl3); 156.5 (carbonyl-C), 148.2 (sulfonamide 2-C)  136.4 (benzyl 1-C), 133.9 
(sulfonamide 4-C), 132.4 (sulfonamide 1-C), 131.8 (sulfonamide 5-C), 131.0 (sulfonamide 
6-C), 128.5 (benzyl 3-C and benzyl 5-C), 128.1 (benzyl 2-C and benzyl 6-C), 128.0 (benzyl 
4-C), 124.3 (sulfonamide 3-C), 76.8 (2’-C), 74.2 (3’-C), 66.8 (benzyl-C), 46.6 (2-C), 38.5 (1’-
C), 37.0 (1-C); νmax/cm−1 (film) 3418, 3298, 2122, 1713, 1544, 1359, 1167; m/z (ESI) 440.1 
(100%, MNa+); HRMS found MNa+, 440.0903. C19H19N3O6S requires MNa, 440.0887.  
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Benzyl-N-{2-[N-(pent-2’-yn-1’-yl)(4-nitrobenzene)sulfonamido]ethyl}carbamate, 
263 
 
By general procedure G, the sulfamidate 199 (600 mg, 2.33 mmol) and the sulfonamide p-
235 (750 mg, 2.80 mmol) gave a crude product. Purification by column chromatography, 
eluting with 7:3 petrol–EtOAc, gave the carbamate 263 (946 mg, 2.12 mmol, 91%) as a 
colourless solid; Rf 0.39 (1:1 petrol‒EtOAc); δH (500 MHz, CDCl3); 8.33 (2H, d, J 8.6, Ar 3-H 
and Ar 5-H), 8.04 (2H, d, J 8.6, Ar 2-H and Ar 6-H), 7.42-7.30 (5H, m, benzyl Ar-H), 5.12 
(3H, br s, N-H and benzyl-H), 4.12 (2H, s, 1’-H), 3.43 (2H, dd, J 11.1, 5.5, 1-H), 3.35 (2H, t, J 
5.4, 2-H), 1.92 (2H, q, J 7.4, 4’-H), 0.89 (2H, t, J 7.5, 5’-H); δC (75 MHz, CDCl3); 129.0 
(sulfonamide 2-C and 6-C),  128.6 (benzyl 3-C and  5-C), 128.2 (benzyl 2-C and 6-C), 128.1 
(benzyl 4-C), 124.0 (sulfonamide 3-C and 5-C), 71.3 (2’-C), 66.9 (benzyl-C), 46.2 (2-C), 38.8 
(1’-C), 37.8 (1-C), 13.4 (5’-C), 12.0 (4’-C); νmax/cm−1 (film) 3406, 2978, 2228, 1720, 1531, 
1351, 1167; m/z (ESI) 468.1 (100%, MNa+); HRMS found MNa+, 468.1206. C21H23N3O6S 
requires MNa, 468.1200.  
tert-Butyl-N-{2-[N-(pent-2’-yn-1’-yl)(2-nitrobenzene)sulfonamido]ethyl}carbamate, 
261 
 
By general procedure G, the sulfamidate 200 (300 mg, 1.34 mmol) and the sulfonamide o-
236 (540 mg, 2.01 mmol) gave a crude product. Purification by column chromatography, 
eluting with 50:1 CH2Cl2–MeOH, gave the carbamate 261 (581 mg, 1.32 mmol, >98%) as a 
colourless oil; Rf 0.61 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3); 8.10-8.01 (1H, m, 
sulfonamide 3-H), 7.75-7.62 (3H, m, sulfonamide 4-H, 5-H and 6-H), 4.85 (2H, br s, N-H), 
4.21 (2H, br s, 1’-H), 3.52 (2H, t, J 5.7, 2-H), 3.36 (2H, dt, J 11.3, 5.7, 1-H), 2.03 (2H, qt, J 7.5, 
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2.2, 4’-H), 1.43 (9H, s, tBu-H), 0.98 (3H, t, J 7.5, 5’-H); δC (75 MHz, CDCl3); 133.6 
(sulfonamide 4-C),  132.7 (sulfonamide 1-C), 131.5 (sulfonamide 3-C), 131.0 (sulfonamide 
6-C), 124.1 (sulfonamide 3-C), 88.1 (3’-C), 79.6 (tBu-C), 72.1 (2’-C), 46.5 (2-C), 38.1 (1’-C), 
37.4 (1-C), 28.4 (tBu-C), 13.6 (5’-C), 12.2 (4’-C); νmax/cm−1 (film) 3418, 2979, 2231, 1708, 
1546, 1366, 1168; m/z (ESI) 434.1 (100%, MNa+); HRMS found MNa+, 434.1376. 
C18H25N3O6S requires MNa, 434.1356.  
Benzyl-N-[2-(prop-2’-yn-1’-yloxy)ethyl]carbamate, 206 
 
By general procedure G, the sulfamidate 199 (391 mg, 1.52 mmol) and propoargyl alcohol 
(0.180 mL, 3.04 mmol) gave a crude product. Purification by column chromatography, 
eluting with 7:3 petrol‒EtOAc, gave the carbamate 206 (463 mg, 1.12 mmol, 73%) as a 
colourless oil; Rf 0.55 (1:1 petrol‒EtOAc); δH (500 MHz, CDCl3); 7.41-7.29 (5H, m, benzyl 
Ar-H), 5.13 (1H, br s, N-H), 5.10 (2H, s, benzyl-H), 4.14 (2H, d, J 2.3, 1’-H), 3.60 (2H, t, J 5.0, 
2-H), 3.42 (2H, m, 1-H), 2.43 (1H, t, J 2.4, 3’-H); δC (75 MHz, CDCl3); 136.5 (benzyl 1-C), 
125.5 (benzyl 3-C and 5C), 128.1 (benzyl 2-C, 4-C and 6-C), 79.3 (2’-C), 74.8 (3’-C), 68.9 (2-
C), 66.7 (benzyl-C), 58.3 (1’-C), 40.8 (1-C); νmax/cm−1 (film) 3294, 2940, 2116, 1712, 1528, 
1257, 1102; m/z (ESI) 256.1 (100%, MNa+); HRMS found MNa+, 256.0947. C13H15NO3 
requires MNa, 256.0944.  
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Benzyl-N-[(2S)-1-phenyl-3-[N-(prop-2’-yn-1’-yl)(2-
nitrobenzene)sulfonamido]propan-2-yl]carbamate, 268 
 
By general procedure G, the sulfamidate 240 (348 mg, 1.04 mmol) and the sulfonamide o-
202 (376 mg, 1.57 mmol) gave a crude product. Purification by column chromatography, 
eluting with 7:3 petrol–EtOAc, gave the carbamate 268 (380 mg, 7.49 mmol, 72%) as a 
colourless soild; Rf 0.45 (1:1 petrol‒EtOAc); [α]D19 −47.1 (c 5.0, CHCl3); δH (300 MHz, 
CDCl3); 8.01-7.90 (1H, m, sulfonamide 3-H), 7.69-7.52 (3H, m, sulfonamide 4-H, 5-H and 6-
H), 7.39-7.14 (10H, m, benzyl Ar and phenyl), 5.05 (1H, d,  J 12.4, benzyl-Ha), 5.00 (1H, d, J 
12.4, benzyl-Hb), 4.82 (1H, d, J 9, 2-H), 4.33 (1H, d, J 18.6, 1’-Ha), 4.16 (2H, m, 1’-Hb and N-
H), 3.57 (1H, dd, J 14.5, 10.4, 3-Ha), 3.45 (1H, dd, J 14.5, 4.6, 3-Hb), 2.93-2.77 (2H, m, 1-H), 
2.06 (1H, d, J 2.3, H-3’); δC (75 MHz, CDCl3); 156.2 (sulfonamide-C), 148.1 (phenyl 1-C), 
136.7 (sulfonamide 4-C), 136.4 (benzyl 1-C), 133.7 (phenyl 5-C), 132.7 (sulfonamide 1-C), 
131.7, 130.9 , 129.2, 128.6 (benzyl  3-C and 5-C), 128.5 (benzyl 2-C and 6-C), 128.0 (benzyl 
4-C), 127.9, 126.8, 124.3, 76.3 (2’-C), 74.3 (3’-C), 66.7 (benzyl-C), 49.7 (2-C), 49.4 (1-C), 
39.0 (1’-C), 36.8 (3-C); νmax/cm−1 (film) 3405, 3298, 2123, 1711, 1544, 1360, 1166; m/z 
(ESI) 530.1 (100%, MNa+); HRMS found MNa+, 530.1359. C26H25N3O6S requires MNa, 
530.1356. 
Benzyl-N-[(2R)-2-[N-(prop-2’-yn-1’-yl)(2-
nitrobenzene)sulfonamido]propyl]carbamate, 270 
 
By general procedure G, the sulfamidate 241 (271 mg, 1.00 mmol) and the sulfonamide o-
202 (360 mg, 1.50 mmol) gave a crude product. Purification by column chromatography, 
eluting with 6:4 petrol–EtOAc, gave the carbamate 270 (407 mg, 0.94 mmol, 94%) as a 
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colourless solid; Rf 0.58 (1:1 petrol‒EtOAc); [α]D19 +20.5 (c 3.3, CHCl3); δH (500 MHz, 
CDCl3); 8.12 (1H, d, J 7.7, sulfonamide 3-H), 7.61  (2H, m, sulfonamide 6-H and 4-H), 7.53 
(1H, m, sulfonamide  3-H), 7.42-7.28 (5H, m, benzyl Ar-H), 5.13 (1H, br s, N-H), 5.02 (1H, d, 
J 12.3, benzyl-Ha), 4.98 (1H, d, J 12.3, benzyl-Hb), 4.24-4.06 (3H, m, 1-H and 2-H), 3.40-3.28 
(2H, m, 1’-H), 2.20 (1H, s, 3’-H), 1.24 (3H, d, J 6.8, 3-H); δC (75 MHz, CDCl3); 156.3 
(carbamate-C), 147.7 (sulfonamide 2-C), 136.4 (benzyl 1-C), 133.7 (sulfonamide 4-C), 
133.3 (sulfonamide 5-C), 131.8 (sulfonamide 1-C), 131.6 (sulfonamide 6-C), 128.5 (benzyl 
3-C and 5-C), 128.1 (benzyl 2-C and 6-C), 128.1 (benzyl 4-C), 124.3 (sulfonamide 3-C), 79.7 
(2’-C), 72.8 (3’-C), 66.7 (benzyl-C), 54.1 (2-C), 43.6 (1-C), 31.9 (1’-C), 16.1 (3-C); νmax/cm−1 
(film) 3425, 3294, 2123, 1717, 1543, 1370, 1158; m/z (ESI) 454.1 (100%, MNa+); HRMS 
found MNa+, 454.1062. C20H21N3O6S requires MNa, 454.1043.  
tert-Butyl-N-[(1S)-1-phenyl-2-[N-(prop-2’-yn-1’-yl)(4-
nitrobenzene)sulfonamido]ethyl]carbamate, 269 
 
By general procedure G, the sulfamidate 239 (1.00 g, 3.34 mmol) and the sulfonamide p-
202 (963 mg, 4.01 mmol) gave a crude product. Purification by column chromatography, 
eluting with 7:3 petrol–EtOAc, gave the carbamate 269 (1.08 g, 2.34 mmol, 70%) as a 
colourless solid; Rf 0.84 (1:1 petrol‒EtOAc); [α]D19 –34.5 (c 1.7, MeOH); δH (500 MHz, 
CDCl3); 8.32 (2H, d, J 8.8, sulfonamide 3-H and 5-H), 8.01 (2H, d, J 8.7, sulfonamide 2-H and 
6-H), 7.43-7.34 (2H, m, phenyl 2 –H and 3-H), 7.32-7.30 (3H, m, phenyl 3-H, 4-H and 5-H), 
5.30 (1H, br s, N-H), 4.94 (1H, br s, 1-H), 4.28 (1H, app. d, J 18.2, 1’-Ha), 4.19-4.06 (1H, m, 
1’-Hb), 3.56 (1H, dd, J 14.3, 9.9, 2-Ha), 3.34 (1H, dd, J 14.3, 4.2, 2-Hb), 2.05 (1H, dd, J 5.3, 3.0, 
3’-H), 1.48 (9H, s, tBu-H); δC (75 MHz, CDCl3); 155.5 (carbamate-C), 150.19 (sulfonamide 
4-C), 144.5 (sulfonamide 1-C), 139.2 (phenyl 1-C), 129.0 (sulfonamide 2-C and 6-C), 128.9 
(phenyl 3-C and 5-C), 128.1 (phenyl 4-C), 126.3 (sulfonamide 3-C and 5-C), 124.2 (phenyl 
2-C and 6-C), 80.2 (tBu-C), 75.5 (2,-C), 75.0 (3’-C), 52.0 (1-C), 51.3 (2-C), 36.8 (1’-C), 28.3 
(tBu-C); νmax/cm−1 (film) 3406, 3294, 2979, 2122, 1706, 1531, 1351, 1167; m/z (ESI) 482.1 
(100%, MNa+); HRMS found MNa+, 482.1365. C22H25N3O6S requires MNa, 482.1356.  
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Benzyl-N-{2-[N-(pent-4’-yn-1’-yl)(2-nitrobenzene)sulfonamido]ethyl}carbamate, 
265 
 
By general procedure G, the sulfamidate 199 (200 mg, 0.77 mmol) and sulfonamide o-237 
(313 mg, 1.17 mmol) gave a crude product. Purification by column chromatography, 
eluting with 7:3 petrol–EtOAc, gave the carbamate 265 (305 mg, 0.68 mmol, 88%) as a 
colourless oil; Rf 0.47 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3); 8.10-7.95 (1H, m, 
sulfonamide 3 -H), 7.71-7.53 (3H, m, sulfonamide 4-H, 5-H and 6-H), 7.42-7.27 (5H, m, 
benzyl-H), 5.07 (1H, br s, N-H), 5.03 (2H, s, benzyl-H), 3.42 (6H, m, 1-H, 2-H and 1’H), 2.25-
2.11 (2H, m, 3’-H), 1.93 (1H, t, J 2.5, 5’-H), 1.85-1.70 (2H, m, 2’-H); δC (75 MHz, CDCl3); 
156.3 (carbamate-C), 133.7 (sulfonamide 4-C), 132.9 (sulfonamide 1-C), 131.7 
(sulfonamide 5-C), 131.1 (sulfonamide 6-C), 128.5 (benzyl 3-C and 5-C), 128.1 (benzyl 4-
C), 128.0 (benzyl 2-C and 6-C), 124.3 (sulfonamide 3-C), 82.7 (4’-C), 69.4 (5’-C), 66.8 
(benzyl-C), 46.8 (2-C), 46.8 (1’-C), 39.2 (1-C), 26.9 (2’-C), 15.7 (3’-C); νmax/cm−1 (film) 3416, 
3295, 2949, 2118, 1719, 1544, 1372, 1163; m/z (ESI) 468.1 (100%, MNa+); HRMS found 
MNa+, 468.1217. C21H23N3O6S requires MNa, 468.1200.   
tert-Butyl-N-{3-[N-(prop-2-yn-1-yl)(2-
nitrobenzene)sulfonamido]propyl}carbamate, 266 
 
By general procedure G, the sulfamidate 238 (500 mg, 2.11 mmol) and the sulfonamide o-
202 (760 mg, 3.16 mmol) gave a crude product. Purification by column chromatography, 
eluting with 100:1 CH2Cl2–MeOH, gave the carbamate 266 (722 mg, 1.82 mmol, 86%) as a 
colourless oil; Rf 0.47 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3); 8.08-7.99 (1H, m, 
sulfonamide 3-H), 7.77-7.61 (3H, m, sulfonamide 4-H, 5-H and 6-H), 4.84 (1H, br s, N-H), 
4.20 (2H, d, J 2.4, 1’-H), 3.48 (2H, t, J 6.8, 3-H), 3.19 (2H, app. q, J 6.2, 1-H), 2.18 (1H, t, J 2.4, 
3’-H), 1.80 (2H, app. p, J 6.7, 2-H), 1.44 (9H, s, tBu-H); δC (75 MHz, CDCl3); 156.0 
(carbamate-C), 148.3 (sulfonamide 2-C),  133.8 (sulfonamide 4-C), 132.6 (sulfonamide 1-
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C), 131.7 (sulfonamide 5-C), 130.8 (sulfonamide 6-C), 124.3 (sulfonamide 3-C), 79.3 (tBu-
C), 77.2 (2’-C), 74.1 (3’-C), 44.3 (3-C), 37.2 (1’-C), 36.4 (1-C), 28.4 (tBu-C), 27.6 (2-C); 
νmax/cm−1 (film) 3294, 2978, 2122, 1703, 1546, 1367, 1167; m/z (ESI) 420.1 (100%, 
MNa+); HRMS found MNa+, 420.1217. C17H23N3O6S requires MNa, 420.1200.  
tert-Butyl-N-{3-[N-(pent-2’-yn-1’-yl)(2-
nitrobenzene)sulfonamido]propyl}carbamate, 267 
 
By general procedure G, the sulfamidate 230 (300 mg, 1.26 mmol) and the sulfonamide o-
235 (510 mg, 1.90 mmol) gave a crude product. Purification by column chromatography, 
eluting with 7:3 petrol–EtOAc, gave the carbamate 267 (447 mg, 1.05 mmol, 83%) as a 
colourless oil; Rf 0.58 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3) 8.11–7.98 (1H, m, 
sulfonamide 3-H), 7.74–7.58 (3H, m, sulfonamide 4-H, 5-H and 6-H), 4.87 (1H, s, N-H), 4.15 
(1H, t, J 2.2, 1’H), 3.46 (2H, t, J 6.7, 3-H), 3.19 (2H, m, 1H), 2.03 (2H, qt, J 7.5, 2.2, 4’-H), 1.78 
(2H, m, 2-H), 1.44 (9H, s, tBu-H), 0.98 (3H, t, J 7.5, 5’-H); δC (75 MHz, CDCl3); 133.5 
(sulfonamide 5-C), 131.4 (sulfonamide  4-C), 130.7 (sulfonamide 6-C), 124.1 (sulfonamide 
3-C), 80.3 (tBu-C), 71.9 (2’-C), 44.1 (3-C), 37.1 (1’-C), 36.8 (1-C), 28.4 (tBu-C), 27.5 (2-C), 
13.6 (5’-C), 12.2 (4’-C); νmax/cm−1 (film) 3422, 2978, 1706, 1547, 1366, 1167; m/z (ESI) 
448.2 (100%, MNa+); HRMS found MNa+, 448.1524. C19H27N3O6S requires MNa, 448.1513.  
(±)-Benzyl-N-{2-[N-(pent-1’-yn-3’-yl)(4-
nitrobenzene)sulfonamido]ethyl}carbamate, 263 
 
By general procedure G, the sulfamidate 199 (600 mg, 2.33 mmol) and the sulfamidate  p-
236 (750 mg, 2.80 mmol) gave a crude product. Purification by column chromatography, 
eluting with 7:3 petrol–EtOAc, gave the carbamate 263 (902 mg, 2.02 mmol, 90%) as a 
colourless solid; Rf 0.84 (1:1 petrol‒EtOAc); δH (500 MHz, CDCl3); 8.35 (2H, d, J 8.5, 
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sulfonamide 3-H and 5-H), 8.03 (2H, d, J 8.4, sulfonamide 2-H and 6-H), 7.41-7.30 (5H, m, 
benzyl-H), 5.20 (1H, br s, N-H), 5.13 (1H, d, J 12.4, benzyl-Ha), 5.09 (1H, d, J 12.4, benzyl-
Hb), 4.56 (1H, m, 3’-H), 3.54-3.43 (2H, m, 1-H), 3.38 (1H, dd, J 14.7, 6.7, 2-Ha), 3.16 (1H, m, 
2-Hb), 2.09 (1H, s, 1’-H), 1.82-1.73 (2H, m, 4’-H), 1.03 (3H, t, J 7.1, 5’-H); δC (75 MHz, CDCl3); 
156.5 (carbamate-C), 150.2 (sulfonamide 4-C), 143.8 (sulfonamide 1-C), 136.3 (benzyl 1-
C), 129.1 (sulfonamide 2-C and 6-C), 128.6 (benzyl 3-C and 5-C), 128.3 (benzyl 2-C and 6-
C), 128.2 (benzyl 4-C), 124.2 (sulfonamide 3-C and 5-C), 79.35 (2’-C), 74.7 (1’-C), 66.9 
(benzyl-C), 53.1 (3’-C), 44.6 (2-C), 41.6 (1-C), 28.8 (4’-C), 10.7 (5’-C); νmax/cm−1 (film) 3279, 
2973, 2110, 1692, 1531, 1347, 1168; m/z (ESI) 468.1 (100%, MNa+); HRMS found MNa+, 
468.1214. C21H23N3O6S requires MNa, 468.1200.  
(±)-tert-Butyl-N-{2-[N-(pent-2’-yn-1’-yl)(2-
nitrobenzene)sulfonamido]ethyl}carbamate, 262 
 
By general procedure G, the sulfamidate 200 (555 mg, 2.49 mmol) and the sulfonamide o-
236 (800 mg, 2.98 mmol) gave a crude product. Purification by column chromatography, 
eluting with 50:1 CH2Cl2–MeOH, gave the carbamate 262 (900 mg, 2.19 mmol, 88%) as a 
colourless oil; Rf 0.84 (1:1 petrol‒EtOAc); δH (300 MHz, CDCl3); 8.06-7.98 (1H, m, 
sulfonamide 3-H), 7.76-7.65 (2H, m, sulfonamide 5-H and 6-H), 7.64-7.58 (1H, m, 
sulfonamide 4-H), 4.95 (1H, br s, N-H), 4.60 (1H, td, J 7.8, 2.3, 3’-H), 3.59-3.45 (1H, m, 2-
Ha), 3.43-3.36 (3H, m, 2-Hb, 1-H), 2.27 (1H, d, J 2.2, 1’-H), 1.89-1.75 (2H, m, 4’-H), 1.44 (9H, 
s, tBu-H), 1.04 (3H, t, J 7.3, 5’-H); δC (75 MHz, CDCl3); 155.9 (carbamate-C), 148.6 
(sulfonamide 2-C), 133.8 (sulfonamide 4-C), 131.9 (sulfonamide 1-C), 131.5 (sulfonamide 
5-C), 130.7 (sulfonamide 6-C), 124.1 (sulfonamide 3-C), 80.2 (tBu-C), 79.5 (2’-C), 74.4 (1’-
C), 52.9 (3’-C), 44.6 (2’-C), 40.8 (1-C), 28.8 (4’-C), 28.4 (tBu-C), 10.7 (5’-C); νmax/cm−1 (film) 
3294, 2976, 2346, 1706, 1546, 1368, 1171; m/z (ESI) 434.1 (100%, MNa+); HRMS found 
MNa+, 434.1375. C18H25N3O6S requires MNa, 434.1356.  
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(2R)-2-{[(tert-Butoxy)carbonyl]amino}-3-[N-(prop-2’-yn-1’-yl)(4-
nitrobenzene)sulfonamido]propyl acetate, 274 
 
By general procedure G, the sulfamidate 243 (100 mg, 0.349 mmol) and the sulfonamide 
p-202 (98.0 mg, 0.410 mmol) gave a crude product. Purification by column 
chromatography, eluting with 7:3 petrol–EtOAc, gave the carbamate 274 (136 mg, 0.30 
mmol, 89%) as a colourless soild; Rf 0.72 (1:1 petrol‒EtOAc); [α]D19 −19.9 (c 5.1 CHCl3); δH 
(500 MHz, CDCl3); 8.28 (2H, d, J 8.9, sulfonamide 3-H and 5-H), 3.97 (2H, d, J 8.9, 
sulfonamide 2-H and 6-H), 4.89 (1H, br d, J 8.3, N-H), 4.29 (1H, d, J 19, 1’-Ha), 4.17-4.06 
(4H, m, 1’-Hb, 2-H and 1’-H), 3.36 (1H, dd, J 13.8 and 9.8, 3-Ha), 3.21 (1H, dd, J 13.9 and 4.5, 
3-Hb), 2.03 (3H, s, acetate-H), 2.00 (1H, t, J 2.4, 3’-H), 1.38 (9H, s, tBu-H); δC (75 MHz, 
CDCl3); 170.7 (acetate-C), 155.6 (carbamate-C), 150.3 (sulfonamide 4-C), 144.5 
(sulfonamide 1-C), 130 (sulfonamide 2-C and 4-C), 124.2 (sulfonamide 3-C and 5-C), 80.3 
(tBu-C), 75.6 (3’-C), 73.5 (2’-C), 63.9 (1-C), 47.3 (3-C), 47.1 (2-C), 37.1 (1’-C), 28.3 (tBu-C), 
20.8 (acetate-C); νmax/cm−1 (film) 3276, 2979, 2121, 1740, 1709, 1532, 1352, 1167; m/z 
(ESI) 478.1 (100%, MNa+); HRMS found MNa+, 478.1272. C19H25N3O8S requires MNa, 
478.1255.  
tert-Butyl-N-[(2S)-3-hydroxy-2-[N-(prop-2-yn-1-yl)(4-
nitrobenzene)sulfonamido]propyl]carbamate, 271 
 
By general procedure G, the sulfamidate 242 (250 mg, 0.680 mmol) and the sulfonamide 
p-202 (200 mg, 0.833 mmol) gave a crude product. Purification by column 
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chromatography, gradient elution with 8:2 to 7:3 petrol–EtOAc, gave the carbamate 271 
(184 mg, 0.445 mmol, 68%) as a colourless solid; Rf 0.59 (1:1 petrol‒EtOAc); [α]D22 –15.0 
(c 0.5, MeOH); δH (500 MHz, CDCl3); 8.34 (2H, d, J 8.9, sulfonamide 3-H and 5-H), 8.12 (2H, 
d, J 8.9, sulfonamide 2-H and 6-H), 4.80 (1H, br t, J 6.1, N-H), 4.43 (1H, dd, J 18.9 and 2.2, 1’-
Ha), 4.32 (1H, dd, J 18.8 and 2.4, 1’-Hb), 4.01-3.91 (1H, m, 2-H), 3.77-3.63 (2H, m, 3-H), 3.47 
(1H, dt, J 13.5 and 6.6, 1-Ha), 3.27 (1H, dt, J 14.2 and 6.9, 1-Hb), 2.74 (1H, t, J 6.5, O-H), 2.23 
(1H, t, J 2.3, 3’-H), 1.43 (9H, s, tBu-H); δC (75 MHz, CDCl3); 150.1 (carbonyl-C), 128.9 
(sulfonamide 2-C and 6-C), 124.1 (sulfonamide 3-C and 5-C), 80.5 (tBu-C), 77.2 (2’-C), 73.3 
(3’-C), 61.2 (3-C), 59.8 (2-C), 39.1 (1-C), 33.4 (1’-C), 28.3 (tBu-C); νmax/cm−1 (film) 3435, 
2980, 1682, 15414, 1349, 1164; m/z (ESI) 136.2 (100%, MNa); HRMS Found MNa+, 
436.1166, C17H23N3O7S requires MNa, 436.1149. 
tert-Butyl-N-[(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-[N-(prop-2’-yn-1’-yl)(4-
nitrobenzene)sulfonamido]propyl]carbamate, 272 
 
 
 
By general procedure G, the sulfamidate 242 (597 mg, 1.62 mmol) and the sulfonamide p-
202 (468 mg, 1.95 mmol) gave a crude product. Purification by column chromatography, 
eluting with 7:3 petrol–EtOAc, gave the carbamate 272 (638 mg, 1.21 mmol, 74%) as a 
colourless oil; Rf 0.82 (1:1 petrol‒EtOAc); [α]D19 −55.1 (c 3.4, CHCl3); δH (500 MHz, CDCl3); 
8.32 (2H, d, J 8.7, sulfonamide 3-H and 5-H), 8.10 (2H, d, J 8.7, sulfonamide 2-H and 6-H), 
4.65 (1H, t, J 5.5, N-H), 4.40 (1H, dd, J 19.8 and 1.8, 1’-Ha), 4.33 (1H, dd, J 18.9 and 1.9, 1’-
Hb), 4.01 (1H, m, 2-H), 3.76 (2H, m, 3-H), 3.42 (1H, ddd, J 14.7, 6.7 and 5.1, 1-Ha), 3.33 (1H, 
dd, J 14.9, 9.1 and 5.1, 1-Hb), 2.19 (1H, t, J 2.1, 2’-H), 1.39 (9H, s, tBuO-H), 1.39 (9H, s, tBuSi-
H), 0.02 (6H, s, 2 × SiMe-H); δC (75 MHz, CDCl3); 155.8 (carbamate-C), 150.0 (sulfonamide 
1-C), 128.8 (sulfonamide  2-C and 6-C), 124.1 (sulfonamide 3-C and 5-C), 79.7 (tBuO-C), 
79.2 (2’-C), 73.2 (3’-C), 61.2 (3-C), 59.5 (2-C), 39.8 (1-C), 33.7 (1’-C), 28.3 (tBuO -C), 25.8 
(tBuSi-C), 18.1 (tBuSi-C), -5.65 (2 × SiMe-C); νmax/cm−1 (film) 3305, 2931, 2122, 1711, 
1532, 1350, 1171; m/z (ESI) 550.2 (100%, MNa+); HRMS found MNa+, 550.2011. 
C23H37N3O7SSi requires MNa, 550.2014. 
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Benzyl-N-[(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-[N-(prop-2’-yn-1’-yl)(4-
nitrobenzene)sulfonamido]propyl]carbamate, 273 
 
By general procedure G, the sulfamidate 244 (2.9 g, 7.22 mmol) and the sulfonamide p-
202 (1.90 g, 7.91 mmol) gave a crude product. Purification by column chromatography, 
eluting with 7:3 petrol–EtOAc, gave the carbamate 273 (2.70 g, 4.81 mmol, 67%) as a 
colourless oil; Rf 0.49 (1:1 petrol‒EtOAc); [α]D19 +5.4 (c 1.8, CHCl3); δH (500 MHz, CDCl3); 
8.21 (2H, d, J 8.7, sulfonamide 3-H and 5-H), 8.05 (2H, d, J 8.7, sulfonamide 2-H and 6-H), 
7.39-7.28 (5H, m, benzyl Ar-H), 5.05 (1H, d, J 12.1, benzyl-Ha), 4.91 (1H, d, J 12.2, benzyl-
Hb), 4.82 (1H, br s, N-H), 4.44 (1H, dd, J 18.8 and 2.3, 1’-Ha), 4.33 (1H, dd, J 18.9 and 2.1, 1’-
Hb), 4.04 (1H, m, 2-H), 3.83-3.72 (2H, m, 3-H), 3.48 (1H, ddd, J 14.7, 6.6 and 4.8, 1-Ha), 3.37 
(1H, ddd, J 15.1, 9.7 and 5.7, 1-Hb), 2.17 (1H, br t, J 2.18, 3’-H), 0.83 (9H, s, tBuSi-H), 0.00 
(3H, s, SiMe-H), -0.01 (3H, s, SiMe-H); δC (75 MHz, CDCl3); 156.9 (carbonyl-C), 150.1 
(sulfonamide 4-C), 145.9 (sulfonamide 1-C), 136.0 (benzyl 1-C), 128.9 (sulfonamide 2-C 
and 6-C), 128.6 (benzyl 3-C and 5-C), 128.4 (benzyl 4-C), 128.2 (benzyl 2-C and 4-C), 124.1 
(sulfonamide 3-C and 5-C), 77.2 (2’-C), 73.4 (3’-C), 67.3 (benzyl-C), 61.3 (3-C), 59.6 (2-C), 
39.5  (1-C), 33.2 (1’-C), 25.7 (tBu-C), 18.1 (tBu-C), -2.95 (2 × SiMe-C); νmax/cm−1 (film) 
3418, 3293, 2955, 2122, 1708, 1530, 1350, 1166; m/z (ESI) 584.2 (100%, MNa); HRMS 
found MNa+, 584.1852. C26H35N3O7SSi requires MNa, 584.1857. 
(±)-1-Benzyl-2-methylpyrrolidine-2-carbonitrile, 21578 
 
The pyrrolidine 215 was prepared following the method of Hammond et al. TMSCN (0.25 
mL, 2.0 mmol) was added to a suspension of the amine 210 ( 86.6 mg, 0.50 mmol) and 
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CuBr (3.6 mg, 25 μmol) in 1,4-dioxane (2 mL) and water (0.04 mL) in a microwave vial 
equipped with a magnetic stirrer. The vial was sealed, flushed with Ar and heated at 100 
°C under microwave irradiation for 30 min. The reaction mixture was concentrated in 
vacuo to give a crude product. Purification by column chromatography, eluting with 4:1 
hexane‒Et2O, gave the pyrrolidine 215 (78 mg, 0.4 mmol, 78%) as a light brown oil; δH 
(500 MHz, CDCl3); 7.36-7.29 (4H, m, benzyl 2-H, 3-H, 5-H and 6-H), 7.29-7.24 (1H, m, 
benzyl 4-H), 4.01 (1H, d, J 13.0, benzyl-Ha), 3.35 (1H, d, J 13.0, benzyl-Hb), 2.99 (1H, td, J 9.4 
and 3.4, 5-Ha), 2.41 (1H, td, J 9.4 and 7.9, 5-Hb), 2.36-2.31 (1H, m, 3-Ha), 1.95-1.72 (3H, m, 
3-Hb, 4-H), 1.56 (3H, s, methyl-H); δC (75 MHz, CDCl3); 138.5 (benzyl 1-C), 128.5 (benzyl 3-
C and 5-C), 128.4 (benzyl 2-C and 6-C), 127.2 (benzyl 4-C), 120.0 (nitrile-C), 61.4 (2-C), 
54.5 (benzyl-C), 51.6 (5-C), 38.9 (3-C), 23.7 (methyl-C), 20.0 (4-C); νmax/cm−1 (film) 2949, 
2210, 1450, 1156; m/z (ESI) 174.1 (100%, M+-CN). 
tert-Butyl-6-methyl-4-[(2-nitrobenzene)sulfonyl]-1,2,3,4-tetrahydropyrazine-1- 
carbamate, 77 
 
By general procedure K, the carbamate 208 (200 mg, 0.52 mmol) gave a crude product. 
Purification by column chromatography, eluting with 1:1 petrol–EtOAc, gave the 
carbamate 77 (194 mg, 0.51 mmol, 98%) as a bright yellow solid; Rf 0.33 (7:3 petrol‒
EtOAc); δH (500 MHz, CDCl3); 7.96 (1H, dd, J 7.3 and 1.9, sulfonamide 3-H), 7.72 (2H, m, 
sulfonamide 5-H and 6-H), 7.63 (1H, m, sulfonamide 4-H), 5.98 (1H, s, 5-H), 3.67-3.61 (2H, 
m, 3-H), 3.61-3.57 (2H, m, 2-H), 2.07 (3H, s, methyl-H), 1.47 (9H, s, tBu-H); δC (75 MHz, 
CDCl3); 152.5 (sulfonamide 2-C), 134.0 (sulfonamide 4-C), 131.8 (sulfonamide 5-C), 131.3 
(sulfonamide 1-C), 130.6 (sulfonamide 6-C), 124.2 (sulfonamide 3-C), 120.1 (6-C), 108.0 
(5-C), 81.7 (tBu-C), 44.6 (3-C), 41.6 (2-C), 28.3 (tBu-C), 20.1 (methyl-C); νmax/cm−1 (film) 
2978, 1701, 1547, 1375, 1175; m/z (ESI) 406.1 (100%, MNa); HRMS found MNa+, 
406.1063, C16H21N3O6S requires MNa, 406.1043. 
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Benzyl-6-methyl-4-[(2-nitrobenzene)sulfonyl]-1,2,3,4-tetrahydropyrazine-1- 
carbamate, 222 
 
By general procedure K, the carbamate 209 (100 mg, 0.24 mmol) gave a crude product. 
Purification by column chromatography, eluting with 100% CH2Cl2, gave the carbamate 
222 (98 mg, 0.23 mmol, 98%) as a bright yellow oil which solidified on standing; Rf 0.22 
(7:3 petrol‒EtOAc); δH (500 MHz, CDCl3); 7.98-7.92 (1H, m, sulfonamide 3-H), 7.75-7.67 
(2H, m, sulfonamide 5-H and 6-H), 7.65-7.61 (1H, m, 4-H), 7.39-7.30 (5H, m, benzyl Ar-H), 
6.03 (1H, s, 5-H), 3.72-3.67 (4H, m, benzyl-H and 3-H), 3.67-3.62 (2H, m, 2-H), 2.08 (3H, s, 
methyl-H); δC (75 MHz, CDCl3); 134.1 (sulfonamide 4-C), 131.8 (sulfonamide 5-C), 130.6 
(sulfonamide 6-C), 128.6 (benzyl 3-C and 5-C), 128.4 (benzyl 4-C), 128.3 (benzyl 2-C and 
6-C), 124.4 (6-C), 124.3 (sulfonamide 3-C), 108.8 (5-C), 68.0 (benzyl -C), 44.5 (3-C), 42.0 
(2-C), 19.8 (methyl-C); νmax/cm−1 (film) 3094, 2345, 1718, 1544, 1371, 1172; m/z (ESI) 
440.1 (100%, MNa); HRMS found MNa+, 440.0898, C19H19N3O6S requires MNa, 440.0887. 
Benzyl-6-methyl-4-[(2-nitrobenzene)sulfonyl]-1,2,3,4-tetrahydropyrazine-1- 
carbamate, 275 
 
By general procedure K, the carbamate 268 (200 mg, 0.39 mmol) gave a crude product. 
Purification by column chromatography, eluting with 1:1 petrol–EtOAc, gave the 
carbamate 275 (179 mg, 0.35 mmol, 90%) as a bright yellow solid; Rf 0.24 (7:3 petrol‒
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EtOAc); [α]D19 −71.2 (c 1.3, CHCl3); δH (500 MHz, CDCl3); 7.94 (1H, d, J 7.9, sulfonamide 3-
H), 7.76-7.60 (3H, m, sulfonamide 4-H, 5-H and 6-H), 7.38-7.29 (3H, m, benzyl 3-H, 4-H and 
5-H), 7.25-7.17 (5H, m, benzyl 2-H and 6-H, phenyl 3-H, 4-H and 5-H), 7.08 (2H, m, phenyl 
2-H and 6-H), 6.15 (1H, s, methly-H), 5.05 (1H, d, J 12.3, benzyl-Ha), 4.97 (1H, d, J 12.3, 
benzyl-Hb), 4.76 (1H, m, 2-H), 3.86 (1H, d, J 12.0, 3-Ha), 3.18 (1H, dd, J 11.9 and 3.3, 3-Hb), 
2.72 (1H, dd, J 13.8 and 7.5, methylene-Ha), 2.70 (1H, dd, J 13.5 and 7.7, methylene-Hb) 
2.10 (3H, s, methyl-H); δC (75 MHz, CDCl3); 137.1 (phenyl 1-C), 135.7 (benzyl 1-C), 134.1 
(sulfonamide 4-C), 131.8 (sulfonamide 5-C), 131.2 (sulfonamide 1-C), 130.6 (sulfonamide 
6-C), 129.4, 128.6, 128.5, 128.3, 128.1, 126.7, 124.4 (sulfonamide 3-C), 108.8 (5-C), 67.8 
(benzyl-C), 51.8 (2-C), 46.0 (3-C), 35.7 (methylene-C), 20.0 (methyl-C); νmax/cm−1 (film) 
3030, 2350, 1712, 1544, 1400, 1372, 1176; m/z (ESI) 530.1 (100%, MNa); HRMS found 
MNa+, 530.1352, C26H25N3O6S requires MNa, 530.1356. 
Benzyl-(3R)-3,6-dimethyl-4-[(2-nitrobenzene)sulfonyl]-1,2,3,4-tetrahydropyrazine-
1- carbamate, 277 
 
By general procedure K, the carbamate 270 (200 mg, 0.46 mmol) gave a crude product. 
Purification by column chromatography, eluting with 7:3 petrol–EtOAc, gave the 
carbamate 277 (192 mg, 0.45 mmol, 96%) as a bright yellow solid; Rf 0.38 (7:3 petrol‒
EtOAc); [α]D19 −234.1 (c 2.4, CHCl3); δH (500 MHz, CDCl3); 8.01-7.94 (1H, m, sulfonamide 3-
H), 7.73-7.67 (2H, m, sulfonamide 5-H and 6-H), 7.43-7.28 (1H, m, sulfonamide 4-H), 7.43-
7.28 (5H, m, benzyl Ar-H), 5.94 (1H, s, 5-H), 5.20 (1H, d, J 12.2, benzyl-Ha), 5.12 (1H, d, J 
12.2, benzyl-Hb), 4.35-4.26 (1H, m, 3-H), 4.21 (1H, d, J 13.2, 2-Ha), 2.66 (1H, dd, J 13.1 and 
2.1, 2-Hb), 2.10 (3H, s, 6-methyl-H), 1.10 (3H, d, J 6.6, 3-methyl-H); δC (75 MHz, CDCl3); 
153.9 (carbamate-C), 148.2 (sulfonamide 2-C), 135.6 (benzyl 1-C), 134.0 (sulfonamide 4-
C), 132.9 (sulfonamide 5-C), 131.6 (sulfonamide 6-C), 128.61 (benzyl 3-C and 5-C), 128.4 
(benzyl 4-C), 128.2 (benzyl 2-C and 6-C), 124.1 (sulfonamide 3-C), 119.1 (5-C), 107.0 (4-C), 
73.9 (benzyl-C), 49.5 (3-C), 46.5 (2-C), 19.7 (6-methyl-C), 17.1 (3-methyl-C), νmax/cm−1 
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(film) 3094, 2933, 2341, 1712, 1544, 1402, 1244; m/z (ESI) 454.1 (100%, MNa); HRMS 
found MNa+, 454.1061, C20H21N3O6S requires MNa, 454.1043. 
tert-Butyl-N-{2-[N-(3’-oxopentyl)(2-nitrobenzene)sulfonamido]ethyl}carbamate, 
285 
 
By general procedure L, the carbamate 261 (150 mg, 0.36 mmol) gave a crude product. 
Purification by column chromatography, eluting with 1:1 petrol–EtOAc, gave the 
carbamate 285 (107 mg, 0.25 mmol, 68%) as a colourless oil; Rf 0.13 (7:3 petrol‒EtOAc); 
δH (500 MHz, CDCl3); 8.01 (1H, dd, J 7.4 and 1.7, sulfonamide 3-H), 7.76-7.67 (2H, m, 
sulfonamide 6-H and 5 -H), 7.67-7.60 (1H, m, sulfonamide 4-H), 4.90 (1H, br s, N-H), 3.56 
(2H, t, J 7.2, 1’-H), 3.40 (2H, t, J 6.0, 2-H), 3.36-3.28 (2H, m, 1-H), 2.81 (2H, t, J 7.1, 2’-H), 
2.44 (2H, q, J 7.3, 4’-H), 1.42 (9H, s, tBu-H), 1.03 (3H, t, J 7.3, 5’-H); δC (75 MHz, CDCl3); 
209.2 (ketone-C), 155.9 (carbamate-C), 148.1 (sulfonamide 2-C), 133.8 (sulfonamide 4-C), 
132.5 (sulfonamide  1-C), 131.9 (sulfonamide  5-C), 131.0 (sulfonamide 6-C), 124.3 
(sulfonamide  3-C), 79.6 (tBu-C), 48.3 (2-C), 43.3 (2’-C), 41.5 (1’C), 39.1 (1-C), 36.3 (4’-C), 
28.4 (tBu-C), 7.6 (5’-C); νmax/cm−1 (film) 3414, 2979, 2391, 1710, 1590, 1545, 1367, 1164; 
m/z (ESI) 452.1 (100%, MNa); HRMS found MNa+, 452.1475, C18H27N3O7S requires MNa, 
452.1462. 
tert-Butyl-N-{3’-[N-(3-oxopentyl)(2-nitrobenzene)sulfonamido]propyl}carbamate, 
288 
 
 By general procedure L, the carbamate 267 (100 mg, 0.24 mmol) gave a crude product. 
Purification by column chromatography, eluting with 1:1 petrol–EtOAc, gave the 
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carbamate 288 (64 mg, 0.14 mmol, 61%) as a colourless oil; Rf 0.11 (7:3 petrol‒EtOAc); δH 
(500 MHz, CDCl3); 8.02-7.95 (1H, m, sulfonamide 3-H), 7.75-7.68 (2H, m, sulfonamide 5-H 
and 6-H), 7.65-7.63 (1H, m, sulfonamide 4-H), 4.85 (1H, br s, N-H), 3.54 (2H, t, J 7.2, 1’-H), 
3.35 (2H, t, J 7.0, 3-H), 3.16 (2H, m, 1-H), 2.77 (2H, t, J 7.1, 2’-H), 2.43 (2H, q, J 7.3, 4’-H), 
1.75 (2H, app. p, J 6.7, 2-H), 1.44 (9H, s, tBu-H), 1.03 (3H, t, J 7.3, 5’-H); δC (75 MHz, CDCl3); 
209.1 (ketone-C), 156.0 (carbamate-C), 148.1 (sulfonamide 2-C), 133.7 (sulfonamide 4-C), 
132.8 (sulfonamide 1-C), 131.8 (sulfonamide 5-C), 130.7 (sulfonamide 6-C), 124.3 
(sulfonamide 3-C), 79.3 (tBu-C), 46.5 (2-C), 42.6 (2’-C), 41.6 (1’-C), 37.4 (1-C), 36.3 (4’-C), 
28.6 (2-C), 28.4 (tBu-C), 7.6 (5’-C); νmax/cm−1 (film) 3407, 2978, 1708, 1590, 1546, 1367, 
1165; m/z (ESI) 466.2 (100%, MNa); HRMS found MNa+, 466.1638, C19H29N3O7S requires 
MNa, 466.1618. 
(±)-Benzyl-N-{2-[N-(2’-oxopentan-3’-yl)(4-
nitrobenzene)sulfonamido]ethyl}carbamate, 287 
 
By general procedure L, the carbamate 264 (150 mg, 0.34 mmol) gave  a crude product. 
Purification by column chromatography, eluting with 1:1 petrol–EtOAc, gave the 
carbamate 287 (72 mg, 0.16 mmol, 46%) as a colourless oil; Rf 0.16 (7:3 petrol‒EtOAc); δH 
(500 MHz, CDCl3); 8.32 (2H, d, J 8.6, sulfonamide 3-H and 5-H), 7.96 (2H, d, J 8.5, 
sulfonamide 2-H and 6-H), 7.40-7.29 (5H, m, phenyl-H), 5.29 (1H, br s, N-H), 5.07 (2H, s, 
benzyl-H), 4.36 (1H, dd, J 10.0 and 4.5, 3’-H), 3.46-3.38 (1H, m, 1-Ha), 3.37-3.23 (3H, m, 1-
Hb and 2-H), 2.15 (3H, s, 1’-H), 2.07-1.98 (1H, m, 4’-Ha), 1.60-1.51 (1H, m, 4-Hb), 0.97 (3H, t, 
J 7.2, 5’-H); δC (75 MHz, CDCl3); 206.2 (ketone), 150.1 (carbamate-C), 128.6 (sulfonamide 
2-C and 6-C), 128.5 (benzyl-C), 128.3 (benzyl-C), 128.1 (benzyl-C), 124.3 (sulfonamide 3-C 
and 5-C), 68.8 (3’-C), 66.8 (benzyl-C), 45.2 (2-C), 41.1 (1-C), 27.8 (1’-C), 21.4 (4’-C), 11.7 
(5’-C) [Sulfonamide 1-C and Ar 4-C were not observed]; νmax/cm−1 (film) 3411, 2973, 2455, 
1721, 1606, 1531, 1312, 1166; m/z (ESI) 486.1 (100%, MNa); (Found MNa+, 486.1320, 
C21H25N3O7S requires MNa, 486.1305). 
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Benzyl-N-{2-[N-(3’-oxopentyl)(4-nitrobenzene)sulfonamido]ethyl}carbamate, 286 
 
By general procedure L, the carbamate 263 (200 mg, 0.45 mmol) gave a crude product. 
Purification by column chromatography, eluting with 1:1 petrol–EtOAc, gave the 
carbamate 286 (176 mg, 0.38 mmol, 85%) as a colourless oil; Rf 0.13 (7:3 petrol‒EtOAc); 
δH (500 MHz, CDCl3); 8.35 (2H, d, J 8.5, sulfonamide 3-H and 5-H), 7.98 (2H, d, J 8.5, 
sulfonamide 2-H and 6-H), 7.42-7.30 (5H, m, benzyl Ar-H), 5.14 (1H, br s, N-H), 5.10 (2H, s, 
benzyl-H), 3.42-3.38 (4H, m, 1-H and 1’), 3.27 (2H, t, J 5.9, 2-H), 2.82 (2H, t, J 7.0, 2’-H), 2.41 
(2H, q, J 7.2, 4’-H), 1.01 (3H, t, J 7.3, 5’-H); δC (75 MHz, CDCl3); 209.1 (ketone-C), 150.2 
(sulfonamide 4-C), 144.4 (sulfonamide 2-C), 136.3 (benzyl 1-C), 128.6 (sulfonamide 2-C 
and 6-C), 128.5 (benzyl  3-C and 5-C), 128.3 (benzyl  4 -C), 128.1 (benzyl  2-C and 6-C), 
124.5 (sulfonamide 3-C and 5-C), 66.9 (benzyl-C), 49.2 (2-C), 44.5 (2’-C), 42.1 (1’-C), 40.1 
(1-C), 36.3 (4’-C), 7.6 (5’-C); νmax/cm−1 (film) 3411, 2973, 1721, 1606, 1531, 1350, 1166; 
m/z (ESI) 486.1 (100%, MNa); HRMS found MNa+, 486.1311, C21H25N3O7S requires MNa, 
486.1305. 
tert-Butyl-(2S)-6-methyl-4-[(4-nitrobenzene)sulfonyl]-2-phenyl-1,2,3,4-
tetrahydropyrazine-1- carbamate, 276 
 
By general procedure K, the carbamate 269 (200 mg, 0.44 mmol) gave a crude product. 
Purification by column chromatography, eluting with 1:1 petrol–EtOAc, gave the 
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carbamate 276 (192 mg, 0.42 mmol, 96%) as a bright yellow solid; Rf 0.66 (7:3 petrol‒
EtOAc);  [α]D19 +23.0 (c 0.5, CHCl3); δH (500 MHz, CDCl3); 8.12 (2H, d, J 8.8, sulfonamide 3-H 
and 5-H), 7.67 (2H, d, J 8.8, sulfonamide 2-H and 6-H),  7.14-7.06 (3H, m, phenyl 3-H, 4-H 
and 5-H), 6.99 (2H, d, J 6.3, phenyl 2-H and 6-H), 6.00 (1H, s, 5-H), 5.60 (1H, app. s, 2-H), 
4.33 (1H, d, J 12.7, 2-Ha), 3.44 (1H, dd, J 12.6 and 3.5, 2-Hb), 2.17 (3H, s, methyl-H), 1.43 
(9H, s, tBu-H); δC (75 MHz, CDCl3); 152.6 (carbamate-C), 149.8 (sulfonamide 4-C), 143.7 
(sulfonamide 1-C), 137.4 (phenyl 1-C), 128.5 (sulfonamide 2-C and 6-C), 127.8 (phenyl 3-C 
and 5-C), 127.3 (phenyl 4-C) 125.7 (phenyl 2-C and 6-C), 124.2 (sulfonamide 3-C and 5-C), 
118.7 (6-C), 107.9 (5-C), 82.2 (tBu-C), 53.2 (1-C), 47.7 (2-C), 28.2 (tBu-C), 20.7 (methyl-C); 
νmax/cm−1 (film) 2978, 1697, 1530, 1348, 1169; m/z (ESI) 482.1 (100%, MNa); HRMS 
found MNa+, 482.1356, C22H25N3O6S requires MNa, 482.1356. 
tert-Butyl-N-{[(3S)-6-methyl-4-[(4-nitrobenzene)sulfonyl]-3,4-dihydro-2,1-H,4-
oxazin-3-yl]methyl}carbamate, 279  
 
By general procedure K, the carbamate 271 (100 mg, 0.24 mmol) gave a mixture of crude 
products. Purification by column chromatography, eluting with 8:2 petrol–EtOAc, gave the 
carbamate 279 (48 mg, 0.12 mmol, 48%) as a bright yellow solid; Rf 0.50 (7:3 petrol‒
EtOAc);  [α]D19 +189.7 (c 0.3, CHCl3); δH (500 MHz, CDCl3); 8.38 (2H, d, J 8.7, sulfonamide 3-
H and 5-H), 7.95 (2H, d, J 8.6, sulfonamide 2-H and 6-H), 5.81 (1H, s, 5-H), 4.94 (1H, br s, N-
H), 4.05 (1H, br s, 3-H), 3.92 (2H, d, J 11.2, 2-Ha), 3.31-3.19 (1H, m, methylene-Ha), 3.17-
3.02 (1H, m, methylene-Hb), 2.78 (2H, d, J 11.2, 2-Hb), 1.77 (3H, s, methyl-H), 1.46 (9H, s, 
tBu-H); δC (75 MHz, CDCl3); 156.2 (carbamate-C), 150.2 (sulfonamide 4-C), 142.5 
(sulfonamide 2-C), 141.5 (6-C), 128.6 (sulfonamide 2-C and 6-C), 124.5 (sulfonamide 3-C 
and 5-C), 97.1 (5-C), 79.9 (tBu-C), 63.7 (2-C), 51.3 (3-C), 40.1 (methylene-C), 28.4 (tBu-C), 
17.7 (methyl-C); νmax/cm−1 (film) 3416, 2980, 1709, 1532, 1351, 1171; m/z (ESI) 436.1 
(100%, MNa); HRMS found MNa+, 136.1157, C17H23N3O7S requires MNa, 436.1149. Also 
isolated was the carbamate 278 (36 mg, 0.09 mmol, 36%) as a bright yellow solid. 
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tert-Butyl(3S)-3-(hydroxymethyl)-6-methyl-4-[(4-nitrobenzene)sulfonyl]-1,2,3,4-
tetrahydropyrazine-1-carbamate, 278 
 
HF (50% in H20, 0.40 mL, 9.47 mmol) was added to a solution of carbamate 280 (1.00 g, 
1.89 mmol) in CH2Cl2 (20 mL) and MeCN (20 mL) and stirred at rt for 2h. Me3SiOMe (1.40 
ml, 10.2 mmol) was added to the reaction mixture and stirred for a further 30 min. The 
reaction mixture was concentrated in vacuo to give a crude product. Purification by 
column chromatography, eluting with 7:3 petrol‒EtOAc, gave the carbamate 278 (611 mg, 
1.48 mmol, 78%) as a yellow solid; Rf 0.34 (7:3 petrol‒EtOAc);  [α]D19 −166.9 (c 1.3, CHCl3); 
δH (500 MHz, CDCl3); 8.39 (2H, d, J 8.4, sulfonamide 3-H and 5-H), 7.97 (2H, d, J 8.5, 
sulfonamide 2-H and 5-H), 6.06 (1H, s, 5-H), 4.36 (1H, d, J 13.6, 2-Ha), 4.01 (1H, br s, 3-H), 
3.65 (1H, dd, J 11.6 and 6.1, methylene-Ha), 3.28 (1H, dd, J 11.5 and 8.9, methylene-Hb), 
2.89 (1H, s, O-H), 2.05 (3H, s, methyl-H), 1.96 (1H, dd, J 13.6 and 2.5, 2-Hb), 1.47 (9H, s, 
tBu-H); δC (75 MHz, CDCl3); 150.3 (sulfonamide 4-C), 143.2 (sulfonamide 1-C), 128.3 
(sulfonamide 2-C and 6-C), 124.6 (sulfonamide 3-C and 5-C), 120.8 (6-C), 107.7 (5-C), 82.6 
(tBu-C), 59.9 (methylene-C), 55.2 (2-C), 40.4 (1-C), 28.1 (tBu-C), 20.0 (methyl-C); 
νmax/cm−1 (film) 3416, 2977, 2932, 1701, 1532, 1367, 1176; m/z (ESI) 436.1 (100%, MNa); 
HRMS found MNa+, 136.1158, C17H23N3O7S requires MNa, 436.1149. 
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tert-Butyl-(3S)-3-{[(tert-butyldimethylsilyl)oxy]methyl}-6-methyl-4-[(4-
nitrobenzene)sulfonyl]-1,2,3,4-tetrahydropyrazine-1- carbamate, 280 
 
By general procedure K, the carbamate 272 (150 mg, 0.28 mmol) gave a crude product. 
Purification by column chromatography, eluting with 7:3 petrol–EtOAc, gave the 
carbamate 280 (119 mg, 0.23 mmol, 79%) as a bright yellow oil which solidified on 
standing; Rf 0.81 (7:3 petrol‒EtOAc); [α]D19 −331.3 (c 3.4, CHCl3); δH (500 MHz, CDCl3); 
8.33 (2H, d, J 8.9, sulfonamide 3-H and 5-H), 7.91 (2H, d, J 8.9, sulfonamide 2-H and 6-H), 
5.87 (1H, s, 5-H), 4.31 (1H, dd, J 13.1 and 1.9, 2-Ha), 3.82 (1H, br s, 2-H), 3.57 (1H, dd, J 9.9 
and 4.9, methylene-Ha), 3.35 (1H, app. t, J 9.9, methlyene-Hb), 2.01 (3H, s, methyl-H), 1.92 
(1H, dd, J 13.1 and 2.8, 2-Hb), 1.39 (9H, s, tBuO), 0.84 (9H, s, tBuSi), 0.02 (3H, s, MeSi), 0.00 
(3H, s, MeSi -H); δC (75 MHz, CDCl3); 152.3 (carbamate-C), 150.2 (sulfonamide 4-C), 143.0 
(sulfonamide 1-C), 128.3 (sulfonamide 2-C and 6-C), 124.6 (sulfonamide 3-C and 5-C), 
121.3 (6-C), 105.6 (5-C), 81.7 (tBuO-C), 60.7 (methylene-C), 54.9 (3-C), 40.0 (2-C), 27.9 
(tBuO-C), 25.9 (tBuSi-C), 20.1 (tBuSi-C), 18.2 (methyl-C), -5.4 (MeSi-C), -5.5 (MeSi -C); 
νmax/cm−1 (film) 2931, 1706, 1533, 1388, 1251, 1178; m/z (ESI) 550.2 (100%, MNa); HRMS 
found MNa+, 550.2017, C23H37N3O7SSi requires MNa, 550.2014. 
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Benzyl-(3S)-3-{[(tert-butyldimethylsilyl)oxy]methyl}-6-methyl-4-[(4-
nitrobenzene)sulfonyl]-1,2,3,4-tetrahydropyrazine-1- carbamate, 281 
 
By general procedure K, the carbamate 273 (2.67 g, 4.80 mmol) gave a crude product. 
Purification by column chromatography, eluting with 8:2 petrol–EtOAc, gave the 
carbamate 281 (2.25 mg, 4.00 mmol, 85%) as a bright yellow solid; Rf 0.81 (7:3 petrol‒
EtOAc); [α]D19 −270.5 (c 1.2, CHCl3); δH (500 MHz, CDCl3); 8.37 (2H, d, J 8.6, sulfonamide 3-
H and 5-H), 7.94 (2H, d, J 8.6, sulfonamide 2-H and 6-H), 7.37-7.27 (5H, m, benzyl Ar-H), 
5.96 (1H, s, 5-H), 5.15 (1H, d, J 12.2, benzyl-Ha), 5.03 (1H, d, J 12.2, benzyl-Hb), 4.43 (1H, dd, 
J 13.1 and 1.4, 2-Ha), 3.94-3.85 (1H, m, 3-H), 3.63 (1H, dd, J 9.9 and 5.0, methylene-Ha), 3.40 
(1H, app. t, J 9.8, methylene-Hb), 2.10-2.01 (4H, m, benzyl-H and 2-Hb), 0.85 (9H, s, tBu-H), 
0.03 (3H, s, MeSi-H), 0.00 (3H, s, MeSi-H); δC (75 MHz, CDCl3); 128.6 (sulfonamide 2-C and 
6-C), 128.4 (benzyl 3-C and 5-C), 128.3 (benzyl 4-C), 128.2 (benzyl 2-C and 6-C), 124.6 
(sulfonamide 3-C and 5-C), 106.2 (5-C), 68.0 (benzyl-C), 60.5 (methylene-C), 54.5 (3-C), 
40.4 (2-C), 25.8 (tBu-C), 19.8 (methyl-C), -5.6 (MeSi-C), -5.6 (MeSi-C) [Carbamate and 
quaternary Ar-C were not observed]; νmax/cm−1 (film) 2954, 1717, 1532, 1401, 1349, 1252, 
1178; m/z (ESI) 584.2 (100%, MNa); HRMS found MNa+, 584.1875, C26H35N3O7SSi requires 
MNa, 584.1857. 
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Benzyl(3S)-3-(hydroxymethyl)-6-methyl-4-[(4-nitrobenzene)sulfonyl]-1,2,3,4-
tetrahydropyrazine-1- carbamate, 312 
 
HF (50% in H20, 0.72 mL, 19.7 mmol) was added to a solution of carbamate 281 (2.21 g, 
3.94 mmol) in CH2Cl2 (30 mL) and MeCN (30 mL) and stirred at rt for 2h. Me3SiOMe (2.7 
ml, 19.7 mmol) was added to the reaction mixture and stirred for a further 30 min. The 
reaction mixture was concentrated in vacuo to give a crude product. Purification by 
column chromatography, eluting with 7:3 petrol‒EtOAc, gave the carbamate 312 (1.41 g, 
3.14 mmol, 80%) as a yellow oil which solidified on standing; Rf 0.28 (7:3 petrol‒EtOAc); 
[α]D19 −314.0 (c 0.8, CHCl3); δH (500 MHz, CDCl3); 8.38 (2H, d, J 8.6, sulfonamide 3-H and 5-
H), 7.96 (2H, d, J 8.7, sulfonamide 2-H and 6-H), 7.40-7.29 (5H, m, benzyl-H), 6.07 (1H, s, 5-
H), 5.19 (1H, d, J 12.1, benzyl-Ha), 5.11 (1H, d, J 12.1, benzyl-Hb), 4.41 (1H, dd, J 13.4 and 
1.1, 2-Ha), 4.00 (1H, m, 3-H), 3.61 (1H, dd, J 10.9 and 5.9, methylene-Ha), 3.27 (1H, app. t, J 
10.2, methylene-Hb), 2.09-2.04 (5H, m, 2-Hb, methyl-H and O-H); δC (75 MHz, CDCl3); 143.1 
(sulfonamide 1-C), 135.4 (benzyl 1-C), 128.7 (sulfonamide 2-C and 6-C), 128.6 (benzyl 3-C 
and 5-C), 128.3 (benzyl 4-C), 128.3 (benzyl 2-C and 6-C), 124.7 (sulfonamide 3-C and 5-C), 
108.0 (5-C), 68.4 (benzyl-C), 60.0 (methylene-C), 55.0 (3-C), 40.9 (1-C), 19.8 (methyl-C) 
[Quaternary Ar-C were not observed]; νmax/cm−1 (film) 3447, 2934, 1709, 1531, 1402, 
1350, 1249, 1175; m/z (ESI) 470.1 (100%, MNa); HRMS found MNa+, 470.1000, 
C20H21N3O7S requires MNa, 470.0992. 
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Benzyl-(3R)-3-(aminomethyl)-6-methyl-4-[(4-nitrobenzene)sulfonyl]-1,2,3,4-
tetrahydropyrazine-1- carbamate, 314 
 
Diphenyl phosphoryl azide (0.96 mL, 4.45 mmol) was added dropwise to a solution of 
carbamate 312 (1.00 g, 2.23 mmol) and PPh3 (1.17 g, 4.46 mmol) in THF (22 mL) at 0 °C 
and the resulting solution was stirred at rt for 4h. The reaction mixture was concentrated 
in vacuo to give a crude azide intermediate which was partially purified by cloumn 
chromatography, eluting with 8:2 petrol–EtOAc. H20 (32 mL) was added to a solution of 
the azide intermediate and PPh3 (645 mg, 2.45 mmol) in THF (10 mL) and the resulting 
solution was stirred at rt for 12h. The reaction mixture was concentrated in vacuo to give a 
crude product. Purification by SCX resin gave the carbamate 314 (572 mg, 1.28 mmol, 
57% over 2 steps) as a yellow oil which solidified on standing; Rf 0.37 (9:1 CH2Cl2‒MeOH; 
[α]D19 −296.4 (c 0.6, CHCl3); δH (500 MHz, CDCl3); 8.37 (2H, d, J 8.8, sulfonamide 3-H and 5-
H), 7.95 (2H, d, J 8.8, sulfonamide 2-H and 6-H), 7.40-7.28 (5H, m, benzyl Ar-H), 6.02 (1H, s, 
5-H), 5.18 (1H, d, J 12.1, benzyl-Ha), 5.07 (1H, d, J 12.1, benzyl-Hb), 4.35 (1H, d, J 13.4, 2-Ha), 
3.83 (1H, m, 3-H), 2.73 (1H, dd, J 13.3 and 6.6, methylene-Ha), 2.51 (1H, dd, J 13.3 and 7.9, 
methylene-Hb), 2.07 (3H, s, methyl-H), 1.97 (1H, dd, J 13.3 and 2.1, 2-Hb), 1.38 (2H, br s, N-
H); δC (75 MHz, CDCl3); 150.3 (sulfonamide 4-C), 142.9 (sulfonamide 1-C), 135.5 (benzyl 1-
C), 128.7 (sulfonamide 2-C and 6-C), 128.6 (benzyl 3-C and 5-C), 128.4 (benzyl 4-C), 128.3 
(benzyl 2-C and 6-C), 124.6 (sulfonamide 3-C and 5-C), 107.0 (5-C), 68.2 (benzyl-C), 55.9 
(3-C), 41.4 (2-C), 41.3 (methylene-C), 19.8 (methyl-C); νmax/cm−1 (film) 3384, 2977, 1531, 
1401, 1349, 1243, 1178; m/z (ESI) 447.1 (100%, MH+); HRMS found MH+, 447.1354, 
C20H22N4O6S requires MH, 447.1333. 
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tert-Butyl-(3R)-3-(aminomethyl)-6-methyl-4-[(4-nitrobenzene)sulfonyl]-1,2,3,4-
tetrahydropyrazine-1-carbamate, 311 
 
Diphenyl phosphoryl azide (0.96 mL, 4.43 mmol) was added dropwise to a solution of 
carbamate 278 (368 mg, 0.90 mmol) and PPh3 (933 mg, 3.56 mmol) in THF (20 mL) at        
0 °C and the resulting solution was stirred at rt for 4h. The reaction mixture was 
concentrated in vacuo to give a crude azide intermediate which was partially purified by 
cloumn chromatography, eluting with 8:2 petrol–EtOAc. H20 (1 mL) was added to a 
solution of the azide intermediate and PPh3 (260 mg, 1.00 mmol) in THF (20 mL) and the 
resulting solution was stirred at rt for 12h. The reaction mixture was concentrated in 
vacuo to give a crude product. Purification by SCX resin gave the carbamate 311 (216 mg, 
0.52 mmol, 59% over 2 steps) as a yellow oil which solidified on standing; Rf 0.37 (9:1 
CH2Cl2‒MeOH); [α]D19 −334.1 (c 0.6, CHCl3); δH (500 MHz, CDCl3); 8.39 (2H, d, J 8.8, 
sulfonamide 3-H and 5-H), 7.97 (2H, d, J 8.7, sulfonamide 2-H and 5-H), 6.00 (1H, s, 5-H), 
4.31 (1H, d, J 13.3, 2-Ha), 3.85 (1H, br s, 3-H), 2.77 (1H, dd, J 13.4 and 6.7, methylene-Ha), 
2.57 (1H, dd, J 13.4 and 7.8, methylene-Hb), 2.05 (3H, s, methyl-H), 1.88 (1H, dd, J 13.4 and 
2.2, 2-Hb), 1.55 (2H, br s, N-H), 1.45 (9H, s, tBu-H); δC (75 MHz, CDCl3); 150.2 (sulfonamide 
4-C), 143.0 (sulfonamide 1-C), 128.4 (sulfonamide 2 –C and 5-C), 124.6 (sulfonamide 3-C 
and 5-C), 121.2 (6-C), 106.5 (5-C), 82.1 (tBu-C), 56.5 (3-C), 41.5 (2-C), 40.9 (methylene-C), 
28.2 (tBu-C), 20.1 (methyl-C) [Carbonyl was not observed]; νmax/cm−1 (film) 3385, 3033, 
1711, 1531, 1401, 1350, 1243; m/z (ESI) 413.1 (100%, MH+); HRMS found MH+, 413.1488, 
C17H24N4O6S requires MH, 413.1489. 
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tert-Butyl(2R)-2-[(acetyloxy)methyl]-6-methyl-4-[(4-nitrobenzene)sulfonyl]-
1,2,3,4-tetrahydropyrazine-1-carbamate, 282 
 
By general procedure K, the carbamate 274 (100 mg, 0.28 mmol) gave a crude product. 
Purification by column chromatography, eluting with 7:3 petrol–EtOAc, gave the 
carbamate 282 (92 mg, 0.20 mmol, 92%) as a bright yellow soild; Rf 0.73 (1:1 petrol‒
EtOAc); [α]D19 −86.8 (c 1.7, CHCl3); δH (500 MHz, CDCl3); 8.38 (2H, d, J 8.7, sulfonamide 3-H 
and 5-H), 7.98 (2H, d, J 8.7, sulfonamide 2-H and 6-H), 6.00 (1H, s, 5-H), 4.80-4.70 (1H, br s, 
2-H), 4.01 (1H, d, J 12.0, 3-Ha), 3.94 (1H, dd, J 11.1 and 7.5, methylene-Ha), 3.77 (1H, dd, J 
11.1 and 7.2, methylene-Hb), 2.96 (1H, dd, J 12.0 and 3.5, 3-Hb), 2.04 (3H, s, acetyl-H), 1.44 
(9H, s, tBu-H); δC (75 MHz, CDCl3); 170.3 (acetyl -C), 152.1 (carbamate-C), 150.3 
(sulfonamide 4-C), 142.9 (sulfonamide 1-C), 128.3 (sulfonamide 2-C and 6-C), 124.6 
(sulfonamide 3-C and 5-C), 124.4 (6-C), 107.0 (5-C), 82.2 (tBu-C), 60.5 (methylene-C), 48.3 
(2-C), 44.1 (3-C), 28.2 (tBu-C), 20.7 (acetyl-C), 20.4 (methyl-C); νmax/cm−1 (film) 3282, 
2979, 1746, 1698, 1532, 1369; m/z (ESI) 478.1 (100%, MNa+); HRMS found MNa+, 
478.1270, C19H25N3O8S requires MNa, 478.1255. 
(±)-3-Methyl-1-[(2-nitrobenzene)sulfonyl]piperazine, 300104 
 
By general procedure M, 77 (50.0 mg, 0.13 mmol) gave a crude product. Purification with 
SCX resin gave the piperazine 300 (28.0 mg, 0.01 mmol, 76%) as a colourless oil;  Rf 0.67 
(9:1 CH2Cl2‒MeOH); δH (500 MHz, CDCl3); 7.97 (1H, dd, J 7.3 and 1.8, sulfonamide 3-H),  
7.71 (2H, m, sulfonamide 5-H and 6-H), 7.66-7.59 (1H, m, sulfonamide 4-H), 3.73 (2H, m, 2-
  
200 
 
Ha and 6-Ha), 3.28 (1H, br s, N-H), 3.12 (1H, m, 6-Hb), 3.01-2.89 (3H, m, 3-H, 5-Ha and 5-Hb), 
2.56 (1H, dd, J 12.1 and 10.4, 2-Hb), 1.16 (3H, d, J 6.4, methyl-H); δC (75 MHz, CDCl3); 133.9 
(Ar 4-C), 131.6 (Ar 5-C), 121.2 (Ar 1-C), 130.9 (Ar 6-C), 124.2 (Ar 3-C), 51.8 (2-C), 50.7 (3-
C), 45.4 (6-C), 45.0 (5-C), 18.6 (methyl-C) [Ar 2-C was not observed]; νmax/cm−1 (film) 
2424, 2979, 1702, 1546, 1367, 1167; m/z (ESI) 286.3 (100%, MH+). 
 (±)-Benzyl-2-methyl-4-[(2-nitrobenzene)sulfonyl]piperazine-1-carbamate, 314 
 
By general procedure M, 222 (50.0 mg, 0.12 mmol) gave a crude product. Purification by 
column chromatography, eluting with 6:4 petrol‒EtOAc, gave the piperazine 314 (36.0 
mg, 0.09 mmol, 72%) as a colourless oil; Rf 0.38 (1:1 petrol‒EtOAc); δH (500 MHz, CDCl3); 
8.00-7.88 (1H, m, sulfonamide 3-H), 7.76-7.65 (2H, m, sulfonamide 5-H and 6-H), 7.64-7.57 
(1H, m, sulfonamide 3-H), 7.40-7.28 (5H, m, phenyl-H), 5.13 (1H, d, J 12.5, benzyl-Ha), 5.11 
(1H, d, J 12.5, benzyl-Hb), 4.46 (1H, br s, 2-H), 4.04 (1H, d, J 13.3, 6-Ha), 3.80 (1H, dd, J 12.4 
and 1.6, 5-Ha), 3.61 (1H, dt, J 12.5 and 1.8, 3-Ha), 3.26 (1H, td, J 13.3 and 3.4, 6-Hb), 2.97 
(1H, dd, J 12.4 and 3.7, 3-Hb), 2.77 (1H, td, J 12.3 and 3.5, 5-Hb), 1.24 (3H, d, J 7.0, methyl-
H); δC (75 MHz, CDCl3); 154.8 (carbonyl-C), 148.4 (sulfonamide 1-C), 136.3 (phenyl 1-C), 
133.9 (sulfonamide 4-C), 131.9 (sulfonamide 5-C), 131.1 (sulfonamide 1-C), 130.94 
(sulfonamide 6-C), 128.6 (phenyl 3-C and 5-C), 128.2 (phenyl 4-C), 128.0 (phenyl 2-C and 
6-C), 124.2 (sulfonamide 3-C), 67.5 (benzyl-C), 50.1 (3-C), 46.7 (2-C), 45.8 (5-C), 38.5 (6-
C), 15.0 (methyl-C); νmax/cm−1 (film) 2923, 1699, 1545, 1374, 1172; m/z (ESI) 442.1 
(100%, MNa+); HRMS found MNa+, 442.1065, C19H21N3O6S requires MNa, 442.1043. 
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(3R, 5S)-3-Methyl-1-[(4-nitrobenzene)sulfonyl]-5-phenylpiperazine, 317 
 
By general procedure M, the carbamate 276 (18.0 mg, 0.04 mmol) gave a crude product. 
Purification with SCX resin gave the piperazine 317 (10.0 mg, 0.03 mmol, 71%, 8:1 dr) as a 
colourless oil; Rf 0.79 (9:1 CH2Cl2‒MeOH); [α]D19 +114.7 (c 0.7, CHCl3),  δH (500 MHz, 
CDCl3);  Major 8.37 (2H, d, J 8.9, sulfonamide 3-H and 5-H), 7.91 (2H, d, J 8.9, sulfonamide 
2-H and 6-H), 7.39-7.27 (5H, m, phenyl-H), 3.98 (1H, dd, J 10.4 and 3.0, 5-H), 3.79 (1H, ddd, 
J 11.0, 2.9 and 1.8, 2-Ha), 3.74 (1H, ddd, J 10.9, 2.7 and 1.8, 6-Ha), 3.16-3.09 (1H, m, 3-H), 
2.18 (1H, app. t, J 10.7, 6-Hb), 2.04 (1H, app. t, J 10.6, 2-Hb), 1.11 (3H, d, J 6.3, methyl); 
Major δC (75 MHz, CDCl3); 150.2 (sulfonamide 4-C), 142.0 (sulfonamide 1-C)128.8 
(sulfonamide 2-C and 6-C), 128.7 (phenyl-C), 128.3 (phenyl -C), 127.0 (phenyl -C), 124.4 
(sulfonamide 3-C and 5-C), 60.0 (5-C), 52.5 (2-C), 52.0 (6-C), 50.7 (3-C), 19.4 (methyl); 
Minor 8.37 (2H, d, J 8.9, sulfonamide 3-H and 5-H), 7.91 (2H, d, J 8.9, sulfonamide 2-H and 
6-H), 7.39-7.27 (5H, m, phenyl-H), 4.30 (1H, dd, J 8.1, 3.4, 5-H), 3.56-3.51 (1H, m, 6-Ha), 
3.37-3.32 (1H, m, 3-H), 3.20-3.16 (1H, m, 2-Ha), 3.03-3.00 (1H, m, 2-Hb), 2.83 (1H, m, 6-Hb), 
1.33 (3H, d, J 6.6, methyl); νmax/cm−1 (film) 3106, 2852, 1530, 1351, 1168; m/z (ESI) 362.1 
(100%, MH+); HRMS found MH+, 362.1182, C17H20N3O4S requires MH, 362.1169. 
rac-(cis)Benzyl-3-ethyl-2-methyl-4-[(4-nitrobenzene)sulfonyl]piperazine-1-
carbamate, 318 
 
By general procedure M, the carbamate 287 (50.0 mg, 0.11 mmol) gave a crude product. 
Purification by column chromatography, eluting with 8:2 petrol‒EtOAc, gave the 
piperazine 318 (42.0 mg, 0.09 mmol, 82%) as a colourless oil; Rf 0.64 (1:1 petrol‒EtOAc); 
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δH (500 MHz, CDCl3); 8.24 (2H, d, J 8.8, sulfonamide 3-H and 5-H), 7.88 (2H, d, J 8.8, 
sulfonamide 2-H and 6-H), 7.33-7.24 (3H, m, benzyl 2-H, 4-H and 6-H), 7.21 (2H, m, benzyl 
3-H and 5-H), 4.97 (1H, d, J 12.4, benzyl-Ha), 4.94 (1H, d, J 12.4, benzyl-Hb), 4.09-4.03 (1H, 
m, 2-H), 3.69-3.59 (2H, m, 6-Ha and 5-Ha), 3.41 (1H, td, J 7.7 and 4.7, 3-H), 3.34-3.19 (2H, m, 
6-Hb and 5-Hb), 1.58 (2H, m, ethyl-H), 1.15 (3H, d, J 6.9, methyl-H), 0.84 (3H, t, J 7.4, ethyl-
H); δC (75 MHz, CDCl3); 154.8 (carbonyl-C), 149.9 (sulfonamide 4-C), 146.8 (sulfonamide 
1-C), 136.2 (benzyl 1-C), 128.6 (sulfonamide 2-C and 6-C), 128.2 (benzyl 3-C and 5-C), 
128.0 (benzyl 4-C), 127.8 (benzyl 2-C and 6-C), 124.5 (sulfonamide 3-C and 5-C), 67.3 
(benzyl-C), 62.4 (3-C), 50.5 (2-C), 45.1 (5-C), 39.9 (6-C), 21.9 (ethyl CH2-C), 13.2 (methyl-
C), 11.0 (ethyl CH3-C); νmax/cm−1 (film) 2973, 1699, 1530, 1350, 1163; m/z (ESI) 470.1 
(100%, MNa+); HRMS found MNa+, 470.1371, C21H25N3O6S requires MNa, 470.1356. 
[(2R)-6-Methyl-4-[(4-nitrobenzene)sulfonyl]piperazin-2-yl]methyl acetate, 316 
 
By general procedure M, the carbamate 282 (50.0 mg, 0.10 mmol) gave a crude product. 
Purification with SCX resin gave the piperazine 316 (30.0 mg, 0.08 mmol, 76%, 2:1 dr) as a 
colourless oil; Rf 0.52 (9:1 CH2Cl2‒MeOH); [α]D19 +17.5 (c 0.7, CHCl3), δH (500 MHz, CDCl3); 
8.40 (2H, d, J 8.8, sulfonamide 3-H and 5-H), 7.95 (2H, d, J 8.8, sulfonamide 2-H and 6-H), 
4.02 (1H, dd, J 11.2 and 5.1, 2-methyl-Ha), 3.92 (1H, dd, J 11.0 and 6.7, 2-methyl-Hb), 3.77 
(1H, d, J 10.6, 3-Ha), 3.69 (1H, d, J 11.2, 5-Ha), 3.18 (1H, m, 2-H), 3.00 (1H, m, 6-H), 2.09-
2.01 (4H, m, OAc and 3-Hb), 2.00-1.92 (1H, m, 5-Hb), 1.08 (3H, d, J 6.3, 6-methyl-H), δC (75 
MHz, CDCl3); 170.5 (OAc-C), 150.3 (sulfonamide 4-C), 141.9 (sulfonamide 1-C), 128.8 
(sulfonamide 2-C and 6-C), 124.5 (sulfonamide 3-C and 5-C), 65.1 (2-methyl-C), 53.8 (5-C), 
52.0 (2-C), 50.2 (4-C), 47.8 (6-C), 20.8 (OAc-C), 19.0 (6-methyl-C), νmax/cm−1 (film) 2967, 
1740, 1606, 1531, 1352, 1170; m/z (ESI) 358.1 (100%, MH+); HRMS found MH+, 358.1080, 
C14H19N3O6S requires MNa, 358.1067. 
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(±)-N-Benzyl-2-methyl-4-[(2-nitrobenzene)sulfonyl]-1-(trifluoroacetyl)piperazine-
2-carboxamide, 301 
 
By general procedure N, the carbamate 77 (200 mg, 0.52 mmol) gave a crude product. 
Purification by column chromatography, eluting with 1:1 petrol‒EtOAc, gave the 
piperazine 301 (187 mg, 0.36 mmol, 70%) as a colourless soild; Rf 0.33 (1:1 petrol‒
EtOAc); δH (500 MHz, CDCl3); 7.98 (1H, d, J 7.7, sulfonamide 3-H), 7.77-7.67 (2H, m, 
sulfonamide 5-H and 6-H), 7.67-7.60 (1H, m, sulfonamide 4-H), 7.37-7.30 (2H, m, benzyl 2-
H and 6-H), 7.30-7.22 (3H, m, benzyl 3-H, 4-H and 5-H), 6.26 (1H, d, J 5.2, N-H), 4.41 (1H, 
dd, J 14.9 and 5.4, benzyl CH2-Ha), 4.36 (2H, dd, J 14.8 and 5.5, benzyl CH2-Hb), 3.96-3.90 
(1H, m, 5-Ha), 3.81-3.71 (3H, m, 5-H, 6-Ha and 3-Hb), 3.66 (1H, d, J 13.7, 3-Hb), 3.53-3.43 
(1H, m, 6-Hb), 1.67 (3H, s, methyl-H); δC (75 MHz, CDCl3); 169.2 (Amide-C), 134.3 
(sulfonamide 4-C), 132.0 (sulfonamide 5-C), 131.2 (sulfonamide 6-C), 128.9 (Phenyl 3-C 
and 5-C), 127.9 (Phenyl 4-C), 127.8 (Phenyl 2-C and 6-C), 124.5 (sulfonamide 3-C), 80.3 (2-
C), 64.2 (3-C), 51.8 (5-C), 44.3 (6-C), 44.2 (benzyl-C), 18.1 (methyl-C) [Quaternary Ar-C 
were not observed]; νmax/cm−1 (film) 3385, 2927, 1703, 1674, 1544, 1372, 1159; m/z (ESI) 
537.1 (100%, MNa+); HRMS found MNa+, 537.1038, C21H21F3N4O6S requires MNa, 
537.1026. 
(±)-N-Benzyl-5-ethyl-1-[(2-nitrobenzene)sulfonyl]-4-(trifluoroacetyl)-1,4-
diazepane-5-carboxamide, 323 
 
By general procedure N, the carbamate 285 (50.0 mg, 0.10 mmol) gave a crude product. 
Purification by column chromatography, eluting with 7:3 petrol‒EtOAc, gave the amide 
323 (43.0 mg, 0.08 mmol, 71%) as a colourless solid; Rf 0.44 (1:1 petrol‒EtOAc); δH (500 
MHz, CDCl3); 7.98-7.88 (1H, m, sulfonamide 3-H), 7.74-7.68 (2H, m, sulfonamide 5H and 6-
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H), 7.65 (1H, m, sulfonamide 4-H), 7.37-7.31 (2H, m, benzyl 2-H and 6-H), 7.31-7.24 (3H, 
m, benzyl 3-H, 4-H and 5-H), 5.92 (1H, t, J 5.2, N-H), 4.47 (1H, dd, J 14.7 and 5.5, benzyl 
CH2-Ha), 4.40 (1H, dd, J 14.7 and 5.4, benzyl CH2-Hb), 4.21 (1H, dd, J 16.8 and 5.4, 3-Ha), 
4.11-4.04 (1H, m, 2-Ha), 3.86 (1H, dd, J 14.6 and 6.7, 7-Ha), 3.60 (1H, dd, J 14.6 and 10.6, 7-
Hb), 3.49 (1H, dd, J 16.8 and 9.0, 3-Hb), 3.36 (1H, dd, J 14.4 and 8.9, 2-Hb), 2.71-2.64 (1H, m, 
ethyl CH2-Ha), 2.58 (1H, dd, J 16.3 and 10.7, 6-Ha), 1.91 (1H, dd, J 16.4 and 6.7, 6-Hb), 1.65-
1.55 (1H, m, ethyl CH2-Hb), 0.93 (3H, t, J 7.3, ethyl-H); δC (75 MHz, CDCl3); 170.7 (amide-C), 
148.0 (Ar-C), 137.8 (benzyl 1-C), 133.9 (Ar-C), 132.4 (Ar-C), 132.0 (Ar-C), 130.5 (Ar-C), 
128.9 (Ar-C), 127.7 (Ar-C), 124.5 (sulfonamide 3-C), 114.4 (CF3-C), 69.1 (5-C), 49.8 (2-C), 
48.5 (3-C), 44.0 (benzyl-C), 43.9 (7-C), 37.4 (6-C), 26.8 (ethyl-C), 7.9 (ethyl-C); νmax/cm−1 
(film); 3424, 3026, 1698, 1670, 1545, 1372, 1207, 1155 m/z (ESI) 565.1 (100%, MNa+); 
HRMS found MNa+, 565.1336, C23H25F3N4O6S requires MNa, 565.1339. 
 [(2R,6R)-6-Methyl-6-{[2’-(morpholin-4-yl)ethyl]carbamoyl}-4-[(4-
nitrobenzene)sulfonyl]-1-(trifluoroacetyl)piperazin-2-yl]methyl acetate, 322 
 
By general procedure N, the carbamate 282 (50.0 mg, 0.09 mmol) gave a crude product. 
Purification by column chromatography, eluting with 1:1 petrol‒EtOAc, gave the amide 
322 (38.0 mg, 0.06 mmol, 65%) as a colourless solid; Rf 0.25 (1:1 petrol‒EtOAc); [α]D19 
+116.7 (c 0.4, CHCl3); δH (500 MHz, CDCl3); 11.0 (1H, br s, N-H), 8.39 (2H, d, J 8.7, 
sulfonamide 3-H and 5-H), 7.96 (2H, d, J 8.7, sulfonamide 2-H and 6-H), 4.16 (1H, app. q, J 
10.4, CH2-Ha), 4.09 (1H, dd, J 10.7, 5.8, CH2-Hb), 4.01 (1H, d, J 15.6, 5-Ha), 3.96-3.88 (1H, m, 
2-H), 3.66 (4H, br s, morpholine 2-H and 6-H), 3.48 (1H, d, J 11.6, 3-Ha), 3.36-3.27 (2H, m, 
2’-H), 2.89 (1H, dd, J 11.5 and 5.3, 3-Hb), 2.53-2.50 (2H, m, 5-Hb and 1’-Ha), 2.44 (1H, d, J 
13.6, 1’-Hb), 2.39 (4H, br s, morpholine 3-H and 5-H), 2.08 (3H, s, acetyl-H), 1.43 (3H, s, 
methyl-H); δC (125 MHz, CDCl3); 170.4 (Acetate-C), 150.4 (sulfonamide 1-C), 142.5 
(sulfonamide 4-C), 128.8 (sulfonamide 2-C and 6-C), 124.5 (sulfonamide 3-C and 5-C), 65.7 
(AcetateCH2-C), 63.7 (morpholine 2-C and 6-C), 59.3 (2’-C), 56.6 (morpholine 3-C and 5-C), 
51.4 (5-C), 47.5  (2-C), 46.1 (3-C), 29.7 (1’-C), 23.8 (methyl-C), 20.8 (acetyl-C); δF (282 
MHz, CDCl3) -82.16; νmax/cm−1 (film) 2924, 1724, 1533, 1353, 1167; m/z (ESI) 610.2 
(100%, MH+); HRMS found MH+, 610.1789, C23H30F3N5O9S requires MH, 610.1789. 
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(2R,6S)-2-Methyl-N-[2’-(morpholin-4-yl)ethyl]-4-[(4-nitrobenzene)sulfonyl]-6-
phenyl-1-(trifluoroacetyl)piperazine-2-carboxamide, 320, and 4-(2-{[(2R,6S)-2-
Methyl-4-[(4-nitrobenzene)sulfonyl]-6-phenylpiperazin-2-
yl]formamido}ethyl)morpholin-4-ium trifluoroacetate, 321 
 
By general procedure N, the carbamate 276 (200 mg, 0.44 mmol) gave a crude product. 
Purification by column chromatography, gradient elution with 1:1 petrol‒EtOAc to 100% 
EtOAc, gave the amide 320 (76.0 mg, 0.12 mmol, 28%) as a colourless soild; Rf 0.45 (1:1 
petrol‒EtOAc); δH (500 MHz, CDCl3); 11.13 (1H, br s, N-H), 8.38 (2H, d, J 8.7, sulfonamide 
3-H and 5-H), 7.96 (2H, d, J 8.7, sulfonamide 2-H and 6-H), 7.46 (2H, d, J 7.7, phenyl 2-H 
and 6-H), 7.32 (2H, t, J 7.5, phenyl 3-H and 5-H), 7.27-7.24 (1H, m, phenyl 4-H), 4.87 (1H, d, 
J 4.9, 6-H), 4.20 (1H, d, J 11.8, 5-Ha), 4.04 (1H, d, J 15.5, 1’-Ha), 3.70 (4H, br s, morpholine 2-
H and 6-H), 3.45-3.33 (2H, m, 5-Hb and 1’-Hb), 3.15 (1H, d, J 11.6, 3-Ha), 2.67 (1H, d, J 11.6, 
3-Hb), 2.56 (1H, app. t, J 11.6, 2’-Hb), 2.45 (1H, d, J 11.7, 2’-H), 2.34 (4H, br s, morpholine 3-
H and 5-H), 0.96 (3H, s, Me-H); δC (75 MHz, CDCl3); 174.0 (amide carbonyl-C), 150.3 
(sulfonamide 4-C), 141.9 (phenyl 1-C), 139.9 (sulfonamide 1-C), 129.0 (sulfonamide-C), 
128.3 (phenyl-C), 127.3 (sulfonamide-C), 124.3 (phenyl-C), 122.7 (q, 1JC-F 290, CF3), 65.7 
(morpholine 2-C), 60.6 (2-C), 56.4 (2’-C), 51.1 (morpholine 3-C), 50.6 (6-C), 46.1 (5-C), 
37.2 (1’-C), 22.4 (methyl-C); δF (282 MHz, CDCl3) -81.2 (s); νmax/cm−1 (film) 3103, 2854, 
2359, 1722, 1533, 1352, 1174; m/z (ESI) 614.2 (100%, MH+); HRMS found MH+, 614.1890. 
C26H30F3N5O7S requires MH, 614.1891. 
Also isolated was and the amide 321 (162 mg, 0.26 mmol, 59%) as a colourless solid; Rf 
0.14 (100% EtOAc); δH (500 MHz, CDCl3); 8.39 (2H, d, J 8.8, sulfonamide 3-H and 5-H), 7.96 
(2H, d, J 8.7, sulfonamide 2-H and 6-H), 7.39-7.29 (5H, m, phenyl-H), 7.17 (1H, br s, N-H), 
4.30 (1H, d, J 11.8, 3-Ha), 4.00-3.94 (1H, m, 6-H), 3.86 (1H, d, J 11.0, 5-Ha), 3.75-3.65 (4H, m, 
morpholine 2-H and 6-H), 3.53-3.48 (1H, m, 2’-Ha), 3.48-3.39 (2H, m, 1’-H), 2.68 (1H, dd, J 
8.8 and 4.1, 2’-Hb), 2.57-2.52 (4H, m, morpholine 3-H and 5-H), 2.30-2.18 (2H, m, 3-Hb and 
5-Ha), 2.07 (1H, d, J 5.3, N-H), 1.28 (3H, s, methyl-H); δC (75 MHz, CDCl3); 173.0 (carbonyl-
C), 150.3 (sulfonamide 4-C), 141.9 (phenyl 1-C), 139.4 (sulfonamide 1-C), 128.8 
(sulfonamide-C), 128.4 (phenyl-C), 128.3 (phenyl-C), 126.7 (sulfonamide-C), 124.5 
(phenyl-C), 66.9 (morpholine 2-C and 6-C), 58.8 (2-C), 57.3 (2’-C), 55.8 (6-C), 53.4 
(morpholine 3-C and 5-C), 51.4 (3-C), 51.3 (5-C) , 36.0 (1’-C), 25.9 (methyl-C); δF (282 
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MHz, CDCl3) -82.2 (s);  νmax/cm−1 (film) 3351, 2818, 1659, 1525, 1349, 1165; m/z (ESI) 
518.2 (100%, MH+); HRMS found MH+, 518.2090. C24H32N5O6S requires MH, 518.2068. 
Benzyl-(2S,6S)-2-benzyl-6-methyl-4-[(2-nitrobenzene)sulfonyl]piperazine-1- 
carbamate, 315 
 
By general procedure M, 275 (100 mg, 0.20 mmol) gave a crude product. Purification by 
column chromatography, eluting with 7:3 petrol‒EtOAc, gave the piperazine 315 (68.0 
mg, 0.14 mmol, 68%, 7.7:1 dr) as a colourless oil; Rf 0.49 (1:1 petrol‒EtOAc); [α]D19 −177.2 
(c 4.2, CHCl3);  δH (500 MHz, CDCl3); 7.97 (1H, d, J 7.8, sulfonamide 3-H), 7.79-7.73 (1H, m, 
sulfonamide 6-H), 7.73-7.62 (2H, m, sulfonamide 4-H and 5-H), 7.41-7.37 (5H, m, 
carbamate Ar-H), 7.12 (3H, m, benzyl 2-H, 4-H and 6-H), 6.89 (2H, m, benzyl 3-H and 5-H), 
5.22 (1H, d, J 12.1, carbamate CH2-Ha), 5.14 (1H, d, J 12.1, carbamate CH2-Hb), 4.25 (1H, m, 
6-H), 4.14 (1H, br d, J 9.7, 2-H), 3.84 (1H, dd, J 12.9 and 3.4, 5-Ha), 3.68 (1H, dd, J 12.9 and 
2.2, 5-Hb), 3.45 (1H, br d, J 11.8, CH2-Ha), 3.39 (1H, dd, J 12.3 and 3.5, CH2-Hb), 3.03 (1H, br 
d, J 12.6, 3-Ha), 2.68 (1H, app. t, J 11.7, 3-Hb), 1.24 (3H, d, J 6.6, methyl-H); δC (75 MHz, 
CDCl3); 154.8 (carbonyl-C), 148.0 (sulfonamide 2-C), 137.5 (benzyl Ar 1-C), 137.0 
(carbamate Ar 1-C), 133.8 (sulfonamide 4-C), 131.8 (sulfonamide 5-C), 131.4 (sulfonamide 
1-C), 129.7 (benzyl 3-C and 5-C), 129.3 (benzyl 4-C), 128.7 (benzyl 2-C and 6-C), 128.4 
(carbamate Ar 3-C and 5-C), 128.3 (carbamate Ar 4-C), 128.3 (carbamate Ar 2-and 6-C), 
126.6 (sulfonamide 6-C), 124.41 (sulfonamide 3-C), 67.6 (carbamate CH2-C), 54.7 (2-C), 
48.4 (5-C), 48.0 (6-C), 42.9 (3-C), 40.2 (benzyl-C), 20.5 (methyl-C); νmax/cm−1 (film) 3029, 
1697, 1603,  1544, 1408, 1372, 1171; m/z (ESI) 532.2 (100%, MNa+); HRMS found MNa+, 
532.1509. C26H27N3O6S requires MNa, 532.1518. 
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5.4 Appendix 
A. Building blocks used in the preparation of virtual libraries using in silico methods 
(Sections 2.2.3 and 3.1.4). 
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